text,labels
In,O
addition,O
to,O
methadone,Chemical
dose,O
",",O
15,O
demographic,O
",",O
biological,O
",",O
and,O
pharmacological,O
variables,O
were,O
considered,O
as,O
potential,O
risk,O
factors,O
for,O
QT,Disease
prolongation,Disease
.,O
In,O
the,O
control,O
group,O
implants,O
contained,O
no,O
PDN,Chemical
.,O
In,O
this,O
paper,O
we,O
aim,O
to,O
draw,O
to,O
the,O
fact,O
that,O
caution,O
is,O
needed,O
when,O
prescribing,O
vitamin,Chemical
A,Chemical
-,O
containing,O
drugs,O
to,O
women,O
of,O
childbearing,O
years,O
.,O
In,O
vitro,O
",",O
fluoxetine,Chemical
induced,O
pulmonary,O
arterial,O
muscle,O
contraction,O
in,O
fetal,O
",",O
but,O
not,O
adult,O
",",O
animals,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
and,O
reduced,O
serotonin,Chemical
-,O
induced,O
contraction,O
at,O
both,O
ages,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
.,O
However,O
",",O
when,O
the,O
dose,O
is,O
adjusted,O
based,O
on,O
clinical,O
response,O
or,O
the,O
development,O
of,O
adverse,O
effects,O
",",O
75,O
%,O
of,O
patients,O
with,O
VT,Disease
or,O
VF,Disease
can,O
be,O
successfully,O
managed,O
with,O
amiodarone,Chemical
.,O
For,O
PCI,O
",",O
argatroban,Chemical
has,O
not,O
been,O
investigated,O
in,O
hepatically,O
impaired,O
patients,O
;,O
dose,O
adjustment,O
is,O
unnecessary,O
for,O
adult,O
age,O
",",O
sex,O
",",O
race,O
/,O
ethnicity,O
or,O
obesity,Disease
",",O
and,O
lesser,O
doses,O
may,O
be,O
adequate,O
with,O
concurrent,O
glycoprotein,O
IIb,O
/,O
IIIa,O
inhibition,O
.,O
Further,O
",",O
steroid,Chemical
myopathy,Disease
recovers,O
naturally,O
and,O
the,O
neurological,O
improvement,O
shown,O
in,O
the,O
NASCIS,O
may,O
be,O
just,O
a,O
recording,O
of,O
this,O
natural,O
motor,O
recovery,O
from,O
the,O
steroid,Chemical
myopathy,Disease
",",O
instead,O
of,O
any,O
protection,O
that,O
methylprednisolone,Chemical
offers,O
to,O
the,O
spinal,Disease
cord,Disease
injury,Disease
.,O
As,O
a,O
result,O
",",O
there,O
is,O
a,O
growing,O
interest,O
in,O
the,O
development,O
of,O
pharmacological,O
agents,O
with,O
potential,O
antipsychotic,O
properties,O
that,O
enhance,O
the,O
activity,O
of,O
the,O
glutamatergic,O
system,O
via,O
a,O
modulation,O
of,O
the,O
NMDA,Chemical
receptor,O
.,O
A,O
67,O
-,O
year,O
-,O
old,O
man,O
who,O
was,O
treated,O
with,O
oxacillin,Chemical
for,O
one,O
week,O
because,O
of,O
Staphylococcus,Disease
aureus,Disease
bacteremia,Disease
",",O
developed,O
renal,Disease
failure,Disease
and,O
diffuse,O
",",O
symmetric,O
",",O
palpable,O
purpuric,Disease
lesions,Disease
on,O
his,O
feet,O
.,O
METHODS,O
:,O
The,O
alteration,O
in,O
the,O
NO,Chemical
pathway,O
was,O
assessed,O
by,O
measuring,O
nitrite,Chemical
levels,O
in,O
serum,O
/,O
urine,O
and,O
by,O
evaluating,O
the,O
changes,O
in,O
vascular,O
reactivity,O
of,O
the,O
isolated,O
perfused,O
rat,O
kidney,O
(,O
IPRK,O
),O
system,O
.,O
Does,O
paracetamol,Chemical
cause,O
urothelial,Disease
cancer,Disease
or,O
renal,Disease
papillary,Disease
necrosis,Disease
?,O
Sprague,O
-,O
Dawley,O
male,O
rats,O
(,O
200,O
~,O
250,O
g,O
),O
were,O
subcutaneously,O
injected,O
with,O
gentamicin,Chemical
(,O
100,O
mg,O
/,O
kg,O
per,O
day,O
),O
for,O
7,O
days,O
",",O
and,O
the,O
expression,O
of,O
tubular,O
transporters,O
was,O
determined,O
by,O
immunoblotting,O
and,O
immunohistochemistry,O
.,O
By,O
using,O
a,O
placebo,O
-,O
controlled,O
",",O
two,O
-,O
way,O
factorial,O
design,O
",",O
tolerance,O
to,O
cold,O
-,O
pressor,O
(,O
CP,O
),O
pain,Disease
was,O
examined,O
",",O
both,O
before,O
and,O
after,O
oral,O
administration,O
of,O
therapeutic,O
doses,O
of,O
common,O
opioid,O
(,O
hydromorphone,Chemical
2,O
mg,O
),O
and,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
(,O
ketorolac,Chemical
10,O
mg,O
),O
analgesic,O
agents,O
.,O
Dopamine,Chemical
D2,O
receptor,O
signaling,O
controls,O
neuronal,O
cell,O
death,O
induced,O
by,O
muscarinic,O
and,O
glutamatergic,O
drugs,O
.,O
It,O
is,O
the,O
third,O
urinary,Disease
tract,Disease
cancer,Disease
reported,O
in,O
association,O
with,O
cyclophosphamide,Chemical
treatment,O
for,O
nonmalignant,O
disease,O
.,O
RESULTS,O
:,O
No,O
reaction,O
was,O
observed,O
with,O
placebo,O
and,O
eight,O
patients,O
(,O
88,O
.,O
8,O
%,O
),O
tolerated,O
CE,Chemical
.,O
This,O
observation,O
demonstrates,O
that,O
prolonged,O
cholestasis,Disease
can,O
follow,O
troleandomycin,Chemical
-,O
induced,O
acute,O
hepatitis,Disease
.,O
An,O
increase,O
in,O
TDR,O
by,O
dl,O
-,O
sotalol,Chemical
facilitated,O
transmural,O
propagation,O
of,O
EADs,O
that,O
initiated,O
multiple,O
episodes,O
of,O
spontaneous,O
TdP,Disease
in,O
3,O
of,O
6,O
rabbit,O
left,O
ventricles,O
.,O
Of,O
the,O
remainder,O
",",O
a,O
relationship,O
to,O
clioquinol,Chemical
was,O
considered,O
probable,O
in,O
42,O
and,O
possible,O
in,O
69,O
cases,O
.,O
Coronary,O
computerized,O
tomography,O
angiography,O
for,O
rapid,O
discharge,O
of,O
low,O
-,O
risk,O
patients,O
with,O
cocaine,Chemical
-,O
associated,O
chest,Disease
pain,Disease
.,O
Expression,O
of,O
the,O
hypoxia,Disease
-,O
responsive,O
transgene,O
increased,O
throughout,O
the,O
observation,O
period,O
",",O
reaching,O
2,O
.,O
2,O
-,O
fold,O
at,O
2,O
weeks,O
in,O
the,O
puromycin,Chemical
aminonucleoside,Chemical
model,O
and,O
2,O
.,O
6,O
-,O
fold,O
at,O
4,O
weeks,O
in,O
the,O
remnant,O
kidney,O
model,O
",",O
whereas,O
that,O
of,O
vascular,O
endothelial,O
growth,O
factor,O
showed,O
a,O
mild,O
decrease,O
",",O
reflecting,O
distinct,O
behaviors,O
of,O
the,O
two,O
genes,O
.,O
Tonic,Disease
-,Disease
clonic,Disease
seizures,Disease
followed,O
intravenous,O
fluorescein,Chemical
injection,O
for,O
fundus,O
angiography,O
in,O
a,O
47,O
-,O
year,O
-,O
old,O
male,O
.,O
This,O
patient,O
presented,O
with,O
symptoms,O
of,O
neuroleptic,Disease
malignant,Disease
syndrome,Disease
(,O
NMS,Disease
),O
",",O
thus,O
demonstrating,O
that,O
NMS,Disease
-,O
like,O
symptoms,O
can,O
occur,O
after,O
combined,O
paroxetine,Chemical
and,O
alprazolam,Chemical
treatment,O
.,O
The,O
results,O
show,O
that,O
pretreatment,O
with,O
TCR,Chemical
may,O
be,O
useful,O
in,O
preventing,O
the,O
damage,O
induced,O
by,O
isoproterenol,Chemical
in,O
rat,O
heart,O
.,O
Fatal,O
myeloencephalopathy,Disease
due,O
to,O
intrathecal,O
vincristine,Chemical
administration,O
.,O
On,O
average,O
",",O
MA,Chemical
abusers,O
had,O
7,O
.,O
8,O
%,O
smaller,O
hippocampal,O
volumes,O
than,O
control,O
subjects,O
(,O
p,O
<,O
0,O
.,O
01,O
;,O
left,O
",",O
p,O
=,O
0,O
.,O
01,O
;,O
right,O
",",O
p,O
<,O
0,O
.,O
05,O
),O
and,O
significant,O
white,O
-,O
matter,O
hypertrophy,Disease
(,O
7,O
.,O
0,O
%,O
;,O
p,O
<,O
0,O
.,O
01,O
),O
.,O
Behavioral,O
and,O
cardiorespiratory,O
responses,O
to,O
a,O
lethal,O
dose,O
of,O
morphine,Chemical
were,O
evaluated,O
in,O
rats,O
pretreated,O
with,O
saline,O
or,O
naloxazone,Chemical
",",O
an,O
antagonist,O
of,O
high,O
-,O
affinity,O
mu,O
1,O
opioid,O
receptors,O
.,O
These,O
findings,O
suggest,O
that,O
NRA0160,Chemical
may,O
have,O
unique,O
antipsychotic,O
activities,O
without,O
the,O
liability,O
of,O
motor,O
side,O
effects,O
typical,O
of,O
classical,O
antipsychotics,O
.,O
Thus,O
",",O
the,O
nephrotoxicity,Disease
induced,O
by,O
CSA,Chemical
has,O
a,O
different,O
pathogenetic,O
mechanism,O
.,O
Since,O
cortical,O
spreading,O
depression,Disease
has,O
been,O
shown,O
to,O
liberate,O
NO,Chemical
in,O
animals,O
",",O
this,O
finding,O
may,O
help,O
our,O
understanding,O
of,O
the,O
coupling,O
between,O
cortical,O
spreading,O
depression,Disease
and,O
headache,Disease
in,O
migraine,Disease
with,Disease
aura,Disease
.,O
Role,O
of,O
activation,O
of,O
bradykinin,Chemical
B2,O
receptors,O
in,O
disruption,O
of,O
the,O
blood,O
-,O
brain,O
barrier,O
during,O
acute,O
hypertension,Disease
.,O
Conversely,O
",",O
enalapril,Chemical
had,O
a,O
relative,O
renoprotective,O
effect,O
(,O
RR,O
1,O
.,O
33,O
",",O
95,O
%,O
CI,O
1,O
.,O
13,O
-,O
1,O
.,O
53,O
),O
compared,O
with,O
placebo,O
(,O
RR,O
1,O
.,O
96,O
",",O
95,O
%,O
CI,O
1,O
.,O
57,O
-,O
2,O
.,O
44,O
),O
in,O
patients,O
with,O
diabetes,Disease
.,O
A,O
43,O
-,O
year,O
-,O
old,O
woman,O
had,O
severe,O
jaundice,Disease
and,O
itching,Disease
1,O
month,O
after,O
receiving,O
methimazole,Chemical
(,O
10,O
mg,O
tid,O
),O
and,O
propranolol,Chemical
(,O
20,O
mg,O
tid,O
),O
for,O
treatment,O
of,O
hyperthyroidism,Disease
.,O
Troponin,O
appears,O
to,O
have,O
an,O
equivalent,O
diagnostic,O
accuracy,O
compared,O
with,O
CK,O
-,O
MB,O
for,O
diagnosing,O
necrosis,Disease
in,O
patients,O
with,O
cocaine,Chemical
-,O
associated,O
chest,Disease
pain,Disease
and,O
suspected,O
MI,Disease
.,O
Lindane,Chemical
is,O
an,O
organochloride,O
pesticide,O
and,O
scabicide,O
.,O
Hepatonecrosis,Disease
and,O
cholangitis,Disease
related,O
to,O
long,O
-,O
term,O
phenobarbital,Chemical
therapy,O
:,O
an,O
autopsy,O
report,O
of,O
two,O
patients,O
.,O
Mitochondrial,O
radiocalcium,Chemical
uptakes,O
were,O
significantly,O
decreased,O
in,O
animals,O
pretreated,O
with,O
acetylsalicylic,Chemical
acid,Chemical
or,O
dipyridamole,Chemical
or,O
when,O
hydrocortisone,Chemical
was,O
added,O
to,O
the,O
epinephrine,Chemical
infusion,O
(,O
2,O
",",O
682,O
",",O
2,O
",",O
803,O
",",O
and,O
3,O
",",O
424,O
counts,O
per,O
minute,O
per,O
gram,O
of,O
dried,O
fraction,O
",",O
respectively,O
),O
.,O
The,O
Flumazenil,Chemical
in,O
Intravenous,O
Conscious,O
Sedation,O
with,O
Diazepam,Chemical
Multicenter,O
Study,O
Group,O
II,O
.,O
We,O
have,O
reported,O
a,O
case,O
of,O
acute,O
oliguric,O
renal,Disease
failure,Disease
with,O
hyperkalemia,Disease
in,O
a,O
patient,O
with,O
cirrhosis,Disease
",",O
ascites,Disease
",",O
and,O
cor,Disease
pulmonale,Disease
after,O
indomethacin,Chemical
therapy,O
.,O
Our,O
findings,O
do,O
suggest,O
that,O
CS,Chemical
-,O
mediated,O
protection,O
is,O
dependent,O
on,O
the,O
action,O
of,O
the,O
intact,O
anionic,O
CS,Chemical
molecule,O
(,O
non,O
-,O
hydrolyzable,O
CSE,Chemical
was,O
as,O
protective,O
as,O
CS,Chemical
),O
",",O
whose,O
mechanism,O
has,O
yet,O
to,O
be,O
defined,O
.,O
The,O
results,O
of,O
the,O
present,O
study,O
suggested,O
that,O
Hibiscus,Chemical
rosa,Chemical
sinensis,Chemical
had,O
a,O
protective,O
role,O
against,O
reserpine,Chemical
-,O
induced,O
orofacial,O
dyskinesia,Disease
and,O
oxidative,O
stress,O
.,O
INTRODUCTION,O
AND,O
OBJECTIVE,O
:,O
Contrast,Chemical
-,O
induced,O
nephropathy,Disease
(,O
CIN,O
),O
significantly,O
increases,O
the,O
morbidity,O
and,O
mortality,O
of,O
patients,O
.,O
Thirty,O
-,O
five,O
consecutive,O
chemotherapy,O
-,O
naive,O
patients,O
with,O
Stage,O
IV,O
NSCLC,Disease
and,O
an,O
Eastern,O
Cooperative,O
Oncology,O
Group,O
performance,O
status,O
of,O
0,O
-,O
2,O
were,O
treated,O
with,O
a,O
combination,O
of,O
paclitaxel,Chemical
(,O
135,O
mg,O
/,O
m,O
(,O
2,O
),O
given,O
intravenously,O
in,O
3,O
hours,O
),O
on,O
Day,O
1,O
",",O
cisplatin,Chemical
(,O
120,O
mg,O
/,O
m,O
(,O
2,O
),O
given,O
intravenously,O
in,O
6,O
hours,O
),O
on,O
Day,O
1,O
",",O
and,O
gemcitabine,Chemical
(,O
800,O
mg,O
/,O
m,O
(,O
2,O
),O
given,O
intravenously,O
in,O
30,O
minutes,O
),O
on,O
Days,O
1,O
and,O
8,O
",",O
every,O
4,O
weeks,O
.,O
Renal,Disease
function,Disease
significantly,Disease
deteriorated,Disease
in,O
the,O
group,O
pretreated,O
with,O
furosemide,Chemical
(,O
p,O
<,O
0,O
.,O
005,O
by,O
ANOVA,O
),O
",",O
with,O
a,O
rise,O
in,O
serum,O
creatinine,Chemical
from,O
145,O
+,O
/,O
-,O
13,O
to,O
182,O
+,O
/,O
-,O
16,O
mumol,O
/,O
l,O
at,O
24,O
h,O
",",O
while,O
no,O
change,O
occurred,O
in,O
the,O
control,O
group,O
(,O
from,O
141,O
+,O
/,O
-,O
6,O
to,O
142,O
+,O
/,O
-,O
7,O
mumol,O
/,O
l,O
),O
.,O
The,O
dexamethasone,Chemical
-,O
treated,O
nonresponder,O
eyes,O
appeared,O
to,O
be,O
morphologically,O
similar,O
to,O
the,O
untreated,O
eyes,O
",",O
although,O
several,O
subtle,O
dexamethasone,Chemical
-,O
induced,O
morphologic,O
changes,O
were,O
evident,O
.,O
Unfractionated,Chemical
heparin,Chemical
(,O
UH,Chemical
),O
is,O
currently,O
the,O
substitute,O
for,O
selected,O
patients,O
.,O
However,O
",",O
inhibition,O
of,O
postsynaptic,O
5,Chemical
-,Chemical
HT,Chemical
receptors,O
neither,O
inhibited,O
nor,O
potentiated,O
reversal,O
of,O
catalepsy,Disease
and,O
leaves,O
open,O
the,O
question,O
as,O
to,O
the,O
site,O
or,O
mechanism,O
for,O
this,O
effect,O
.,O
BACKGROUND,O
:,O
An,O
association,O
between,O
the,O
use,O
of,O
oral,Chemical
contraceptives,Chemical
and,O
the,O
risk,O
of,O
myocardial,Disease
infarction,Disease
has,O
been,O
found,O
in,O
some,O
",",O
but,O
not,O
all,O
",",O
studies,O
.,O
During,O
follow,O
-,O
up,O
(,O
median,O
5,O
years,O
),O
",",O
there,O
were,O
no,O
significant,O
differences,O
in,O
rejection,O
(,O
acute,O
and,O
chronic,O
),O
",",O
graft,O
failure,O
or,O
survival,O
between,O
the,O
groups,O
(,O
acetaminophen,Chemical
-,O
induced,O
ALF,Disease
1,O
year,O
87,O
%,O
",",O
5,O
years,O
75,O
%,O
;,O
non,O
-,O
acetaminophen,Chemical
-,O
induced,O
ALF,Disease
88,O
%,O
",",O
78,O
%,O
;,O
CLD,Disease
93,O
%,O
",",O
82,O
%,O
:,O
P,O
>,O
0,O
.,O
6,O
log,O
rank,O
),O
.,O
We,O
therefore,O
sought,O
to,O
determine,O
the,O
prevalence,O
and,O
clinical,O
associations,O
of,O
hyperkalemia,Disease
and,O
renal,Disease
insufficiency,Disease
in,O
heart,Disease
failure,Disease
patients,O
treated,O
with,O
spironolactone,Chemical
.,O
Non,O
-,O
invasive,O
detection,O
of,O
coronary,Disease
artery,Disease
disease,Disease
by,O
body,O
surface,O
electrocardiographic,O
mapping,O
after,O
dipyridamole,Chemical
infusion,O
.,O
On,O
readmission,O
",",O
11,O
patients,O
received,O
therapeutic,O
heparin,Chemical
",",O
which,O
worsened,O
the,O
patients,O
',O
clinical,O
condition,O
and,O
",",O
in,O
all,O
11,O
cases,O
",",O
decreased,O
the,O
platelet,O
count,O
(,O
mean,O
at,O
readmission,O
",",O
143,O
x,O
10,O
(,O
9,O
),O
cells,O
/,O
L,O
;,O
mean,O
nadir,O
after,O
heparin,Chemical
re,O
-,O
exposure,O
",",O
39,O
x,O
10,O
(,O
9,O
),O
cells,O
/,O
L,O
),O
.,O
In,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
+,O
LID,Disease
",",O
the,O
force,O
involved,O
in,O
pressing,O
down,O
the,O
object,O
before,O
lifting,O
was,O
significantly,O
increased,O
by,O
levodopa,Chemical
(,O
by,O
61,O
%,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
.,O
A,O
2,O
-,O
year,O
-,O
old,O
child,O
with,O
known,O
neurologic,Disease
impairment,Disease
developed,O
a,O
dyskinesia,Disease
soon,O
after,O
starting,O
phenobarbital,Chemical
therapy,O
for,O
seizures,Disease
.,O
The,O
protection,O
by,O
overexpression,O
of,O
superoxide,Chemical
dismutase,O
supports,O
the,O
hypothesis,O
that,O
oxidant,O
stress,O
plays,O
a,O
significant,O
role,O
in,O
aminoglycoside,Chemical
-,O
induced,O
ototoxicity,Disease
.,O
STZ,Chemical
treatment,O
showed,O
decrease,O
expression,O
of,O
post,O
synaptic,O
markers,O
CaMKIIa,O
and,O
PSD,O
-,O
95,O
",",O
while,O
",",O
expression,O
of,O
pre,O
synaptic,O
markers,O
(,O
synaptophysin,O
and,O
SNAP,O
-,O
25,O
),O
remains,O
unaltered,O
indicating,O
selective,O
post,O
synaptic,O
neurotoxicity,Disease
.,O
The,O
effects,O
on,O
isoproterenol,Chemical
tachycardia,Disease
were,O
determined,O
before,O
and,O
after,O
atropine,Chemical
(,O
0,O
.,O
04,O
mg,O
/,O
kg,O
IV,O
),O
.,O
Learning,Disease
and,Disease
memory,Disease
deficits,Disease
in,O
ecstasy,Chemical
users,O
and,O
their,O
neural,O
correlates,O
during,O
a,O
face,O
-,O
learning,O
task,O
.,O
These,O
results,O
indicate,O
that,O
early,O
changes,O
in,O
glutamate,Chemical
transport,O
may,O
be,O
related,O
to,O
the,O
development,O
of,O
vacuous,O
chewing,O
movements,O
in,O
rats,O
.,O
In,O
conclusion,O
",",O
hyperammonemic,Disease
encephalopathy,Disease
can,O
occur,O
in,O
patients,O
receiving,O
continuous,O
infusion,O
of,O
5,Chemical
-,Chemical
FU,Chemical
.,O
Prevention,O
and,O
treatment,O
of,O
endometrial,Disease
disease,Disease
in,O
climacteric,O
women,O
receiving,O
oestrogen,Chemical
therapy,O
.,O
Encephalopathy,Disease
induced,O
by,O
levetiracetam,Chemical
added,O
to,O
valproate,Chemical
.,O
Dexrazoxane,Chemical
protects,O
against,O
myelosuppression,Disease
from,O
the,O
DNA,O
cleavage,O
-,O
enhancing,O
drugs,O
etoposide,Chemical
and,O
daunorubicin,Chemical
but,O
not,O
doxorubicin,Chemical
.,O
Nephrolithiasis,Disease
is,O
a,O
complication,O
of,O
acetazolamide,Chemical
but,O
does,O
not,O
preclude,O
its,O
use,O
.,O
Dysregulated,O
diurnal,O
cortisol,Chemical
may,O
be,O
indicative,O
of,O
inappropriate,O
anticipation,O
of,O
forthcoming,O
demands,O
and,O
hypersecretion,O
may,O
lead,O
to,O
the,O
increased,O
psychological,O
and,O
physical,O
morbidity,O
associated,O
with,O
heavy,O
recreational,O
use,O
of,O
ecstasy,Chemical
.,O
Intra,O
-,O
arterial,O
BCNU,Chemical
chemotherapy,O
for,O
treatment,O
of,O
malignant,Disease
gliomas,Disease
of,O
the,O
central,O
nervous,O
system,O
.,O
These,O
effects,O
suggest,O
that,O
the,O
protection,O
from,O
hemolysis,Disease
by,O
tocopherols,Chemical
is,O
related,O
to,O
a,O
decreased,O
TAM,Chemical
incorporation,O
in,O
condensed,O
membranes,O
and,O
the,O
structural,O
damage,O
of,O
the,O
erythrocyte,O
membrane,O
is,O
consequently,O
avoided,O
.,O
The,O
mechanisms,O
underlying,O
the,O
activity,O
of,O
aniracetam,Chemical
and,O
its,O
',O
therapeutic,O
window,O
',O
are,O
unknown,O
.,O
In,O
conclusion,O
we,O
found,O
that,O
thiazide,Chemical
diuretics,O
cause,O
hypokalemia,Disease
and,O
depletion,O
of,O
body,O
potassium,Chemical
.,O
The,O
patient,O
was,O
diagnosed,O
with,O
drug,O
-,O
induced,O
baboon,Disease
syndrome,Disease
based,O
on,O
his,O
history,O
",",O
which,O
included,O
prior,O
sensitivity,O
to,O
topical,O
ketoconazole,Chemical
",",O
a,O
physical,O
examination,O
",",O
and,O
histopathological,O
findings,O
.,O
Reduced,O
progression,O
of,O
adriamycin,Chemical
nephropathy,Disease
in,O
spontaneously,O
hypertensive,Disease
rats,O
treated,O
by,O
losartan,Chemical
.,O
Fifty,O
-,O
six,O
days,O
after,O
initiation,O
of,O
the,O
treatment,O
the,O
patient,O
presented,O
hallucinations,Disease
that,O
only,O
stopped,O
after,O
the,O
withdrawal,O
of,O
psycho,O
-,O
active,O
drugs,O
and,O
tramadol,Chemical
.,O
In,O
female,O
rats,O
",",O
CP,Chemical
200,O
mg,O
.,O
/,O
kg,O
.,O
Anthracyclines,Chemical
are,O
effective,O
antineoplastic,O
drugs,O
",",O
but,O
they,O
frequently,O
cause,O
dose,O
-,O
related,O
cardiotoxicity,Disease
.,O
Intravenous,O
ribavirin,Chemical
treatment,O
for,O
severe,O
adenovirus,Disease
disease,Disease
in,O
immunocompromised,O
children,O
.,O
We,O
investigated,O
the,O
efficacy,O
and,O
toxicity,Disease
of,O
a,O
3,O
-,O
hour,O
paclitaxel,Chemical
infusion,O
in,O
a,O
phase,O
II,O
trial,O
in,O
patients,O
with,O
inoperable,O
stage,O
IIIB,O
or,O
IV,O
NSCLC,Disease
.,O
RESULTS,O
:,O
The,O
number,O
of,O
damaged,O
cardiomyocytes,O
was,O
9,O
.,O
6,O
-,O
fold,O
(,O
95,O
%,O
CI,O
4,O
.,O
4,O
-,O
21,O
.,O
0,O
),O
higher,O
in,O
mice,O
treated,O
with,O
DOX,Chemical
alone,O
than,O
that,O
in,O
animals,O
of,O
the,O
control,O
group,O
.,O
Carboplatin,Chemical
has,O
been,O
reported,O
to,O
cause,O
acute,Disease
renal,Disease
failure,Disease
when,O
administered,O
in,O
high,O
doses,O
to,O
adult,O
patients,O
.,O
These,O
results,O
indicated,O
that,O
nocistatin,Chemical
",",O
a,O
new,O
biologically,O
active,O
peptide,O
",",O
ameliorates,O
impairments,O
of,O
spontaneous,O
alternation,O
and,O
passive,O
avoidance,O
induced,O
by,O
scopolamine,Chemical
",",O
and,O
suggested,O
that,O
these,O
peptides,O
play,O
opposite,O
roles,O
in,O
learning,O
and,O
memory,O
.,O
Muscle,O
strength,O
",",O
contractures,O
",",O
functional,O
ability,O
and,O
pulmonary,O
function,O
were,O
tested,O
at,O
baseline,O
",",O
and,O
6,O
and,O
12,O
months,O
after,O
treatment,O
with,O
mazindol,Chemical
(,O
3,O
mg,O
/,O
d,O
),O
or,O
placebo,O
.,O
Of,O
the,O
15,O
spinal,O
cords,O
of,O
the,O
animals,O
that,O
received,O
2,Chemical
-,Chemical
chloroprocaine,Chemical
-,Chemical
CE,Chemical
",",O
13,O
showed,O
subpial,Disease
necrosis,Disease
;,O
the,O
nerve,O
roots,O
and,O
subarachnoid,O
vessels,O
were,O
normal,O
.,O
The,O
acute,O
cytolytic,O
hepatitis,Disease
occurred,O
rapidly,O
after,O
meloxicam,Chemical
administration,O
and,O
was,O
associated,O
with,O
the,O
development,O
of,O
antinuclear,O
antibodies,O
suggesting,O
a,O
hypersensitivity,Disease
mechanism,O
.,O
CONCLUSIONS,O
:,O
The,O
methodology,O
used,O
allowed,O
the,O
detection,O
of,O
lymphocyte,O
sensitization,O
to,O
sera,O
containing,O
ex,O
vivo,O
-,O
prepared,O
dilevalol,Chemical
antigens,O
",",O
suggesting,O
the,O
involvement,O
of,O
an,O
immunologic,O
mechanism,O
in,O
dilevalol,Chemical
-,O
induced,O
liver,Disease
injury,Disease
.,O
Levodopa,Chemical
and,O
the,O
DA,Chemical
D2,O
-,O
like,O
receptor,O
agonist,O
",",O
LY,Chemical
-,Chemical
171555,Chemical
(,O
[,Chemical
4aR,Chemical
-,Chemical
trans,Chemical
],Chemical
-,Chemical
4,Chemical
",",Chemical
4a,Chemical
",",Chemical
5,Chemical
",",Chemical
6,Chemical
",",Chemical
7,Chemical
",",Chemical
8,Chemical
",",Chemical
8a,Chemical
",",Chemical
9,Chemical
-,Chemical
o,Chemical
-,Chemical
dihydro,Chemical
-,Chemical
5n,Chemical
-,Chemical
propyl,Chemical
-,Chemical
2H,Chemical
-,Chemical
pyrazo,Chemical
lo,Chemical
-,Chemical
3,Chemical
-,Chemical
4,Chemical
-,Chemical
quinoline,Chemical
hydrochloride,Chemical
),O
were,O
also,O
used,O
for,O
comparison,O
.,O
This,O
study,O
describes,O
neuropsychiatric,O
side,O
effects,O
in,O
patients,O
after,O
treatment,O
with,O
mefloquine,Chemical
.,O
Control,O
rats,O
were,O
found,O
to,O
have,O
a,O
lower,O
capacity,O
to,O
transport,O
deoxycholic,Chemical
acid,Chemical
than,O
taurodeoxycholic,Chemical
acid,Chemical
",",O
and,O
both,O
were,O
decreased,O
by,O
ethinyl,Chemical
estradiol,Chemical
treatment,O
.,O
Women,O
who,O
had,O
received,O
tamoxifen,Chemical
were,O
significantly,O
more,O
likely,O
to,O
have,O
endometrial,Disease
cancer,Disease
diagnosed,O
than,O
those,O
who,O
had,O
not,O
(,O
crude,O
relative,O
risk,O
=,O
4,O
.,O
9,O
",",O
p,O
=,O
0,O
.,O
0001,O
),O
.,O
Persistent,O
nephrogenic,Disease
diabetes,Disease
insipidus,Disease
following,O
lithium,Chemical
therapy,O
.,O
Pyrazinamide,Chemical
can,O
have,O
adverse,O
effects,O
such,O
as,O
hepatic,Disease
toxicity,Disease
",",O
hyperuricemia,Disease
or,O
digestive,O
disorders,O
.,O
Repeated,O
trimipramine,Chemical
induces,O
dopamine,Chemical
D2,O
/,O
D3,O
and,O
alpha1,O
-,O
adrenergic,O
up,O
-,O
regulation,O
.,O
Challenge,O
tests,O
with,O
AX,Chemical
were,O
performed,O
in,O
23,O
subjects,O
(,O
43,O
%,O
),O
to,O
establish,O
the,O
diagnosis,O
of,O
immediate,O
allergic,Disease
reaction,Disease
to,O
AX,Chemical
",",O
and,O
in,O
15,O
cases,O
(,O
28,O
%,O
),O
both,O
skin,O
test,O
and,O
RAST,O
for,O
AX,Chemical
were,O
negative,O
.,O
Physicians,O
and,O
patients,O
should,O
be,O
alert,O
to,O
the,O
potential,O
cardiac,O
risk,O
associated,O
with,O
the,O
use,O
of,O
PPA,Chemical
",",O
even,O
at,O
doses,O
generally,O
considered,O
to,O
be,O
safe,O
.,O
The,O
BALB,O
/,O
C,O
mouse,O
was,O
the,O
most,O
sensitive,O
strain,O
and,O
could,O
serve,O
as,O
the,O
strain,O
of,O
choice,O
for,O
evaluating,O
the,O
side,O
effects,O
of,O
amantadine,Chemical
.,O
Cutaneous,Disease
leucocytoclastic,Disease
vasculitis,Disease
associated,O
with,O
oxacillin,Chemical
.,O
He,O
received,O
a,O
10,O
-,O
day,O
course,O
of,O
bupropion,Chemical
as,O
an,O
aid,O
for,O
smoking,O
cessation,O
10,O
weeks,O
prior,O
to,O
presentation,O
.,O
Phase,O
II,O
trial,O
of,O
vinorelbine,Chemical
in,O
metastatic,O
squamous,Disease
cell,Disease
esophageal,Disease
carcinoma,Disease
.,O
Elevations,O
in,O
the,O
serum,O
GOT,O
and,O
GPT,O
were,O
maximum,O
in,O
the,O
sedentary,O
-,O
isoproterenols,Chemical
and,O
minimum,O
in,O
the,O
exercise,O
-,O
controls,O
.,O
Patients,O
who,O
are,O
switched,O
from,O
cyclosporine,Chemical
to,O
tacrolimus,Chemical
or,O
vice,O
versa,O
should,O
be,O
closely,O
monitored,O
for,O
the,O
signs,O
and,O
symptoms,O
of,O
recurrent,O
TMA,Disease
.,O
Blood,O
samples,O
for,O
the,O
analysis,O
of,O
plasma,O
potassium,Chemical
",",O
terbutaline,Chemical
",",O
metoprolol,Chemical
(,O
racemic,O
",",O
R,O
-,O
and,O
S,O
-,O
isomer,O
),O
",",O
and,O
alpha,Chemical
-,Chemical
hydroxymetoprolol,Chemical
concentrations,O
were,O
taken,O
at,O
regular,O
time,O
intervals,O
",",O
during,O
8,O
hr,O
after,O
metoprolol,Chemical
.,O
Clinicians,O
should,O
be,O
aware,O
of,O
potential,O
hepatotoxicity,Disease
with,O
simvastatin,Chemical
-,Chemical
ezetimibe,Chemical
especially,O
in,O
elderly,O
patients,O
and,O
should,O
carefully,O
monitor,O
serum,O
aminotransferase,O
levels,O
when,O
starting,O
therapy,O
and,O
titrating,O
the,O
dosage,O
.,O
Linezolid,Chemical
-,O
induced,O
optic,Disease
neuropathy,Disease
.,O
Amiloride,Chemical
reduced,O
the,O
drinking,O
and,O
urine,O
volume,O
of,O
rats,O
in,O
an,O
acute,O
(,O
6,O
or,O
12,O
h,O
),O
and,O
a,O
subacute,O
(,O
3,O
days,O
),O
experiment,O
.,O
Fewer,O
subjects,O
reported,O
adverse,O
events,O
following,O
treatment,O
with,O
desipramine,Chemical
alone,O
than,O
when,O
receiving,O
desipramine,Chemical
with,O
cinacalcet,Chemical
(,O
33,O
versus,O
86,O
%,O
),O
",",O
the,O
most,O
frequent,O
of,O
which,O
(,O
nausea,Disease
and,O
headache,Disease
),O
have,O
been,O
reported,O
for,O
patients,O
treated,O
with,O
either,O
desipramine,Chemical
or,O
cinacalcet,Chemical
.,O
It,O
has,O
been,O
proposed,O
that,O
modest,O
changes,O
in,O
plasma,O
potassium,Chemical
can,O
alter,O
the,O
tendency,O
towards,O
cardiac,Disease
arrhythmias,Disease
.,O
CONCLUSIONS,O
:,O
The,O
data,O
show,O
that,O
valsartan,Chemical
is,O
at,O
least,O
as,O
effective,O
as,O
amlodipine,Chemical
in,O
the,O
treatment,O
of,O
mild,O
to,O
moderate,O
hypertension,Disease
.,O
BACKGROUND,O
:,O
We,O
clinically,O
and,O
pathologically,O
analyzed,O
renal,O
allografts,O
from,O
1,O
9,O
renal,O
transplant,O
patients,O
treated,O
with,O
tacrolimus,Chemical
(,O
FK506,Chemical
),O
for,O
more,O
than,O
1,O
year,O
.,O
Milk,Disease
-,Disease
alkali,Disease
syndrome,Disease
was,O
first,O
described,O
70,O
years,O
ago,O
in,O
the,O
context,O
of,O
the,O
treatment,O
of,O
peptic,Disease
ulcer,Disease
disease,Disease
with,O
large,O
amounts,O
of,O
calcium,Chemical
and,O
alkali,Chemical
.,O
Ketoconazole,Chemical
-,O
induced,O
neurologic,Disease
sequelae,Disease
.,O
RAST,O
for,O
BPO,Chemical
-,Chemical
PLL,Chemical
and,O
AX,Chemical
-,O
PLL,O
was,O
done,O
.,O
After,O
a,O
minimum,O
of,O
1,O
week,O
of,O
treatment,O
",",O
serum,O
levetiracetam,Chemical
concentrations,O
were,O
measured,O
before,O
and,O
2,O
",",O
4,O
",",O
and,O
6,O
hours,O
after,O
drug,O
administration,O
",",O
and,O
maximum,O
and,O
minimum,O
serum,O
concentrations,O
and,O
elimination,O
half,O
-,O
life,O
were,O
calculated,O
.,O
We,O
report,O
a,O
case,O
of,O
severe,O
citrate,Chemical
toxicity,Disease
during,O
volunteer,O
donor,O
apheresis,O
platelet,O
collection,O
.,O
The,O
expression,O
analysis,O
of,O
Ca,Chemical
(,O
2,O
+,O
),O
handling,O
proteins,O
demonstrated,O
that,O
aconitine,Chemical
promoted,O
Ca,Chemical
(,O
2,O
+,O
),O
overload,O
through,O
the,O
expression,O
regulation,O
of,O
Ca,Chemical
(,O
2,O
+,O
),O
handling,O
proteins,O
.,O
Intravenous,O
pretreatment,O
of,O
the,O
rats,O
with,O
diazepam,Chemical
",",O
although,O
causing,O
no,O
change,O
in,O
the,O
adrenaline,Chemical
-,O
induced,O
pressor,O
effect,O
",",O
did,O
enhance,O
the,O
adrenaline,Chemical
-,O
induced,O
reflex,O
bradycardia,Disease
.,O
8,O
of,O
the,O
10,O
monkeys,O
developed,O
congestive,Disease
heart,Disease
failure,Disease
at,O
an,O
average,O
cumulative,O
adriamycin,Chemical
dose,O
(,O
310,O
mg,O
/,O
m2,O
),O
well,O
below,O
that,O
considered,O
the,O
safe,O
upper,O
limit,O
(,O
550,O
mg,O
/,O
m2,O
),O
in,O
man,O
.,O
Adverse,O
events,O
considered,O
to,O
be,O
related,O
to,O
levofloxacin,Chemical
administration,O
were,O
reported,O
by,O
29,O
patients,O
(,O
9,O
%,O
),O
.,O
Hypotension,Disease
was,O
induced,O
for,O
236,O
.,O
9,O
+,O
/,O
-,O
15,O
.,O
1,O
min,O
by,O
increasing,O
the,O
isoflurane,Chemical
inspired,O
concentration,O
to,O
maintain,O
a,O
mean,O
arterial,O
pressure,O
of,O
59,O
.,O
8,O
+,O
/,O
-,O
0,O
.,O
4,O
mmHg,O
.,O
The,O
safety,O
and,O
efficacy,O
of,O
combination,O
N,Chemical
-,Chemical
butyl,Chemical
-,Chemical
deoxynojirimycin,Chemical
(,O
SC,Chemical
-,Chemical
48334,Chemical
),O
and,O
zidovudine,Chemical
in,O
patients,O
with,O
HIV,Disease
-,Disease
1,Disease
infection,Disease
and,O
200,O
-,O
500,O
CD4,O
cells,O
/,O
mm3,O
.,O
We,O
found,O
significant,O
positive,O
correlations,O
between,O
the,O
preoperative,O
levodopa,Chemical
responsiveness,O
of,O
motor,O
signs,O
and,O
the,O
levodopa,Chemical
responsiveness,O
of,O
scores,O
in,O
timed,O
tests,O
(,O
Core,O
Assessment,O
Program,O
for,O
Intracerebral,O
Transplantations,O
),O
in,O
the,O
contralateral,O
limbs,O
and,O
the,O
improvement,O
in,O
these,O
scores,O
after,O
surgery,O
",",O
whereas,O
there,O
was,O
no,O
correlation,O
with,O
the,O
improvement,O
in,O
LID,Disease
.,O
In,O
conclusion,O
",",O
ENaC,O
mRNA,O
expression,O
",",O
especially,O
alphaENaC,O
",",O
is,O
increased,O
in,O
the,O
very,O
early,O
phase,O
of,O
the,O
experimental,O
model,O
of,O
PAN,Chemical
-,O
induced,O
nephrotic,Disease
syndrome,Disease
in,O
rats,O
",",O
but,O
appears,O
to,O
escape,O
from,O
the,O
regulation,O
by,O
aldosterone,Chemical
after,O
day,O
3,O
.,O
Methylergonovine,Chemical
was,O
administered,O
continuously,O
at,O
a,O
rate,O
of,O
10,O
micrograms,O
/,O
min,O
up,O
to,O
50,O
micrograms,O
.,O
These,O
findings,O
suggest,O
that,O
thrombin,O
plays,O
an,O
important,O
role,O
in,O
the,O
pathogenesis,O
of,O
puromycin,Chemical
aminonucleoside,Chemical
-,O
induced,O
nephrotic,Disease
syndrome,Disease
.,O
Prolonged,O
left,Disease
ventricular,Disease
dysfunction,Disease
occurs,O
in,O
patients,O
with,O
coronary,Disease
artery,Disease
disease,Disease
after,O
both,O
dobutamine,Chemical
and,O
exercise,O
induced,O
myocardial,Disease
ischaemia,Disease
.,O
Initial,O
evaluation,O
confirmed,O
FHF,Disease
from,O
acetaminophen,Chemical
and,O
cerebral,Disease
edema,Disease
.,O
Suprofen,Chemical
",",O
a,O
new,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
",",O
was,O
marketed,O
in,O
early,O
1986,O
as,O
an,O
analgesic,O
agent,O
.,O
A,O
case,O
of,O
oral,O
penicillin,Chemical
anaphylaxis,Disease
is,O
described,O
",",O
and,O
the,O
terminology,O
",",O
occurrence,O
",",O
clinical,O
manifestations,O
",",O
pathogenesis,O
",",O
prevention,O
",",O
and,O
treatment,O
of,O
anaphylaxis,Disease
are,O
reviewed,O
.,O
An,O
antisialogue,O
was,O
usually,O
unnecessary,O
in,O
operations,O
lasting,O
up,O
to,O
2,O
h,O
",",O
glycopyrrolate,Chemical
being,O
the,O
best,O
choice,O
for,O
its,O
lowest,O
psychotropic,O
and,O
chronotropic,O
effects,O
",",O
especially,O
in,O
a,O
hot,O
climate,O
.,O
Differences,O
in,O
the,O
parameters,O
of,O
training,O
under,O
the,O
influence,O
of,O
pentobarbital,Chemical
between,O
Groups,O
1,O
and,O
2,O
were,O
revealed,O
.,O
Methimazole,Chemical
is,O
a,O
widely,O
used,O
and,O
generally,O
well,O
-,O
tolerated,O
antithyroid,O
agent,O
.,O
RESULTS,O
:,O
In,O
the,O
12,O
patients,O
switched,O
because,O
of,O
chronic,O
nephrotoxicity,Disease
there,O
was,O
a,O
significant,O
decrease,O
in,O
serum,O
creatinine,Chemical
[,O
233,O
+,O
/,O
-,O
34,O
to,O
210,O
+,O
/,O
-,O
56,O
micromol,O
/,O
liter,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
at,O
6,O
months,O
],O
.,O
Questions,O
remain,O
about,O
the,O
optimal,O
dose,O
of,O
ribavirin,Chemical
and,O
the,O
incidence,O
of,O
RIHA,Disease
in,O
a,O
real,O
-,O
world,O
population,O
.,O
MMP,O
-,O
2,O
",",O
MMP,O
-,O
9,O
",",O
ADAM,O
-,O
10,O
and,O
ADAM,O
-,O
17,O
mRNA,O
levels,O
were,O
increased,O
in,O
CaCl,Chemical
(,Chemical
2,Chemical
),Chemical
-,O
treated,O
segments,O
(,O
all,O
p,O
<,O
0,O
.,O
01,O
),O
",",O
with,O
trends,O
of,O
elevation,O
in,O
CaCl,Chemical
(,Chemical
2,Chemical
),Chemical
-,O
untreated,O
segments,O
",",O
as,O
compared,O
with,O
NaCl,Chemical
-,O
treated,O
segments,O
.,O
Trimethoprim,Chemical
-,O
induced,O
immune,O
hemolytic,Disease
anemia,Disease
in,O
a,O
pediatric,O
oncology,O
patient,O
presenting,O
as,O
an,O
acute,O
hemolytic,O
transfusion,O
reaction,O
.,O
METHODS,O
:,O
For,O
this,O
paper,O
",",O
the,O
current,O
medical,O
literature,O
on,O
LMWH,Chemical
in,O
patients,O
with,O
mechanical,O
heart,O
valves,O
was,O
extensively,O
reviewed,O
.,O
All,O
4,O
patients,O
presented,O
with,O
skin,Disease
eruptions,Disease
that,O
developed,O
after,O
receiving,O
warfarin,Chemical
for,O
several,O
years,O
.,O
Administration,O
of,O
GM,Chemical
at,O
40,O
mg,O
/,O
kg,O
sc,O
for,O
13,O
days,O
to,O
rats,O
induced,O
a,O
significant,O
reduction,O
in,O
renal,O
blood,O
flow,O
(,O
RBF,O
),O
and,O
inulin,O
clearance,O
(,O
CIn,O
),O
as,O
well,O
as,O
marked,O
tubular,Disease
damage,Disease
.,O
The,O
time,O
course,O
and,O
concentration,O
-,O
effect,O
relationship,O
of,O
terbutaline,Chemical
-,O
induced,O
hypokalemia,Disease
was,O
studied,O
",",O
using,O
computer,O
-,O
aided,O
pharmacokinetic,O
-,O
dynamic,O
modeling,O
.,O
Effects,O
of,O
acute,O
steroid,Chemical
administration,O
on,O
ventilatory,O
and,O
peripheral,O
muscles,O
in,O
rats,O
.,O
Therefore,O
",",O
three,O
novel,O
sigma,O
receptor,O
ligands,O
with,O
antagonist,O
activity,O
were,O
evaluated,O
in,O
Swiss,O
Webster,O
mice,O
:,O
BD1018,Chemical
(,O
3S,Chemical
-,Chemical
1,Chemical
-,Chemical
[,Chemical
2,Chemical
-,Chemical
(,Chemical
3,Chemical
",",Chemical
4,Chemical
-,Chemical
dichlorophenyl,Chemical
),Chemical
ethyl,Chemical
],Chemical
-,Chemical
1,Chemical
",",Chemical
4,Chemical
-,Chemical
diazabicyclo,Chemical
[,Chemical
4,Chemical
.,Chemical
3,Chemical
.,Chemical
0,Chemical
],Chemical
nonane,Chemical
),O
",",O
BD1063,Chemical
(,O
1,Chemical
-,Chemical
[,Chemical
2,Chemical
-,Chemical
(,Chemical
3,Chemical
",",Chemical
4,Chemical
-,Chemical
dichlorophenyl,Chemical
),Chemical
ethyl,Chemical
],Chemical
-,Chemical
4,Chemical
-,Chemical
methylpiperazine,Chemical
),O
",",O
and,O
LR132,Chemical
(,O
1R,O
",",O
2S,O
-,O
(,O
+,O
),O
-,O
cis,O
-,O
N,O
-,O
[,O
2,O
-,O
(,O
3,O
",",O
4,O
-,O
dichlorophenyl,O
),O
ethyl,O
],O
-,O
2,O
-,O
(,O
1,O
-,O
pyrrolidinyl,O
),O
cyclohexylamine,O
),O
.,O
Rabbit,Disease
syndrome,Disease
",",O
antidepressant,Chemical
use,O
",",O
and,O
cerebral,O
perfusion,O
SPECT,O
scan,O
findings,O
.,O
Despite,O
the,O
absence,O
of,O
rigidity,Disease
",",O
animals,O
that,O
received,O
ketanserin,Chemical
(,O
greater,O
than,O
0,O
.,O
31,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
followed,O
by,O
alfentanil,Chemical
were,O
motionless,O
",",O
flaccid,O
",",O
and,O
less,O
responsive,O
to,O
external,O
stimuli,O
than,O
were,O
animals,O
receiving,O
alfentanil,Chemical
alone,O
.,O
Is,O
phenytoin,Chemical
administration,O
safe,O
in,O
a,O
hypothermic,Disease
child,O
?,O
Ketamine,Chemical
in,O
war,O
/,O
tropical,O
surgery,O
(,O
a,O
final,O
tribute,O
to,O
the,O
racemic,O
mixture,O
),O
.,O
Pyrrolidine,Chemical
dithiocarbamate,Chemical
protects,O
the,O
piriform,O
cortex,O
in,O
the,O
pilocarpine,Chemical
status,Disease
epilepticus,Disease
model,O
.,O
METHODS,O
:,O
Male,O
albino,O
Swiss,O
mice,O
were,O
treated,O
sub,O
-,O
chronically,O
(,O
twice,O
a,O
day,O
for,O
4,O
days,O
),O
with,O
L,Chemical
-,Chemical
NOARG,Chemical
(,O
40,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
or,O
haloperidol,Chemical
(,O
1,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
.,O
The,O
dose,O
of,O
UFH,Chemical
was,O
changed,O
according,O
to,O
the,O
activated,O
clotting,O
time,O
level,O
.,O
Plasma,O
cortisol,Chemical
concentrations,O
were,O
significantly,O
raised,O
during,O
the,O
active,O
phase,O
(,O
323,O
+,O
/,O
-,O
43,O
to,O
1082,O
+,O
/,O
-,O
245,O
mmol,O
/,O
L,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
.,O
The,O
protective,O
effect,O
of,O
oral,O
administration,O
of,O
the,O
thiol,Chemical
compound,O
sodium,Chemical
2,Chemical
-,Chemical
mercaptoethane,Chemical
sulphonate,Chemical
(,O
MESNA,Chemical
),O
against,O
urothelial,Disease
toxicity,Disease
induced,O
by,O
ifosfamide,Chemical
(,O
IF,Chemical
),O
was,O
tested,O
in,O
a,O
group,O
of,O
45,O
patients,O
with,O
inoperable,O
lung,Disease
cancer,Disease
under,O
treatment,O
with,O
IF,Chemical
(,O
2250,O
mg,O
/,O
m2,O
on,O
days,O
2,O
-,O
5,O
),O
as,O
part,O
of,O
a,O
polychemotherapy,O
regimen,O
repeated,O
in,O
a,O
4,O
-,O
week,O
cycle,O
.,O
In,O
rats,O
given,O
1,O
%,O
BHA,Chemical
",",O
RA,Chemical
co,O
-,O
administered,O
at,O
a,O
dose,O
of,O
0,O
.,O
05,O
",",O
0,O
.,O
1,O
",",O
0,O
.,O
2,O
or,O
0,O
.,O
25,O
%,O
showed,O
a,O
dose,O
-,O
dependent,O
enhancing,O
effect,O
on,O
the,O
development,O
of,O
the,O
BHA,Chemical
-,O
induced,O
epithelial,Disease
hyperplasia,Disease
.,O
We,O
investigated,O
the,O
diagnostic,O
value,O
of,O
cTnI,O
and,O
cTnT,O
for,O
the,O
diagnosis,O
of,O
myocardial,Disease
damage,Disease
in,O
a,O
rat,O
model,O
of,O
doxorubicin,Chemical
(,O
DOX,Chemical
),O
-,O
induced,O
cardiomyopathy,Disease
",",O
and,O
we,O
examined,O
the,O
relationship,O
between,O
serial,O
cTnI,O
and,O
cTnT,O
with,O
the,O
development,O
of,O
cardiac,Disease
disorders,Disease
monitored,O
by,O
echocardiography,O
and,O
histological,O
examinations,O
in,O
this,O
model,O
.,O
CONCLUSIONS,O
:,O
RAPA,Chemical
conversion,O
provides,O
adequate,O
immunosuppression,O
to,O
enable,O
CsA,Chemical
withdrawal,O
.,O
BACKGROUND,O
:,O
The,O
activity,O
of,O
the,O
combination,O
of,O
carboplatin,Chemical
and,O
liposomal,O
doxorubicin,Chemical
was,O
tested,O
in,O
a,O
Phase,O
II,O
study,O
of,O
patients,O
with,O
recurrent,O
cervical,Disease
carcinoma,Disease
.,O
Conditions,O
that,O
will,O
be,O
required,O
for,O
studies,O
of,O
1,Chemical
",",Chemical
3,Chemical
-,Chemical
butadiene,Chemical
are,O
discussed,O
.,O
After,O
6,O
months,O
of,O
hyperprolactinemia,Disease
",",O
dopamine,Chemical
(,O
DA,Chemical
),O
concentrations,O
in,O
the,O
median,O
eminence,O
(,O
ME,O
),O
increased,O
by,O
84,O
%,O
over,O
the,O
control,O
group,O
.,O
Moreover,O
",",O
urinary,O
potassium,Chemical
losses,O
were,O
significantly,O
less,O
in,O
patients,O
receiving,O
AmB,Chemical
and,O
spironolactone,Chemical
than,O
those,O
receiving,O
AmB,Chemical
alone,O
(,O
P,O
=,O
0,O
.,O
040,O
),O
.,O
PATIENTS,O
:,O
One,O
hundred,O
and,O
one,O
patients,O
(,O
28,O
men,O
and,O
73,O
women,O
),O
with,O
bipolar,Disease
disorder,Disease
receiving,O
lithium,Chemical
maintenance,O
therapy,O
ranging,O
from,O
1,O
year,O
',O
s,O
to,O
32,O
years,O
',O
duration,O
.,O
Furthermore,O
",",O
microinjection,O
of,O
CCK,Chemical
-,Chemical
8,Chemical
(,O
0,O
.,O
1,O
and,O
1ug,O
",",O
i,O
.,O
c,O
.,O
v,O
.,O
),O
also,O
significantly,O
augmented,O
hippocampal,O
LTP,O
in,O
saline,O
-,O
treated,O
(,O
1ml,O
/,O
kg,O
",",O
s,O
.,O
c,O
.,O
),O
rats,O
.,O
The,O
norepinephrine,Chemical
content,O
was,O
significantly,O
increased,O
while,O
epinephrine,Chemical
remained,O
unchanged,O
.,O
When,O
discharged,O
less,O
than,O
24,O
hours,O
later,O
",",O
he,O
was,O
receiving,O
metoprolol,Chemical
and,O
aspirin,Chemical
",",O
with,O
follow,O
-,O
up,O
plans,O
for,O
echocardiography,O
and,O
nuclear,O
imaging,O
to,O
assess,O
perfusion,O
.,O
The,O
heart,O
tissue,O
antioxidant,O
enzymes,O
such,O
as,O
superoxide,Chemical
dismutase,O
",",O
catalase,O
",",O
glutathione,Chemical
peroxidase,O
",",O
glutathione,Chemical
transferase,O
and,O
glutathione,Chemical
reductase,O
activities,O
",",O
non,O
-,O
enzymic,O
antioxidants,O
such,O
as,O
cerruloplasmin,O
",",O
Vitamin,Chemical
C,Chemical
",",O
Vitamin,Chemical
E,Chemical
and,O
glutathione,Chemical
levels,O
were,O
altered,O
in,O
MI,Disease
rats,O
.,O
Indomethacin,Chemical
-,O
induced,O
hyperkalemia,Disease
in,O
three,O
patients,O
with,O
gouty,Disease
arthritis,Disease
.,O
Reduction,O
of,O
heparan,Chemical
sulphate,Chemical
-,O
associated,O
anionic,O
sites,O
in,O
the,O
glomerular,O
basement,O
membrane,O
of,O
rats,O
with,O
streptozotocin,Chemical
-,O
induced,O
diabetic,Disease
nephropathy,Disease
.,O
Changing,O
epidemiology,O
of,O
infections,Disease
such,O
as,O
infective,Disease
endocarditis,Disease
(,O
IE,Disease
),O
has,O
led,O
to,O
an,O
increase,O
in,O
the,O
use,O
of,O
rifampicin,Chemical
for,O
Staphylococcal,Disease
infections,Disease
.,O
During,O
hypotension,Disease
",",O
the,O
serum,O
creatinine,Chemical
concentration,O
rose,O
significantly,O
in,O
all,O
groups,O
from,O
the,O
values,O
before,O
hypotension,Disease
and,O
returned,O
postoperatively,O
to,O
the,O
initial,O
level,O
in,O
the,O
other,O
groups,O
",",O
except,O
the,O
isoflurane,Chemical
group,O
.,O
METHODS,O
:,O
38,O
female,O
Wistar,O
rats,O
were,O
injected,O
with,O
gentamicin,Chemical
",",O
40,O
mg,O
/,O
kg,O
",",O
twice,O
a,O
day,O
for,O
9,O
days,O
",",O
38,O
with,O
gentamicin,Chemical
+,O
PDTC,Chemical
",",O
and,O
28,O
with,O
0,O
.,O
15,O
M,O
NaCl,Chemical
solution,O
.,O
BACKGROUND,O
AND,O
OBJECTIVES,O
:,O
This,O
report,O
aimed,O
to,O
present,O
a,O
case,O
of,O
lateral,O
antebrachial,O
cutaneous,O
neuropathy,Disease
(,O
LACNP,O
),O
that,O
occurred,O
after,O
a,O
steroid,Chemical
injection,O
in,O
the,O
lateral,O
epicondyle,O
to,O
treat,O
lateral,Disease
epicondylitis,Disease
in,O
a,O
40,O
-,O
year,O
-,O
old,O
woman,O
.,O
The,O
present,O
study,O
was,O
undertaken,O
to,O
investigate,O
the,O
effects,O
of,O
TET,Chemical
and,O
FAN,Chemical
on,O
the,O
experimental,O
thrombosis,Disease
induced,O
by,O
collagen,O
plus,O
epinephrine,Chemical
(,O
EP,Chemical
),O
in,O
mice,O
",",O
and,O
platelet,Disease
aggregation,Disease
and,O
blood,Disease
coagulation,Disease
in,O
vitro,O
.,O
Tic,Disease
disorders,Disease
can,O
be,O
effectively,O
treated,O
by,O
atypical,O
antipsychotics,O
such,O
as,O
risperidone,Chemical
",",O
olanzapine,Chemical
and,O
ziprasidone,Chemical
.,O
Blood,O
pressure,O
effects,O
of,O
i,O
.,O
v,O
.,O
levodopa,Chemical
were,O
examined,O
in,O
parkinsonian,Disease
patients,O
with,O
stable,O
and,O
fluctuating,O
responses,O
to,O
levodopa,Chemical
.,O
A,O
case,O
of,O
branch,O
retinal,Disease
vein,Disease
occlusion,Disease
associated,O
with,O
fluoxetine,Chemical
-,O
induced,O
secondary,O
hypertension,Disease
is,O
described,O
.,O
Cerebral,O
blood,O
flow,O
and,O
metabolism,O
during,O
isoflurane,Chemical
-,O
induced,O
hypotension,Disease
in,O
patients,O
subjected,O
to,O
surgery,O
for,O
cerebral,Disease
aneurysms,Disease
.,O
There,O
were,O
no,O
significant,O
differences,O
in,O
renal,O
sodium,Chemical
excretion,O
",",O
oxygen,Chemical
consumption,O
",",O
or,O
urinary,O
flow,O
rates,O
in,O
kidneys,O
perfused,O
with,O
suprofen,Chemical
compared,O
with,O
the,O
drug,O
-,O
free,O
control,O
groups,O
.,O
Central,O
cardiovascular,O
effects,O
of,O
AVP,Chemical
and,O
ANP,O
in,O
normotensive,O
and,O
spontaneously,O
hypertensive,Disease
rats,O
.,O
The,O
stimulation,O
of,O
locomotor,O
activity,O
by,O
intracerebroventricularly,O
administered,O
methoxamine,Chemical
was,O
not,O
affected,O
by,O
repeated,O
treatment,O
with,O
fluvoxamine,Chemical
.,O
Median,O
number,O
of,O
courses,O
of,O
MFL,Chemical
regimen,Chemical
given,O
was,O
six,O
and,O
the,O
median,O
cumulative,O
dose,O
of,O
mitoxantrone,Chemical
was,O
68,O
.,O
35,O
mg,O
/,O
m2,O
.,O
Epicardial,O
coronary,O
collateral,O
vessels,O
were,O
demonstrated,O
in,O
all,O
four,O
patients,O
;,O
a,O
coronary,O
"""",O
steal,O
"""",O
phenomenon,O
may,O
be,O
the,O
mechanism,O
of,O
the,O
dipyridamole,Chemical
-,O
induced,O
ischemia,Disease
observed,O
.,O
CONCLUSIONS,O
:,O
These,O
data,O
show,O
that,O
inhibition,O
of,O
NF,O
-,O
kappaB,O
activation,O
attenuates,O
tubulointerstitial,Disease
nephritis,Disease
induced,O
by,O
gentamicin,Chemical
.,O
Ecstasy,Chemical
users,O
demonstrated,O
impaired,Disease
overnight,Disease
memory,Disease
consolidation,O
",",O
a,O
finding,O
that,O
was,O
more,O
pronounced,O
following,O
associative,O
interference,O
.,O
Granisetron,Chemical
was,O
well,O
tolerated,O
at,O
all,O
doses,O
.,O
BACKGROUND,O
:,O
Hemolytic,Disease
anemia,Disease
is,O
one,O
of,O
the,O
major,O
adverse,O
events,O
of,O
the,O
combination,O
therapy,O
of,O
interferon,Chemical
and,O
ribavirin,Chemical
.,O
The,O
possibility,O
of,O
reproducing,O
the,O
same,O
renal,Disease
abnormality,Disease
with,O
captopril,Chemical
was,O
examined,O
in,O
SHR,O
.,O
Development,O
of,O
proteinuria,Disease
after,O
switch,O
to,O
sirolimus,Chemical
-,O
based,O
immunosuppression,O
in,O
long,O
-,O
term,O
cardiac,O
transplant,O
patients,O
.,O
Administered,O
at,O
the,O
dose,O
of,O
20,O
mg,O
.,O
intravesically,O
",",O
CP,Chemical
did,O
not,O
produce,O
any,O
behavioral,O
effects,O
",",O
whereas,O
acrolein,Chemical
at,O
0,O
.,O
5,O
mg,O
.,O
intravesically,O
induced,O
behavioral,O
modifications,O
identical,O
to,O
those,O
under,O
CP,Chemical
200,O
mg,O
.,O
/,O
kg,O
.,O
The,O
aim,O
was,O
to,O
evaluate,O
the,O
effects,O
of,O
high,O
frequency,O
hippocampal,O
stimulation,O
on,O
cortical,O
epileptic,Disease
activity,O
in,O
penicillin,Chemical
-,O
induced,O
epilepsy,Disease
model,O
.,O
The,O
present,O
study,O
was,O
done,O
to,O
investigate,O
the,O
protective,O
effect,O
of,O
TCR,Chemical
on,O
experimentally,O
induced,O
myocardial,Disease
infarction,Disease
in,O
rats,O
.,O
Frequencies,O
of,O
ventricular,Disease
fibrillation,Disease
were,O
significantly,O
lower,O
(,O
p,O
less,O
than,O
0,O
.,O
05,O
),O
after,O
iopentol,Chemical
(,O
0,O
%,O
),O
and,O
iohexol,Chemical
(,O
3,O
%,O
),O
than,O
after,O
metrizoate,Chemical
(,O
22,O
%,O
),O
.,O
RESULTS,O
:,O
In,O
diarrhoea,Disease
-,O
predominant,O
patients,O
significant,O
differences,O
in,O
contraction,O
characteristics,O
were,O
observed,O
between,O
the,O
cisapride,Chemical
and,O
placebo,O
groups,O
.,O
We,O
present,O
a,O
49,O
-,O
year,O
-,O
old,O
woman,O
who,O
developed,O
a,O
delusional,Disease
parasitosis,Disease
during,O
treatment,O
with,O
pegylated,Chemical
interferon,Chemical
alpha,Chemical
-,Chemical
2b,Chemical
weekly,O
and,O
ribavirin,Chemical
.,O
Naloxone,Chemical
inhibited,O
the,O
induced,O
cataleptic,Disease
effects,O
.,O
Rechallenge,O
of,O
patients,O
who,O
developed,O
oral,Disease
candidiasis,Disease
or,O
hoarseness,Disease
with,O
beclomethasone,Chemical
dipropionate,Chemical
.,O
Cells,O
were,O
pretreated,O
with,O
maltolyl,Chemical
p,Chemical
-,Chemical
coumarate,Chemical
",",O
before,O
exposed,O
to,O
amyloid,Chemical
beta,Chemical
peptide,Chemical
(,Chemical
1,Chemical
-,Chemical
42,Chemical
),Chemical
",",O
glutamate,Chemical
or,O
H2O2,Chemical
.,O
These,O
results,O
suggest,O
that,O
hydroxytyrosol,Chemical
improve,O
the,O
mitochondrial,O
electron,O
transport,O
chain,O
.,O
Control,O
rats,O
were,O
injected,O
with,O
saline,O
instead,O
of,O
pilocarpine,Chemical
.,O
Forty,O
-,O
eight,O
hr,O
of,O
REMD,Disease
increased,O
apomorphine,Chemical
-,O
induced,O
aggressiveness,Disease
",",O
and,O
reduced,O
(,O
immediately,O
after,O
completing,O
of,O
REMD,Disease
),O
or,O
increased,O
(,O
96,O
hr,O
after,O
completing,O
of,O
REMD,Disease
),O
quipazine,Chemical
-,O
induced,O
head,Disease
twitches,Disease
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
report,O
of,O
a,O
pseudo,O
-,O
allergy,Disease
caused,O
by,O
paramethasone,Chemical
.,O
A,O
patient,O
who,O
developed,O
paraplegia,Disease
following,O
the,O
intrathecal,O
instillation,O
of,O
methotrexate,Chemical
is,O
discribed,O
.,O
Follow,O
-,O
up,O
visits,O
were,O
scheduled,O
with,O
2,O
-,O
drug,O
therapy,O
every,O
6,O
to,O
8,O
weeks,O
",",O
an,O
average,O
of,O
10,O
.,O
3,O
visits,O
per,O
patient,O
",",O
with,O
741,O
batteries,O
of,O
6,O
liver,O
function,O
tests,O
and,O
714,O
creatine,Chemical
phosphokinase,O
levels,O
measured,O
.,O
The,O
implications,O
of,O
using,O
famotidine,Chemical
in,O
elderly,O
persons,O
are,O
discussed,O
.,O
We,O
report,O
the,O
successful,O
treatment,O
of,O
risperidone,Chemical
-,O
induced,O
hyperprolactinemia,Disease
with,O
cabergoline,Chemical
in,O
youth,O
.,O
The,O
development,O
of,O
cardiac,Disease
hypertrophy,Disease
was,O
studied,O
in,O
adult,O
female,O
Wistar,O
rats,O
following,O
daily,O
subcutaneous,O
injections,O
of,O
isoproterenol,Chemical
(,O
ISO,Chemical
),O
(,O
0,O
.,O
3,O
mg,O
/,O
kg,O
body,O
weight,O
),O
.,O
CONCLUSIONS,O
:,O
Our,O
results,O
suggest,O
that,O
the,O
antagonistic,O
effect,O
of,O
nicotine,Chemical
on,O
caffeine,Chemical
-,O
induced,O
anxiety,Disease
is,O
specific,O
to,O
caffeine,Chemical
",",O
instead,O
of,O
a,O
non,O
-,O
specific,O
anxiolytic,O
effect,O
.,O
RESULTS,O
:,O
Nicotine,Chemical
(,O
0,O
.,O
05,O
-,O
0,O
.,O
25,O
mg,O
/,O
kg,O
),O
itself,O
did,O
not,O
produce,O
any,O
significant,O
effect,O
in,O
the,O
EPM,O
test,O
",",O
whereas,O
caffeine,Chemical
(,O
70,O
mg,O
/,O
kg,O
),O
and,O
pentylenetetrazole,Chemical
(,O
30,O
mg,O
/,O
kg,O
),O
produced,O
an,O
anxiogenic,O
effect,O
",",O
apparent,O
with,O
decreases,O
in,O
open,O
-,O
arm,O
time,O
and,O
entry,O
.,O
Increase,O
in,O
intragastric,O
pressure,O
during,O
suxamethonium,Chemical
-,O
induced,O
muscle,Disease
fasciculations,Disease
in,O
children,O
:,O
inhibition,O
by,O
alfentanil,Chemical
.,O
Administration,O
of,O
phenytoin,Chemical
in,O
the,O
presence,O
of,O
hypothermia,Disease
may,O
lead,O
to,O
an,O
adverse,O
cardiac,O
event,O
in,O
children,O
.,O
Synthesis,O
and,O
preliminary,O
pharmacological,O
investigations,O
of,O
1,Chemical
-,Chemical
(,Chemical
1,Chemical
",",Chemical
2,Chemical
-,Chemical
dihydro,Chemical
-,Chemical
2,Chemical
-,Chemical
acenaphthylenyl,Chemical
),Chemical
piperazine,Chemical
derivatives,O
as,O
potential,O
atypical,O
antipsychotic,O
agents,O
in,O
mice,O
.,O
Safety,O
and,O
compliance,O
with,O
once,O
-,O
daily,O
niacin,Chemical
extended,Chemical
-,Chemical
release,Chemical
/,Chemical
lovastatin,Chemical
as,O
initial,O
therapy,O
in,O
the,O
Impact,O
of,O
Medical,O
Subspecialty,O
on,O
Patient,O
Compliance,O
to,O
Treatment,O
(,O
IMPACT,O
),O
study,O
.,O
The,O
deformations,Disease
caused,O
by,O
both,O
coniine,Chemical
and,O
nicotine,Chemical
sulfate,O
were,O
excessive,Disease
flexion,Disease
or,Disease
extension,Disease
of,Disease
one,Disease
or,Disease
more,Disease
toes,Disease
.,O
Variations,O
and,O
malformations,Disease
were,O
similar,O
when,O
ASA,Chemical
was,O
administered,O
as,O
a,O
single,O
dose,O
or,O
during,O
the,O
period,O
of,O
organogenesis,O
(,O
GDs,O
6,O
to,O
17,O
),O
.,O
He,O
was,O
found,O
to,O
have,O
atrial,Disease
flutter,Disease
at,O
a,O
ventricular,O
rate,O
of,O
70,O
/,O
min,O
which,O
slowed,O
down,O
to,O
30,O
-,O
40,O
/,O
min,O
when,O
nifedipine,Chemical
(,O
60,O
mg,O
),O
in,O
3,O
divided,O
doses,O
",",O
during,O
which,O
he,O
was,O
paced,O
at,O
a,O
rate,O
of,O
70,O
/,O
min,O
.,O
Bile,Disease
duct,Disease
hamartoma,Disease
occurring,O
in,O
association,O
with,O
long,O
-,O
term,O
treatment,O
with,O
danazol,Chemical
.,O
Celecoxib,Chemical
(,O
CE,Chemical
),O
is,O
a,O
novel,O
drug,O
",",O
with,O
high,O
selectivity,O
and,O
affinity,O
for,O
COX,O
-,O
2,O
enzyme,O
.,O
RESULTS,O
:,O
Switches,O
to,O
hypomania,Disease
or,O
mania,Disease
occurred,O
in,O
27,O
%,O
of,O
all,O
patients,O
(,O
N,O
=,O
12,O
),O
(,O
and,O
in,O
24,O
%,O
of,O
the,O
subgroup,O
of,O
patients,O
treated,O
with,O
SSRIs,Chemical
[,O
8,O
/,O
33,O
],O
),O
;,O
16,O
%,O
(,O
N,O
=,O
7,O
),O
experienced,O
manic,Disease
episodes,O
",",O
and,O
11,O
%,O
(,O
N,O
=,O
5,O
),O
experienced,O
hypomanic,Disease
episodes,O
.,O
The,O
following,O
case,O
is,O
a,O
report,O
of,O
cauda,Disease
equina,Disease
syndrome,Disease
possibly,O
caused,O
by,O
epidural,O
injection,O
of,O
triamcinolone,Chemical
and,O
bupivacaine,Chemical
.,O
The,O
studies,O
suggest,O
that,O
propranolol,Chemical
is,O
a,O
useful,O
drug,O
in,O
selected,O
patients,O
with,O
severe,O
idiopathic,Disease
orthostatic,Disease
hypotension,Disease
.,O
Similar,O
results,O
were,O
obtained,O
by,O
acetic,Chemical
acid,Chemical
writhing,O
tests,O
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
whether,O
tachyphylaxis,O
occurs,O
during,O
prolonged,O
treatment,O
with,O
high,O
dose,O
inhaled,O
salbutamol,Chemical
.,O
Fourteen,O
of,O
84,O
(,O
17,O
%,O
),O
patients,O
had,O
symptoms,O
and,O
signs,O
consistent,O
with,O
CYA,Chemical
cardiotoxicity,Disease
within,O
ten,O
days,O
of,O
receiving,O
1,O
to,O
4,O
doses,O
of,O
CYA,Chemical
.,O
Based,O
on,O
nonoverdose,O
pharmacokinetics,O
and,O
pharmacodynamics,O
of,O
venlafaxine,Chemical
and,O
the,O
potential,O
risks,O
of,O
available,O
interventions,O
",",O
no,O
emergent,O
therapy,O
was,O
instituted,O
.,O
Calcitonin,O
gene,O
-,O
related,O
peptide,O
levels,O
during,O
nitric,Chemical
oxide,Chemical
-,O
induced,O
headache,Disease
in,O
patients,O
with,O
chronic,O
tension,Disease
-,Disease
type,Disease
headache,Disease
.,O
The,O
prompt,O
discontinuation,O
of,O
D,Chemical
-,Chemical
penicillamine,Chemical
and,O
vigorous,O
treatment,O
measures,O
could,O
allow,O
for,O
a,O
good,O
prognosis,O
as,O
in,O
this,O
case,O
.,O
After,O
15,O
days,O
of,O
E2,Chemical
exposure,O
",",O
VEGF,O
/,O
VPF,O
protein,O
expression,O
",",O
in,O
the,O
non,O
-,O
endothelial,O
cell,O
population,O
",",O
sharply,O
declined,O
and,O
was,O
restricted,O
to,O
the,O
blood,O
vessels,O
.,O
Clarithromycin,Chemical
is,O
the,O
most,O
documented,O
cytochrome,O
P450,O
3A4,O
(,O
CYP3A4,O
),O
inhibitor,O
to,O
cause,O
an,O
adverse,O
interaction,O
with,O
simvastatin,Chemical
.,O
Other,O
known,O
reasons,O
for,O
seizures,Disease
were,O
ruled,O
out,O
and,O
the,O
convulsions,Disease
stopped,O
a,O
few,O
hours,O
after,O
cessation,O
of,O
morphine,Chemical
and,O
did,O
not,O
reoccur,O
in,O
the,O
subsequent,O
8,O
months,O
.,O
Intravenous,O
ribavirin,Chemical
is,O
the,O
treatment,O
of,O
choice,O
for,O
infection,Disease
with,Disease
hemorrhagic,Disease
fever,Disease
viruses,Disease
.,O
OBJECTIVES,O
:,O
To,O
determine,O
the,O
incidence,O
of,O
major,O
hemorrhage,Disease
and,O
stroke,Disease
in,O
people,O
aged,O
76,O
and,O
older,O
with,O
atrial,Disease
fibrillation,Disease
on,O
adjusted,O
-,O
dose,O
warfarin,Chemical
who,O
had,O
been,O
recently,O
been,O
admitted,O
to,O
hospital,O
.,O
Two,O
hundred,O
four,O
people,O
with,O
epilepsy,Disease
were,O
grouped,O
on,O
the,O
basis,O
of,O
antiepileptic,O
drug,O
therapy,O
(,O
current,O
",",O
previous,O
",",O
or,O
no,O
exposure,O
to,O
VGB,Chemical
),O
.,O
Acute,Disease
renal,Disease
failure,Disease
associated,O
with,O
prolonged,O
intake,O
of,O
slimming,O
pills,O
containing,O
anthraquinones,Chemical
.,O
The,O
amount,O
of,O
fibrin,O
in,O
the,O
kidneys,O
was,O
also,O
considerably,O
lower,O
than,O
in,O
animals,O
which,O
received,O
thrombin,O
and,O
AMCA,Chemical
alone,O
.,O
Iopentol,Chemical
and,O
iohexol,Chemical
also,O
produced,O
significantly,O
less,O
decrease,O
in,O
aortic,O
blood,O
pressure,O
than,O
metrizoate,Chemical
at,O
the,O
different,O
doses,O
.,O
When,O
dietary,O
and,O
supplemental,O
vitamin,Chemical
C,Chemical
were,O
analyzed,O
separately,O
",",O
only,O
supplemental,O
vitamin,Chemical
C,Chemical
showed,O
a,O
positive,O
association,O
with,O
mortality,O
endpoints,O
.,O
BACKGROUND,O
:,O
Atrial,Disease
tachycardia,Disease
-,O
induced,O
remodeling,O
promotes,O
the,O
occurrence,O
and,O
maintenance,O
of,O
atrial,Disease
fibrillation,Disease
(,O
AF,Disease
),O
and,O
decreases,O
L,O
-,O
type,O
Ca,Chemical
(,O
2,O
+,O
),O
current,O
.,O
CONCLUSION,O
:,O
Despite,O
theoretical,O
concerns,O
that,O
lidocaine,Chemical
may,O
enhance,O
cocaine,Chemical
toxicity,Disease
",",O
the,O
use,O
of,O
lidocaine,Chemical
in,O
patients,O
with,O
cocaine,Chemical
-,O
associated,O
MI,Disease
was,O
not,O
associated,O
with,O
significant,O
cardiovascular,Disease
or,Disease
central,Disease
nervous,Disease
system,Disease
toxicity,Disease
.,O
We,O
recently,O
demonstrated,O
that,O
recombinant,O
hGH,O
exacerbates,O
renal,O
functional,O
and,O
structural,O
injury,O
in,O
chronic,O
puromycin,Chemical
aminonucleoside,Chemical
(,O
PAN,Chemical
),O
nephropathy,Disease
",",O
an,O
experimental,O
model,O
of,O
glomerular,Disease
disease,Disease
.,O
The,O
fits,Disease
ceased,O
within,O
4,O
hours,O
of,O
administering,O
intramuscular,O
pyridoxine,Chemical
",",O
suggesting,O
an,O
aetiology,O
of,O
pyridoxine,Chemical
deficiency,O
secondary,O
to,O
isoniazid,Chemical
medication,O
.,O
When,O
serum,O
prolactin,O
levels,O
normalized,O
in,O
all,O
four,O
subjects,O
(,O
mean,O
11,O
.,O
2,O
+,O
/,O
-,O
10,O
.,O
9,O
ng,O
/,O
mL,O
),O
",",O
the,O
cabergoline,Chemical
dose,O
was,O
reduced,O
to,O
1,O
mg,O
/,O
week,O
in,O
three,O
of,O
four,O
subjects,O
.,O
All,Chemical
-,Chemical
trans,Chemical
retinoic,Chemical
acid,Chemical
(,O
ATRA,Chemical
),O
",",O
a,O
component,O
of,O
standard,O
therapy,O
for,O
acute,Disease
promyelocytic,Disease
leukemia,Disease
(,O
APL,Disease
),O
",",O
is,O
associated,O
with,O
potentially,O
serious,O
but,O
treatable,O
adverse,O
effects,O
involving,O
numerous,O
organ,O
systems,O
",",O
including,O
rare,O
skeletal,O
muscle,O
involvement,O
.,O
These,O
results,O
indicate,O
that,O
delayed,O
toxicity,Disease
of,O
CY,Chemical
in,O
female,O
DBA,O
/,O
2,O
mice,O
causes,O
a,O
bladder,O
pathology,O
that,O
is,O
not,O
observed,O
in,O
C57BL,O
/,O
6,O
mice,O
.,O
PARP,O
-,O
1,O
+,O
/,O
+,O
and,O
PARP,O
-,O
1,O
-,O
/,O
-,O
mice,O
received,O
a,O
single,O
injection,O
of,O
DOX,Chemical
(,O
25,O
mg,O
/,O
kg,O
i,O
.,O
p,O
),O
.,O
INTERPRETATION,O
:,O
Smoking,O
of,O
crack,Chemical
cocaine,Chemical
was,O
found,O
to,O
be,O
an,O
independent,O
risk,O
factor,O
for,O
HIV,Disease
seroconversion,Disease
among,O
people,O
who,O
were,O
injection,O
drug,O
users,O
.,O
Effect,O
of,O
calcium,Chemical
chloride,Chemical
and,O
4,Chemical
-,Chemical
aminopyridine,Chemical
therapy,O
on,O
desipramine,Chemical
toxicity,Disease
in,O
rats,O
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
screen,O
for,O
efficacy,O
of,O
a,O
different,O
formulation,O
of,O
adenosine,Chemical
marketed,O
in,O
the,O
US,O
",",O
using,O
both,O
acute,O
noxious,O
stimulation,O
and,O
capsaicin,Chemical
-,O
evoked,O
mechanical,O
hypersensitivity,Disease
.,O
An,O
increase,O
of,O
creatine,Chemical
phosphokinase,O
to,O
>,O
5,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
occurred,O
in,O
0,O
.,O
24,O
%,O
of,O
patients,O
",",O
and,O
no,O
cases,O
of,O
drug,O
-,O
induced,O
myopathy,Disease
were,O
observed,O
.,O
Compared,O
with,O
placebo,O
subjects,O
",",O
alprazolam,Chemical
patients,O
developed,O
more,O
adverse,O
reactions,O
(,O
21,O
%,O
v,O
.,O
0,O
%,O
),O
of,O
depression,Disease
",",O
enuresis,Disease
",",O
disinhibition,O
and,O
aggression,Disease
;,O
and,O
more,O
side,O
-,O
effects,O
",",O
particularly,O
sedation,O
",",O
irritability,Disease
",",O
impaired,Disease
memory,Disease
",",O
weight,Disease
loss,Disease
and,O
ataxia,Disease
.,O
Further,O
studies,O
are,O
needed,O
to,O
explore,O
tissue,O
bupivacaine,Chemical
levels,O
of,O
propofol,Chemical
in,O
medialipid,O
and,O
adapt,O
these,O
results,O
to,O
clinical,O
practice,O
.,O
This,O
was,O
most,O
frequently,O
found,O
in,O
children,O
",",O
many,O
of,O
whom,O
had,O
received,O
clioquinol,Chemical
as,O
treatment,O
for,O
acrodermatitis,Disease
enteropathica,Disease
.,O
In,O
the,O
present,O
study,O
",",O
cis,Chemical
-,Chemical
platin,Chemical
(,O
80,O
-,O
120,O
mg,O
/,O
m2BSA,O
),O
and,O
5,Chemical
-,Chemical
FU,Chemical
(,O
1000,O
mg,O
/,O
m2BSA,O
daily,O
as,O
a,O
continuous,O
infusion,O
during,O
5,O
days,O
),O
were,O
given,O
to,O
76,O
patients,O
before,O
radiotherapy,O
and,O
surgery,O
.,O
Furthermore,O
",",O
the,O
effects,O
are,O
mediated,O
through,O
dopamine,Chemical
rather,O
than,O
norepinephrine,Chemical
and,O
do,O
not,O
require,O
the,O
carotid,O
sinus,O
baroreceptors,O
.,O
The,O
cases,O
of,O
five,O
depressed,Disease
adolescents,O
",",O
14,O
-,O
16,O
years,O
of,O
age,O
",",O
who,O
developed,O
mania,Disease
during,O
pharmacotherapy,O
with,O
fluoxetine,Chemical
",",O
are,O
reported,O
here,O
.,O
Alfentanil,Chemical
50,O
micrograms,O
kg,O
-,O
1,O
effectively,O
inhibits,O
the,O
incidence,O
and,O
intensity,O
of,O
suxamethonium,Chemical
-,O
induced,O
muscle,Disease
fasciculations,Disease
;,O
moreover,O
",",O
intragastric,O
pressure,O
remains,O
at,O
its,O
control,O
value,O
.,O
To,O
demonstrate,O
the,O
relationship,O
between,O
peripheral,O
iron,Chemical
overload,O
and,O
dopaminergic,O
neuron,O
loss,O
in,O
rat,O
substantia,O
nigra,O
(,O
SN,O
),O
",",O
in,O
the,O
present,O
study,O
we,O
used,O
fast,O
cyclic,O
voltammetry,O
",",O
tyrosine,Chemical
hydroxylase,O
(,O
TH,O
),O
immunohistochemistry,O
",",O
Perls,O
',O
iron,Chemical
staining,O
",",O
and,O
high,O
performance,O
liquid,O
chromatography,O
-,O
electrochemical,O
detection,O
to,O
study,O
the,O
degeneration,Disease
of,Disease
dopaminergic,Disease
neurons,Disease
and,O
increased,O
iron,Chemical
content,O
in,O
the,O
SN,O
of,O
iron,Chemical
dextran,Chemical
overloaded,O
animals,O
.,O
Therapeutic,O
ranges,O
for,O
antidepressants,Chemical
that,O
have,O
been,O
derived,O
from,O
general,O
adult,O
population,O
studies,O
may,O
not,O
be,O
appropriate,O
for,O
the,O
elderly,O
.,O
All,O
patients,O
had,O
bilateral,O
symptoms,O
and,O
their,O
levodopa,Chemical
equivalent,O
dosing,O
were,O
analysed,O
.,O
In,O
animals,O
pretreated,O
with,O
nicotine,Chemical
for,O
14,O
days,O
",",O
the,O
nicotine,Chemical
-,O
induced,O
locomotor,O
response,O
remained,O
to,O
be,O
potentiated,O
.,O
Diffuse,O
skeletal,O
pain,Disease
after,O
administration,O
of,O
alendronate,Chemical
.,O
Valproate,Chemical
-,O
induced,O
encephalopathy,Disease
.,O
The,O
basal,O
MAP,O
of,O
conscious,O
SHR,O
was,O
reduced,O
to,O
a,O
similar,O
extent,O
by,O
prazosin,Chemical
(,O
-,O
23,O
%,O
(,O
-,O
),O
-,O
26,O
%,O
MAP,O
),O
and,O
rauwolscine,Chemical
(,O
-,O
16,O
%,O
(,O
-,O
),O
-,O
33,O
%,O
MAP,O
),O
.,O
Skin,O
tests,O
with,O
AX,Chemical
were,O
positive,O
in,O
34,O
(,O
63,O
%,O
),O
patients,O
.,O
Long,O
-,O
term,O
oral,O
galactose,Chemical
treatment,O
prevents,O
cognitive,Disease
deficits,Disease
in,O
male,O
Wistar,O
rats,O
treated,O
intracerebroventricularly,O
with,O
streptozotocin,Chemical
.,O
Additionally,O
",",O
20,O
to,O
25,O
%,O
of,O
paracetamol,Chemical
-,O
treated,O
rats,O
developed,O
hyperplasia,Disease
of,O
the,O
bladder,O
epithelium,O
",",O
which,O
was,O
not,O
coincident,O
with,O
the,O
presence,O
of,O
bladder,Disease
calculi,Disease
.,O
Renal,O
angiotensin,Chemical
II,Chemical
receptor,O
type,O
2,O
(,O
AT2R,O
),O
gene,O
expression,O
in,O
adult,O
offspring,O
was,O
reduced,O
by,O
PCE,O
",",O
whereas,O
the,O
renal,O
angiotensin,Chemical
II,Chemical
receptor,O
type,O
1a,O
(,O
AT1aR,O
),O
/,O
AT2R,O
expression,O
ratio,O
was,O
increased,O
.,O
In,O
both,O
ecstasy,Chemical
and,O
cannabis,Chemical
groups,O
brain,O
activation,O
was,O
decreased,O
in,O
the,O
right,O
medial,O
frontal,O
gyrus,O
",",O
left,O
parahippocampal,O
gyrus,O
",",O
left,O
dorsal,O
cingulate,O
gyrus,O
",",O
and,O
left,O
caudate,O
.,O
CaCl2,Chemical
and,O
4,Chemical
-,Chemical
aminopyridine,Chemical
.,O
There,O
was,O
no,O
significant,O
association,O
between,O
level,O
of,O
alcohol,Chemical
use,O
and,O
CD4,O
+,O
T,O
-,O
cell,O
counts,O
.,O
In,O
group,O
I,O
",",O
cyclosporine,Chemical
was,O
given,O
before,O
the,O
procedure,O
at,O
a,O
loading,O
dose,O
of,O
17,O
.,O
5,O
mg,O
/,O
kg,O
and,O
then,O
continued,O
after,O
the,O
procedure,O
to,O
keep,O
a,O
whole,O
blood,O
level,O
about,O
1000,O
ng,O
/,O
ml,O
.,O
Finally,O
",",O
to,O
show,O
that,O
the,O
bladder,O
is,O
essential,O
for,O
the,O
CP,Chemical
-,O
induced,O
behavioral,O
modifications,O
",",O
female,O
rats,O
also,O
received,O
CP,Chemical
at,O
doses,O
of,O
200,O
mg,O
.,O
/,O
kg,O
.,O
Twenty,O
of,O
41,O
(,O
48,O
%,O
),O
patients,O
received,O
GEM,Chemical
-,O
P,O
as,O
second,O
-,O
line,O
treatment,O
and,O
11,O
/,O
41,O
(,O
27,O
%,O
),O
as,O
third,O
-,O
line,O
therapy,O
.,O
After,O
EE,Chemical
treatment,O
",",O
changes,O
in,O
immunostaining,O
for,O
7H6,O
and,O
ZO,O
-,O
1,O
were,O
similar,O
to,O
those,O
seen,O
in,O
periportal,O
hepatocytes,O
after,O
BDL,O
",",O
but,O
distributed,O
more,O
diffusely,O
throughout,O
the,O
lobule,O
.,O
Pain,Disease
severity,O
and,O
analgesic,O
requirements,O
were,O
unaffected,O
by,O
the,O
omission,O
of,O
fentanyl,Chemical
.,O
All,O
these,O
effects,O
of,O
DES,Chemical
were,O
more,O
pronounced,O
among,O
previously,O
ovariectomized,O
animals,O
.,O
Immunohistochemistry,O
displayed,O
significantly,O
increased,O
expressions,O
of,O
MMP,O
-,O
2,O
",",O
MMP,O
-,O
9,O
",",O
ADAM,O
-,O
10,O
and,O
ADAM,O
-,O
17,O
(,O
all,O
p,O
<,O
0,O
.,O
01,O
),O
in,O
intima,O
and,O
media,O
for,O
CaCl,Chemical
(,Chemical
2,Chemical
),Chemical
-,O
treated,O
segments,O
.,O
Effects,O
of,O
ginsenosides,Chemical
on,O
opioid,O
-,O
induced,O
hyperalgesia,Disease
in,O
mice,O
.,O
It,O
is,O
therefore,O
very,O
important,O
to,O
follow,O
the,O
changes,O
of,O
gallbladder,O
function,O
during,O
long,O
-,O
term,O
octreotide,Chemical
therapy,O
of,O
acromegalic,Disease
patients,O
.,O
We,O
describe,O
a,O
patient,O
who,O
developed,O
tetany,Disease
with,O
sudden,O
respiratory,Disease
arrest,Disease
after,O
the,O
infusion,O
of,O
intravenous,O
diltiazem,Chemical
.,O
In,O
the,O
first,O
case,O
a,O
caesarean,O
section,O
was,O
done,O
one,O
week,O
after,O
replacement,O
of,O
warfarin,Chemical
with,O
heparin,Chemical
.,O
Comparison,O
of,O
slow,O
-,O
wave,O
sleep,O
time,O
",",O
total,O
sleep,O
time,O
",",O
and,O
sleep,O
latency,O
in,O
cocaine,Chemical
-,O
dependent,O
and,O
healthy,O
participants,O
revealed,O
a,O
normalizing,O
effect,O
of,O
modafinil,Chemical
in,O
cocaine,Chemical
-,O
dependent,O
participants,O
.,O
Therapeutic,O
drug,O
monitoring,O
of,O
tobramycin,Chemical
:,O
once,O
-,O
daily,O
versus,O
twice,O
-,O
daily,O
dosage,O
schedules,O
.,O
Nested,O
within,O
the,O
cohort,O
",",O
a,O
matched,O
case,O
-,O
control,O
study,O
was,O
performed,O
to,O
estimate,O
the,O
association,O
between,O
cyclophosphamide,Chemical
and,O
bladder,Disease
cancer,Disease
using,O
odds,O
ratios,O
(,O
ORs,O
),O
as,O
relative,O
risk,O
.,O
However,O
",",O
the,O
oral,O
dose,O
of,O
d,Chemical
",",Chemical
l,Chemical
-,Chemical
sotalol,Chemical
was,O
significantly,O
lower,O
in,O
patients,O
with,O
torsades,Disease
de,Disease
pointes,Disease
(,O
200,O
+,O
/,O
-,O
46,O
vs,O
.,O
328,O
+,O
/,O
-,O
53,O
mg,O
/,O
day,O
;,O
p,O
=,O
0,O
.,O
0017,O
),O
.,O
This,O
study,O
was,O
designed,O
to,O
discern,O
whether,O
the,O
reduction,O
in,O
urinary,O
NOx,O
in,O
lead,Chemical
-,O
induced,O
hypertension,Disease
is,O
",",O
in,O
part,O
",",O
due,O
to,O
depressed,O
NO,Chemical
synthase,O
(,O
NOS,O
),O
expression,O
.,O
PURPOSE,O
:,O
To,O
determine,O
the,O
natural,O
history,O
of,O
visual,Disease
field,Disease
defects,Disease
in,O
a,O
group,O
of,O
patients,O
known,O
to,O
have,O
Vigabatrin,Chemical
-,O
associated,O
changes,O
who,O
elected,O
to,O
continue,O
the,O
medication,O
because,O
of,O
good,O
seizure,Disease
control,O
.,O
It,O
is,O
concluded,O
that,O
flestolol,Chemical
is,O
a,O
potent,O
",",O
well,O
-,O
tolerated,O
",",O
ultra,O
-,O
short,O
-,O
acting,O
beta,O
-,O
adrenergic,O
blocking,O
agent,O
.,O
Upon,O
additional,O
retrospective,O
analysis,O
",",O
it,O
was,O
noted,O
that,O
bumetanide,Chemical
is,O
a,O
loop,Chemical
diuretic,Chemical
that,O
may,O
cause,O
significant,O
hypocalcemia,Disease
.,O
Bradycardia,Disease
due,O
to,O
trihexyphenidyl,Chemical
hydrochloride,Chemical
.,O
Although,O
large,O
-,O
dose,O
amiodarone,Chemical
is,O
highly,O
effective,O
in,O
the,O
long,O
-,O
term,O
treatment,O
of,O
VT,Disease
or,O
VF,Disease
refractory,O
to,O
conventional,O
antiarrhythmic,O
drugs,O
",",O
it,O
causes,O
significant,O
toxicity,Disease
in,O
approximately,O
50,O
%,O
of,O
patients,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
the,O
effect,O
of,O
Rg1,Chemical
on,O
learning,Disease
impairment,Disease
by,O
chronic,O
morphine,Chemical
administration,O
and,O
the,O
mechanism,O
responsible,O
for,O
this,O
effect,O
.,O
However,O
",",O
the,O
behavioral,O
effects,O
of,O
centrally,O
administered,O
U,Chemical
-,Chemical
II,Chemical
have,O
received,O
little,O
attention,O
.,O
Importantly,O
",",O
GNC92H2,Chemical
prevented,O
death,Disease
even,O
post,O
-,O
cocaine,Chemical
injection,O
.,O
Visual,Disease
and,Disease
auditory,Disease
neurotoxicity,Disease
was,O
previously,O
documented,O
in,O
42,O
of,O
89,O
patients,O
with,O
transfusion,O
-,O
dependent,O
anemia,Disease
who,O
were,O
receiving,O
iron,Chemical
chelation,O
therapy,O
with,O
daily,O
subcutaneous,O
deferoxamine,Chemical
.,O
Clentiazem,Chemical
also,O
did,O
not,O
prevent,O
the,O
enhanced,O
responses,O
to,O
calcium,Chemical
seen,O
in,O
the,O
epinephrine,Chemical
-,O
treated,O
animals,O
",",O
although,O
the,O
high,O
dose,O
of,O
clentiazem,Chemical
partially,O
attenuated,O
the,O
maximal,O
response,O
to,O
calcium,Chemical
compared,O
to,O
epinephrine,Chemical
-,O
treated,O
animals,O
.,O
Saline,O
-,O
pretreated,O
controls,O
given,O
a,O
test,O
dose,O
of,O
morphine,Chemical
(,O
20,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
showed,O
a,O
pronounced,O
rigidity,Disease
recorded,O
as,O
tonic,O
activity,O
in,O
the,O
electromyogram,O
.,O
Head,O
-,O
up,O
tilts,O
in,O
these,O
rats,O
did,O
not,O
produce,O
orthostatic,Disease
hypotension,Disease
when,O
performed,O
either,O
prior,O
to,O
or,O
after,O
acute,O
dosing,O
of,O
prazosin,Chemical
(,O
0,O
.,O
1,O
mg,O
kg,O
-,O
1,O
i,O
.,O
p,O
.,O
),O
.,O
We,O
conclude,O
that,O
ATRA,Chemical
is,O
a,O
valid,O
therapeutic,O
choice,O
for,O
patients,O
with,O
APL,Disease
",",O
although,O
the,O
procoagulant,O
tendency,O
is,O
not,O
completely,O
corrected,O
.,O
Neither,O
a,O
tumor,Disease
-,O
protective,O
effect,O
nor,O
reduced,O
toxicity,Disease
to,O
normal,O
tissues,O
was,O
observed,O
with,O
the,O
addition,O
of,O
amifostine,Chemical
to,O
cisplatin,Chemical
in,O
this,O
trial,O
.,O
The,O
current,O
study,O
investigated,O
the,O
visual,O
fields,O
and,O
visual,O
electrophysiology,O
of,O
eight,O
patients,O
with,O
known,O
vigabatrin,Chemical
-,O
attributed,O
visual,Disease
field,Disease
loss,Disease
",",O
three,O
of,O
whom,O
were,O
reported,O
previously,O
.,O
MESNA,Chemical
was,O
given,O
orally,O
on,O
the,O
days,O
of,O
treatment,O
with,O
IF,Chemical
in,O
3,O
doses,O
of,O
840,O
mg,O
/,O
m2,O
",",O
each,O
administered,O
at,O
0,O
hr,O
(,O
=,O
injection,O
of,O
IF,Chemical
),O
",",O
4,O
hr,O
and,O
8,O
hr,O
p,O
.,O
i,O
.,O
Electrocardiographic,O
changes,O
after,O
dipyridamole,Chemical
infusion,O
(,O
0,O
.,O
568,O
mg,O
/,O
kg,O
/,O
4,O
min,O
),O
were,O
studied,O
in,O
41,O
patients,O
with,O
coronary,Disease
artery,Disease
disease,Disease
and,O
compared,O
with,O
those,O
after,O
submaximal,O
treadmill,O
exercise,O
by,O
use,O
of,O
the,O
body,O
surface,O
mapping,O
technique,O
.,O
Preliminary,O
studies,O
suggest,O
that,O
statins,Chemical
could,O
interfere,O
with,O
the,O
risk,O
of,O
recurrence,O
after,O
electrical,O
cardioversion,O
.,O
A,O
prospective,O
evaluation,O
of,O
the,O
efficacy,O
and,O
safety,O
of,O
vancomycin,Chemical
was,O
conducted,O
in,O
54,O
consecutive,O
patients,O
over,O
a,O
16,O
-,O
month,O
period,O
.,O
Stereological,O
methods,O
reveal,O
the,O
robust,O
size,O
and,O
stability,O
of,O
ectopic,O
hilar,O
granule,O
cells,O
after,O
pilocarpine,Chemical
-,O
induced,O
status,Disease
epilepticus,Disease
in,O
the,O
adult,O
rat,O
.,O
Furthermore,O
",",O
glomerulosclerosis,Disease
index,O
was,O
significantly,O
increased,O
in,O
the,O
nitrendipine,Chemical
-,O
treated,O
group,O
compared,O
with,O
the,O
hypertensive,Disease
controls,O
(,O
0,O
.,O
38,O
+,O
/,O
-,O
0,O
.,O
1,O
versus,O
0,O
.,O
13,O
+,O
/,O
-,O
0,O
.,O
04,O
),O
.,O
Over,O
the,O
total,O
postinfusion,O
period,O
systolic,O
and,O
diastolic,O
arterial,O
pressure,O
were,O
6,O
(,O
SEM,O
2,O
),O
%,O
and,O
7,O
(,O
2,O
),O
%,O
",",O
respectively,O
",",O
higher,O
than,O
after,O
dextrose,Chemical
infusion,O
(,O
ANOVA,O
",",O
p,O
less,O
than,O
0,O
.,O
001,O
),O
.,O
Administration,O
of,O
nocistatin,Chemical
(,O
1,O
.,O
5,O
and,O
/,O
or,O
5,O
.,O
0,O
nmol,O
mouse,O
-,O
1,O
",",O
i,O
.,O
c,O
.,O
v,O
.,O
),O
30,O
min,O
before,O
spontaneous,O
alternation,O
performance,O
or,O
the,O
training,O
session,O
of,O
the,O
passive,O
avoidance,O
task,O
",",O
attenuated,O
the,O
scopolamine,Chemical
-,O
induced,O
impairment,O
of,O
spontaneous,O
alternation,O
and,O
passive,O
avoidance,O
behaviours,O
.,O
Aggregation,O
was,O
lower,O
(,O
P,O
<,O
.,O
05,O
),O
in,O
the,O
ketoprofen,Chemical
group,O
than,O
in,O
the,O
acetaminophen,Chemical
group,O
just,O
before,O
surgery,O
and,O
on,O
the,O
third,O
postoperative,O
day,O
.,O
Conventional,O
LW,O
rats,O
",",O
implanted,O
with,O
testosterone,Chemical
at,O
age,O
4,O
months,O
",",O
developed,O
a,O
higher,O
incidence,O
of,O
prostate,Disease
cancer,Disease
after,O
an,O
average,O
interval,O
of,O
14,O
months,O
:,O
24,O
%,O
had,O
developed,O
gross,O
tumors,Disease
",",O
and,O
40,O
%,O
when,O
it,O
included,O
microscopic,O
tumors,Disease
.,O
Chronic,O
T,Chemical
treatment,O
significantly,O
decreased,O
5,Chemical
-,Chemical
HT,Chemical
and,O
5,Chemical
-,Chemical
HIAA,Chemical
in,O
certain,O
brain,O
areas,O
",",O
but,O
to,O
a,O
much,O
lesser,O
extent,O
than,O
PCPA,Chemical
.,O
There,O
were,O
no,O
appreciable,O
differences,O
between,O
the,O
MESNA,Chemical
series,O
and,O
the,O
conventional,O
prophylaxis,O
series,O
with,O
respect,O
to,O
either,O
haematological,O
or,O
systemic,O
toxicity,Disease
of,O
the,O
cytostatic,O
treatment,O
.,O
Clinically,O
reversible,O
veno,Disease
-,Disease
occlusive,Disease
disease,Disease
of,Disease
the,Disease
liver,Disease
developed,O
in,O
a,O
23,O
-,O
year,O
-,O
old,O
man,O
with,O
acute,Disease
lymphocytic,Disease
leukemia,Disease
after,O
10,O
months,O
of,O
maintenance,O
therapy,O
with,O
6,Chemical
-,Chemical
thioguanine,Chemical
.,O
Two,O
patients,O
with,O
type,Disease
II,Disease
diabetes,Disease
mellitus,Disease
developed,O
an,O
acute,Disease
hepatitis,Disease
-,Disease
like,Disease
syndrome,Disease
soon,O
after,O
initiation,O
of,O
glyburide,Chemical
therapy,O
.,O
Thermal,O
enhancement,O
of,O
Adriamycin,Chemical
-,O
mediated,O
antitumor,O
activity,O
and,O
normal,O
tissue,O
toxicities,Disease
by,O
whole,O
body,O
hyperthermia,Disease
were,O
compared,O
using,O
a,O
F344,O
rat,O
model,O
.,O
Daidzein,Chemical
activates,O
choline,Chemical
acetyltransferase,O
from,O
MC,O
-,O
IXC,O
cells,O
and,O
improves,O
drug,O
-,O
induced,O
amnesia,Disease
.,O
The,O
analgesic,O
effect,O
of,O
the,O
mu,O
-,O
agonist,O
morphine,Chemical
was,O
dose,O
-,O
dependently,O
antagonized,O
by,O
naloxone,Chemical
and,O
prevented,O
by,O
co,O
-,O
injection,O
of,O
pertussis,O
toxin,O
.,O
Central,Disease
nervous,Disease
system,Disease
toxicity,Disease
following,O
the,O
administration,O
of,O
levobupivacaine,Chemical
for,O
lumbar,O
plexus,O
block,O
:,O
A,O
report,O
of,O
two,O
cases,O
.,O
CPT,Chemical
(,O
8,Chemical
-,Chemical
cyclopentyltheophylline,Chemical
),O
-,O
-,O
A1,O
receptor,O
antagonist,O
",",O
did,O
not,O
show,O
any,O
influence,O
in,O
this,O
test,O
.,O
The,O
average,O
recovery,O
time,O
of,O
BAEP,O
waveforms,O
to,O
pre,O
-,O
papaverine,Chemical
baseline,O
values,O
was,O
39,O
min,O
.,O
Intravascular,O
hemolysis,Disease
and,O
acute,Disease
renal,Disease
failure,Disease
following,O
intermittent,O
rifampin,Chemical
therapy,O
.,O
In,O
the,O
course,O
of,O
developing,O
this,O
model,O
",",O
a,O
common,O
vehicle,O
",",O
propylene,Chemical
glycol,Chemical
",",O
by,O
itself,O
in,O
high,O
doses,O
",",O
was,O
found,O
to,O
exhibit,O
protective,O
properties,O
against,O
induced,O
seizures,Disease
and,O
inhibited,O
weight,Disease
gain,Disease
.,O
RESULTS,O
:,O
Person,O
-,O
years,O
of,O
exposure,O
among,O
non,O
-,O
users,O
of,O
aspirin,Chemical
were,O
:,O
75,O
",",O
761,O
to,O
acetaminophen,Chemical
",",O
42,O
",",O
671,O
to,O
rofecoxib,Chemical
65,O
",",O
860,O
to,O
celecoxib,Chemical
",",O
and,O
37,O
",",O
495,O
to,O
NS,O
-,O
NSAIDs,O
.,O
We,O
report,O
a,O
case,O
of,O
nonalcoholic,Disease
fatty,Disease
liver,Disease
disease,Disease
(,O
NAFLD,Disease
),O
arising,O
in,O
a,O
child,O
who,O
developed,O
obesity,Disease
during,O
VPA,Chemical
treatment,O
.,O
The,O
renal,Disease
failure,Disease
usually,O
develops,O
about,O
8,O
-,O
10,O
mth,O
after,O
start,O
of,O
mitomycin,Chemical
C,Chemical
treatment,O
and,O
the,O
mortality,O
is,O
approximately,O
60,O
%,O
from,O
renal,Disease
failure,Disease
or,O
pulmonary,Disease
edema,Disease
.,O
The,O
present,O
results,O
suggest,O
that,O
blockade,O
of,O
the,O
glycine,Chemical
site,O
of,O
NMDA,Chemical
receptors,O
in,O
the,O
rostral,O
part,O
of,O
the,O
striatum,O
may,O
be,O
mainly,O
responsible,O
for,O
the,O
antiparkinsonian,O
action,O
of,O
this,O
drug,O
.,O
Furthermore,O
",",O
it,O
was,O
observed,O
that,O
TAM,Chemical
inhibits,O
the,O
peroxidation,O
of,O
human,O
erythrocytes,O
induced,O
by,O
AAPH,Chemical
",",O
thus,O
ruling,O
out,O
TAM,Chemical
-,O
induced,O
cell,O
oxidative,O
stress,O
.,O
The,O
otoprotectant,O
L,Chemical
-,Chemical
NAME,Chemical
was,O
administered,O
topically,O
to,O
12,O
/,O
27,O
animals,O
.,O
Times,O
to,O
ambulate,O
and,O
to,O
void,O
were,O
similar,O
after,O
lidocaine,Chemical
and,O
prilocaine,Chemical
(,O
150,O
vs,O
.,O
165,O
min,O
and,O
238,O
vs,O
.,O
253,O
min,O
",",O
respectively,O
),O
but,O
prolonged,O
after,O
bupivacaine,Chemical
(,O
200,O
and,O
299,O
min,O
",",O
respectively,O
;,O
P,O
<,O
0,O
.,O
05,O
),O
.,O
In,O
our,O
patient,O
",",O
there,O
was,O
no,O
other,O
etiology,O
identified,O
that,O
could,O
explain,O
QT,Disease
prolongation,Disease
or,O
TDP,Disease
The,O
complete,O
disappearance,O
of,O
NSVT,Disease
and,O
premature,Disease
ventricular,Disease
contractions,Disease
followed,O
by,O
normalization,O
of,O
QT,O
interval,O
after,O
the,O
drug,O
was,O
stopped,O
strongly,O
suggests,O
fluconazole,Chemical
as,O
the,O
etiology,O
.,O
Improvement,O
of,O
levodopa,Chemical
-,O
induced,O
dyskinesia,Disease
by,O
propranolol,Chemical
in,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
.,O
We,O
describe,O
a,O
47,O
-,O
year,O
-,O
old,O
woman,O
with,O
an,O
acute,O
myocardial,Disease
infarction,Disease
after,O
administration,O
of,O
sumatriptan,Chemical
6,O
mg,O
subcutaneously,O
for,O
cluster,Disease
headache,Disease
.,O
Melatonin,Chemical
pre,O
-,O
treatment,O
affected,O
in,O
a,O
dual,O
manner,O
barbiturate,Chemical
narcosis,Disease
",",O
however,O
",",O
no,O
dose,O
-,O
effect,O
correlation,O
was,O
found,O
.,O
We,O
recorded,O
the,O
eye,O
movements,O
of,O
two,O
patients,O
with,O
reversible,O
downbeat,Disease
nystagmus,Disease
related,O
to,O
carbamazepine,Chemical
therapy,O
.,O
RESULTS,O
:,O
Response,O
rates,O
did,O
not,O
significantly,O
differ,O
between,O
olanzapine,Chemical
(,O
43,O
.,O
7,O
%,O
",",O
95,O
%,O
CI,O
=,O
28,O
.,O
8,O
%,O
-,O
58,O
.,O
6,O
%,O
),O
and,O
risperidone,Chemical
(,O
54,O
.,O
3,O
%,O
",",O
95,O
%,O
CI,O
=,O
39,O
.,O
9,O
%,O
-,O
68,O
.,O
7,O
%,O
),O
.,O
Quinidine,Chemical
phenylethylbarbiturate,Chemical
-,O
induced,O
fulminant,O
hepatitis,Disease
in,O
a,O
pregnant,O
woman,O
.,O
We,O
report,O
a,O
venlafaxine,Chemical
-,O
MAOI,O
interaction,O
that,O
resulted,O
in,O
the,O
serotonin,Disease
syndrome,Disease
in,O
a,O
23,O
-,O
y,O
-,O
old,O
male,O
who,O
was,O
taking,O
tranylcypromine,Chemical
for,O
depression,Disease
.,O
Mazindol,Chemical
did,O
not,O
benefit,O
strength,O
at,O
any,O
point,O
in,O
the,O
study,O
.,O
OBJECTIVE,O
:,O
This,O
study,O
investigated,O
the,O
efficacy,O
and,O
tolerability,O
of,O
valsartan,Chemical
(,O
VAL,Chemical
),O
or,O
hydrochlorothiazide,Chemical
(,O
HCTZ,Chemical
),O
-,O
monotherapy,O
and,O
higher,O
-,O
dose,O
combinations,O
in,O
patients,O
with,O
essential,Disease
hypertension,Disease
.,O
Our,O
results,O
support,O
the,O
view,O
that,O
MESNA,Chemical
",",O
given,O
orally,O
in,O
conjunction,O
with,O
combined,O
cytostatic,O
regimens,O
which,O
include,O
IF,Chemical
",",O
simplifies,O
the,O
treatment,O
and,O
provides,O
optimum,O
protection,O
for,O
the,O
urinary,O
epithelium,O
.,O
In,O
the,O
last,O
few,O
years,O
delayed,O
reactions,O
several,O
hours,O
after,O
the,O
injection,O
of,O
radiographic,O
and,O
contrast,Chemical
materials,Chemical
(,O
PRC,Chemical
),O
have,O
been,O
described,O
with,O
increasing,O
frequency,O
.,O
Fundus,O
fluorescein,Chemical
angiography,O
confirmed,O
macular,O
capillary,O
closure,O
and,O
telangiectasis,Disease
.,O
An,O
unproportional,O
release,O
of,O
vasopressin,Chemical
compared,O
to,O
plasma,O
osmolality,O
may,O
be,O
induced,O
by,O
the,O
absence,O
of,O
an,O
adjusting,O
control,O
of,O
angiotensin,Chemical
II,O
forming,O
and,O
receptor,O
binding,O
capacity,O
for,O
sodium,Chemical
balance,O
in,O
the,O
brain,O
.,O
These,O
tachykinins,Chemical
",",O
in,O
turn,O
",",O
initiate,O
a,O
micturition,O
reflex,O
by,O
stimulating,O
NK1,O
and,O
NK2,O
receptors,O
.,O
Chemical,O
analysis,O
of,O
gall,Disease
stones,Disease
retrieved,O
at,O
cholecystectomy,O
from,O
two,O
patients,O
",",O
showed,O
that,O
they,O
contained,O
71,O
%,O
and,O
87,O
%,O
cholesterol,Chemical
by,O
weight,O
.,O
Combined,O
antiretroviral,O
therapy,O
causes,O
cardiomyopathy,Disease
and,O
elevates,O
plasma,O
lactate,Chemical
in,O
transgenic,O
AIDS,Disease
mice,O
.,O
Conversion,O
to,O
SRL,Chemical
prevented,O
CsA,Chemical
-,O
induced,O
renal,Disease
damage,Disease
evolution,O
(,O
absent,O
/,O
mild,O
grade,O
lesions,O
),O
",",O
while,O
NGAL,O
(,O
serum,O
versus,O
urine,O
),O
seems,O
to,O
be,O
a,O
feasible,O
biomarker,O
of,O
CsA,Chemical
replacement,O
to,O
SRL,Chemical
.,O
CASE,O
REPORT,O
:,O
Two,O
",",O
3,O
-,O
year,O
-,O
old,O
male,O
",",O
identical,O
twin,O
siblings,O
presented,O
to,O
the,O
emergency,O
department,O
after,O
found,O
playing,O
with,O
a,O
an,O
empty,O
bottle,O
of,O
pemoline,Chemical
originally,O
containing,O
59,O
tablets,O
.,O
In,O
these,O
animals,O
",",O
only,O
minor,O
increases,O
of,O
serum,O
transaminase,O
activities,O
were,O
measured,O
in,O
the,O
presence,O
of,O
AAP,Chemical
",",O
and,O
unlike,O
the,O
exacerbation,O
caused,O
by,O
ethanol,Chemical
in,O
mice,O
on,O
a,O
standard,O
diet,O
",",O
the,O
liver,Disease
damage,Disease
was,O
inhibited,O
by,O
50,O
%,O
by,O
ethanol,Chemical
.,O
The,O
data,O
of,O
the,O
present,O
study,O
suggest,O
that,O
S,O
.,O
virgaurea,O
extract,O
exerts,O
its,O
protective,O
effect,O
by,O
decreasing,O
MDA,Chemical
level,O
and,O
increasing,O
the,O
antioxidant,O
status,O
in,O
isoproterenol,Chemical
-,O
treated,O
rats,O
.,O
Epithelial,O
sodium,Chemical
channel,O
(,O
ENaC,O
),O
subunit,O
mRNA,O
and,O
protein,O
expression,O
in,O
rats,O
with,O
puromycin,Chemical
aminonucleoside,Chemical
-,O
induced,O
nephrotic,Disease
syndrome,Disease
.,O
Antineutrophil,Disease
cytoplasmic,Disease
antibody,Disease
(,Disease
ANCA,Disease
),Disease
-,Disease
-,Disease
associated,Disease
vasculitis,Disease
is,O
a,O
potentially,O
life,O
-,O
threatening,O
adverse,O
effect,O
of,O
antithyroidmedications,Chemical
.,O
RESULTS,O
:,O
The,O
average,O
time,O
from,O
intravenous,O
administration,O
of,O
ketamine,Chemical
to,O
manipulation,O
of,O
the,O
fracture,Disease
or,O
dislocation,Disease
was,O
one,O
minute,O
and,O
thirty,O
-,O
six,O
seconds,O
(,O
range,O
",",O
twenty,O
seconds,O
to,O
five,O
minutes,O
),O
",",O
and,O
the,O
average,O
time,O
from,O
intramuscular,O
administration,O
to,O
manipulation,O
was,O
four,O
minutes,O
and,O
forty,O
-,O
two,O
seconds,O
(,O
range,O
",",O
sixty,O
seconds,O
to,O
fifteen,O
minutes,O
),O
.,O
Phase,O
II,O
study,O
of,O
the,O
amsacrine,Chemical
analogue,O
CI,Chemical
-,Chemical
921,Chemical
(,O
NSC,Chemical
343499,Chemical
),O
in,O
non,Disease
-,Disease
small,Disease
cell,Disease
lung,Disease
cancer,Disease
.,O
D,Chemical
-,Chemical
Penicillamine,Chemical
caused,O
nephrotic,Disease
syndrome,Disease
in,O
1,O
patient,O
and,O
milder,O
reversible,O
proteinuria,Disease
in,O
3,O
other,O
patients,O
;,O
none,O
developed,O
renal,Disease
insufficiency,Disease
.,O
Ethambutol,Chemical
is,O
known,O
to,O
cause,O
optic,Disease
neuropathy,Disease
and,O
",",O
more,O
rarely,O
",",O
axonal,O
polyneuropathy,Disease
.,O
Patients,O
with,O
CHF,Disease
on,O
amiodarone,Chemical
may,O
suffer,O
serious,O
morbidity,O
and,O
mortality,O
from,O
hypothyroidism,Disease
",",O
and,O
thus,O
may,O
deserve,O
closer,O
follow,O
up,O
for,O
thyroid,O
stimulating,O
hormone,O
(,O
TSH,O
),O
levels,O
.,O
Therefore,O
",",O
concomitant,O
administration,O
of,O
small,O
doses,O
of,O
bradykinin,Chemical
receptor,O
antagonists,O
and,O
NO,Chemical
synthase,O
inhibitors,O
can,O
be,O
effective,O
in,O
alleviation,O
of,O
neuropathic,Disease
pain,Disease
",",O
even,O
in,O
hospital,O
care,O
.,O
RESULTS,O
:,O
A,O
2,O
.,O
0,O
-,O
mg,O
oral,O
dose,O
of,O
trihexyphenidyl,Chemical
resulted,O
in,O
increased,O
subjective,O
ratings,O
of,O
mental,Disease
slowness,Disease
in,O
carriers,O
of,O
the,O
APOE,O
epsilon4,O
allele,O
only,O
.,O
Control,O
rats,O
received,O
halothane,Chemical
anesthesia,O
(,O
1,O
MAC,O
),O
for,O
one,O
hour,O
",",O
followed,O
by,O
SNP,Chemical
infusion,O
",",O
40,O
microgram,O
/,O
kg,O
/,O
min,O
",",O
for,O
30,O
min,O
",",O
followed,O
by,O
a,O
30,O
-,O
min,O
recovery,O
period,O
.,O
Median,O
time,O
to,O
CR,O
when,O
RD,Chemical
was,O
given,O
as,O
2nd,O
or,O
>,O
2,O
(,O
nd,O
),O
-,O
line,O
treatment,O
at,O
4,O
and,O
11,O
months,O
",",O
respectively,O
.,O
Myoclonic,Disease
movements,Disease
are,O
evaluated,O
",",O
which,O
were,O
observed,O
and,O
graded,O
according,O
to,O
clinical,O
severity,O
during,O
the,O
2,O
minutes,O
after,O
etomidate,Chemical
injection,O
.,O
She,O
developed,O
leucopenia,Disease
after,O
being,O
treated,O
with,O
quetiapine,Chemical
.,O
In,O
addition,O
",",O
AMN082,Chemical
reduces,O
the,O
duration,O
of,O
haloperidol,Chemical
-,O
induced,O
catalepsy,Disease
in,O
a,O
mGlu7,O
receptor,O
-,O
dependent,O
manner,O
in,O
wild,O
-,O
type,O
but,O
not,O
mGlu7,O
receptor,O
knockout,O
mice,O
.,O
Asterixis,Disease
induced,O
by,O
carbamazepine,Chemical
therapy,O
.,O
The,O
occurrence,O
of,O
a,O
myocardial,Disease
infarction,Disease
is,O
reported,O
after,O
chemotherapy,O
containing,O
etoposide,Chemical
",",O
in,O
a,O
man,O
with,O
no,O
risk,O
factors,O
for,O
coronary,Disease
heart,Disease
disease,Disease
.,O
Amiodarone,Chemical
-,O
related,O
pulmonary,Disease
mass,Disease
and,O
unique,O
membranous,Disease
glomerulonephritis,Disease
in,O
a,O
patient,O
with,O
valvular,Disease
heart,Disease
disease,Disease
:,O
Diagnostic,O
pitfall,O
and,O
new,O
findings,O
.,O
Quinine,Chemical
is,O
known,O
to,O
block,O
voltage,O
-,O
",",O
calcium,Chemical
-,O
and,O
ATP,Chemical
-,O
sensitive,O
K,Chemical
(,O
+,O
),O
-,O
channels,O
while,O
4,Chemical
-,Chemical
aminopyridine,Chemical
is,O
known,O
to,O
block,O
voltage,O
-,O
sensitive,O
K,Chemical
(,O
+,O
),O
-,O
channels,O
.,O
METHODS,O
:,O
We,O
conducted,O
a,O
retrospective,O
review,O
of,O
70,O
consecutive,O
microvascular,O
decompression,O
operations,O
and,O
studied,O
those,O
patients,O
who,O
received,O
topical,O
papaverine,Chemical
for,O
vasospasm,Disease
.,O
Procainamide,Chemical
-,O
induced,O
polymorphous,O
ventricular,Disease
tachycardia,Disease
.,O
CONCLUSIONS,O
:,O
Both,O
timolol,Chemical
solution,O
and,O
timolol,Chemical
gellan,O
decrease,O
the,O
mean,O
24,O
-,O
hour,O
heart,O
rate,O
compared,O
with,O
placebo,O
.,O
Can,O
it,O
be,O
treated,O
with,O
bromocriptine,Chemical
?,O
Anaesthesia,O
with,O
a,O
propofol,Chemical
infusion,O
and,O
avoidance,O
of,O
serotonin,Chemical
antagonists,O
provided,O
a,O
nausea,Disease
-,O
free,O
postoperative,O
course,O
without,O
exacerbation,O
of,O
the,O
depression,Disease
disorder,Disease
.,O
Attenuation,O
of,O
nephrotoxicity,Disease
by,O
a,O
novel,O
lipid,O
nanosphere,O
(,O
NS,O
-,O
718,O
),O
incorporating,O
amphotericin,Chemical
B,Chemical
.,O
Both,O
the,O
pressor,O
and,O
bradycardia,Disease
effects,O
of,O
cirazoline,Chemical
were,O
abolished,O
in,O
chronic,O
prazosin,Chemical
treated,O
SHR,O
(,O
n,O
=,O
4,O
),O
as,O
compared,O
to,O
the,O
untreated,O
SHR,O
(,O
n,O
=,O
4,O
),O
.,O
CONCLUSION,O
:,O
Our,O
data,O
suggest,O
that,O
Asian,O
patients,O
may,O
be,O
at,O
increased,O
risk,O
of,O
hyponatremia,Disease
and,O
/,O
or,O
SIADH,Disease
associated,O
with,O
vincristine,Chemical
use,O
.,O
In,O
contrast,O
",",O
learning,O
of,O
new,O
tasks,O
was,O
enhanced,O
and,O
correlated,O
with,O
the,O
increase,O
of,O
nNOS,O
activity,O
and,O
the,O
decrease,O
of,O
glutathione,Chemical
peroxidase,O
.,O
The,O
study,O
involved,O
129,O
patients,O
with,O
diabetes,Disease
with,O
serum,O
creatinine,Chemical
concentrations,O
of,O
1,O
.,O
5,O
to,O
3,O
.,O
5,O
mg,O
per,O
deciliter,O
who,O
underwent,O
coronary,O
or,O
aortofemoral,O
angiography,O
.,O
Calcium,Chemical
carbonate,Chemical
toxicity,Disease
:,O
the,O
updated,O
milk,Disease
-,Disease
alkali,Disease
syndrome,Disease
;,O
report,O
of,O
3,O
cases,O
and,O
review,O
of,O
the,O
literature,O
.,O
Serotonin,Chemical
and,O
N,Chemical
-,Chemical
acetyl,Chemical
serotonin,Chemical
which,O
augmented,O
ketamine,Chemical
DOC,O
",",O
did,O
not,O
do,O
so,O
in,O
the,O
absence,O
of,O
the,O
pineal,O
gland,O
",",O
whereas,O
melatonin,Chemical
potentiated,O
the,O
ketamine,Chemical
DOC,O
in,O
both,O
the,O
intact,O
and,O
pinealectomized,O
chick,O
.,O
There,O
was,O
a,O
direct,O
relationship,O
between,O
CHP,Chemical
concentration,O
and,O
patients,O
',O
ratings,O
of,O
pain,Disease
on,O
an,O
analogue,O
scale,O
.,O
BACKGROUND,O
:,O
Reports,O
of,O
severe,O
bradyarrhythmia,Disease
during,O
amiodarone,Chemical
therapy,O
are,O
infrequent,O
and,O
limited,O
to,O
studies,O
assessing,O
the,O
therapy,O
',O
s,O
use,O
in,O
the,O
management,O
of,O
patients,O
with,O
ventricular,Disease
arrhythmias,Disease
.,O
CONCLUSION,O
:,O
We,O
conclude,O
that,O
pre,O
-,O
treatment,O
with,O
propofol,Chemical
in,O
intralipid,O
",",O
compared,O
with,O
propofol,Chemical
in,O
medialipid,O
or,O
saline,O
",",O
delayed,O
the,O
onset,O
of,O
bupivacaine,Chemical
-,O
induced,O
cardiotoxic,Disease
effects,O
as,O
well,O
as,O
reduced,O
plasma,O
bupivacaine,Chemical
levels,O
.,O
Pharmacological,O
characteristics,O
and,O
side,O
effects,O
of,O
a,O
new,O
galenic,O
formulation,O
of,O
propofol,Chemical
without,O
soyabean,O
oil,O
.,O
The,O
effects,O
of,O
continuous,O
positive,O
airway,O
pressure,O
(,O
CPAP,O
),O
on,O
cardiovascular,O
dynamics,O
and,O
pulmonary,O
shunt,O
(,O
QS,O
/,O
QT,O
),O
were,O
investigated,O
in,O
12,O
dogs,O
before,O
and,O
during,O
sodium,Chemical
nitroprusside,Chemical
infusion,O
that,O
decreased,O
mean,O
arterial,O
blood,O
pressure,O
40,O
-,O
50,O
per,O
cent,O
.,O
However,O
",",O
when,O
converting,O
patients,O
to,O
RAPA,Chemical
drug,O
levels,O
should,O
be,O
monitored,O
to,O
avoid,O
over,O
-,O
immunosuppression,O
and,O
adequate,O
antiviral,O
and,O
Pneumocystis,Disease
carinii,Disease
pneumonia,Disease
prophylaxis,O
should,O
be,O
given,O
.,O
Ketamine,Chemical
elicited,O
psychosis,Disease
like,O
psychopathology,O
.,O
In,O
this,O
article,O
",",O
we,O
report,O
a,O
patient,O
with,O
SRC,Disease
induced,O
by,O
tacrolimus,Chemical
and,O
corticosteroids,Chemical
.,O
To,O
clarify,O
the,O
effects,O
of,O
bromocriptine,Chemical
on,O
prolactinoma,Disease
cells,O
in,O
vivo,O
",",O
immunohistochemical,O
",",O
ultrastructural,O
and,O
morphometrical,O
analyses,O
were,O
applied,O
to,O
estrogen,Chemical
-,O
induced,O
rat,O
prolactinoma,Disease
cells,O
1,O
h,O
and,O
6,O
h,O
after,O
injection,O
of,O
bromocriptine,Chemical
(,O
3,O
mg,O
/,O
kg,O
of,O
body,O
weight,O
),O
.,O
CONCLUSIONS,O
:,O
High,O
-,O
dose,O
5,Chemical
-,Chemical
FU,Chemical
/,O
FA,Chemical
/,O
MMC,Chemical
is,O
an,O
effective,O
and,O
well,O
-,O
tolerated,O
outpatient,O
regimen,O
for,O
AGC,Disease
(,O
objective,O
response,O
rate,O
54,O
.,O
6,O
%,O
),O
.,O
After,O
exercise,O
",",O
ejection,O
fraction,O
was,O
reduced,O
at,O
15,O
and,O
30,O
minutes,O
compared,O
with,O
baseline,O
(,O
mean,O
(,O
SEM,O
),O
",",O
-,O
5,O
.,O
6,O
(,O
1,O
.,O
5,O
),O
%,O
",",O
p,O
<,O
0,O
.,O
05,O
;,O
and,O
-,O
6,O
.,O
1,O
(,O
2,O
.,O
2,O
),O
%,O
",",O
p,O
<,O
0,O
.,O
01,O
),O
",",O
and,O
at,O
30,O
and,O
45,O
minutes,O
after,O
dobutamine,Chemical
(,O
-,O
10,O
.,O
8,O
(,O
1,O
.,O
8,O
),O
%,O
and,O
-,O
5,O
.,O
5,O
(,O
1,O
.,O
8,O
),O
%,O
",",O
both,O
p,O
<,O
0,O
.,O
01,O
),O
.,O
We,O
conclude,O
that,O
lidocaine,Chemical
reduces,O
the,O
incidence,O
and,O
severity,O
of,O
propofol,Chemical
injection,O
pain,Disease
in,O
ambulatory,O
patients,O
whereas,O
thiopentone,Chemical
only,O
reduces,O
its,O
severity,O
.,O
These,O
injuries,O
",",O
partly,O
mediated,O
by,O
a,O
rise,O
in,O
reactive,O
oxygen,Chemical
species,O
from,O
the,O
electron,O
transfer,O
chain,O
",",O
were,O
significantly,O
decreased,O
by,O
metformin,Chemical
.,O
CONCLUSIONS,O
:,O
The,O
data,O
suggest,O
that,O
neuropsychiatric,Disease
disorders,Disease
in,O
PD,Disease
are,O
more,O
likely,O
an,O
interaction,O
between,O
levodopa,Chemical
and,O
the,O
disease,O
state,O
than,O
a,O
consequence,O
of,O
sensitisation,O
to,O
repeated,O
dopaminergic,O
therapy,O
.,O
Can,O
lidocaine,Chemical
reduce,O
succinylcholine,Chemical
induced,O
postoperative,Disease
myalgia,Disease
?,O
The,O
lead,Chemical
-,O
treated,O
group,O
exhibited,O
a,O
rise,O
in,O
blood,O
pressure,O
and,O
plasma,O
MDA,Chemical
concentration,O
",",O
a,O
fall,O
in,O
urinary,O
NOx,O
excretion,O
",",O
and,O
a,O
paradoxical,O
rise,O
in,O
vascular,O
and,O
renal,O
tissue,O
eNOS,O
and,O
iNOS,O
expression,O
.,O
Sirolimus,Chemical
(,O
SRL,Chemical
),O
is,O
a,O
new,O
",",O
potent,O
immunosuppressive,O
agent,O
.,O
Two,O
patients,O
had,O
a,O
cholestatic,Disease
hepatitis,Disease
induced,O
by,O
carbimazole,Chemical
(,O
N,Chemical
omercazole,Chemical
),O
.,O
These,O
episodes,O
reversed,O
after,O
the,O
administration,O
of,O
diazepam,Chemical
1,O
mg,O
intravenously,O
.,O
On,O
the,O
13th,O
day,O
",",O
antinociceptive,O
effects,O
were,O
assessed,O
using,O
a,O
model,O
of,O
inflammatory,O
nociception,O
",",O
pain,Disease
-,O
induced,O
functional,O
impairment,O
model,O
",",O
and,O
the,O
charcoal,Chemical
meal,O
test,O
was,O
used,O
to,O
evaluate,O
the,O
intestinal,O
transit,O
.,O
She,O
had,O
developed,O
a,O
severe,O
acute,O
major,Disease
depression,Disease
disorder,Disease
almost,O
immediately,O
thereafter,O
",",O
possibly,O
related,O
to,O
the,O
use,O
of,O
a,O
serotonin,Chemical
antagonist,O
.,O
Mitomycin,Chemical
C,Chemical
associated,O
Hemolytic,Disease
Uremic,Disease
Syndrome,Disease
(,O
HUS,Disease
),O
is,O
a,O
potentially,O
fatal,O
but,O
uncommon,O
condition,O
that,O
is,O
not,O
yet,O
widely,O
recognised,O
.,O
A,O
search,O
of,O
the,O
literature,O
on,O
the,O
thromboembolic,Disease
complications,O
of,O
CC,Chemical
does,O
not,O
include,O
this,O
severe,O
ophthalmic,O
complication,O
",",O
although,O
mild,O
visual,Disease
disturbance,Disease
after,O
CC,Chemical
intake,O
is,O
not,O
uncommon,O
.,O
There,O
was,O
no,O
change,O
in,O
hepatic,O
tissue,O
total,O
glutathione,Chemical
following,O
intestinal,O
ischemia,Disease
-,O
reperfusion,Disease
injury,Disease
.,O
Takotsubo,Disease
syndrome,Disease
(,O
or,O
apical,Disease
ballooning,Disease
syndrome,Disease
),O
secondary,O
to,O
Zolmitriptan,Chemical
.,O
CONCLUSION,O
:,O
In,O
this,O
preliminary,O
report,O
",",O
divalproex,Chemical
sodium,Chemical
was,O
a,O
superior,O
alternative,O
to,O
lithium,Chemical
in,O
bipolar,Disease
patients,O
experiencing,O
cognitive,Disease
deficits,Disease
",",O
loss,Disease
of,Disease
creativity,Disease
",",O
and,O
functional,Disease
impairments,Disease
.,O
D,O
-,O
1,O
agonist,O
SKF,Chemical
38393,Chemical
or,O
D,O
-,O
2,O
agonist,O
quinpirole,Chemical
decreased,O
the,O
catalepsy,Disease
induced,O
by,O
fluphenazine,Chemical
",",O
SCH,Chemical
23390,Chemical
or,O
sulpiride,Chemical
.,O
During,O
the,O
SNP,Chemical
infusion,O
the,O
control,O
animals,O
demonstrated,O
a,O
progressive,O
increase,Disease
in,Disease
blood,Disease
pressure,Disease
to,O
61,O
torr,O
",",O
whereas,O
the,O
saralasin,Chemical
-,O
treated,O
animals,O
showed,O
no,O
change,O
.,O
Unpremedicated,O
patients,O
were,O
given,O
fentanyl,Chemical
1,O
microgram,O
/,O
kg,O
followed,O
by,O
etomidate,Chemical
0,O
.,O
3,O
mg,O
/,O
kg,O
.,O
Striatal,O
microglia,O
expressing,O
eGFP,O
constitutively,O
show,O
morphological,O
changes,O
after,O
METH,Chemical
that,O
are,O
characteristic,O
of,O
activation,O
.,O
Studies,O
were,O
performed,O
to,O
evaluate,O
whether,O
chronic,O
prazosin,Chemical
treatment,O
alters,O
the,O
alpha,O
2,O
-,O
adrenoceptor,O
function,O
for,O
orthostatic,O
control,O
of,O
arterial,O
blood,O
pressure,O
in,O
conscious,O
spontaneously,O
hypertensive,Disease
rats,O
(,O
SHR,O
),O
.,O
However,O
",",O
the,O
mechanisms,O
of,O
myocardial,Disease
ischemia,Disease
induced,O
by,O
epinephrine,Chemical
were,O
significantly,O
different,O
from,O
those,O
of,O
exercise,O
.,O
It,O
is,O
suggested,O
that,O
nefiracetam,Chemical
augments,O
molecular,O
processes,O
in,O
the,O
early,O
stages,O
of,O
events,O
which,O
ultimately,O
lead,O
to,O
consolidation,O
of,O
memory,O
.,O
This,O
case,O
contributes,O
to,O
the,O
previous,O
observations,O
that,O
non,O
-,O
metastasizing,O
hepatic,Disease
neoplasms,Disease
and,O
peliosis,Disease
can,O
develop,O
in,O
patients,O
with,O
androgen,Chemical
-,O
and,O
corticosteroid,Chemical
-,O
treated,O
Fanconi,Disease
',Disease
s,Disease
anemia,Disease
.,O
These,O
data,O
suggest,O
that,O
during,O
concomitant,O
treatment,O
with,O
cinacalcet,Chemical
",",O
dose,O
adjustment,O
may,O
be,O
necessary,O
for,O
drugs,O
that,O
demonstrate,O
a,O
narrow,O
therapeutic,O
index,O
and,O
are,O
metabolized,O
by,O
CYP2D6,O
.,O
However,O
",",O
ketone,Chemical
bodies,O
were,O
consistently,O
present,O
in,O
urine,O
and,O
several,O
lethalities,O
occurred,O
during,O
multiple,O
dosing,O
of,O
captopril,Chemical
in,O
SHR,O
.,O
In,O
previous,O
experiments,O
we,O
found,O
that,O
decreases,O
in,O
food,O
intake,O
were,O
induced,O
by,O
local,O
administration,O
of,O
calcitonin,Chemical
into,O
several,O
hypothalamic,O
sites,O
and,O
into,O
the,O
nucleus,O
accumbens,O
.,O
Focal,O
glutamate,Chemical
photostimulation,O
of,O
the,O
granule,O
cell,O
layer,O
at,O
sites,O
distant,O
from,O
the,O
recording,O
pipette,O
resulted,O
in,O
population,O
responses,O
of,O
1,O
-,O
30,O
s,O
duration,O
in,O
slices,O
from,O
SE,Disease
survivors,O
but,O
not,O
other,O
groups,O
.,O
Group,O
ADR,Chemical
+,O
LOS,Chemical
(,O
6,O
),O
received,O
losartan,Chemical
(,O
10,O
mg,O
/,O
kg,O
/,O
b,O
.,O
w,O
.,O
/,O
day,O
by,O
gavages,O
),O
for,O
6,O
weeks,O
and,O
group,O
ADR,Chemical
+,O
LOS,Chemical
(,O
12,O
),O
for,O
12,O
weeks,O
after,O
second,O
injection,O
of,O
ADR,Chemical
.,O
Therefore,O
",",O
DCE,Chemical
may,O
prove,O
to,O
be,O
a,O
useful,O
remedy,O
for,O
the,O
management,O
of,O
cognitive,Disease
dysfunctions,Disease
on,O
account,O
of,O
its,O
multifarious,O
beneficial,O
effects,O
such,O
as,O
",",O
memory,O
improving,O
property,O
",",O
cholesterol,Chemical
lowering,O
property,O
and,O
anticholinesterase,O
activity,O
.,O
Experimental,O
cyclosporine,Chemical
nephrotoxicity,Disease
:,O
risk,O
of,O
concomitant,O
chemotherapy,O
.,O
Clinical,O
safety,O
of,O
lidocaine,Chemical
in,O
patients,O
with,O
cocaine,Chemical
-,O
associated,O
myocardial,Disease
infarction,Disease
.,O
Intravenous,O
propranolol,Chemical
after,O
PPA,Chemical
also,O
decreased,O
blood,O
pressure,O
.,O
Vasodilation,O
of,O
large,O
and,O
small,O
coronary,O
vessels,O
and,O
hypotension,Disease
induced,O
by,O
cromakalim,Chemical
and,O
pinacidil,Chemical
were,O
not,O
affected,O
by,O
prior,O
combined,O
beta,Chemical
adrenergic,Chemical
and,Chemical
muscarinic,Chemical
receptors,Chemical
blockade,Chemical
but,O
drug,O
-,O
induced,O
tachycardia,Disease
was,O
abolished,O
.,O
RESULTS,O
:,O
The,O
results,O
showed,O
that,O
IP,O
administration,O
of,O
bupropion,Chemical
HCl,Chemical
120,O
mg,O
/,O
kg,O
by,O
bolus,O
injection,O
induced,O
convulsions,Disease
in,O
6,O
out,O
of,O
10,O
mice,O
(,O
60,O
%,O
of,O
convulsing,O
mice,O
),O
in,O
group,O
1,O
.,O
Ketoprofen,Chemical
but,O
not,O
acetaminophen,Chemical
impaired,O
platelet,O
function,O
in,O
patients,O
with,O
SAH,Disease
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
case,O
report,O
of,O
simvastatin,Chemical
-,Chemical
ezetimibe,Chemical
-,O
induced,O
liver,Disease
failure,Disease
that,O
resulted,O
in,O
liver,O
transplantation,O
.,O
The,O
0,O
.,O
25,O
per,O
cent,O
CHP,Chemical
cream,O
was,O
closest,O
to,O
AgSD,Chemical
in,O
pain,Disease
tolerance,O
;,O
however,O
",",O
none,O
of,O
the,O
treatments,O
differed,O
statistically,O
from,O
AgSD,Chemical
or,O
from,O
each,O
other,O
.,O
Logistic,O
regression,O
showed,O
no,O
significant,O
difference,O
in,O
the,O
risk,O
of,O
VTE,Disease
between,O
users,O
of,O
third,O
-,O
generation,O
and,O
second,O
-,O
generation,O
OCs,Chemical
.,O
Neuroactive,O
steroids,Chemical
protect,O
against,O
pilocarpine,Chemical
-,O
and,O
kainic,Chemical
acid,Chemical
-,O
induced,O
limbic,O
seizures,Disease
and,O
status,Disease
epilepticus,Disease
in,O
mice,O
.,O
A,O
78,O
-,O
year,O
-,O
old,O
with,O
healed,O
septal,O
necrosis,Disease
suffered,O
a,O
recurrent,O
myocardial,Disease
infarction,Disease
of,O
the,O
anterior,O
wall,O
following,O
the,O
administration,O
of,O
isosorbide,Chemical
dinitrate,Chemical
5,O
mg,O
sublingually,O
.,O
Antitumor,O
activity,O
",",O
cardiotoxicity,Disease
",",O
and,O
nephrotoxicity,Disease
induced,O
by,O
doxorubicin,Chemical
were,O
studied,O
in,O
LOU,O
/,O
M,O
/,O
WSL,O
inbred,O
rats,O
each,O
bearing,O
a,O
transplantable,O
solid,O
IgM,O
immunocytoma,Disease
.,O
The,O
heart,Disease
block,Disease
was,O
treated,O
by,O
pacemaker,O
insertion,O
and,O
the,O
heart,Disease
failure,Disease
resolved,O
spontaneously,O
following,O
chloroquine,Chemical
discontinuation,O
.,O
On,O
the,O
other,O
hand,O
",",O
pretreatment,O
with,O
p,Chemical
-,Chemical
chlorophenylalamine,Chemical
(,O
3,O
X,O
320,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
",",O
24,O
hr,O
),O
",",O
a,O
serotonin,Chemical
depletor,O
",",O
caused,O
no,O
significant,O
change,O
in,O
the,O
hyperactivity,Disease
.,O
AIM,O
:,O
This,O
study,O
was,O
carried,O
out,O
to,O
determine,O
the,O
effect,O
of,O
injection,O
duration,O
on,O
bruising,Disease
and,O
pain,Disease
following,O
the,O
administration,O
of,O
the,O
subcutaneous,O
injection,O
of,O
heparin,Chemical
.,O
DESIGN,O
:,O
A,O
prospective,O
study,O
to,O
monitor,O
indinavir,Chemical
-,O
related,O
nephrotoxicity,Disease
in,O
a,O
cohort,O
of,O
30,O
human,Disease
immunodeficiency,Disease
virus,Disease
type,Disease
1,Disease
-,Disease
infected,Disease
children,O
treated,O
with,O
indinavir,Chemical
.,O
In,O
L,O
-,O
W,O
rats,O
",",O
TP,Chemical
acted,O
as,O
a,O
tumor,Disease
enhancement,O
agent,O
",",O
with,O
primary,O
emphasis,O
on,O
the,O
development,O
of,O
prostate,Disease
cancer,Disease
.,O
Reversible,O
valproic,Chemical
acid,Chemical
-,O
induced,O
dementia,Disease
was,O
documented,O
in,O
a,O
21,O
-,O
year,O
-,O
old,O
man,O
with,O
epilepsy,Disease
who,O
had,O
a,O
3,O
-,O
year,O
history,O
of,O
insidious,O
progressive,O
decline,O
in,O
global,O
cognitive,O
abilities,O
documented,O
by,O
serial,O
neuropsychological,O
studies,O
.,O
CONCLUSIONS,O
:,O
This,O
is,O
the,O
first,O
study,O
to,O
link,O
risperidone,Chemical
-,O
induced,O
hyperprolactinemia,Disease
and,O
SSRI,O
treatment,O
to,O
lower,O
BMD,O
in,O
children,O
and,O
adolescents,O
.,O
Amiodarone,Chemical
-,O
induced,O
torsade,Disease
de,Disease
pointes,Disease
during,O
bladder,O
irrigation,O
:,O
an,O
unusual,O
presentation,O
-,O
-,O
a,O
case,O
report,O
.,O
L,Chemical
-,Chemical
NAME,Chemical
reduced,O
gentamicin,Chemical
-,O
induced,O
hearing,Disease
loss,Disease
in,O
the,O
high,O
-,O
frequency,O
range,O
",",O
but,O
gave,O
no,O
protection,O
in,O
the,O
middle,O
or,O
low,O
frequencies,O
.,O
Also,O
",",O
digoxin,Chemical
has,O
undesirable,O
effects,O
such,O
as,O
increasing,O
peripheral,O
resistance,O
and,O
myocardial,O
demands,O
",",O
and,O
causing,O
arrhythmias,Disease
.,O
CONCLUSIONS,O
:,O
Ethambutol,Chemical
usage,O
is,O
associated,O
with,O
permanent,O
visual,Disease
loss,Disease
and,O
should,O
be,O
avoided,O
if,O
possible,O
or,O
used,O
with,O
caution,O
and,O
proper,O
ophthalmological,O
follow,O
-,O
up,O
.,O
The,O
first,O
patient,O
died,O
without,O
a,O
diagnosis,O
;,O
the,O
second,O
patient,O
had,O
a,O
dramatic,O
recovery,O
following,O
the,O
administration,O
of,O
vitamin,Chemical
B6,Chemical
.,O
The,O
results,O
revealed,O
that,O
the,O
adult,O
offspring,O
kidneys,O
in,O
the,O
PCE,O
group,O
exhibited,O
glomerulosclerosis,Disease
as,O
well,O
as,O
interstitial,Disease
fibrosis,Disease
",",O
accompanied,O
by,O
elevated,O
levels,O
of,O
serum,O
creatinine,Chemical
and,O
urine,O
protein,O
.,O
The,O
beneficial,O
effects,O
of,O
vitamin,Chemical
C,Chemical
administration,O
to,O
gentamicin,Chemical
-,O
treated,O
animals,O
are,O
also,O
confirmed,O
through,O
:,O
lower,O
level,O
of,O
blood,O
urea,Chemical
and,O
creatinine,Chemical
and,O
higher,O
level,O
of,O
potassium,Chemical
.,O
Moreover,O
",",O
it,O
transiently,O
diminished,O
the,O
methamphetamine,Chemical
(,O
10,O
mg,O
/,O
kg,O
sc,O
),O
-,O
induced,O
hyperthermia,Disease
and,O
reduced,O
basal,O
body,O
temperature,O
.,O
Activation,O
of,O
presynaptic,O
alpha2,O
-,O
adrenoceptors,O
is,O
the,O
most,O
widely,O
accepted,O
mechanism,O
of,O
action,O
of,O
the,O
antisympathetic,O
drug,O
clonidine,Chemical
;,O
however,O
",",O
other,O
target,O
proteins,O
have,O
been,O
postulated,O
to,O
contribute,O
to,O
the,O
in,O
vivo,O
actions,O
of,O
clonidine,Chemical
.,O
Vitamin,Chemical
B12,Chemical
and,O
folinic,Chemical
acid,Chemical
supplementation,O
of,O
ZDV,Chemical
therapy,O
does,O
not,O
seem,O
useful,O
in,O
preventing,O
or,O
reducing,O
ZDV,Chemical
-,O
induced,O
myelotoxicity,Disease
in,O
the,O
overall,O
treated,O
population,O
",",O
although,O
a,O
beneficial,O
effect,O
in,O
certain,O
subgroups,O
of,O
patients,O
cannot,O
be,O
excluded,O
.,O
L,Chemical
-,Chemical
NAME,Chemical
(,O
100,O
mg,O
/,O
kg,O
",",O
i,O
.,O
p,O
.,O
),O
and,O
diazepam,Chemical
(,O
2,O
mg,O
/,O
kg,O
),O
significantly,O
decreased,O
the,O
incidence,O
of,O
lidocaine,Chemical
(,O
50,O
mg,O
/,O
kg,O
),O
-,O
induced,O
convulsions,Disease
.,O
Famotidine,Chemical
-,O
associated,O
delirium,Disease
.,O
Hepatitis,Disease
B,Disease
immune,O
globulin,O
(,O
HBIG,O
),O
and,O
immune,O
serum,O
globulin,O
(,O
ISG,O
),O
were,O
examined,O
in,O
a,O
randomized,O
",",O
double,O
-,O
blind,O
trial,O
to,O
assess,O
their,O
relative,O
efficacies,O
in,O
preventing,O
type,Disease
B,Disease
hepatitis,Disease
after,O
needle,O
-,O
stick,O
exposure,O
to,O
hepatitis,Chemical
B,Chemical
surface,Chemical
antigen,Chemical
(,O
HBsAG,Chemical
),O
-,O
positive,O
donors,O
.,O
Clinicians,O
should,O
be,O
alert,O
to,O
the,O
possibility,O
of,O
hyperkalemia,Disease
",",O
especially,O
in,O
elderly,O
patients,O
using,O
ACE,O
/,O
ARB,O
in,O
combination,O
with,O
potassium,Chemical
sparing,O
agents,O
and,O
who,O
have,O
mild,O
renal,Disease
disturbance,Disease
.,O
A,O
total,O
of,O
60,O
male,O
Wistar,O
albino,O
rats,O
were,O
randomly,O
divided,O
into,O
four,O
groups,O
(,O
15,O
/,O
group,O
),O
:,O
The,O
control,O
group,O
injected,O
with,O
single,O
doses,O
of,O
normal,O
saline,O
(,O
i,O
.,O
c,O
.,O
v,O
),O
followed,O
24,O
h,O
later,O
by,O
BCNU,Chemical
solvent,O
(,O
i,O
.,O
v,O
),O
.,O
These,O
data,O
are,O
consistent,O
with,O
the,O
hypothesis,O
that,O
exercise,O
-,O
induced,O
tachycardia,Disease
results,O
largely,O
from,O
beta,O
1,O
-,O
receptor,O
activation,O
that,O
is,O
blocked,O
by,O
both,O
cardioselective,O
and,O
nonselective,O
drugs,O
",",O
whereas,O
isoproterenol,Chemical
activates,O
both,O
beta,O
1,O
-,O
and,O
beta,O
2,O
-,O
receptors,O
so,O
that,O
after,O
cardioselective,O
blockade,O
there,O
remains,O
a,O
beta,O
2,O
-,O
component,O
that,O
can,O
be,O
blocked,O
with,O
a,O
nonselective,O
drug,O
.,O
The,O
patient,O
described,O
developed,O
chronic,Disease
active,Disease
hepatitis,Disease
after,O
six,O
months,O
therapy,O
with,O
diclofenac,Chemical
sodium,Chemical
which,O
progressed,O
despite,O
the,O
withdrawal,O
of,O
the,O
drug,O
",",O
a,O
finding,O
not,O
previously,O
reported,O
.,O
CONCLUSION,O
:,O
The,O
use,O
of,O
light,O
propofol,Chemical
sedation,O
decreased,O
the,O
prevalence,O
of,O
postoperative,Disease
delirium,Disease
by,O
50,O
%,O
compared,O
with,O
deep,O
sedation,O
.,O
KF17837,Chemical
also,O
reduced,O
the,O
catalepsy,Disease
induced,O
by,O
haloperidol,Chemical
(,O
1,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
and,O
by,O
reserpine,Chemical
(,O
5,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
.,O
As,O
compared,O
with,O
controls,O
",",O
fluoxetine,Chemical
exposure,O
resulted,O
in,O
fetal,Disease
pulmonary,Disease
hypertension,Disease
as,O
evidenced,O
by,O
an,O
increase,O
in,O
the,O
weight,O
ratio,O
of,O
the,O
right,O
ventricle,O
to,O
the,O
left,O
ventricle,O
plus,O
septum,O
(,O
P,O
=,O
0,O
.,O
02,O
),O
and,O
by,O
an,O
increase,O
in,O
pulmonary,O
arterial,O
medial,O
thickness,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
.,O
Testosterone,Chemical
replacement,O
in,O
castrated,O
DS,O
rats,O
increased,O
BP,O
",",O
renal,Disease
injury,Disease
",",O
and,O
upregulation,O
of,O
renal,O
angiotensinogen,O
associated,O
with,O
HS,O
diet,O
.,O
On,O
amphetamine,Chemical
-,O
induced,O
hyperactivity,Disease
",",O
THP,Chemical
(,O
3,O
.,O
75,O
and,O
7,O
.,O
5,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
reduced,O
locomotor,O
time,O
",",O
distance,O
traveled,O
and,O
average,O
speed,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
.,O
The,O
anaemia,Disease
induced,O
by,O
3,Chemical
',Chemical
-,Chemical
azido,Chemical
-,Chemical
3,Chemical
',Chemical
dideoxythymidine,Chemical
(,O
AZT,Chemical
),O
is,O
poorly,O
understood,O
.,O
Heparin,Chemical
was,O
injected,O
over,O
10,O
seconds,O
on,O
the,O
right,O
abdominal,O
site,O
and,O
30,O
seconds,O
on,O
the,O
left,O
abdominal,O
site,O
.,O
Recent,O
preclinical,O
and,O
clinical,O
data,O
from,O
promising,O
lines,O
of,O
research,O
focus,O
on,O
the,O
differential,O
role,O
of,O
presynaptic,O
versus,O
postsynaptic,O
mechanisms,O
",",O
dopamine,Chemical
receptor,O
subtypes,O
",",O
ionotropic,O
and,O
metabotropic,O
glutamate,Chemical
receptors,O
",",O
and,O
non,O
-,O
dopaminergic,O
neurotransmitter,O
systems,O
in,O
the,O
pathophysiology,O
of,O
levodopa,Chemical
-,O
induced,O
dyskinesias,Disease
.,O
The,O
incidence,O
of,O
hypokalemia,Disease
was,O
lower,O
with,O
VAL,Chemical
/,O
HCTZ,Chemical
combinations,O
(,O
1,O
.,O
8,O
%,O
-,O
6,O
.,O
1,O
%,O
),O
than,O
with,O
HCTZ,Chemical
monotherapies,O
(,O
7,O
.,O
1,O
%,O
-,O
13,O
.,O
3,O
%,O
),O
.,O
To,O
determine,O
sensitivity,O
we,O
assessed,O
tremor,Disease
in,O
44,O
patients,O
with,O
obstructive,Disease
lung,Disease
disease,Disease
after,O
administration,O
of,O
cumulative,O
doses,O
of,O
salbutamol,Chemical
.,O
Our,O
findings,O
",",O
showing,O
no,O
interaction,O
between,O
capsaicin,Chemical
treatment,O
and,O
attentional,O
modulation,O
suggest,O
that,O
capsaicin,Chemical
-,O
induced,O
secondary,O
hyperalgesia,Disease
and,O
attention,O
might,O
affect,O
mechanical,O
pain,Disease
through,O
independent,O
mechanisms,O
.,O
After,O
further,O
adjustment,O
for,O
potential,O
confounders,O
",",O
the,O
odds,O
ratio,O
in,O
women,O
who,O
reported,O
using,O
cocaine,Chemical
and,O
/,O
or,O
amphetamine,Chemical
was,O
7,O
.,O
0,O
(,O
95,O
%,O
confidence,O
interval,O
=,O
2,O
.,O
8,O
-,O
17,O
.,O
9,O
),O
.,O
Drowsiness,Disease
and,O
altered,Disease
taste,Disease
perception,Disease
were,O
increased,O
significantly,O
over,O
placebo,O
only,O
in,O
the,O
high,O
-,O
dose,O
azelastine,Chemical
group,O
.,O
Busulfan,Chemical
is,O
known,O
to,O
be,O
neurotoxic,Disease
in,O
animals,O
and,O
humans,O
",",O
but,O
its,O
acute,O
neurotoxicity,Disease
remains,O
poorly,O
characterized,O
in,O
children,O
.,O
The,O
present,O
experiments,O
were,O
performed,O
to,O
study,O
the,O
effect,O
of,O
the,O
flavonoid,Chemical
apigenin,Chemical
(,O
20,O
mg,O
/,O
kg,O
intraperitoneally,O
(,O
i,O
.,O
p,O
.,O
),O
",",O
1,O
h,O
before,O
acquisition,O
),O
",",O
on,O
24,O
h,O
retention,O
performance,O
and,O
forgetting,O
of,O
a,O
step,O
-,O
through,O
passive,O
avoidance,O
task,O
",",O
in,O
young,O
male,O
Wistar,O
rats,O
.,O
In,O
the,O
double,O
blind,O
study,O
with,O
haloperidol,Chemical
",",O
both,O
substances,O
were,O
found,O
to,O
be,O
highly,O
effective,O
in,O
the,O
treatment,O
of,O
psychotic,Disease
syndromes,Disease
belonging,Disease
predominantly,Disease
to,Disease
the,Disease
schizophrenia,Disease
group,Disease
.,O
The,O
findings,O
showed,O
that,O
peripheral,O
iron,Chemical
dextran,Chemical
overload,O
increased,O
the,O
iron,Chemical
staining,O
positive,O
cells,O
and,O
reduced,O
the,O
number,O
of,O
TH,O
-,O
immunoreactive,O
neurons,O
in,O
the,O
SN,O
.,O
Renal,O
blood,O
flow,O
(,O
RBF,O
),O
increased,O
during,O
fenoldopam,Chemical
-,O
induced,O
hypotension,Disease
11,O
+,O
/,O
-,O
7,O
per,O
cent,O
and,O
decreased,O
21,O
+,O
/,O
-,O
8,O
per,O
cent,O
during,O
sodium,Chemical
nitroprusside,Chemical
-,O
induced,O
hypotension,Disease
(,O
P,O
less,O
than,O
0,O
.,O
01,O
),O
.,O
Aconitine,Chemical
-,O
induced,O
Ca2,Chemical
+,O
overload,O
causes,O
arrhythmia,Disease
and,O
triggers,O
apoptosis,O
through,O
p38,O
MAPK,O
signaling,O
pathway,O
in,O
rats,O
.,O
RESULTS,O
:,O
Anxiety,Disease
was,O
documented,O
in,O
both,O
groups,O
of,O
PDN,Chemical
treated,O
rats,O
compared,O
with,O
controls,O
.,O
We,O
report,O
here,O
the,O
first,O
case,O
of,O
Dexatrim,Chemical
(,O
PPA,Chemical
),O
-,O
induced,O
myocardial,Disease
injury,Disease
in,O
a,O
young,O
woman,O
who,O
was,O
using,O
it,O
at,O
recommended,O
doses,O
for,O
weight,O
control,O
.,O
We,O
prospectively,O
evaluated,O
the,O
adverse,O
reactions,O
of,O
apraclonidine,Chemical
in,O
20,O
normal,O
volunteers,O
by,O
instilling,O
a,O
single,O
drop,O
of,O
1,O
%,O
apraclonidine,Chemical
in,O
their,O
right,O
eyes,O
.,O
This,O
study,O
supports,O
the,O
high,O
frequency,O
of,O
restrictive,O
valve,Disease
regurgitation,Disease
in,O
PD,Disease
patients,O
treated,O
with,O
pergolide,Chemical
and,O
reveals,O
that,O
a,O
significant,O
improvement,O
is,O
usual,O
when,O
the,O
treatment,O
is,O
converted,O
to,O
non,O
-,O
ergot,O
dopamine,Chemical
agonists,O
.,O
The,O
topical,O
application,O
of,O
a,O
glycopyrrolate,Chemical
pad,O
appeared,O
to,O
be,O
safe,O
",",O
efficacious,O
",",O
well,O
tolerated,O
",",O
and,O
a,O
convenient,O
method,O
of,O
treatment,O
for,O
moderate,O
to,O
severe,O
symptoms,O
of,O
gustatory,Disease
hyperhidrosis,Disease
in,O
post,O
transthoracic,O
endoscopic,O
sympathectomy,O
or,O
sympathicotomy,O
patients,O
",",O
with,O
few,O
side,O
effects,O
.,O
Concentration,O
of,O
dopamine,Chemical
and,O
its,O
metabolites,O
were,O
decreased,O
in,O
the,O
striatum,O
of,O
substantia,O
nigra,O
lesioned,O
rats,O
.,O
CaCO3,Chemical
dosage,O
",",O
calculated,O
dietary,O
calcium,Chemical
intake,O
",",O
and,O
circulating,O
levels,O
of,O
vitamin,Chemical
D,Chemical
metabolites,O
were,O
similar,O
in,O
both,O
groups,O
.,O
Stopping,O
minocycline,Chemical
led,O
to,O
amelioration,O
of,O
symptoms,O
and,O
normalization,O
of,O
CRP,O
level,O
.,O
While,O
the,O
use,O
of,O
MDMA,Chemical
in,O
quantities,O
that,O
may,O
be,O
considered,O
"""",O
moderate,O
"""",O
is,O
not,O
associated,O
with,O
impaired,Disease
memory,Disease
functioning,Disease
",",O
heavy,O
use,O
of,O
MDMA,Chemical
use,O
may,O
lead,O
to,O
long,O
lasting,O
memory,Disease
impairments,Disease
.,O
AIM,O
:,O
Hemorrhagic,Disease
cystitis,Disease
(,O
HC,Disease
),O
is,O
a,O
limiting,O
side,O
-,O
effect,O
of,O
chemotherapy,O
with,O
ifosfamide,Chemical
(,O
IFS,Chemical
),O
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
study,O
the,O
effect,O
of,O
histamine,Chemical
H,O
(,O
3,O
),O
-,O
receptor,O
ligands,O
on,O
neuroleptic,O
-,O
induced,O
catalepsy,Disease
",",O
apomorphine,Chemical
-,O
induced,O
climbing,O
behavior,O
and,O
amphetamine,Chemical
-,O
induced,O
locomotor,O
activities,O
in,O
mice,O
.,O
After,O
4,O
weeks,O
the,O
PAN,Chemical
rats,O
were,O
severely,O
proteinuric,Disease
(,O
190,O
+,O
/,O
-,O
80,O
mg,O
/,O
24,O
hr,O
),O
",",O
and,O
all,O
rats,O
were,O
given,O
colloidal,O
carbon,Chemical
(,O
CC,O
),O
intravenously,O
.,O
Application,O
of,O
an,O
irreversible,O
inhibitor,O
of,O
GABA,Chemical
transaminase,O
",",O
gamma,Chemical
-,Chemical
vinyl,Chemical
-,Chemical
GABA,Chemical
(,O
D,Chemical
",",Chemical
L,Chemical
-,Chemical
4,Chemical
-,Chemical
amino,Chemical
-,Chemical
hex,Chemical
-,Chemical
5,Chemical
-,Chemical
enoic,Chemical
acid,Chemical
),O
",",O
5,O
micrograms,O
",",O
into,O
the,O
SNR,O
",",O
bilaterally,O
",",O
suppressed,O
the,O
appearance,O
of,O
electrographic,O
and,O
behavioral,O
seizures,Disease
produced,O
by,O
pilocarpine,Chemical
",",O
380,O
mg,O
/,O
kg,O
.,O
We,O
report,O
a,O
case,O
of,O
hypotension,Disease
",",O
bradycardia,Disease
",",O
and,O
asystole,Disease
after,O
intravenous,O
administration,O
of,O
high,O
-,O
dose,O
methylprednisolone,Chemical
in,O
a,O
73,O
-,O
year,O
-,O
old,O
patient,O
who,O
underwent,O
electrocardiographic,O
(,O
ECG,O
),O
monitoring,O
throughout,O
the,O
episode,O
.,O
Increased,O
anxiogenic,O
effects,O
of,O
caffeine,Chemical
in,O
panic,Disease
disorders,Disease
.,O
This,O
suggests,O
that,O
benztropine,Chemical
is,O
not,O
the,O
anticholinergic,O
drug,O
of,O
choice,O
in,O
the,O
treatment,O
of,O
neuroleptic,O
-,O
induced,O
parkinsonian,Disease
symptoms,Disease
",",O
because,O
of,O
its,O
more,O
toxic,O
central,O
and,O
peripheral,O
atropinic,O
effect,O
.,O
An,O
open,O
-,O
label,O
phase,O
II,O
study,O
of,O
low,O
-,O
dose,O
thalidomide,Chemical
in,O
androgen,Chemical
-,O
independent,O
prostate,Disease
cancer,Disease
.,O
BACKGROUND,O
:,O
A,O
previous,O
randomized,O
controlled,O
trial,O
evaluating,O
the,O
use,O
of,O
spironolactone,Chemical
in,O
heart,Disease
failure,Disease
patients,O
reported,O
a,O
low,O
risk,O
of,O
hyperkalemia,Disease
(,O
2,O
%,O
),O
and,O
renal,Disease
insufficiency,Disease
(,O
0,O
%,O
),O
.,O
A,O
significant,O
reduction,O
in,O
urinary,O
guanosine,Chemical
3,Chemical
',Chemical
",",Chemical
5,Chemical
',Chemical
-,Chemical
cyclic,Chemical
monophosphate,Chemical
(,O
cGMP,Chemical
),O
excretion,O
and,O
a,O
significant,O
increase,O
in,O
renal,O
cortical,O
renin,O
and,O
endothelin,O
-,O
1,O
contents,O
were,O
also,O
observed,O
in,O
GM,Chemical
-,O
mediated,O
nephropathy,Disease
.,O
Initial,O
testing,O
in,O
a,O
time,O
-,O
dependent,O
forgetting,O
task,O
employing,O
a,O
24,O
-,O
h,O
delay,O
between,O
training,O
and,O
testing,O
showed,O
that,O
metrifonate,Chemical
improved,O
object,O
recognition,O
(,O
at,O
10,O
and,O
30,O
mg,O
/,O
kg,O
",",O
p,O
.,O
o,O
.,O
),O
",",O
whereas,O
Ro4368554,Chemical
was,O
inactive,O
.,O
When,O
circumflex,O
artery,O
blood,O
flow,O
was,O
maintained,O
constant,O
",",O
the,O
increases,O
in,O
CxAD,O
induced,O
by,O
cromakalim,Chemical
(,O
10,O
micrograms,O
/,O
kg,O
),O
",",O
pinacidil,Chemical
(,O
30,O
micrograms,O
/,O
kg,O
),O
and,O
nitroglycerin,Chemical
(,O
10,O
micrograms,O
/,O
kg,O
),O
were,O
reduced,O
by,O
68,O
+,O
/,O
-,O
7,O
",",O
54,O
+,O
/,O
-,O
9,O
and,O
1,O
+,O
/,O
-,O
1,O
%,O
",",O
respectively,O
.,O
A,O
dose,O
of,O
0,O
.,O
5,O
mg,O
.,O
/,O
kg,O
.,O
produced,O
a,O
reduction,O
of,O
almost,O
50,O
%,O
of,O
the,O
behavioral,O
score,O
induced,O
by,O
CP,Chemical
200,O
mg,O
.,O
/,O
kg,O
.,O
The,O
specific,O
aim,O
of,O
this,O
retrospective,O
",",O
observational,O
study,O
was,O
to,O
assess,O
safety,O
and,O
efficacy,O
of,O
long,O
-,O
term,O
(,O
21,O
months,O
/,O
patient,O
),O
",",O
open,O
-,O
label,O
",",O
gemfibrozil,Chemical
-,O
lovastatin,Chemical
treatment,O
in,O
80,O
patients,O
with,O
primary,O
mixed,O
hyperlipidemia,Disease
(,O
68,O
%,O
of,O
whom,O
had,O
atherosclerotic,Disease
vascular,Disease
disease,Disease
),O
.,O
Persistent,O
sterile,O
leukocyturia,Disease
is,O
associated,O
with,O
impaired,Disease
renal,Disease
function,Disease
in,O
human,Disease
immunodeficiency,Disease
virus,Disease
type,Disease
1,Disease
-,Disease
infected,Disease
children,O
treated,O
with,O
indinavir,Chemical
.,O
The,O
role,O
of,O
nicotine,Chemical
in,O
smoking,O
-,O
related,O
cardiovascular,Disease
disease,Disease
.,O
Seizures,Disease
induced,O
by,O
combined,O
levomepromazine,Chemical
-,O
fluvoxamine,Chemical
treatment,O
.,O
AChE,O
activity,O
was,O
significantly,O
decreased,O
in,O
the,O
hippocampus,O
of,O
mice,O
with,O
BPA,Chemical
compared,O
to,O
control,O
mice,O
",",O
whereas,O
no,O
difference,O
was,O
found,O
in,O
the,O
prefrontal,O
cortex,O
",",O
hypothalamus,O
and,O
cerebellum,O
.,O
The,O
present,O
results,O
demonstrate,O
that,O
CCK,Chemical
-,Chemical
8,Chemical
attenuates,O
the,O
effect,O
of,O
morphine,Chemical
on,O
hippocampal,O
LTP,O
through,O
CCK2,O
receptors,O
and,O
suggest,O
an,O
ameliorative,O
function,O
of,O
CCK,Chemical
-,Chemical
8,Chemical
on,O
morphine,Chemical
-,O
induced,O
memory,Disease
impairment,Disease
.,O
Daptomycin,Chemical
serum,O
and,O
CSF,O
trough,O
concentrations,O
were,O
11,O
.,O
21,O
ug,O
/,O
mL,O
and,O
0,O
.,O
52,O
ug,O
/,O
mL,O
",",O
respectively,O
",",O
prior,O
to,O
the,O
third,O
dose,O
.,O
A,O
single,O
PPA,Chemical
/,O
caffeine,Chemical
administration,O
(,O
same,O
dose,O
),O
lead,O
to,O
acute,O
hypertension,Disease
in,O
both,O
the,O
normotensive,O
and,O
hypertensive,Disease
animals,O
.,O
In,O
individuals,O
with,O
preexisting,O
",",O
high,O
-,O
grade,O
coronary,O
arterial,O
narrowing,O
",",O
acute,Disease
myocardial,Disease
infarction,Disease
may,O
result,O
from,O
an,O
increase,O
in,O
myocardial,O
oxygen,Chemical
demand,O
associated,O
with,O
cocaine,Chemical
-,O
induced,O
increase,O
in,O
rate,O
-,O
pressure,O
product,O
.,O
Hannover,O
Wistar,O
rats,O
were,O
dosed,O
with,O
1,O
.,O
25,O
mg,O
/,O
kg,O
DOX,Chemical
weekly,O
for,O
8,O
weeks,O
followed,O
by,O
a,O
4,O
week,O
off,O
-,O
dosing,O
"""",O
recovery,O
"""",O
period,O
.,O
In,O
contrast,O
",",O
the,O
protein,O
abundances,O
of,O
Na,Chemical
(,O
+,O
),O
/,O
H,Chemical
(,O
+,O
),O
exchanger,O
type,O
3,O
(,O
NHE3,O
),O
",",O
Na,Chemical
(,O
+,O
),O
-,O
K,Chemical
(,O
+,O
),O
-,O
2Cl,Chemical
(,O
-,O
),O
cotransporter,O
(,O
BSC,O
-,O
1,O
),O
",",O
and,O
thiazide,Chemical
-,O
sensitive,O
Na,Chemical
(,O
+,O
),O
-,O
Cl,Chemical
(,O
-,O
),O
cotransporter,O
(,O
TSC,O
),O
were,O
decreased,O
.,O
Two,O
groups,O
of,O
patients,O
receiving,O
tacrolimus,Chemical
were,O
compared,O
over,O
a,O
period,O
of,O
1,O
year,O
",",O
one,O
group,O
comprising,O
hypertensive,Disease
patients,O
who,O
were,O
receiving,O
nifedipine,Chemical
",",O
and,O
the,O
other,O
comprising,O
nonhypertensive,O
patients,O
not,O
receiving,O
nifedipine,Chemical
.,O
Reversal,O
of,O
ammonia,Chemical
coma,Disease
in,O
rats,O
by,O
L,Chemical
-,Chemical
dopa,Chemical
:,O
a,O
peripheral,O
effect,O
.,O
The,O
results,O
showed,O
that,O
aconitine,Chemical
stimulated,O
apoptosis,O
time,O
-,O
dependently,O
.,O
These,O
results,O
further,O
support,O
the,O
view,O
that,O
calcium,Chemical
ions,O
in,O
excess,O
have,O
an,O
atropine,Chemical
-,O
like,O
action,O
also,O
in,O
the,O
central,O
nervous,O
system,O
.,O
One,O
patient,O
in,O
the,O
ketoprofen,Chemical
group,O
developed,O
a,O
postoperative,O
intracranial,O
hematoma,Disease
.,O
In,O
vitro,O
characterization,O
of,O
parasympathetic,O
and,O
sympathetic,O
responses,O
in,O
cyclophosphamide,Chemical
-,O
induced,O
cystitis,Disease
in,O
the,O
rat,O
.,O
CONCLUSIONS,O
:,O
Cocaine,Chemical
and,O
ethanol,Chemical
in,O
combination,O
were,O
more,O
toxic,O
than,O
either,O
substance,O
alone,O
.,O
However,O
",",O
olanzapine,Chemical
-,O
treated,O
patients,O
had,O
a,O
statistically,O
significant,O
greater,O
mean,O
(,O
+,O
/,O
-,O
SD,O
),O
weight,Disease
gain,Disease
than,O
placebo,O
-,O
treated,O
patients,O
(,O
2,O
.,O
1,O
+,O
/,O
-,O
2,O
.,O
8,O
vs,O
0,O
.,O
45,O
+,O
/,O
-,O
2,O
.,O
3,O
kg,O
",",O
respectively,O
),O
and,O
also,O
experienced,O
more,O
treatment,O
-,O
emergent,O
somnolence,Disease
(,O
21,O
patients,O
[,O
38,O
.,O
2,O
%,O
],O
vs,O
5,O
[,O
8,O
.,O
3,O
%,O
],O
",",O
respectively,O
),O
.,O
A,O
time,O
course,O
was,O
established,O
for,O
the,O
change,O
in,O
tissue,O
mass,O
",",O
RNA,O
and,O
DNA,O
content,O
",",O
as,O
well,O
as,O
hydroxyproline,Chemical
content,O
.,O
Plasma,O
malondialdehyde,Chemical
",",O
which,O
was,O
present,O
in,O
minimal,O
amount,O
at,O
zero,O
time,O
(,O
0,O
.,O
058,O
mumol,O
/,O
liter,O
plasma,O
;,O
SD,O
0,O
.,O
015,O
),O
",",O
increased,O
after,O
5,O
min,O
of,O
ischemia,Disease
",",O
resulting,O
in,O
a,O
fivefold,O
increase,O
after,O
30,O
min,O
of,O
carotid,O
occlusion,O
(,O
0,O
.,O
298,O
mumol,O
/,O
liter,O
plasma,O
;,O
SD,O
0,O
.,O
078,O
),O
.,O
CONCLUSION,O
:,O
This,O
study,O
showed,O
that,O
spironolactone,Chemical
can,O
reduce,O
potassium,Chemical
requirements,O
and,O
prevent,O
hypokalemia,Disease
by,O
reducing,O
urinary,O
potassium,Chemical
loss,O
in,O
neutropenic,Disease
patients,O
on,O
AmB,Chemical
treatment,O
.,O
Morphine,Chemical
did,O
not,O
",",O
however,O
",",O
alter,O
the,O
hyperalgesia,Disease
induced,O
by,O
8,Chemical
-,Chemical
bromo,Chemical
cyclic,Chemical
adenosine,Chemical
monophosphate,Chemical
.,O
Such,O
interactions,O
may,O
result,O
in,O
serious,O
cardiovascular,Disease
complications,Disease
even,O
after,O
cessation,O
of,O
an,O
infusion,O
of,O
ritodrine,Chemical
.,O
In,O
an,O
attempt,O
to,O
overcome,O
this,O
problem,O
",",O
a,O
clinical,O
trial,O
of,O
CB,Chemical
3717,Chemical
administered,O
with,O
alkaline,O
diuresis,O
is,O
under,O
way,O
.,O
Venlafaxine,Chemical
is,O
a,O
new,O
antidepressant,O
agent,O
that,O
inhibits,O
the,O
reuptake,O
of,O
serotonin,Chemical
and,O
norepinephrine,Chemical
.,O
Mitomycin,Chemical
C,Chemical
associated,O
hemolytic,Disease
uremic,Disease
syndrome,Disease
.,O
Four,O
cases,O
of,O
water,Disease
intoxication,Disease
in,O
connection,O
with,O
oxytocin,Chemical
administration,O
during,O
saline,O
-,O
induced,O
abortions,Disease
are,O
described,O
.,O
The,O
maximum,O
tolerated,O
dose,O
of,O
cyclophosphamide,Chemical
was,O
defined,O
as,O
900,O
mg,O
/,O
m,O
(,O
2,O
),O
.,O
One,O
of,O
the,O
patients,O
developed,O
cardiac,Disease
failure,Disease
after,O
30,O
mg,O
m,O
-,O
2,O
MMC,Chemical
and,O
only,O
150,O
mg,O
m,O
-,O
2,O
doxorubicin,Chemical
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
determine,O
whether,O
chronic,O
administration,O
of,O
temocapril,Chemical
",",O
a,O
long,O
-,O
acting,O
non,O
-,O
SH,O
group,O
angiotensin,Chemical
converting,O
enzyme,O
(,O
ACE,O
),O
inhibitor,O
",",O
reduced,O
proteinuria,Disease
",",O
inhibited,O
glomerular,O
hypertrophy,Disease
and,O
prevented,O
glomerulosclerosis,Disease
in,O
chronic,O
puromycin,Chemical
aminonucleoside,Chemical
(,O
PAN,Chemical
),O
-,O
induced,O
nephrotic,Disease
rats,O
.,O
METHODS,O
:,O
Twenty,O
renal,O
transplant,O
recipients,O
were,O
switched,O
to,O
fixed,O
dose,O
rapamycin,Chemical
(,O
RAPA,Chemical
),O
(,O
5,O
mg,O
/,O
day,O
),O
0,O
to,O
204,O
months,O
posttransplant,O
.,O
In,O
two,O
of,O
them,O
",",O
the,O
MPO,O
-,O
ANCA,O
titres,O
transiently,O
increased,O
to,O
12,O
.,O
8,O
and,O
15,O
.,O
0,O
U,O
/,O
ml,O
",",O
respectively,O
",",O
despite,O
continued,O
PTU,Chemical
therapy,O
",",O
but,O
no,O
vasculitic,Disease
disorders,Disease
developed,O
.,O
Bladder,O
afferent,O
cells,O
in,O
the,O
L6,O
-,O
S1,O
DRG,O
labeled,O
by,O
Fluorogold,O
(,O
40,O
microliters,O
),O
injected,O
into,O
the,O
bladder,O
wall,O
did,O
not,O
exhibit,O
NOS,O
-,O
IR,O
in,O
control,O
animals,O
;,O
however,O
",",O
following,O
chronic,O
CYP,Chemical
administration,O
",",O
a,O
significant,O
percentage,O
of,O
bladder,O
afferent,O
neurons,O
were,O
NOS,O
-,O
IR,O
:,O
L6,O
(,O
19,O
.,O
8,O
+,O
/,O
-,O
4,O
.,O
6,O
%,O
),O
and,O
S1,O
(,O
25,O
.,O
3,O
+,O
/,O
-,O
2,O
.,O
9,O
%,O
),O
.,O
DOX,Chemical
-,O
induced,O
cardiac,Disease
damage,Disease
presumably,O
results,O
from,O
the,O
formation,O
of,O
free,O
radicals,O
by,O
DOX,Chemical
.,O
Atrial,Disease
thrombosis,Disease
involving,O
the,O
heart,O
of,O
F,O
-,O
344,O
rats,O
ingesting,O
quinacrine,Chemical
hydrochloride,Chemical
.,O
Amikacin,Chemical
is,O
an,O
aminoglycoside,Chemical
commonly,O
used,O
to,O
provide,O
empirical,O
double,O
gram,O
-,O
negative,O
treatment,O
for,O
febrile,Disease
neutropenia,Disease
and,O
other,O
suspected,O
infections,Disease
.,O
Early,O
identification,O
of,O
fetal,O
alcohol,Chemical
exposure,O
and,O
maternal,O
abstinence,O
led,O
to,O
better,O
infant,O
outcomes,O
.,O
In,O
males,O
",",O
the,O
non,O
-,O
competitive,O
NMDA,Chemical
antagonist,O
dextromethorphan,Chemical
enhanced,O
the,O
antihyperalgesic,O
effect,O
of,O
low,O
to,O
moderate,O
doses,O
of,O
morphine,Chemical
in,O
a,O
dose,O
-,O
and,O
time,O
-,O
dependent,O
manner,O
.,O
Individual,O
differences,O
in,O
renal,O
ACE,O
activity,O
in,O
healthy,O
rats,O
predict,O
susceptibility,O
to,O
adriamycin,Chemical
-,O
induced,O
renal,Disease
damage,Disease
.,O
In,O
ICH,Disease
induction,O
using,O
0,O
.,O
014,O
-,O
unit,O
collagenase,O
",",O
heparin,Chemical
enhanced,O
the,O
hematoma,Disease
volume,O
3,O
.,O
4,O
-,O
fold,O
over,O
that,O
seen,O
in,O
control,O
ICH,Disease
animals,O
and,O
the,O
bleeding,Disease
7,O
.,O
6,O
-,O
fold,O
.,O
The,O
TDP,Disease
resolved,O
when,O
fluconazole,Chemical
was,O
discontinued,O
;,O
however,O
",",O
the,O
patient,O
continued,O
to,O
have,O
premature,Disease
ventricular,Disease
contractions,Disease
and,O
nonsustained,O
ventricular,Disease
tachycardia,Disease
(,O
NSVT,Disease
),O
until,O
six,O
days,O
after,O
drug,O
cessation,O
DISCUSSION,O
:,O
Use,O
of,O
the,O
Naranjo,O
probability,O
scale,O
indicates,O
a,O
probable,O
relationship,O
between,O
the,O
use,O
of,O
fluconazole,Chemical
and,O
the,O
development,O
of,O
TDP,Disease
.,O
OBJECTIVES,O
:,O
The,O
objectives,O
of,O
this,O
study,O
were,O
to,O
examine,O
the,O
relationship,O
between,O
APOE,O
epsilon4,O
and,O
subjective,O
effects,O
of,O
trihexyphenidyl,Chemical
on,O
measures,O
reflecting,O
sedation,O
and,O
confusion,Disease
and,O
to,O
investigate,O
the,O
relationship,O
between,O
trihexyphenidyl,Chemical
-,O
induced,O
subjective,O
effects,O
and,O
objective,O
memory,O
performance,O
.,O
We,O
measured,O
serum,O
thyroxine,Chemical
and,O
urine,O
-,O
concentrating,O
ability,O
(,O
Umax,O
),O
in,O
response,O
to,O
desmopressin,O
(,O
DDAVP,O
),O
in,O
85,O
patients,O
receiving,O
lithium,Chemical
.,O
Thus,O
",",O
three,O
of,O
six,O
patients,O
had,O
their,O
menstrual,O
irregularity,O
successfully,O
corrected,O
with,O
bromocriptine,Chemical
.,O
The,O
patient,O
was,O
treated,O
with,O
steroid,Chemical
pulse,O
",",O
plasmapheresis,O
",",O
cyclophosphamide,Chemical
and,O
antiplatelet,Chemical
agents,Chemical
.,O
In,O
laboratory,O
animals,O
",",O
histology,O
is,O
most,O
commonly,O
used,O
to,O
study,O
doxorubicin,Chemical
-,O
induced,O
cardiotoxicity,Disease
.,O
Rats,O
were,O
treated,O
with,O
seven,O
day,O
intravenous,O
infusion,O
of,O
fucoidan,Chemical
(,O
30,O
micrograms,O
h,O
-,O
1,O
),O
or,O
vehicle,O
.,O
The,O
contents,O
of,O
albumin,O
in,O
the,O
lungs,O
were,O
not,O
changed,O
",",O
indicating,O
that,O
Captopril,Chemical
did,O
not,O
influence,O
the,O
extravasation,O
of,O
protein,O
.,O
This,O
depressive,Disease
-,O
like,O
profile,O
induced,O
by,O
METH,Chemical
was,O
accompanied,O
by,O
a,O
marked,O
depletion,O
of,O
frontostriatal,O
dopaminergic,O
and,O
serotonergic,O
neurotransmission,O
",",O
indicated,O
by,O
a,O
reduction,O
in,O
the,O
levels,O
of,O
dopamine,Chemical
",",O
DOPAC,Chemical
and,O
HVA,Chemical
",",O
tyrosine,Chemical
hydroxylase,O
and,O
serotonin,Chemical
",",O
observed,O
at,O
both,O
3,O
and,O
49,O
days,O
post,O
-,O
administration,O
.,O
The,O
management,O
options,O
in,O
the,O
ED,O
",",O
as,O
exemplified,O
by,O
four,O
individual,O
case,O
reports,O
",",O
in,O
particular,O
the,O
use,O
of,O
a,O
minimally,O
invasive,O
method,O
of,O
intracorporal,O
epinephrine,Chemical
instillation,O
",",O
are,O
discussed,O
.,O
A,O
phase,O
I,O
study,O
of,O
4,Chemical
',Chemical
-,Chemical
0,Chemical
-,Chemical
tetrahydropyranyladriamycin,Chemical
.,O
Delayed,O
toxicity,Disease
of,O
cyclophosphamide,Chemical
on,O
the,O
bladder,O
of,O
DBA,O
/,O
2,O
and,O
C57BL,O
/,O
6,O
female,O
mouse,O
.,O
The,O
risk,O
of,O
serious,O
thrombotic,Disease
events,O
was,O
also,O
similar,O
for,O
each,O
valdecoxib,Chemical
dose,O
.,O
CONCLUSIONS,O
:,O
Reduction,O
of,O
ribavirin,Chemical
at,O
hemoglobin,O
level,O
>,O
or,O
=,O
10,O
g,O
/,O
dl,O
is,O
suitable,O
in,O
terms,O
of,O
efficacy,O
and,O
side,O
effects,O
.,O
Adrenaline,Chemical
-,O
induced,O
hypertension,Disease
was,O
used,O
to,O
destroy,O
the,O
BBB,O
",",O
which,O
was,O
evaluated,O
using,O
triphenyltetrazolium,Chemical
(,O
TTC,Chemical
),O
staining,O
of,O
the,O
brain,O
slices,O
just,O
after,O
giving,O
adrenaline,Chemical
for,O
30,O
s,O
.,O
Compared,O
with,O
the,O
young,O
group,O
",",O
the,O
elderly,O
group,O
had,O
greater,O
scopolamine,Chemical
-,O
induced,O
impairment,Disease
in,Disease
word,Disease
recall,Disease
60,O
",",O
90,O
and,O
120,O
minutes,O
after,O
administration,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
.,O
CONCLUSIONS,O
:,O
Clonidine,Chemical
",",O
used,O
alone,O
or,O
with,O
methylphenidate,Chemical
",",O
appears,O
safe,O
and,O
well,O
tolerated,O
in,O
childhood,O
ADHD,Disease
.,O
Laboratory,O
test,O
findings,O
on,O
admission,O
were,O
notable,O
only,O
for,O
a,O
flecainide,Chemical
plasma,O
concentration,O
of,O
1360,O
microg,O
/,O
L,O
(,O
reference,O
range,O
200,O
-,O
1000,O
),O
.,O
Severe,O
rhabdomyolysis,Disease
and,O
acute,Disease
renal,Disease
failure,Disease
secondary,O
to,O
concomitant,O
use,O
of,O
simvastatin,Chemical
",",O
amiodarone,Chemical
",",O
and,O
atazanavir,Chemical
.,O
Briefly,O
",",O
cells,O
were,O
differentiated,O
for,O
72,O
h,O
with,O
100,O
nM,O
PMA,O
to,O
obtain,O
a,O
macrophage,O
-,O
like,O
phenotype,O
in,O
the,O
presence,O
or,O
absence,O
of,O
1,O
nM,O
17beta,Chemical
-,Chemical
estradiol,Chemical
(,O
E2,Chemical
),O
",",O
100,O
nM,O
progesterone,Chemical
or,O
vehicle,O
(,O
0,O
.,O
01,O
%,O
ethanol,Chemical
),O
.,O
However,O
",",O
10,O
of,O
37,O
patients,O
with,O
reduction,O
of,O
ribavirin,Chemical
could,O
not,O
continue,O
combination,O
therapy,O
because,O
their,O
<,O
8,O
.,O
5,O
g,O
/,O
dl,O
hemoglobin,O
values,O
decreased,O
to,O
or,O
anemia,Disease
-,O
related,O
severe,O
side,O
effects,O
occurred,O
(,O
group,O
B,O
),O
.,O
Plasma,O
paclitaxel,Chemical
concentrations,O
were,O
measured,O
at,O
the,O
completion,O
of,O
paclitaxel,Chemical
infusion,O
and,O
at,O
24,O
hours,O
in,O
19,O
patients,O
.,O
Both,O
agents,O
show,O
substantial,O
clinical,O
efficacy,O
",",O
with,O
reductions,O
in,O
total,O
cholesterol,Chemical
of,O
over,O
30,O
%,O
and,O
in,O
LDL,O
-,O
cholesterol,Chemical
of,O
40,O
%,O
in,O
clinical,O
studies,O
.,O
This,O
was,O
associated,O
with,O
elevated,O
renal,O
mPGES,O
-,O
1,O
protein,O
expression,O
and,O
increased,O
urine,O
PGE,Chemical
(,Chemical
2,Chemical
),Chemical
excretion,O
.,O
Phenylpropanolamine,Chemical
(,O
PPA,Chemical
),O
is,O
a,O
drug,O
that,O
has,O
been,O
associated,O
with,O
serious,O
side,O
effects,O
including,O
stroke,Disease
.,O
The,O
withdrawal,O
and,O
the,O
gradual,O
reintroduction,O
of,O
quetiapine,Chemical
2,O
weeks,O
later,O
",",O
which,O
led,O
to,O
another,O
severe,O
agitation,Disease
",",O
enabled,O
us,O
to,O
attribute,O
the,O
agitation,Disease
specifically,O
to,O
quetiapine,Chemical
.,O
The,O
present,O
study,O
examines,O
the,O
effect,O
of,O
6,O
-,O
day,O
epinephrine,Chemical
treatment,O
(,O
100,O
micrograms,O
/,O
kg,O
per,O
h,O
",",O
s,O
.,O
c,O
.,O
),O
on,O
stimulus,O
-,O
induced,O
(,O
1,O
Hz,O
),O
endogenous,O
neurotransmitter,O
overflow,O
from,O
the,O
isolated,O
perfused,O
kidney,O
of,O
vehicle,O
-,O
and,O
epinephrine,Chemical
-,O
treated,O
rats,O
.,O
The,O
patient,O
developed,O
acute,Disease
encephalopathy,Disease
evidenced,O
by,O
behavioral,O
changes,O
",",O
aphasia,Disease
",",O
incontinence,Disease
",",O
visual,Disease
hallucinations,Disease
",",O
and,O
right,O
-,O
sided,O
weakness,Disease
with,O
diffuse,O
cerebral,Disease
vasospasm,Disease
on,O
magnetic,O
resonance,O
angiography,O
after,O
the,O
administration,O
of,O
intrathecal,O
cytarabine,Chemical
.,O
Efficacy,O
of,O
everolimus,Chemical
(,O
RAD001,Chemical
),O
in,O
patients,O
with,O
advanced,O
NSCLC,Disease
previously,O
treated,O
with,O
chemotherapy,O
alone,O
or,O
with,O
chemotherapy,O
and,O
EGFR,O
inhibitors,O
.,O
Intramuscular,O
hepatitis,Disease
B,Disease
immune,O
globulin,O
combined,O
with,O
lamivudine,Chemical
in,O
prevention,O
of,O
hepatitis,Disease
B,Disease
recurrence,O
after,O
liver,O
transplantation,O
.,O
Microangiopathic,Disease
hemolytic,Disease
anemia,Disease
complicating,O
FK506,Chemical
(,O
tacrolimus,Chemical
),O
therapy,O
.,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
investigate,O
the,O
effects,O
of,O
propofol,Chemical
in,O
intralipid,O
or,O
medialipid,O
emulsions,O
on,O
bupivacaine,Chemical
-,O
induced,O
cardiotoxicity,Disease
.,O
Other,O
possible,O
adverse,O
effects,O
-,O
-,O
such,O
as,O
gastrointestinal,Disease
disorders,Disease
",",O
orthostatic,Disease
hypotension,Disease
",",O
levodopa,Chemical
-,O
induced,O
psychosis,Disease
",",O
sleep,Disease
disturbances,Disease
or,O
parasomnias,Disease
",",O
or,O
drug,O
interactions,O
-,O
-,O
also,O
require,O
carefully,O
monitored,O
individual,O
treatment,O
.,O
In,O
Group,O
1,O
the,O
rats,O
were,O
trained,O
under,O
the,O
influence,O
of,O
pentobarbital,Chemical
to,O
run,O
to,O
the,O
same,O
shelf,O
as,O
in,O
the,O
normal,O
state,O
.,O
Newborn,O
rats,O
were,O
given,O
terbutaline,Chemical
(,O
10,O
mg,O
/,O
kg,O
),O
daily,O
on,O
postnatal,O
days,O
(,O
PN,O
),O
2,O
to,O
5,O
or,O
PN,O
11,O
to,O
14,O
and,O
examined,O
24,O
h,O
after,O
the,O
last,O
dose,O
and,O
at,O
PN,O
30,O
.,O
The,O
catechol,Chemical
and,O
hydroquinone,Chemical
metabolites,O
",",O
NCQ436,Chemical
and,O
NCQ344,Chemical
",",O
induced,O
apoptosis,O
in,O
HL60,O
and,O
HBMP,O
cells,O
in,O
a,O
time,O
-,O
and,O
concentration,O
dependent,O
manner,O
",",O
while,O
the,O
phenols,Chemical
",",O
NCR181,O
",",O
FLA873,O
",",O
and,O
FLA797,Chemical
",",O
and,O
the,O
derivatives,O
formed,O
by,O
oxidation,O
of,O
the,O
pyrrolidine,Chemical
ring,O
",",O
FLA838,O
",",O
NCM001,O
",",O
and,O
NCL118,O
",",O
had,O
no,O
effect,O
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
changes,O
in,O
plasma,O
and,O
urinary,O
lipoproteins,O
during,O
the,O
administration,O
of,O
puromycin,Chemical
aminonucleoside,Chemical
(,O
20,O
mg,O
/,O
kg,O
for,O
7,O
days,O
),O
and,O
the,O
subsequent,O
development,O
of,O
nephrotic,Disease
syndrome,Disease
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
We,O
studied,O
with,O
a,O
2,O
.,O
5,O
years,O
follow,O
-,O
up,O
the,O
changes,O
in,O
plasma,O
cholesterols,Chemical
(,O
C,Chemical
),O
",",O
triglycerides,Chemical
(,O
TG,Chemical
),O
",",O
lipoproteins,O
(,O
LP,O
),O
",",O
and,O
apolipoproteins,O
(,O
Apo,O
),O
B,O
-,O
100,O
",",O
A,O
-,O
I,O
",",O
and,O
A,O
-,O
II,O
pro,O
fi,O
les,O
in,O
24,O
patients,O
of,O
mean,O
age,O
60,O
years,O
with,O
low,O
risk,O
prostate,Disease
cancer,Disease
(,O
stage,O
:,O
T1cN0M0,O
",",O
Gleason,O
score,O
:,O
2,O
-,O
5,O
),O
during,O
treatment,O
with,O
cyproterone,Chemical
acetate,Chemical
(,O
CPA,Chemical
),O
without,O
surgical,O
management,O
or,O
radiation,O
therapy,O
.,O
Potent,O
DA,Chemical
D1,O
receptor,O
agents,O
with,O
an,O
intermediate,O
duration,O
of,O
efficacy,O
such,O
as,O
A,Chemical
-,Chemical
86929,Chemical
(,O
approximately,O
4,O
hr,O
at,O
higher,O
doses,O
tested,O
),O
are,O
potential,O
therapeutic,O
tools,O
in,O
PD,Disease
and,O
merit,O
further,O
attention,O
.,O
In,O
vivo,O
microdialysis,O
demonstrated,O
that,O
an,O
intraperitoneal,O
administration,O
of,O
pilocarpine,Chemical
induced,O
a,O
pronounced,O
increment,O
of,O
hippocampal,O
glutamate,Chemical
and,O
aspartate,Chemical
whereas,O
no,O
significant,O
change,O
was,O
observed,O
on,O
the,O
level,O
of,O
glycine,Chemical
and,O
GABA,Chemical
.,O
Injection,O
of,O
Captopril,Chemical
(,O
1,O
mg,O
/,O
kg,O
),O
",",O
an,O
inhibitor,O
of,O
angiotensin,Chemical
converting,O
enzyme,O
(,O
ACE,O
),O
",",O
reduced,O
both,O
pulmonary,Disease
and,Disease
renal,Disease
insufficiency,Disease
in,O
this,O
rat,O
model,O
.,O
In,O
the,O
second,O
experiment,O
",",O
four,O
groups,O
of,O
mice,O
received,O
similar,O
treatment,O
in,O
the,O
first,O
experiment,O
",",O
and,O
30,O
min,O
after,O
these,O
injections,O
",",O
all,O
mice,O
received,O
a,O
higher,O
dose,O
of,O
lidocaine,Chemical
(,O
80,O
mg,O
/,O
kg,O
),O
.,O
Whether,O
proteinuria,Disease
was,O
due,O
to,O
sirolimus,Chemical
or,O
only,O
a,O
consequence,O
of,O
calcineurin,O
inhibitors,O
withdrawal,O
remained,O
unsolved,O
until,O
high,O
range,O
proteinuria,Disease
has,O
been,O
observed,O
during,O
sirolimus,Chemical
therapy,O
in,O
islet,O
transplantation,O
and,O
in,O
patients,O
who,O
received,O
sirolimus,Chemical
de,O
novo,O
.,O
Tachyphylaxis,O
to,O
systemic,O
but,O
not,O
to,O
airway,O
responses,O
during,O
prolonged,O
therapy,O
with,O
high,O
dose,O
inhaled,O
salbutamol,Chemical
in,O
asthmatics,Disease
.,O
Venous,O
discomfort,O
was,O
assessed,O
with,O
a,O
visual,O
analogue,O
scale,O
(,O
VAS,O
),O
5,O
-,O
15,O
sec,O
after,O
commencing,O
propofol,Chemical
administration,O
using,O
an,O
infusion,O
pump,O
(,O
rate,O
1000,O
micrograms,O
.,O
kg,O
-,O
1,O
.,O
min,O
-,O
1,O
),O
.,O
Patients,O
were,O
monitored,O
for,O
23,O
+,O
/,O
-,O
4,O
hours,O
before,O
5,Chemical
-,Chemical
FU,Chemical
infusion,O
",",O
and,O
98,O
+,O
/,O
-,O
9,O
hours,O
during,O
5,Chemical
-,Chemical
FU,Chemical
infusion,O
.,O
Of,O
these,O
",",O
clarithromycin,Chemical
was,O
implicated,O
in,O
23,O
(,O
27,O
.,O
6,O
%,O
),O
cases,O
",",O
ciprofloxacin,Chemical
in,O
12,O
(,O
14,O
.,O
4,O
%,O
),O
cases,O
",",O
and,O
ofloxacin,Chemical
in,O
10,O
(,O
12,O
%,O
),O
cases,O
.,O
The,O
dosing,O
schedule,O
",",O
duration,O
of,O
lithium,Chemical
treatment,O
",",O
and,O
daily,O
dose,O
of,O
lithium,Chemical
did,O
not,O
affect,O
maximum,O
osmolality,O
or,O
creatinine,Chemical
clearance,O
.,O
It,O
was,O
concluded,O
that,O
formulations,O
at,O
or,O
below,O
0,O
.,O
5,O
per,O
cent,O
CHP,Chemical
may,O
prove,O
acceptable,O
for,O
wound,O
care,O
",",O
but,O
the,O
vehicle,O
system,O
needs,O
pharmaceutical,O
improvement,O
to,O
render,O
it,O
more,O
tolerable,O
and,O
easier,O
to,O
use,O
.,O
CONCLUSIONS,O
:,O
Topical,O
papaverine,Chemical
for,O
the,O
treatment,O
of,O
vasospasm,Disease
was,O
associated,O
with,O
the,O
onset,O
of,O
a,O
transient,O
disturbance,O
in,O
neurophysiological,O
function,O
of,O
the,O
ascending,O
auditory,O
brainstem,O
pathway,O
.,O
The,O
likely,O
frequency,O
of,O
serious,O
hepatotoxicity,Disease
with,O
sulfasalazine,Chemical
was,O
estimated,O
at,O
0,O
.,O
4,O
%,O
of,O
treated,O
patients,O
.,O
Intraoperative,O
dialysis,O
during,O
liver,O
transplantation,O
with,O
citrate,Chemical
dialysate,O
.,O
The,O
epidemiological,O
studies,O
that,O
assessed,O
the,O
risk,O
of,O
venous,Disease
thromboembolism,Disease
(,O
VTE,Disease
),O
associated,O
with,O
newer,O
oral,Chemical
contraceptives,Chemical
(,O
OC,Chemical
),O
did,O
not,O
distinguish,O
between,O
patterns,O
of,O
OC,Chemical
use,O
",",O
namely,O
first,O
-,O
time,O
users,O
",",O
repeaters,O
and,O
switchers,O
.,O
In,O
a,O
more,O
complex,O
task,O
commonly,O
used,O
to,O
evaluate,O
major,O
akinetic,Disease
symptoms,O
of,O
PD,Disease
patients,O
",",O
5,O
mg,O
/,O
kg,O
AMN082,Chemical
reverses,O
the,O
increased,O
reaction,O
time,O
to,O
respond,O
to,O
a,O
cue,O
of,O
bilateral,O
6,Chemical
-,Chemical
OHDA,Chemical
-,O
lesioned,O
rats,O
.,O
Oxyhemoglobin,O
did,O
not,O
affect,O
helodermin,Chemical
-,O
induced,O
hypotension,Disease
",",O
whereas,O
it,O
shortened,O
the,O
duration,O
of,O
acetylcholine,Chemical
(,O
ACh,Chemical
),O
-,O
produced,O
hypotension,Disease
.,O
These,O
results,O
suggest,O
that,O
chemotherapy,O
-,O
induced,O
anemia,Disease
reduces,O
cytotoxicity,Disease
of,O
cyclophosphamide,Chemical
in,O
tumors,Disease
",",O
whereas,O
correction,O
of,O
anemia,Disease
by,O
rHuEPO,O
treatment,O
(,O
epoetin,O
alpha,O
),O
increases,O
the,O
sensitivity,O
",",O
probably,O
as,O
a,O
result,O
of,O
an,O
improved,O
oxygen,Chemical
supply,O
to,O
tumor,Disease
tissue,O
.,O
Patients,O
given,O
prilocaine,Chemical
were,O
more,O
likely,O
to,O
develop,O
hearing,Disease
loss,Disease
(,O
10,O
out,O
of,O
22,O
),O
than,O
those,O
given,O
bupivacaine,Chemical
(,O
4,O
out,O
of,O
22,O
),O
(,O
P,O
<,O
0,O
.,O
05,O
),O
.,O
Since,O
plasma,O
pharmacokinetic,O
studies,O
showed,O
a,O
faster,O
busulfan,Chemical
clearance,O
in,O
children,O
than,O
in,O
adults,O
",",O
this,O
new,O
dose,O
may,O
approximate,O
more,O
closely,O
the,O
adult,O
systemic,O
exposure,O
obtained,O
after,O
the,O
usual,O
16,O
-,O
mg,O
/,O
kg,O
total,O
dose,O
",",O
with,O
potential,O
inferences,O
in,O
terms,O
of,O
anticancer,O
or,O
myeloablative,O
effects,O
.,O
However,O
",",O
unlike,O
these,O
latter,O
",",O
SSR103800,Chemical
did,O
not,O
produce,O
catalepsy,Disease
(,O
retention,O
on,O
the,O
bar,O
test,O
),O
up,O
to,O
30,O
mg,O
/,O
kg,O
p,O
.,O
o,O
.,O
Further,O
analysis,O
of,O
these,O
data,O
suggests,O
that,O
the,O
duration,O
of,O
therapy,O
",",O
plasma,O
aminoglycoside,Chemical
levels,O
",",O
liver,Disease
disease,Disease
",",O
advanced,O
age,O
",",O
high,O
initial,O
estimated,O
creatinine,Chemical
clearance,O
and,O
",",O
possibly,O
",",O
female,O
gender,O
all,O
increase,O
the,O
risk,O
for,O
nephrotoxicity,Disease
.,O
No,O
arrhythmias,Disease
were,O
induced,O
by,O
these,O
doses,O
of,O
denopamine,Chemical
.,O
The,O
efficacy,O
and,O
tolerability,O
of,O
VAL,Chemical
/,O
HCTZ,Chemical
combinations,O
were,O
maintained,O
during,O
the,O
extension,O
(,O
797,O
patients,O
),O
.,O
A,O
deficient,O
L,Chemical
-,Chemical
arginine,Chemical
-,O
nitric,Chemical
oxide,Chemical
system,O
is,O
implicated,O
in,O
cortisol,Chemical
-,O
induced,O
hypertension,Disease
.,O
Measurement,O
of,O
resting,O
norepinephrine,Chemical
spillover,O
rate,O
to,O
plasma,O
and,O
norepinephrine,Chemical
uptake,O
indicated,O
that,O
overall,O
resting,O
sympathetic,O
nervous,O
system,O
activity,O
was,O
not,O
increased,O
.,O
Intrarenal,O
compared,O
with,O
intravenous,O
infusion,O
of,O
noradrenaline,Chemical
caused,O
higher,O
plasma,O
noradrenaline,Chemical
concentrations,O
and,O
a,O
shift,O
of,O
the,O
plasma,O
noradrenaline,Chemical
concentration,O
-,O
blood,O
pressure,O
effect,O
curve,O
towards,O
lower,O
plasma,O
noradrenaline,Chemical
levels,O
.,O
Induction,O
of,O
the,O
obstructive,Disease
sleep,Disease
apnea,Disease
syndrome,Disease
in,O
a,O
woman,O
by,O
exogenous,O
androgen,Chemical
administration,O
.,O
Ibuprofen,Chemical
",",O
sulindac,Chemical
",",O
mefenamic,Chemical
acid,Chemical
",",O
and,O
low,O
dose,O
meclofenamic,Chemical
acid,Chemical
increased,O
the,O
latency,O
-,O
to,O
-,O
onset,O
in,O
the,O
flurothyl,Chemical
and,O
/,O
or,O
PTZ,Chemical
models,O
;,O
the,O
electroshock,O
",",O
picrotoxin,Chemical
and,O
bicuculline,Chemical
models,O
were,O
not,O
significantly,O
affected,O
by,O
any,O
of,O
the,O
pretreatment,O
agents,O
.,O
Though,O
this,O
fall,O
would,O
be,O
associated,O
with,O
a,O
decrease,O
in,O
wall,O
tension,O
",",O
and,O
",",O
therefore,O
",",O
of,O
myocardial,O
oxygen,Chemical
consumption,O
",",O
it,O
may,O
not,O
be,O
of,O
sufficient,O
magnitude,O
to,O
prevent,O
a,O
net,O
increase,O
in,O
myocardial,O
oxygen,Chemical
consumption,O
.,O
MEASUREMENTS,O
:,O
Plasma,O
total,O
",",O
low,O
-,O
density,O
lipoprotein,O
(,O
LDL,O
),O
",",O
and,O
high,O
-,O
density,O
lipoprotein,O
(,O
HDL,O
),O
cholesterol,Chemical
",",O
and,O
triglycerides,Chemical
;,O
and,O
laboratory,O
and,O
clinical,O
evidence,O
of,O
adverse,O
events,O
monitored,O
periodically,O
throughout,O
the,O
study,O
.,O
Haloperidol,Chemical
-,O
induced,O
catalepsy,Disease
was,O
challenged,O
with,O
prior,O
intracollicular,O
microinjections,O
of,O
glutamate,Chemical
NMDA,Chemical
receptor,O
antagonists,O
",",O
MK,Chemical
-,Chemical
801,Chemical
(,O
15,O
or,O
30,O
mmol,O
/,O
0,O
.,O
5,O
microl,O
),O
and,O
AP7,Chemical
(,O
10,O
or,O
20,O
nmol,O
/,O
0,O
.,O
5,O
microl,O
),O
",",O
or,O
of,O
the,O
NMDA,Chemical
receptor,O
agonist,O
N,Chemical
-,Chemical
methyl,Chemical
-,Chemical
d,Chemical
-,Chemical
aspartate,Chemical
(,O
NMDA,Chemical
",",O
20,O
or,O
30,O
nmol,O
/,O
0,O
.,O
5,O
microl,O
),O
.,O
MAP,O
and,O
HR,O
were,O
monitored,O
before,O
and,O
after,O
i,O
.,O
v,O
.,O
injections,O
of,O
either,O
vehicle,O
or,O
1,O
",",O
10,O
and,O
50,O
ng,O
of,O
AVP,Chemical
and,O
25,O
",",O
125,O
and,O
500,O
ng,O
of,O
ANP,O
.,O
Adriamycin,Chemical
(,O
50,O
mg,O
/,O
50,O
ml,O
),O
was,O
administered,O
intravesically,O
within,O
24,O
h,O
after,O
transurethral,O
resection,O
of,O
TA,O
-,O
T1,O
(,O
O,O
-,O
A,O
),O
bladder,Disease
tumors,Disease
.,O
Sorafenib,Chemical
is,O
a,O
multikinase,O
inhibitor,O
that,O
targets,O
signaling,O
pathways,O
necessary,O
for,O
cellular,O
proliferation,O
and,O
survival,O
.,O
This,O
study,O
investigated,O
behavioral,O
phenotypes,O
and,O
AChE,O
activity,O
in,O
male,O
mice,O
following,O
BPA,Chemical
exposure,O
during,O
puberty,O
.,O
Postpartum,O
psychosis,Disease
induced,O
by,O
bromocriptine,Chemical
.,O
Oral,O
pre,O
-,O
treatment,O
with,O
PK,O
(,O
80,O
mg,O
kg,O
(,O
-,O
1,O
),O
day,O
(,O
-,O
1,O
),O
for,O
15,O
days,O
),O
significantly,O
prevented,O
the,O
isoproterenol,Chemical
-,O
induced,O
myocardial,Disease
infarction,Disease
and,O
maintained,O
the,O
rats,O
at,O
near,O
normal,O
status,O
.,O
Tiazofurin,Chemical
is,O
an,O
experimental,O
chemotherapeutic,O
agent,O
currently,O
undergoing,O
clinical,O
evaluation,O
.,O
The,O
treatment,O
of,O
HIT,Disease
mandates,O
an,O
immediate,O
cessation,O
of,O
all,O
heparin,Chemical
exposure,O
and,O
the,O
institution,O
of,O
an,O
antithrombotic,O
therapy,O
",",O
most,O
commonly,O
using,O
a,O
direct,Chemical
thrombin,Chemical
inhibitor,Chemical
.,O
BACKGROUND,O
:,O
It,O
is,O
not,O
known,O
if,O
there,O
is,O
a,O
relationship,O
between,O
input,O
rate,O
and,O
incidence,O
of,O
bupropion,Chemical
-,O
induced,O
seizures,Disease
.,O
The,O
ocular,Disease
myasthenia,Disease
associated,O
with,O
combination,O
therapy,O
of,O
pegylated,Chemical
IFN,Chemical
alpha,Chemical
-,Chemical
2b,Chemical
and,O
ribavirin,Chemical
for,O
CHC,Disease
is,O
very,O
rarely,O
reported,O
;,O
therefore,O
",",O
we,O
present,O
this,O
case,O
with,O
a,O
review,O
of,O
the,O
various,O
eye,O
complications,O
of,O
IFN,Chemical
therapy,O
.,O
Crocin,Chemical
reduced,O
inhibition,O
of,O
ERK,O
activation,O
and,O
diazinon,Chemical
-,O
induced,O
hyperlipemia,Disease
and,O
increased,O
levels,O
of,O
LDLr,O
transcript,O
.,O
Coronary,O
blood,O
flow,O
",",O
cardiac,O
work,O
and,O
metabolism,O
were,O
studied,O
in,O
dogs,O
under,O
sodium,Chemical
nitroprusside,Chemical
(,O
SNP,Chemical
),O
and,O
trimetaphan,Chemical
(,O
TMP,Chemical
),O
deliberate,O
hypotension,Disease
(,O
20,O
%,O
and,O
40,O
%,O
mean,O
pressure,O
decrease,O
from,O
baseline,O
),O
.,O
High,O
-,O
dose,O
intravenous,O
melphalan,Chemical
followed,O
by,O
peripheral,O
blood,O
stem,O
cell,O
transplant,O
(,O
PBSCT,O
),O
appears,O
to,O
be,O
the,O
most,O
promising,O
therapy,O
",",O
but,O
treatment,O
mortality,O
can,O
be,O
high,O
.,O
Vancomycin,Chemical
nephrotoxicity,Disease
is,O
infrequent,O
but,O
may,O
result,O
from,O
coadministration,O
with,O
a,O
nephrotoxic,Disease
agent,O
.,O
METHOD,O
:,O
Thirteen,O
patients,O
who,O
developed,O
optic,Disease
neuropathy,Disease
after,O
being,O
treated,O
with,O
ethambutol,Chemical
for,O
tuberculosis,Disease
of,Disease
the,Disease
lung,Disease
or,Disease
lymph,Disease
node,Disease
at,O
Siriraj,O
Hospital,O
between,O
1997,O
and,O
2001,O
were,O
retrospectively,O
reviewed,O
.,O
A,O
history,O
of,O
drug,O
exposure,O
also,O
was,O
taken,O
with,O
special,O
attention,O
on,O
the,O
use,O
of,O
antidepressants,O
",",O
anorexigens,O
",",O
and,O
amphetamines,Chemical
.,O
Bupivacaine,Chemical
",",O
levobupivacaine,Chemical
",",O
or,O
ropivacaine,Chemical
was,O
infused,O
at,O
a,O
rate,O
of,O
2,O
mg,O
.,O
Increased,O
sulfation,O
and,O
decreased,O
7alpha,O
-,O
hydroxylation,O
of,O
deoxycholic,Chemical
acid,Chemical
in,O
ethinyl,Chemical
estradiol,Chemical
-,O
induced,O
cholestasis,Disease
in,O
rats,O
.,O
Nasal,Disease
hypoplasia,Disease
with,O
or,O
without,O
stippled,Disease
epiphyses,Disease
has,O
now,O
been,O
reported,O
in,O
11,O
infants,O
born,O
to,O
mothers,O
treated,O
with,O
warfarin,Chemical
during,O
the,O
first,O
trimester,O
",",O
and,O
a,O
causal,O
association,O
is,O
probable,O
.,O
The,O
optical,O
isomers,O
of,O
propranolol,Chemical
have,O
been,O
compared,O
for,O
their,O
beta,O
-,O
blocking,O
and,O
antiarrhythmic,O
activities,O
.,O
2,O
.,O
DESIGN,O
/,O
METHODS,O
:,O
We,O
retrospectively,O
reviewed,O
the,O
medical,O
records,O
of,O
5,O
children,O
treated,O
with,O
intravenous,O
ribavirin,Chemical
for,O
documented,O
severe,O
adenovirus,Disease
disease,Disease
.,O
BACKGROUND,O
:,O
Doxorubicin,Chemical
induces,O
a,O
self,O
-,O
perpetuating,O
nephropathy,Disease
characterized,O
by,O
early,O
glomerular,Disease
and,Disease
late,Disease
-,Disease
onset,Disease
tubular,Disease
lesions,Disease
in,O
rats,O
.,O
PG,Chemical
-,Chemical
9,Chemical
was,O
also,O
able,O
to,O
increase,O
the,O
amount,O
of,O
NGF,O
secreted,O
in,O
vitro,O
by,O
astrocytes,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
Sub,O
-,O
chronic,O
low,O
dose,O
gamma,Chemical
-,Chemical
vinyl,Chemical
GABA,Chemical
(,O
vigabatrin,Chemical
),O
inhibits,O
cocaine,Chemical
-,O
induced,O
increases,O
in,O
nucleus,O
accumbens,O
dopamine,Chemical
.,O
Codeine,Chemical
catalepsy,Disease
was,O
increased,O
by,O
clonidine,Chemical
and,O
decreased,O
by,O
naphazoline,Chemical
and,O
xylometazoline,Chemical
.,O
Acute,O
treatment,O
with,O
metformin,Chemical
has,O
a,O
protective,O
effect,O
in,O
myocardial,Disease
infarction,Disease
by,O
suppression,O
of,O
inflammatory,O
responses,O
due,O
to,O
activation,O
of,O
AMP,Chemical
-,O
activated,O
protein,O
kinase,O
(,O
AMPK,O
),O
.,O
The,O
rate,O
of,O
NA,Chemical
turnover,O
was,O
not,O
altered,O
by,O
analgesics,O
except,O
for,O
the,O
higher,O
dose,O
of,O
fentanyl,Chemical
(,O
0,O
.,O
2,O
mg,O
/,O
kg,O
),O
following,O
which,O
the,O
disappearance,O
of,O
NA,Chemical
from,O
the,O
brain,O
was,O
diminished,O
.,O
HOMER1,O
is,O
a,O
protein,O
with,O
pivotal,O
function,O
in,O
glutamate,Chemical
transmission,O
",",O
which,O
has,O
been,O
related,O
to,O
the,O
pathogenesis,O
of,O
these,O
complications,O
.,O
BACKGROUND,O
:,O
Although,O
different,O
methods,O
to,O
prevent,O
bruising,Disease
and,O
pain,Disease
following,O
the,O
subcutaneous,O
injection,O
of,O
heparin,Chemical
have,O
been,O
widely,O
studied,O
and,O
described,O
",",O
the,O
effect,O
of,O
injection,O
duration,O
on,O
the,O
occurrence,O
of,O
bruising,Disease
and,O
pain,Disease
is,O
little,O
documented,O
.,O
Urinary,O
NGF,O
",",O
PGF2alpha,Chemical
and,O
PGI2,Chemical
did,O
not,O
correlate,O
with,O
urodynamic,O
parameters,O
in,O
patients,O
with,O
OAB,Disease
.,O
Usually,O
it,O
is,O
a,O
self,O
-,O
limited,O
disorder,O
",",O
but,O
corticosteroid,Chemical
therapy,O
may,O
be,O
needed,O
in,O
life,O
-,O
threatening,O
cases,O
since,O
early,O
treatment,O
with,O
corticosteroids,Chemical
in,O
severe,O
cases,O
can,O
prevent,O
complications,O
.,O
Chronic,O
effects,O
of,O
a,O
novel,O
synthetic,O
anthracycline,Chemical
derivative,O
(,O
SM,Chemical
-,Chemical
5887,Chemical
),O
on,O
normal,O
heart,O
and,O
doxorubicin,Chemical
-,O
induced,O
cardiomyopathy,Disease
in,O
beagle,O
dogs,O
.,O
NGF,O
",",O
PGE2,Chemical
",",O
PGF2alpha,Chemical
and,O
PGI2,Chemical
were,O
measured,O
using,O
enzyme,O
-,O
linked,O
immunosorbent,O
assay,O
and,O
compared,O
between,O
the,O
groups,O
.,O
Angiotensin,Chemical
-,O
converting,O
enzyme,O
inhibitors,O
and,O
angiotensin,Chemical
II,Chemical
receptor,O
-,O
blocking,O
drugs,O
hold,O
promise,O
in,O
atrial,Disease
fibrillation,Disease
through,O
cardiac,Disease
remodelling,Disease
.,O
Neuroleptic,Disease
malignant,Disease
syndrome,Disease
induced,O
by,O
combination,O
therapy,O
with,O
tetrabenazine,Chemical
and,O
tiapride,Chemical
in,O
a,O
Japanese,O
patient,O
with,O
Huntington,Disease
',Disease
s,Disease
disease,Disease
at,O
the,O
terminal,O
stage,O
of,O
recurrent,O
breast,Disease
cancer,Disease
.,O
Paired,O
eyes,O
were,O
perfused,O
in,O
serum,O
-,O
free,O
media,O
with,O
or,O
without,O
10,O
(,O
-,O
7,O
),O
M,O
dexamethasone,Chemical
for,O
12,O
days,O
.,O
Responses,O
of,O
urinary,O
strip,O
preparations,O
from,O
control,O
and,O
cyclophosphamide,Chemical
-,O
pretreated,O
rats,O
to,O
electrical,O
field,O
stimulation,O
and,O
to,O
agonists,O
were,O
assessed,O
in,O
the,O
absence,O
and,O
presence,O
of,O
muscarinic,O
",",O
adrenergic,O
and,O
purinergic,O
receptor,O
antagonists,O
.,O
The,O
prophylactic,O
lamivudin,Chemical
group,O
consisted,O
of,O
37,O
patients,O
who,O
received,O
prophylactic,O
lamivudine,Chemical
treatment,O
.,O
(,Chemical
RS,Chemical
),Chemical
-,Chemical
1,Chemical
-,Chemical
aminoindan,Chemical
-,Chemical
1,Chemical
",",Chemical
5,Chemical
-,Chemical
dicarboxylic,Chemical
acid,Chemical
(,O
AIDA,Chemical
;,O
0,O
.,O
5,O
-,O
15,O
microg,O
/,O
0,O
.,O
5,O
microl,O
),O
",",O
a,O
potent,O
and,O
selective,O
mGluR1,O
antagonist,O
",",O
or,O
(,Chemical
2R,Chemical
",",Chemical
4R,Chemical
),Chemical
-,Chemical
4,Chemical
-,Chemical
aminopyrrolidine,Chemical
-,Chemical
2,Chemical
",",Chemical
4,Chemical
-,Chemical
dicarboxylate,Chemical
(,O
2R,Chemical
",",Chemical
4R,Chemical
-,Chemical
APDC,Chemical
;,O
7,O
.,O
5,O
-,O
15,O
microg,O
/,O
0,O
.,O
5,O
microl,O
),O
",",O
a,O
selective,O
group,O
II,O
agonist,O
",",O
was,O
injected,O
bilaterally,O
into,O
the,O
striatum,O
of,O
haloperidol,Chemical
-,O
treated,O
animals,O
.,O
Twelve,O
asthmatic,Disease
patients,O
(,O
FEV1,O
",",O
81,O
+,O
/,O
-,O
4,O
%,O
predicted,O
),O
",",O
requiring,O
only,O
occasional,O
inhaled,O
beta,O
-,O
agonists,O
as,O
their,O
sole,O
therapy,O
",",O
were,O
given,O
a,O
14,O
-,O
day,O
treatment,O
with,O
high,O
dose,O
inhaled,O
salbutamol,Chemical
(,O
HDS,O
),O
",",O
4,O
",",O
000,O
micrograms,O
daily,O
",",O
low,O
dose,O
inhaled,O
salbutamol,Chemical
(,O
LDS,O
),O
",",O
800,O
micrograms,O
daily,O
",",O
or,O
placebo,O
(,O
PI,O
),O
by,O
metered,O
-,O
dose,O
inhaler,O
in,O
a,O
double,O
-,O
blind,O
",",O
randomized,O
crossover,O
design,O
.,O
Halogenated,O
anesthetics,O
form,O
liver,O
adducts,O
and,O
antigens,O
that,O
cross,O
-,O
react,O
with,O
halothane,Chemical
-,O
induced,O
antibodies,O
.,O
Effects,O
of,O
suprofen,Chemical
on,O
the,O
isolated,O
perfused,O
rat,O
kidney,O
.,O
Using,O
macaque,O
monkeys,O
with,O
different,O
types,O
of,O
MPTP,Chemical
-,O
induced,O
parkinsonism,Disease
",",O
the,O
current,O
study,O
evaluated,O
the,O
degree,O
to,O
which,O
rate,O
of,O
symptom,O
progression,O
",",O
symptom,O
severity,O
",",O
and,O
response,O
to,O
and,O
duration,O
of,O
levodopa,Chemical
therapy,O
may,O
be,O
involved,O
in,O
the,O
development,O
of,O
LIDs,Disease
.,O
However,O
",",O
pretreatment,O
with,O
RAMH,Chemical
significantly,O
reversed,O
such,O
an,O
effect,O
of,O
THP,Chemical
(,O
15,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
),O
.,O
Furthermore,O
",",O
dopamine,Chemical
appeared,O
to,O
act,O
on,O
systems,O
more,O
closely,O
involved,O
with,O
the,O
induction,O
of,O
ketamine,Chemical
catatonia,Disease
rather,O
than,O
directly,O
on,O
the,O
pituitary,O
.,O
The,O
choline,Chemical
acetyltransferase,O
(,O
ChAT,O
),O
activator,O
",",O
which,O
enhances,O
cholinergic,O
transmission,O
via,O
an,O
augmentation,O
of,O
the,O
enzymatic,O
production,O
of,O
acetylcholine,Chemical
(,O
ACh,Chemical
),O
",",O
is,O
an,O
important,O
factor,O
in,O
the,O
treatment,O
of,O
Alzheimer,Disease
',Disease
s,Disease
disease,Disease
(,O
AD,Disease
),O
.,O
These,O
results,O
show,O
that,O
15,O
-,O
day,O
isoproterenol,Chemical
pretreatment,O
not,O
only,O
abolished,O
but,O
reversed,O
bromocriptine,Chemical
-,O
induced,O
tachycardia,Disease
to,O
bradycardia,Disease
",",O
an,O
effect,O
that,O
is,O
mainly,O
related,O
to,O
further,O
cardiac,O
beta,O
-,O
adrenoceptor,O
desensitization,O
rather,O
than,O
to,O
impairment,O
of,O
autonomic,O
regulation,O
of,O
the,O
heart,O
.,O
Hemolytic,Disease
anemia,Disease
improved,O
after,O
stopping,O
the,O
drug,O
and,O
initiation,O
of,O
steroid,Chemical
therapy,O
.,O
In,O
conclusion,O
",",O
clentiazem,Chemical
attenuated,O
epinephrine,Chemical
-,O
induced,O
cardiac,Disease
injury,Disease
",",O
possibly,O
through,O
its,O
effect,O
on,O
the,O
adrenergic,O
pathway,O
.,O
The,O
possible,O
contribution,O
of,O
the,O
triazolo,Chemical
group,O
to,O
changes,O
in,O
affective,O
status,O
is,O
discussed,O
.,O
Mice,O
lacking,O
mPGES,O
-,O
1,O
are,O
resistant,O
to,O
lithium,Chemical
-,O
induced,O
polyuria,Disease
.,O
However,O
",",O
tAMCA,Chemical
has,O
been,O
shown,O
to,O
cause,O
epileptic,Disease
seizures,Disease
.,O
5,Chemical
-,Chemical
HTP,Chemical
(,O
5,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
),O
decreased,O
blood,O
pressure,O
and,O
heart,O
rate,O
and,O
decreased,O
the,O
reflex,O
bradycardia,Disease
to,O
norepinephrine,Chemical
.,O
Neuropathy,Disease
may,O
thus,O
be,O
a,O
common,O
complication,O
of,O
thalidomide,Chemical
in,O
older,O
patients,O
.,O
Pretreatment,O
with,O
L,O
-,O
NOArg,O
and,O
L,O
-,O
NIL,O
but,O
not,O
7,O
-,O
NI,O
",",O
significantly,O
increases,O
antihyperalgesic,O
activity,O
both,O
HOE,Chemical
140,Chemical
and,O
des,Chemical
Arg10,Chemical
HOE,Chemical
140,Chemical
.,O
RESULTS,O
:,O
Six,O
cases,O
of,O
levofloxacin,Chemical
-,O
induced,O
seizures,Disease
have,O
been,O
reported,O
in,O
the,O
literature,O
.,O
Objective,O
signs,O
of,O
ischemia,Disease
and,O
factors,O
increasing,O
myocardial,O
oxygen,Chemical
consumption,O
were,O
compared,O
during,O
epinephrine,Chemical
infusion,O
and,O
supine,O
bicycle,O
exercise,O
.,O
Wilson,Disease
',Disease
s,Disease
disease,Disease
is,O
an,O
autosomal,O
recessive,O
disorder,O
of,O
hepatic,O
copper,Chemical
metabolism,O
with,O
consequent,O
copper,Chemical
accumulation,O
and,O
toxicity,Disease
in,O
many,O
tissues,O
and,O
consequent,O
hepatic,Disease
",",Disease
neurologic,Disease
and,Disease
psychiatric,Disease
disorders,Disease
.,O
Mannitol,Chemical
concentrations,O
were,O
measured,O
in,O
plasma,O
and,O
white,O
matter,O
by,O
a,O
modified,O
version,O
of,O
the,O
enzyme,O
assay,O
of,O
Blonquist,O
et,O
al,O
.,O
This,O
concerns,O
2,O
male,O
patients,O
who,O
experienced,O
incontinence,Disease
while,O
taking,O
venlafaxine,Chemical
.,O
Since,O
18,O
of,O
the,O
22,O
patients,O
were,O
initially,O
receiving,O
deferoxamine,Chemical
doses,O
in,O
excess,O
of,O
the,O
commonly,O
recommended,O
50,O
mg,O
/,O
kg,O
per,O
dose,O
",",O
therapy,O
was,O
restarted,O
with,O
lower,O
doses,O
",",O
usually,O
50,O
mg,O
/,O
kg,O
per,O
dose,O
or,O
less,O
depending,O
on,O
the,O
degree,O
of,O
auditory,Disease
abnormality,Disease
",",O
and,O
with,O
the,O
exception,O
of,O
two,O
cases,O
no,O
further,O
toxicity,Disease
was,O
demonstrated,O
.,O
In,O
addition,O
to,O
tiaprofenic,Chemical
acid,Chemical
",",O
indomethacin,Chemical
has,O
been,O
reported,O
to,O
be,O
associated,O
with,O
this,O
condition,O
.,O
She,O
underwent,O
recent,O
chemotherapy,O
with,O
fluorouracil,Chemical
for,O
metastatic,O
colorectal,Disease
cancer,Disease
.,O
Angiotensin,Chemical
-,O
converting,O
enzyme,O
(,O
ACE,O
),O
inhibitors,O
should,O
be,O
used,O
first,O
as,O
they,O
are,O
safer,O
",",O
do,O
not,O
require,O
blood,O
level,O
monitoring,O
",",O
modify,O
progression,O
of,O
disease,O
",",O
relieve,O
symptoms,O
",",O
improve,O
exercise,O
tolerance,O
and,O
reduce,O
mortality,O
.,O
Activities,O
of,O
heart,O
tissue,O
enzymic,O
antioxidants,O
and,O
serum,O
non,O
-,O
enzymic,O
antioxidants,O
levels,O
rose,O
significantly,O
upon,O
mangiferin,Chemical
administration,O
as,O
compared,O
to,O
ISPH,Chemical
-,O
induced,O
MI,Disease
rats,O
.,O
An,O
alternate,O
class,O
III,O
agent,O
",",O
sotalol,Chemical
",",O
was,O
also,O
effective,O
for,O
the,O
prevention,O
of,O
VT,Disease
.,O
Myositis,Disease
",",O
attributable,O
to,O
the,O
drug,O
combination,O
and,O
symptomatic,O
enough,O
to,O
discontinue,O
it,O
",",O
occurred,O
in,O
3,O
%,O
of,O
patients,O
",",O
and,O
in,O
1,O
%,O
with,O
concurrent,O
high,O
creatine,Chemical
phosphokinase,O
(,O
769,O
U,O
/,O
liter,O
),O
;,O
no,O
patients,O
had,O
rhabdomyolysis,Disease
or,O
myoglobinuria,Disease
.,O
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
CONCLUSION,O
:,O
Myocet,Chemical
improves,O
the,O
therapeutic,O
index,O
of,O
doxorubicin,Chemical
by,O
significantly,O
reducing,O
cardiotoxicity,Disease
and,O
grade,O
4,O
neutropenia,Disease
and,O
provides,O
comparable,O
antitumor,O
efficacy,O
",",O
when,O
used,O
in,O
combination,O
with,O
cyclophosphamide,Chemical
as,O
first,O
-,O
line,O
therapy,O
for,O
MBC,Disease
.,O
Here,O
we,O
report,O
multiple,O
cases,O
of,O
bilateral,O
abductor,O
paralysis,Disease
following,O
Botox,Chemical
injections,O
for,O
ADSD,Disease
",",O
a,O
complication,O
previously,O
unreported,O
.,O
Recombinant,O
human,O
erythropoietin,O
has,O
been,O
used,O
to,O
manage,O
ribavirin,Chemical
-,O
associated,O
anemia,Disease
but,O
has,O
other,O
potential,O
disadvantages,O
.,O
Experiments,O
with,O
analogues,O
and,O
derivatives,O
of,O
CCK,O
-,O
5,O
-,O
8,O
demonstrated,O
that,O
the,O
effectiveness,O
of,O
the,O
beta,O
-,O
alanyl,O
derivatives,O
of,O
CCK,O
-,O
5,O
-,O
8,O
were,O
enhanced,O
and,O
that,O
they,O
were,O
equipotent,O
with,O
CCK,Chemical
-,Chemical
8,Chemical
-,O
SE,O
.,O
When,O
the,O
metoclopramide,Chemical
administration,O
was,O
discontinued,O
",",O
the,O
abnormal,Disease
movements,Disease
gradually,O
improved,O
to,O
a,O
considerable,O
extent,O
.,O
Compression,Disease
neuropathy,Disease
of,Disease
the,Disease
radial,Disease
nerve,Disease
due,O
to,O
pentazocine,Chemical
-,O
induced,O
fibrous,Disease
myopathy,Disease
.,O
We,O
describe,O
a,O
female,O
patient,O
with,O
stable,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
who,O
has,O
shown,O
a,O
marked,O
worsening,O
of,O
her,O
motor,O
functions,O
following,O
therapy,O
of,O
menopause,O
related,O
symptoms,O
with,O
veralipride,Chemical
",",O
as,O
well,O
as,O
the,O
improvement,O
of,O
her,O
symptoms,O
back,O
to,O
baseline,O
after,O
discontinuation,O
of,O
the,O
drug,O
.,O
Seventy,O
-,O
one,O
participants,O
completed,O
2,O
separate,O
study,O
days,O
and,O
were,O
blind,O
to,O
medication,O
condition,O
(,O
placebo,O
",",O
10,O
-,O
mg,O
oxycodone,Chemical
),O
.,O
We,O
report,O
a,O
case,O
about,O
a,O
female,O
with,O
essential,O
hypertension,Disease
on,O
drug,O
treatment,O
with,O
amlodipine,Chemical
developed,O
loss,Disease
of,Disease
taste,Disease
sensation,Disease
.,O
Comparative,O
study,O
:,O
Endografine,Chemical
(,O
diatrizoate,Chemical
),O
",",O
Vasurix,Chemical
polyvidone,Chemical
(,O
acetrizoate,Chemical
),O
",",O
Dimer,Chemical
-,Chemical
X,Chemical
(,O
iocarmate,Chemical
),O
and,O
Hexabrix,Chemical
(,O
ioxaglate,Chemical
),O
in,O
hysterosalpingography,O
.,O
CCB,O
was,O
measured,O
before,O
and,O
after,O
administration,O
of,O
either,O
vehicle,O
",",O
AVP,Chemical
",",O
ANP,O
",",O
or,O
both,O
peptides,O
together,O
.,O
Second,O
",",O
the,O
anticonvulsant,O
effect,O
of,O
MK,Chemical
-,Chemical
801,Chemical
in,O
the,O
lithium,Chemical
-,O
pilocarpine,Chemical
model,O
only,O
occurred,O
after,O
initial,O
periods,O
of,O
seizure,Disease
activity,O
.,O
KF17837,Chemical
:,O
a,O
novel,O
selective,O
adenosine,Chemical
A2A,O
receptor,O
antagonist,O
with,O
anticataleptic,O
activity,O
.,O
We,O
report,O
a,O
case,O
of,O
acute,O
interstitial,Disease
nephritis,Disease
(,O
AIN,Disease
),O
due,O
to,O
nicergoline,Chemical
(,O
Sermion,Chemical
),O
.,O
Enhanced,O
bradycardia,Disease
induced,O
by,O
beta,O
-,O
adrenoceptor,O
antagonists,O
in,O
rats,O
pretreated,O
with,O
isoniazid,Chemical
.,O
The,O
data,O
indicate,O
that,O
the,O
effects,O
of,O
streptozotocin,Chemical
-,O
induced,O
diabetes,Disease
on,O
urinary,O
bladder,O
function,O
are,O
both,O
prevented,O
and,O
reversed,O
by,O
insulin,O
treatment,O
.,O
Due,O
to,O
severe,O
systolic,Disease
dysfunction,Disease
losartan,Chemical
was,O
prescribed,O
.,O
Amphotericin,Chemical
B,Chemical
concentrations,O
in,O
the,O
kidney,O
in,O
NS,O
-,O
718,O
-,O
treated,O
rats,O
were,O
higher,O
than,O
those,O
in,O
D,Chemical
-,Chemical
AmB,Chemical
-,O
treated,O
rats,O
.,O
Recent,O
data,O
suggest,O
that,O
tricyclic,O
antidepressants,O
inhibit,O
calcium,Chemical
influx,O
in,O
some,O
tissues,O
.,O
This,O
",",O
together,O
with,O
our,O
previous,O
findings,O
that,O
allopurinol,Chemical
failed,O
to,O
prevent,O
adrenocorticotrophic,O
hormone,O
induced,O
hypertension,Disease
",",O
suggests,O
that,O
XO,O
activity,O
is,O
not,O
a,O
major,O
determinant,O
of,O
GC,O
-,O
HT,Disease
in,O
the,O
rat,O
.,O
Adverse,O
interaction,O
between,O
beta,Chemical
-,Chemical
adrenergic,Chemical
blocking,Chemical
drugs,Chemical
and,O
verapamil,Chemical
-,O
-,O
report,O
of,O
three,O
cases,O
.,O
Cocaine,Chemical
was,O
found,O
to,O
activate,O
the,O
discharge,O
system,O
and,O
thus,O
induce,O
abnormal,O
behaviors,O
that,O
are,O
generated,O
at,O
the,O
discharge,O
site,O
and,O
at,O
distant,O
sites,O
to,O
which,O
the,O
discharge,O
propagates,O
.,O
The,O
influence,O
of,O
L,Chemical
-,Chemical
dopa,Chemical
on,O
the,O
renal,O
excretion,O
of,O
potassium,Chemical
was,O
studied,O
in,O
3,O
patients,O
with,O
hypokalemia,Disease
and,O
in,O
5,O
normokalemic,O
patients,O
by,O
determination,O
of,O
renal,O
plasma,O
flow,O
",",O
glomerular,O
filtration,O
rate,O
",",O
plasma,O
concentration,O
of,O
potassium,Chemical
and,O
sodium,Chemical
as,O
well,O
as,O
urinary,O
excretion,O
of,O
potassium,Chemical
",",O
sodium,Chemical
and,O
aldosterone,Chemical
.,O
Monosodium,Chemical
glutamate,Chemical
(,O
MSG,Chemical
),O
administration,O
to,O
neonatal,O
rodents,O
produces,O
convulsions,Disease
and,O
results,O
in,O
numerous,O
biochemical,O
and,O
behavioral,O
deficits,O
.,O
The,O
FK506,Chemical
plus,O
SRL,Chemical
combination,O
showed,O
only,O
a,O
marginally,O
higher,O
degree,O
of,O
fibrosis,Disease
as,O
compared,O
with,O
controls,O
(,O
P,O
=,O
0,O
.,O
05,O
),O
.,O
Additionally,O
",",O
this,O
may,O
have,O
been,O
the,O
first,O
report,O
on,O
AMI,Chemical
-,O
induced,O
apoptotic,O
death,O
in,O
the,O
lung,O
tissue,O
.,O
The,O
subcutaneous,O
injection,O
of,O
isoproterenol,Chemical
(,O
30,O
mg,O
/,O
kg,O
),O
into,O
rats,O
twice,O
at,O
an,O
interval,O
of,O
24,O
h,O
",",O
for,O
two,O
consecutive,O
days,O
",",O
led,O
to,O
a,O
significant,O
increase,O
in,O
serum,O
lactate,Chemical
dehydrogenase,O
",",O
creatine,Chemical
phosphokinase,O
",",O
alanine,Chemical
transaminase,O
",",O
aspartate,Chemical
transaminase,O
",",O
and,O
angiotensin,Chemical
-,O
converting,O
enzyme,O
activities,O
",",O
total,O
cholesterol,Chemical
",",O
triglycerides,Chemical
",",O
free,O
serum,O
fatty,Chemical
acid,Chemical
",",O
cardiac,O
tissue,O
malondialdehyde,Chemical
(,O
MDA,Chemical
),O
",",O
and,O
nitric,Chemical
oxide,Chemical
levels,O
and,O
a,O
significant,O
decrease,O
in,O
levels,O
of,O
glutathione,Chemical
and,O
superoxide,Chemical
dismutase,O
in,O
cardiac,O
tissue,O
as,O
compared,O
to,O
the,O
normal,O
control,O
group,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
.,O
Protective,O
effect,O
of,O
a,O
specific,O
platelet,O
-,O
activating,O
factor,O
antagonist,O
",",O
BN,Chemical
52021,Chemical
",",O
on,O
bupivacaine,Chemical
-,O
induced,O
cardiovascular,Disease
impairments,Disease
in,O
rats,O
.,O
Reduced,O
cardiotoxicity,Disease
and,O
preserved,O
antitumor,O
efficacy,O
of,O
liposome,O
-,O
encapsulated,O
doxorubicin,Chemical
and,O
cyclophosphamide,Chemical
compared,O
with,O
conventional,O
doxorubicin,Chemical
and,O
cyclophosphamide,Chemical
in,O
a,O
randomized,O
",",O
multicenter,O
trial,O
of,O
metastatic,O
breast,Disease
cancer,Disease
.,O
In,O
patients,O
with,O
OAB,Disease
urinary,O
PGE2,Chemical
positively,O
correlated,O
with,O
volume,O
at,O
first,O
desire,O
to,O
void,O
and,O
maximum,O
cystometric,O
capacity,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
.,O
We,O
estimated,O
the,O
direct,O
cost,O
of,O
treating,O
clinically,O
significant,O
RIHA,Disease
to,O
be,O
170,O
per,O
patient,O
receiving,O
combination,O
therapy,O
per,O
48,O
-,O
week,O
treatment,O
course,O
(,O
range,O
68,O
-,O
692,O
),O
.,O
Serum,O
levels,O
known,O
to,O
be,O
effective,O
against,O
neuroblastoma,Disease
in,O
vitro,O
were,O
achieved,O
at,O
this,O
dose,O
.,O
No,O
panic,Disease
attack,Disease
was,O
observed,O
after,O
the,O
caffeine,Chemical
-,O
free,O
solution,O
intake,O
.,O
RESULTS,O
:,O
Two,O
of,O
eight,O
dogs,O
in,O
the,O
C,O
+,O
E,O
group,O
experienced,O
cardiovascular,Disease
collapse,Disease
.,O
Pain,Disease
rating,O
was,O
performed,O
using,O
a,O
computerized,O
visual,O
analogue,O
scale,O
(,O
0,O
-,O
100,O
),O
digitized,O
at,O
1,O
/,O
s,O
",",O
either,O
immediately,O
online,O
or,O
one,O
hour,O
or,O
one,O
day,O
after,O
injection,O
.,O
Venous,O
pain,Disease
occurred,O
in,O
68,O
%,O
of,O
patients,O
and,O
50,O
%,O
had,O
redness,O
",",O
pain,Disease
or,O
swelling,Disease
related,O
to,O
the,O
injection,O
site,O
",",O
in,O
some,O
cases,O
lasting,O
up,O
to,O
three,O
weeks,O
after,O
anaesthesia,O
.,O
The,O
incidence,O
of,O
non,O
-,O
hematological,O
toxicities,Disease
was,O
low,O
and,O
grade,O
3,O
-,O
4,O
hematological,O
toxicities,Disease
were,O
reported,O
in,O
20,O
patients,O
(,O
mainly,O
lymphopenia,Disease
and,O
neutropenia,Disease
),O
.,O
Addition,O
of,O
excess,O
calcium,Chemical
reversed,O
the,O
depression,Disease
in,O
both,O
tissues,O
",",O
but,O
calcium,Chemical
-,O
independent,O
catecholamine,Chemical
release,O
by,O
acetaldehyde,Chemical
was,O
not,O
blocked,O
by,O
NH4Ac,Chemical
.,O
To,O
determine,O
if,O
the,O
addition,O
of,O
a,O
buffering,O
solution,O
to,O
adjust,O
the,O
pH,O
of,O
lidocaine,Chemical
into,O
the,O
physiologic,O
range,O
would,O
reduce,O
pain,Disease
during,O
injection,O
",",O
we,O
performed,O
a,O
blinded,O
randomized,O
study,O
in,O
patients,O
undergoing,O
cardiac,O
catheterization,O
.,O
Information,O
on,O
these,O
effects,O
could,O
be,O
obtained,O
from,O
angiograms,O
of,O
patients,O
with,O
cocaine,Chemical
-,O
associated,O
subarachnoid,Disease
hemorrhage,Disease
(,O
SAH,Disease
),O
who,O
underwent,O
angiography,O
shortly,O
after,O
cocaine,Chemical
use,O
.,O
The,O
ocular,Disease
hypotensive,Disease
effects,O
were,O
statistically,O
significant,O
for,O
apraclonidine,Chemical
-,O
treated,O
eyes,O
throughout,O
the,O
study,O
and,O
also,O
statistically,O
significant,O
for,O
contralateral,O
eyes,O
from,O
three,O
hours,O
after,O
topical,O
administration,O
of,O
1,O
%,O
apraclonidine,Chemical
.,O
Tiapride,Chemical
",",O
a,O
substituted,O
benzamide,Chemical
derivative,O
closely,O
related,O
to,O
metoclopramide,Chemical
",",O
reduced,O
levodopa,Chemical
-,O
induced,O
peak,O
dose,O
involuntary,Disease
movements,Disease
in,O
16,O
patients,O
with,O
idiopathic,Disease
Parkinson,Disease
',Disease
s,Disease
disease,Disease
.,O
Twenty,O
-,O
two,O
patients,O
in,O
the,O
affected,O
group,O
had,O
abnormal,Disease
audiograms,Disease
with,Disease
deficits,Disease
mostly,Disease
in,Disease
the,Disease
high,Disease
frequency,Disease
range,Disease
of,Disease
4,Disease
",",Disease
000,Disease
to,Disease
8,Disease
",",Disease
000,Disease
Hz,Disease
and,O
in,O
the,O
hearing,O
threshold,O
levels,O
of,O
30,O
to,O
100,O
decibels,O
.,O
Over,O
the,O
long,O
-,O
term,O
chronic,O
phase,O
(,O
120,O
days,O
after,O
transplantation,O
),O
",",O
only,O
25,O
%,O
of,O
BMC,O
-,O
treated,O
epileptic,Disease
animals,O
had,O
seizures,Disease
",",O
but,O
with,O
a,O
lower,O
frequency,O
and,O
duration,O
compared,O
to,O
the,O
epileptic,Disease
control,O
group,O
.,O
Severe,O
side,O
effects,O
in,O
terms,O
of,O
mental,O
confusion,Disease
and,O
progressive,O
hyperbilirubinemia,Disease
",",O
however,O
",",O
point,O
to,O
an,O
enhancement,O
not,O
only,O
of,O
antineoplastic,O
effects,O
but,O
also,O
of,O
toxicity,Disease
in,O
normal,O
tissues,O
.,O
Five,O
cases,O
of,O
paranoid,Disease
exacerbation,O
with,O
the,O
serotonin,Chemical
reuptake,O
inhibitors,O
fluoxetine,Chemical
and,O
amitriptyline,Chemical
are,O
reported,O
here,O
.,O
The,O
common,O
factor,O
relating,O
thromboembolism,Disease
and,O
thrombocytopenia,Disease
is,O
heparin,Chemical
-,O
induced,O
platelet,Disease
aggregation,Disease
.,O
Protocols,O
of,O
conversion,O
from,O
cyclosporin,Chemical
A,Chemical
(,O
CsA,Chemical
),O
to,O
sirolimus,Chemical
(,O
SRL,Chemical
),O
have,O
been,O
widely,O
used,O
in,O
immunotherapy,O
after,O
transplantation,O
to,O
prevent,O
CsA,Chemical
-,O
induced,O
nephropathy,Disease
",",O
but,O
the,O
molecular,O
mechanisms,O
underlying,O
these,O
protocols,O
remain,O
nuclear,O
.,O
The,O
results,O
of,O
serum,O
liver,O
function,O
tests,O
suggested,O
hepatocellular,Disease
injury,Disease
in,O
10,O
(,O
63,O
%,O
),O
;,O
the,O
rest,O
showed,O
a,O
mixed,O
pattern,O
.,O
A,O
busulfan,Chemical
dose,O
calculated,O
on,O
the,O
basis,O
of,O
body,O
surface,O
area,O
",",O
resulting,O
in,O
higher,O
doses,O
in,O
young,O
children,O
",",O
was,O
followed,O
by,O
increased,O
neurotoxicity,Disease
",",O
close,O
to,O
neurotoxicity,Disease
incidence,O
observed,O
in,O
adults,O
.,O
Thus,O
",",O
the,O
precipitating,O
cause,O
of,O
convulsions,Disease
was,O
believed,O
to,O
be,O
an,O
overdose,Disease
of,O
TNA,Chemical
.,O
We,O
tested,O
the,O
sulfated,O
polysaccharide,O
fucoidan,Chemical
",",O
which,O
has,O
been,O
reported,O
to,O
reduce,O
inflammatory,O
brain,Disease
damage,Disease
",",O
in,O
a,O
rat,O
model,O
of,O
intracerebral,Disease
hemorrhage,Disease
induced,O
by,O
injection,O
of,O
bacterial,O
collagenase,O
into,O
the,O
caudate,O
nucleus,O
.,O
OBJECTIVES,O
/,O
HYPOTHESIS,O
:,O
Botulinum,O
toxin,O
(,O
Botox,Chemical
),O
injections,O
into,O
the,O
thyroarytenoid,O
muscles,O
are,O
the,O
current,O
standard,O
of,O
care,O
for,O
adductor,Disease
spasmodic,Disease
dysphonia,Disease
(,O
ADSD,Disease
),O
.,O
A,O
phase,O
II,O
study,O
of,O
thalidomide,Chemical
in,O
advanced,O
metastatic,O
renal,Disease
cell,Disease
carcinoma,Disease
.,O
Pretreatment,O
of,O
animals,O
with,O
BNPP,Chemical
prior,O
to,O
APAP,Chemical
or,O
PAP,Chemical
administration,O
resulted,O
in,O
marked,O
reduction,O
of,O
APAP,Chemical
(,O
900,O
mg,O
/,O
kg,O
),O
nephrotoxicity,Disease
but,O
not,O
PAP,Chemical
nephrotoxicity,Disease
.,O
The,O
peptide,O
CCK,O
-,O
5,O
-,O
8,O
had,O
weak,O
anticonvulsant,O
activity,O
in,O
comparison,O
to,O
the,O
octapeptides,O
",",O
3,O
.,O
2,O
mumol,O
/,O
kg,O
and,O
larger,O
doses,O
of,O
the,O
reference,O
drug,O
",",O
diazepam,Chemical
",",O
totally,O
prevented,O
picrotoxin,Chemical
-,O
induced,O
seizures,Disease
and,O
mortality,O
.,O
We,O
present,O
a,O
15,O
-,O
year,O
-,O
old,O
girl,O
schizophrenic,Disease
who,O
developed,O
frequent,O
involuntary,Disease
eye,Disease
-,Disease
blinking,Disease
movements,Disease
after,O
5,O
months,O
of,O
amisulpride,Chemical
treatment,O
(,O
1000,O
mg,O
per,O
day,O
),O
.,O
.,O
Hypertension,Disease
and,O
treatment,O
with,O
bevacizumab,Chemical
appear,O
to,O
be,O
additional,O
risk,O
factors,O
.,O
CONCLUSIONS,O
:,O
Severe,O
adverse,O
effects,O
of,O
sirolimus,Chemical
include,O
fever,Disease
",",O
anemia,Disease
",",O
and,O
capillary,Disease
leak,Disease
syndrome,Disease
.,O
Five,O
months,O
after,O
starting,O
nifedipine,Chemical
(,O
Adalat,Chemical
),O
",",O
two,O
patients,O
developed,O
photodistributed,O
facial,O
telangiectasia,Disease
",",O
which,O
became,O
more,O
noticeable,O
with,O
time,O
.,O
Posttransplant,O
anemia,Disease
is,O
a,O
common,O
problem,O
that,O
may,O
hinder,O
patients,O
',O
quality,O
of,O
life,O
.,O
Long,O
-,O
term,O
follow,O
-,O
up,O
of,O
ifosfamide,Chemical
renal,Disease
toxicity,Disease
in,O
children,O
treated,O
for,O
malignant,Disease
mesenchymal,Disease
tumors,Disease
:,O
an,O
International,O
Society,O
of,O
Pediatric,O
Oncology,O
report,O
.,O
Paclitaxel,Chemical
",",O
cisplatin,Chemical
",",O
and,O
gemcitabine,Chemical
combination,O
chemotherapy,O
within,O
a,O
multidisciplinary,O
therapeutic,O
approach,O
in,O
metastatic,O
nonsmall,Disease
cell,Disease
lung,Disease
carcinoma,Disease
.,O
We,O
conclude,O
that,O
mPGES,O
-,O
1,O
-,O
derived,O
PGE,Chemical
(,Chemical
2,Chemical
),Chemical
mediates,O
lithium,Chemical
-,O
induced,O
polyuria,Disease
likely,O
via,O
inhibition,O
of,O
AQP2,O
and,O
NKCC2,O
expression,O
.,O
Decrease,O
of,O
fetal,O
length,O
was,O
the,O
only,O
signs,O
of,O
the,O
DFU,Chemical
developmental,O
toxicity,Disease
observed,O
in,O
pups,O
exposed,O
to,O
the,O
highest,O
compound,O
dose,O
.,O
Extensive,O
literature,O
search,O
revealed,O
multiple,O
cases,O
of,O
coronary,Disease
artery,Disease
vasospasm,Disease
secondary,O
to,O
zolmitriptan,Chemical
",",O
but,O
none,O
of,O
the,O
cases,O
were,O
associated,O
with,O
TS,Disease
.,O
Postoperative,Disease
delirium,Disease
was,O
assessed,O
as,O
defined,O
by,O
Diagnostic,O
and,O
Statistical,O
Manual,O
of,O
Mental,Disease
Disorders,Disease
(,O
Third,O
Edition,O
Revised,O
),O
criteria,O
using,O
the,O
Confusion,O
Assessment,O
Method,O
beginning,O
at,O
any,O
time,O
from,O
the,O
second,O
day,O
after,O
surgery,O
.,O
alpha,Chemical
-,Chemical
TC,Chemical
and,O
DFO,Chemical
attenuated,O
the,O
MA,Chemical
-,O
induced,O
hyperthermia,Disease
as,O
well,O
as,O
the,O
alterations,O
in,O
the,O
locomotor,O
activity,O
.,O
The,O
authors,O
describe,O
the,O
unusual,O
association,O
between,O
diffuse,O
B,O
-,O
cell,O
gastric,Disease
lymphoma,Disease
and,O
myotonic,Disease
dystrophy,Disease
",",O
the,O
most,O
common,O
form,O
of,O
adult,O
muscular,Disease
dystrophy,Disease
",",O
and,O
sudden,O
atrial,Disease
fibrillation,Disease
following,O
one,O
cycle,O
of,O
doxorubicin,Chemical
-,O
based,O
chemotherapy,O
in,O
the,O
same,O
patient,O
.,O
The,O
reduction,O
of,O
amphetamine,Chemical
hyperactivity,Disease
induced,O
by,O
DSP4,Chemical
was,O
blocked,O
by,O
pretreatment,O
with,O
the,O
noradrenaline,Chemical
-,O
uptake,O
blocking,O
agent,O
",",O
desipramine,Chemical
",",O
which,O
prevents,O
the,O
neurotoxic,Disease
action,O
of,O
DSP4,Chemical
.,O
While,O
the,O
mutual,O
potentiation,O
",",O
antagonism,O
and,O
tolerance,O
suggest,O
common,O
mechanisms,O
for,O
the,O
induced,O
catalepsy,Disease
",",O
differences,O
in,O
latency,O
",",O
rigidity,Disease
and,O
behavior,O
",",O
asymmetry,O
of,O
cross,O
-,O
tolerance,O
and,O
a,O
widely,O
-,O
different,O
ID50,O
for,O
naloxone,Chemical
would,O
argue,O
against,O
an,O
action,O
at,O
a,O
single,O
opioid,O
site,O
.,O
Octreotide,Chemical
-,O
induced,O
hypoxemia,Disease
and,O
pulmonary,Disease
hypertension,Disease
in,O
premature,O
neonates,O
.,O
The,O
reports,O
illustrate,O
the,O
need,O
for,O
clinicians,O
to,O
consider,O
acetaminophen,Chemical
in,O
patients,O
with,O
hypotension,Disease
of,O
unknown,O
origin,O
.,O
We,O
have,O
described,O
a,O
unique,O
patient,O
who,O
had,O
reversible,O
and,O
dose,O
-,O
related,O
myasthenia,Disease
gravis,Disease
after,O
penicillamine,Chemical
and,O
chloroquine,Chemical
therapy,O
for,O
rheumatoid,Disease
arthritis,Disease
.,O
In,O
this,O
case,O
",",O
the,O
authors,O
postulate,O
that,O
the,O
use,O
of,O
estradiol,Chemical
and,O
progesterone,Chemical
and,O
the,O
underlying,O
DM,Disease
increased,O
vascular,O
thrombogenicity,O
",",O
which,O
provided,O
a,O
common,O
denominator,O
for,O
thrombosis,Disease
of,Disease
both,Disease
the,Disease
ICA,Disease
and,Disease
the,Disease
venous,Disease
sinus,Disease
.,O
99mTc,Chemical
-,Chemical
glucarate,Chemical
was,O
easy,O
to,O
prepare,O
",",O
stable,O
for,O
96,O
h,O
and,O
was,O
used,O
to,O
study,O
its,O
biodistribution,O
in,O
rats,O
with,O
isoproterenol,Chemical
-,O
induced,O
acute,O
myocardial,Disease
infarction,Disease
.,O
New,O
chemotherapy,O
combinations,O
with,O
higher,O
activity,O
and,O
lower,O
toxicity,Disease
are,O
needed,O
for,O
elderly,O
patients,O
with,O
advanced,O
NSCLC,Disease
.,O
Four,O
types,O
of,O
experimental,O
arrhythmia,Disease
are,O
used,O
-,O
-,O
with,O
BaCl2,Chemical
",",O
with,O
chloroform,Chemical
-,O
adrenaline,Chemical
",",O
with,O
strophantine,Chemical
G,Chemical
and,O
with,O
aconitine,Chemical
.,O
Hiccups,Disease
were,O
persistent,O
and,O
exhausting,O
.,O
Cardioprotective,O
effect,O
of,O
ethanolic,Chemical
extract,Chemical
of,Chemical
Terminalia,Chemical
chebula,Chemical
fruits,Chemical
(,O
500,O
mg,O
/,O
kg,O
body,O
wt,O
),O
was,O
examined,O
in,O
isoproterenol,Chemical
(,O
200,O
mg,O
/,O
kg,O
body,O
wt,O
),O
induced,O
myocardial,Disease
damage,Disease
in,O
rats,O
.,O
When,O
the,O
parameters,O
were,O
examined,O
individually,O
",",O
duration,O
of,O
therapy,O
and,O
total,O
AUC,O
correlated,O
significantly,O
(,O
P,O
less,O
than,O
.,O
05,O
),O
with,O
nephrotoxicity,Disease
.,O
A,O
prospective,O
clinical,O
trial,O
is,O
suggested,O
to,O
quantify,O
the,O
risk,O
of,O
cardiac,Disease
complications,Disease
to,O
patients,O
receiving,O
phenothiazines,Chemical
or,O
tricyclic,O
antidepressant,O
drugs,O
.,O
Bradycardia,Disease
",",O
cholinergic,O
symptoms,O
and,O
asystole,Disease
occurred,O
.,O
The,O
patient,O
was,O
treated,O
with,O
hyperosmolar,O
therapy,O
",",O
hyperventilation,Disease
",",O
sedation,O
",",O
and,O
chemical,O
paralysis,Disease
.,O
A,O
right,O
nephroureterectomy,O
was,O
required,O
for,O
control,O
of,O
bleeding,Disease
.,O
Pain,Disease
recall,O
after,O
one,O
week,O
was,O
similarly,O
precise,O
(,O
magnitude,O
:,O
p,O
<,O
0,O
.,O
01,O
",",O
duration,O
:,O
p,O
<,O
0,O
.,O
05,O
),O
.,O
Our,O
findings,O
indicate,O
that,O
beta2,O
-,O
adrenoceptor,O
overstimulation,O
during,O
an,O
early,O
critical,O
period,O
results,O
in,O
microglial,O
activation,O
associated,O
with,O
innate,O
neuroinflammatory,O
pathways,O
and,O
behavioral,Disease
abnormalities,Disease
",",O
similar,O
to,O
those,O
described,O
in,O
autism,Disease
.,O
This,O
case,O
study,O
reveals,O
an,O
unusual,O
finding,O
of,O
rapidly,O
proliferative,O
crescentic,O
glomerulonephritis,Disease
in,O
a,O
patient,O
treated,O
with,O
rifampin,Chemical
who,O
had,O
no,O
other,O
identifiable,O
causes,O
for,O
developing,O
this,O
disease,O
.,O
All,O
36,O
patients,O
receiving,O
lamivudine,Chemical
had,O
a,O
decrease,O
in,O
hepatitis,Disease
B,Disease
virus,O
(,O
HBV,O
),O
DNA,O
values,O
of,O
>,O
90,O
%,O
(,O
P,O
<,O
.,O
001,O
compared,O
with,O
placebo,O
),O
.,O
Protection,O
against,O
amphetamine,Chemical
-,O
induced,O
neurotoxicity,Disease
toward,O
striatal,O
dopamine,Chemical
neurons,O
in,O
rodents,O
by,O
LY274614,Chemical
",",O
an,O
excitatory,O
amino,Chemical
acid,Chemical
antagonist,O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
effect,O
of,O
crocins,Chemical
on,O
sporadic,O
Alzheimer,Disease
',Disease
s,Disease
disease,Disease
induced,O
by,O
intracerebroventricular,O
(,O
icv,O
),O
streptozocin,Chemical
(,O
STZ,Chemical
),O
in,O
male,O
rats,O
was,O
investigated,O
.,O
Frequency,O
of,O
transient,O
ipsilateral,O
vocal,Disease
cord,Disease
paralysis,Disease
in,O
patients,O
undergoing,O
carotid,O
endarterectomy,O
under,O
local,O
anesthesia,O
.,O
However,O
",",O
an,O
increase,O
of,O
serum,O
creatinine,Chemical
at,O
various,O
times,O
postoperatively,O
is,O
more,O
predictive,O
of,O
the,O
development,O
of,O
CRF,Disease
or,O
ESRD,Disease
.,O
We,O
present,O
the,O
case,O
of,O
a,O
28,O
-,O
year,O
-,O
old,O
man,O
on,O
chronic,O
warfarin,Chemical
therapy,O
who,O
sustained,O
a,O
minor,O
muscle,Disease
tear,Disease
and,O
developed,O
increasing,O
pain,Disease
and,O
a,O
flexure,O
contracture,Disease
of,O
the,O
right,O
hip,O
.,O
In,O
behavioral,O
studies,O
",",O
pre,O
-,O
treatment,O
of,O
mice,O
with,O
BD1018,Chemical
",",O
BD1063,Chemical
",",O
or,O
LR132,Chemical
significantly,O
attenuated,O
cocaine,Chemical
-,O
induced,O
convulsions,Disease
and,O
lethality,O
.,O
RESULTS,O
:,O
Six,O
percent,O
of,O
MC,O
patients,O
versus,O
21,O
%,O
(,O
including,O
five,O
cases,O
of,O
CHF,Disease
),O
of,O
AC,O
patients,O
developed,O
cardiotoxicity,Disease
(,O
P,O
=,O
.,O
0002,O
),O
.,O
Ancrod,O
has,O
been,O
used,O
successfully,O
for,O
prophylaxis,O
against,O
development,O
of,O
thrombosis,Disease
in,O
patients,O
with,O
heparin,Chemical
induced,O
platelet,Disease
aggregation,Disease
who,O
require,O
brief,O
reexposure,O
to,O
heparin,Chemical
",",O
but,O
its,O
success,O
in,O
patients,O
who,O
have,O
developed,O
the,O
thrombosis,Disease
syndrome,O
is,O
not,O
well,O
defined,O
.,O
Hepatic,Disease
dysfunction,Disease
and,O
acidosis,Disease
are,O
contributing,O
risk,O
factors,O
.,O
Rosaceiform,O
dermatitis,Disease
associated,O
with,O
topical,O
tacrolimus,Chemical
treatment,O
.,O
Five,O
patients,O
receiving,O
fluoxetine,Chemical
for,O
the,O
treatment,O
of,O
obsessive,Disease
compulsive,Disease
disorder,Disease
or,O
major,Disease
depression,Disease
developed,O
akathisia,Disease
.,O
Succinylcholine,Chemical
apnoea,Disease
:,O
attempted,O
reversal,O
with,O
anticholinesterases,O
.,O
Forty,O
patients,O
with,O
a,O
diagnosis,O
consistent,O
with,O
a,O
hematologic,Disease
/,Disease
oncologic,Disease
disorder,Disease
that,O
required,O
treatment,O
with,O
an,O
aminoglycoside,Chemical
were,O
randomized,O
to,O
either,O
conventional,O
or,O
extended,O
-,O
interval,O
amikacin,Chemical
.,O
Prolonged,O
cholestasis,Disease
after,O
troleandomycin,Chemical
-,O
induced,O
acute,O
hepatitis,Disease
.,O
We,O
report,O
a,O
case,O
of,O
intractable,O
hemorrhagic,Disease
cystitis,Disease
due,O
to,O
cyclophosphamide,Chemical
therapy,O
for,O
Wegener,Disease
',Disease
s,Disease
granulomatosis,Disease
.,O
Oral,O
administration,O
of,O
CBZ,Chemical
as,O
an,O
aqueous,O
suspension,O
every,O
8,O
h,O
at,O
a,O
dose,O
of,O
250,O
mg,O
/,O
kg,O
was,O
continuously,O
protective,O
against,O
HFDE,Chemical
-,O
induced,O
seizures,Disease
and,O
was,O
minimally,O
toxic,O
as,O
measured,O
by,O
weight,Disease
gain,Disease
over,O
8,O
weeks,O
of,O
treatment,O
.,O
The,O
male,O
Wistar,O
rats,O
consuming,O
a,O
diet,O
that,O
contained,O
LiCl,Chemical
(,O
60,O
mmol,O
/,O
kg,O
),O
for,O
4,O
weeks,O
developed,O
marked,O
polyuria,Disease
.,O
BACKGROUND,O
:,O
Pemoline,Chemical
is,O
an,O
oxazolidine,Chemical
derivative,O
that,O
is,O
structurally,O
different,O
from,O
amphetamines,Chemical
and,O
used,O
in,O
the,O
treatment,O
of,O
attention,Disease
deficit,Disease
disorder,Disease
.,O
Effects,O
of,O
cisapride,Chemical
on,O
symptoms,O
and,O
postcibal,O
small,O
-,O
bowel,O
motor,O
function,O
in,O
patients,O
with,O
irritable,Disease
bowel,Disease
syndrome,Disease
.,O
Recent,O
studies,O
show,O
that,O
the,O
YMDD,O
motif,O
mutants,O
(,O
resistant,O
hepatitis,Disease
B,Disease
virus,O
),O
occur,O
as,O
natural,O
genome,O
variability,O
in,O
lamivudine,Chemical
-,O
untreated,O
chronic,Disease
hepatitis,Disease
B,Disease
patients,O
.,O
Our,O
observations,O
demonstrated,O
an,O
association,O
of,O
hearing,Disease
loss,Disease
with,O
a,O
higher,O
incidence,O
of,O
perinatal,O
complications,O
.,O
We,O
describe,O
three,O
patients,O
in,O
whom,O
severe,O
",",O
life,O
-,O
threatening,O
hyperkalemia,Disease
and,O
renal,Disease
insufficiency,Disease
developed,O
after,O
treatment,O
of,O
acute,O
gouty,Disease
arthritis,Disease
with,O
indomethacin,Chemical
.,O
Wistar,O
rats,O
(,O
180,O
g,O
),O
were,O
treated,O
by,O
DEN,Chemical
alone,O
or,O
by,O
DEN,Chemical
+,O
PB,Chemical
during,O
2,O
",",O
4,O
and,O
6,O
weeks,O
according,O
to,O
our,O
schedule,O
for,O
hepatocarcinogenesis,Disease
.,O
TFL,O
is,O
an,O
active,O
",",O
well,O
-,O
tolerated,O
regimen,O
in,O
metastatic,O
breast,Disease
cancer,Disease
.,O
It,O
was,O
associated,O
with,O
co,O
-,O
morbid,O
affective,Disease
disorder,Disease
",",O
antisocial,Disease
personality,Disease
",",O
and,O
heavy,O
methamphetamine,Chemical
use,O
.,O
Ketamine,Chemical
sedation,O
for,O
the,O
reduction,O
of,O
children,O
',O
s,O
fractures,Disease
in,O
the,O
emergency,O
department,O
.,O
The,O
role,O
of,O
the,O
renin,O
-,O
-,O
angiotensin,Chemical
system,O
in,O
the,O
maintenance,O
of,O
blood,O
pressure,O
during,O
halothane,Chemical
anesthesia,O
and,O
sodium,Chemical
nitroprusside,Chemical
(,O
SNP,Chemical
),O
-,O
induced,O
hypotension,Disease
was,O
evaluated,O
.,O
DISCUSSION,O
:,O
Cholestatic,Disease
hepatitis,Disease
is,O
a,O
rare,O
complication,O
of,O
the,O
antiplatelet,O
agent,O
ticlopidine,Chemical
;,O
several,O
cases,O
have,O
been,O
reported,O
but,O
few,O
in,O
the,O
English,O
literature,O
.,O
Neuromuscular,Disease
blockade,Disease
with,O
magnesium,Chemical
sulfate,Chemical
and,O
nifedipine,Chemical
.,O
What,O
is,O
less,O
well,O
known,O
is,O
a,O
phenomenon,O
whereby,O
statins,Chemical
may,O
induce,O
a,O
myopathy,Disease
",",O
which,O
persists,O
or,O
may,O
progress,O
after,O
stopping,O
the,O
drug,O
.,O
The,O
SNAP,O
index,O
can,O
be,O
used,O
to,O
monitor,O
peripheral,Disease
neuropathy,Disease
",",O
but,O
not,O
for,O
early,O
detection,O
.,O
Glial,O
activation,O
and,O
post,O
-,O
synaptic,O
neurotoxicity,Disease
:,O
the,O
key,O
events,O
in,O
Streptozotocin,Chemical
(,O
ICV,O
),O
induced,O
memory,Disease
impairment,Disease
in,O
rats,O
.,O
This,O
case,O
report,O
shows,O
that,O
ciprofloxacin,Chemical
may,O
precipitate,O
life,O
-,O
threatening,O
thrombocytopenia,Disease
and,O
haemolytic,Disease
anaemia,Disease
",",O
even,O
in,O
the,O
early,O
phases,O
of,O
treatment,O
and,O
without,O
apparent,O
previous,O
exposures,O
.,O
Reversible,O
cerebral,Disease
lesions,Disease
associated,O
with,O
tiazofurin,Chemical
usage,O
:,O
MR,O
demonstration,O
.,O
Light,O
microscopic,O
analysis,O
showed,O
a,O
significant,O
protection,O
against,O
ADR,Chemical
-,O
induced,O
cardiac,Disease
morphological,Disease
alterations,Disease
.,O
Twenty,O
-,O
one,O
reports,O
of,O
antimicrobial,O
-,O
induced,O
mania,Disease
were,O
found,O
in,O
the,O
literature,O
.,O
Chronic,O
CBZ,Chemical
also,O
decreased,O
the,O
incidence,O
of,O
seizure,Disease
-,O
related,O
mortality,O
in,O
the,O
cocaine,Chemical
-,O
injected,O
rats,O
.,O
All,Chemical
-,Chemical
trans,Chemical
-,Chemical
retinoic,Chemical
acid,Chemical
-,O
induced,O
erythema,Disease
nodosum,Disease
in,O
patients,O
with,O
acute,Disease
promyelocytic,Disease
leukemia,Disease
.,O
Her,O
delirium,Disease
significantly,O
improved,O
after,O
misoprostol,Chemical
was,O
discontinued,O
and,O
her,O
mental,O
status,O
returned,O
to,O
normal,O
within,O
a,O
week,O
.,O
A,O
47,O
-,O
year,O
-,O
old,O
woman,O
with,O
right,O
hydroureteronephrosis,Disease
due,O
to,O
ureterovesical,O
junction,O
obstruction,O
had,O
gross,O
hematuria,Disease
after,O
being,O
treated,O
for,O
five,O
years,O
wtih,O
cyclophosphamide,Chemical
for,O
cerebral,Disease
vasculitis,Disease
.,O
Neuroleptic,O
-,O
induced,O
catalepsy,Disease
",",O
a,O
model,O
of,O
neuroleptic,O
-,O
induced,O
extrapyramidal,O
side,O
effects,O
",",O
was,O
considered,O
suitable,O
as,O
a,O
model,O
for,O
predicting,O
neuroleptic,O
-,O
induced,O
akathisia,Disease
in,O
humans,O
",",O
although,O
neuroleptic,O
-,O
induced,O
catalepsy,Disease
was,O
not,O
considered,O
a,O
specific,O
test,O
for,O
neuroleptic,O
-,O
induced,O
akathisia,Disease
.,O
All,O
participants,O
were,O
interviewed,O
about,O
any,O
experience,O
of,O
syncope,Disease
.,O
We,O
report,O
the,O
case,O
of,O
a,O
patient,O
with,O
amoxicillin,Chemical
-,Chemical
clavulanic,Chemical
acid,Chemical
-,O
induced,O
hepatitis,Disease
with,O
histologic,O
multiple,O
granulomas,Disease
.,O
Consequently,O
",",O
whereas,O
all,O
participants,O
exhibited,O
normotensive,O
levels,O
during,O
the,O
resting,O
predrug,O
baseline,O
",",O
33,O
%,O
of,O
borderline,O
subjects,O
achieved,O
hypertensive,Disease
BP,O
levels,O
after,O
caffeine,Chemical
ingestion,O
.,O
The,O
patients,O
had,O
developed,O
transient,O
renal,Disease
failure,Disease
after,O
the,O
intermittent,O
administration,O
of,O
rifampicin,Chemical
.,O
Three,O
complete,O
responses,O
were,O
observed,O
in,O
marrow,O
metastases,Disease
.,O
We,O
conclude,O
from,O
these,O
studies,O
that,O
CX3CR1,O
signaling,O
does,O
not,O
modulate,O
METH,Chemical
neurotoxicity,Disease
or,O
microglial,O
activation,O
.,O
Impaired,O
Umax,O
was,O
found,O
in,O
both,O
euthyroid,O
and,O
hypothyroid,Disease
patients,O
while,O
some,O
hypothyroid,Disease
patients,O
concentrated,O
their,O
urine,O
well,O
.,O
CONCLUSION,O
:,O
Our,O
data,O
indicate,O
that,O
long,O
-,O
term,O
use,O
of,O
nonaspirin,O
analgesic,O
drugs,O
and,O
NSAIDs,O
is,O
not,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
ESRD,Disease
.,O
Although,O
the,O
transaminases,O
gradually,O
returned,O
to,O
baseline,O
after,O
withholding,O
the,O
beta,Chemical
lactam,Chemical
antibiotic,O
",",O
there,O
was,O
a,O
gradual,O
increase,O
in,O
serum,O
bilirubin,Chemical
and,O
a,O
decrease,O
in,O
hemoglobin,O
concentration,O
caused,O
by,O
an,O
autoimmune,Disease
hemolytic,Disease
anemia,Disease
and,O
erythroblastocytopenia,Disease
.,O
The,O
most,O
distinctive,O
aspect,O
of,O
the,O
barium,Chemical
effect,O
was,O
a,O
demonstrated,O
hypersensitivity,Disease
of,O
the,O
cardiovascular,O
system,O
to,O
sodium,Chemical
pentobarbital,Chemical
.,O
An,O
accurate,O
autopsy,O
revealed,O
most,O
organs,O
with,O
diffuse,O
petechial,O
haemorrhages,Disease
.,O
Four,O
hours,O
after,O
MCAO,Disease
",",O
the,O
rats,O
were,O
killed,O
and,O
the,O
brains,O
harvested,O
.,O
DESIGN,O
:,O
A,O
randomised,O
crossover,O
study,O
of,O
recovery,O
time,O
of,O
systolic,O
and,O
diastolic,O
left,O
ventricular,O
function,O
after,O
exercise,O
and,O
dobutamine,Chemical
induced,O
ischaemia,Disease
.,O
Spironolactone,Chemical
:,O
is,O
it,O
a,O
novel,O
drug,O
for,O
the,O
prevention,O
of,O
amphotericin,Chemical
B,Chemical
-,O
related,O
hypokalemia,Disease
in,O
cancer,Disease
patients,O
?,O
Liver,Disease
enlargement,Disease
and,O
muscle,Disease
wastage,Disease
occurred,O
in,O
Wistar,O
rats,O
following,O
the,O
subcutaneous,O
administration,O
of,O
prednisolone,Chemical
.,O
This,O
reaction,O
demonstrates,O
that,O
nifedipine,Chemical
can,O
seriously,O
potentiate,O
the,O
toxicity,Disease
of,O
magnesium,Chemical
.,O
BACKGROUND,O
:,O
Tamoxifen,Chemical
is,O
a,O
candidate,O
chemopreventive,O
agent,O
in,O
breast,Disease
cancer,Disease
",",O
although,O
the,O
drug,O
may,O
be,O
associated,O
with,O
the,O
development,O
of,O
endometrial,Disease
cancer,Disease
.,O
Dimensions,O
of,O
the,O
bruising,Disease
on,O
the,O
heparin,Chemical
applied,O
areas,O
were,O
measured,O
using,O
transparent,O
millimetric,O
measuring,O
paper,O
.,O
Nonopaque,O
crystal,O
deposition,O
causing,O
ureteric,Disease
obstruction,Disease
in,O
patients,O
with,O
HIV,O
undergoing,O
indinavir,Chemical
therapy,O
.,O
Reduction,O
of,O
pain,Disease
during,O
induction,O
with,O
target,O
-,O
controlled,O
propofol,Chemical
and,O
remifentanil,Chemical
.,O
OBJECTIVES,O
:,O
To,O
investigate,O
the,O
effects,O
of,O
subchronic,O
L,Chemical
-,Chemical
NOARG,Chemical
treatment,O
in,O
haloperidol,Chemical
-,O
induced,O
catalepsy,Disease
and,O
the,O
number,O
of,O
NOS,O
neurons,O
in,O
areas,O
related,O
to,O
motor,O
control,O
.,O
Histopathologically,O
",",O
typical,O
findings,O
were,O
observed,O
in,O
the,O
cerebella,O
from,O
the,O
control,O
groups,O
",",O
but,O
the,O
findings,O
consistent,O
with,O
early,O
embryonic,O
development,O
were,O
noted,O
in,O
BCNU,Chemical
-,O
exposed,O
cortical,Disease
dysplasia,Disease
group,O
.,O
MEASUREMENTS,O
:,O
Platelet,O
counts,O
",",O
onset,O
of,O
objectively,O
determined,O
thromboembolism,Disease
",",O
results,O
of,O
heparin,Chemical
-,O
induced,O
platelet,O
factor,O
4,O
antibody,O
tests,O
",",O
and,O
outcomes,O
.,O
With,O
all,O
second,O
-,O
generation,O
OCs,Chemical
as,O
the,O
reference,O
",",O
the,O
odds,O
ratios,O
for,O
VTE,Disease
were,O
3,O
.,O
49,O
(,O
1,O
.,O
21,O
-,O
10,O
.,O
12,O
),O
for,O
desogestrel,Chemical
plus,O
20,O
g,O
ethinyloestradiol,Chemical
and,O
1,O
.,O
18,O
(,O
0,O
.,O
66,O
-,O
2,O
.,O
17,O
),O
for,O
the,O
other,O
third,O
-,O
generation,O
progestagens,Chemical
.,O
Chloroacetaldehyde,Chemical
as,O
a,O
sulfhydryl,Chemical
reagent,O
:,O
the,O
role,O
of,O
critical,O
thiol,Chemical
groups,O
in,O
ifosfamide,Chemical
nephropathy,Disease
.,O
Thus,O
",",O
the,O
absence,O
of,O
D2R,O
lowers,O
the,O
threshold,O
for,O
seizures,Disease
induced,O
by,O
both,O
glutamate,Chemical
and,O
acetylcholine,Chemical
.,O
Trazodone,Chemical
at,O
30,O
",",O
40,O
and,O
50,O
mg,O
/,O
kg,O
i,O
.,O
p,O
.,O
induced,O
catalepsy,Disease
and,O
antagonized,O
apomorphine,Chemical
and,O
dexamphetamine,Chemical
stereotypies,O
.,O
Severity,O
of,O
peak,O
-,O
dose,O
dyskinesias,Disease
was,O
strongly,O
correlated,O
with,O
grip,O
force,O
in,O
ON,O
-,O
state,O
(,O
r,O
=,O
0,O
.,O
79,O
with,O
peak,O
force,O
",",O
P,O
<,O
0,O
.,O
01,O
),O
.,O
Cardiotoxicity,Disease
is,O
a,O
rare,O
complication,O
occurring,O
during,O
5,Chemical
-,Chemical
fluorouracil,Chemical
(,O
5,Chemical
-,Chemical
FU,Chemical
),O
treatment,O
for,O
malignancies,Disease
.,O
High,O
doses,O
of,O
vitamin,Chemical
D,Chemical
are,O
known,O
to,O
cause,O
calcification,Disease
of,Disease
the,Disease
artery,Disease
media,O
in,O
as,O
little,O
as,O
3,O
to,O
4,O
days,O
.,O
Ximelagatran,Chemical
",",O
an,O
oral,O
direct,O
thrombin,O
inhibitor,O
",",O
was,O
found,O
to,O
be,O
as,O
efficient,O
as,O
vitamin,Chemical
K,Chemical
antagonist,O
drugs,O
in,O
the,O
prevention,O
of,O
embolic,Disease
events,Disease
",",O
but,O
has,O
been,O
recently,O
withdrawn,O
because,O
of,O
abnormal,Disease
liver,Disease
function,Disease
tests,O
.,O
The,O
obtained,O
data,O
revealed,O
that,O
BCNU,Chemical
administration,O
resulted,O
in,O
deterioration,Disease
of,Disease
learning,Disease
and,Disease
short,Disease
-,Disease
term,Disease
memory,Disease
(,O
STM,O
),O
",",O
as,O
measured,O
by,O
using,O
radial,O
arm,O
water,O
maze,O
",",O
accompanied,O
with,O
decreased,O
hippocampal,O
glutathione,Chemical
reductase,O
(,O
GR,O
),O
activity,O
and,O
reduced,O
glutathione,Chemical
(,O
GSH,Chemical
),O
content,O
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
investigate,O
the,O
soluble,O
form,O
of,O
Fas,O
in,O
patients,O
with,O
acute,Disease
liver,Disease
failure,Disease
.,O
Pure,Disease
red,Disease
cell,Disease
aplasia,Disease
associated,O
with,O
diphenylhydantoin,Chemical
medication,O
has,O
been,O
reported,O
in,O
3,O
patients,O
.,O
Serum,O
testosterone,Chemical
concentration,O
increased,O
with,O
pubertal,O
status,O
but,O
was,O
not,O
affected,O
by,O
hyperprolactinemia,Disease
.,O
Conjunctival,Disease
blanching,Disease
and,O
mydriasis,Disease
were,O
commonly,O
found,O
.,O
Hyperkalemia,Disease
induced,O
by,O
indomethacin,Chemical
and,O
naproxen,Chemical
and,O
reversed,O
by,O
fludrocortisone,Chemical
.,O
METHODS,O
:,O
All,O
PD,Disease
patients,O
in,O
the,O
Amiens,O
area,O
treated,O
with,O
pergolide,Chemical
were,O
invited,O
to,O
attend,O
a,O
cardiologic,O
assessment,O
including,O
transthoracic,O
echocardiography,O
.,O
Side,O
effects,O
of,O
yohimbine,Chemical
included,O
excessive,O
sweating,O
",",O
increased,O
anxiety,Disease
",",O
and,O
a,O
wound,O
-,O
up,O
feeling,O
in,O
some,O
patients,O
.,O
Levodopa,Chemical
is,O
the,O
most,O
effective,O
drug,O
for,O
the,O
treatment,O
of,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
.,O
Among,O
all,O
animals,O
",",O
glomerular,Disease
and,Disease
tubular,Disease
injury,Disease
were,O
inversely,O
correlated,O
with,O
mtDNA,O
levels,O
",",O
mtDNA,O
-,O
encoded,O
respiratory,O
chain,O
activities,O
and,O
with,O
the,O
expression,O
of,O
the,O
mtDNA,O
-,O
encoded,O
respiratory,O
chain,O
subunit,O
COX,O
-,O
I,O
.,O
Amiodarone,Chemical
-,O
induced,O
myxoedema,Disease
coma,Disease
.,O
Ballistic,O
and,O
choreic,O
dyskinesia,Disease
were,O
markedly,O
ameliorated,O
",",O
whereas,O
dystonia,Disease
was,O
not,O
.,O
Toxicity,Disease
in,O
rhesus,O
monkeys,O
following,O
administration,O
of,O
the,O
8,Chemical
-,Chemical
aminoquinoline,Chemical
8,Chemical
-,Chemical
[,Chemical
(,Chemical
4,Chemical
-,Chemical
amino,Chemical
-,Chemical
l,Chemical
-,Chemical
methylbutyl,Chemical
),Chemical
amino,Chemical
],Chemical
-,Chemical
5,Chemical
-,Chemical
(,Chemical
l,Chemical
-,Chemical
hexyloxy,Chemical
),Chemical
-,Chemical
6,Chemical
-,Chemical
methoxy,Chemical
-,Chemical
4,Chemical
-,Chemical
methylquinoline,Chemical
(,O
WR242511,Chemical
),O
.,O
AZT,Chemical
-,O
induced,O
peripheral,O
anaemia,Disease
in,O
the,O
face,O
of,O
increased,O
numbers,O
of,O
BFU,O
-,O
e,O
and,O
increased,O
levels,O
of,O
plasma,O
EPO,O
suggest,O
a,O
lesion,O
in,O
terminal,O
differentiation,O
.,O
The,O
renal,O
function,O
of,O
74,O
children,O
with,O
malignant,Disease
mesenchymal,Disease
tumors,Disease
in,O
complete,O
remission,O
and,O
who,O
have,O
received,O
the,O
same,O
ifosfamide,Chemical
chemotherapy,O
protocol,O
(,O
International,O
Society,O
of,O
Pediatric,O
Oncology,O
Malignant,Disease
Mesenchymal,Disease
Tumor,Disease
Study,O
84,O
[,O
SIOP,O
MMT,O
84,O
],O
),O
were,O
studied,O
1,O
year,O
after,O
the,O
completion,O
of,O
treatment,O
.,O
The,O
episode,O
was,O
characterized,O
by,O
a,O
vasculitic,Disease
skin,Disease
rash,Disease
associated,O
with,O
large,O
joint,O
arthritis,Disease
",",O
pyrexia,Disease
and,O
parotiditis,Disease
but,O
no,O
renal,O
or,O
pulmonary,O
involvement,O
.,O
Although,O
initially,O
thought,O
to,O
be,O
free,O
of,O
extrapyramidal,O
side,O
effects,O
",",O
sulpiride,Chemical
-,O
induced,O
tardive,Disease
dyskinesia,Disease
and,O
parkinsonism,Disease
have,O
been,O
reported,O
occasionally,O
.,O
It,O
has,O
been,O
suggested,O
that,O
adenylate,O
cyclase,O
inhibition,O
may,O
be,O
important,O
in,O
the,O
development,O
of,O
both,O
nephrogenic,Disease
diabetes,Disease
insipidus,Disease
and,O
hypothyroidism,Disease
during,O
lithium,Chemical
treatment,O
.,O
The,O
two,O
hypotensive,Disease
patients,O
required,O
treatment,O
for,O
shock,Disease
.,O
85,O
percent,O
of,O
patients,O
with,O
dyskinesias,Disease
were,O
relieved,O
of,O
symptoms,O
",",O
regardless,O
of,O
whether,O
the,O
pallidotomies,O
were,O
performed,O
with,O
the,O
Gamma,O
Knife,O
or,O
radiofrequency,O
methods,O
.,O
BACKGROUND,O
AND,O
AIM,O
OF,O
THE,O
STUDY,O
:,O
Undersized,O
mitral,O
annuloplasty,O
(,O
MAP,O
),O
is,O
effective,O
in,O
patients,O
with,O
dilated,Disease
cardiomyopathy,Disease
and,O
functional,O
mitral,Disease
regurgitation,Disease
(,O
MR,Disease
),O
since,O
",",O
as,O
well,O
as,O
addressing,O
the,O
MR,Disease
",",O
the,O
MAP,O
may,O
also,O
reshape,O
the,O
dilated,O
left,O
ventricular,O
(,O
LV,O
),O
base,O
.,O
Thirty,O
to,O
135,O
min,O
after,O
the,O
injection,O
of,O
crystalline,O
insulin,O
",",O
ISO,Chemical
was,O
given,O
subcutaneously,O
and,O
when,O
ISO,Chemical
induced,O
fibrosis,Disease
in,O
the,O
myocardium,O
was,O
morphometrically,O
analyzed,O
7,O
days,O
later,O
",",O
a,O
highly,O
significant,O
correlation,O
(,O
r,O
=,O
0,O
.,O
83,O
",",O
2,O
p,O
=,O
0,O
.,O
006,O
),O
to,O
the,O
slope,O
of,O
the,O
fall,O
in,O
blood,O
glucose,Chemical
after,O
insulin,O
treatment,O
appeared,O
.,O
Detailed,O
spectral,O
profile,O
analysis,O
of,O
penicillin,Chemical
-,O
induced,O
epileptiform,Disease
activity,Disease
in,O
anesthetized,O
rats,O
.,O
Cardiotoxicity,Disease
that,O
was,O
thought,O
to,O
be,O
related,O
to,O
CYA,Chemical
occurred,O
in,O
1,O
/,O
32,O
(,O
3,O
%,O
),O
of,O
patients,O
in,O
Group,O
1,O
and,O
in,O
13,O
/,O
52,O
(,O
25,O
%,O
),O
patients,O
in,O
Group,O
2,O
(,O
P,O
less,O
than,O
0,O
.,O
025,O
),O
.,O
There,O
was,O
no,O
significant,O
difference,O
in,O
the,O
frequency,O
of,O
signs,O
or,O
symptoms,O
between,O
the,O
two,O
groups,O
although,O
neurotoxicity,Disease
symptoms,O
presented,O
mostly,O
with,O
lower,O
scores,O
of,O
severity,O
in,O
group,O
G,O
.,O
PURPOSE,O
:,O
We,O
present,O
a,O
case,O
of,O
a,O
patient,O
who,O
developed,O
seizures,Disease
shortly,O
after,O
initiating,O
treatment,O
with,O
levofloxacin,Chemical
and,O
to,O
discuss,O
the,O
potential,O
drug,O
-,O
drug,O
interactions,O
related,O
to,O
the,O
inhibition,O
of,O
cytochrome,O
P450,O
(,O
CYP,O
),O
1A2,O
in,O
this,O
case,O
",",O
as,O
well,O
as,O
in,O
other,O
cases,O
",",O
of,O
levofloxacin,Chemical
-,O
induced,O
seizures,Disease
.,O
Thus,O
",",O
gentamicin,Chemical
was,O
associated,O
with,O
renal,Disease
failure,Disease
more,O
than,O
three,O
times,O
as,O
often,O
as,O
was,O
tobramycin,Chemical
.,O
The,O
effects,O
of,O
oral,O
administration,O
of,O
caffeine,Chemical
(,O
10,O
mg,O
/,O
kg,O
),O
on,O
behavioral,O
ratings,O
",",O
somatic,O
symptoms,O
",",O
blood,O
pressure,O
and,O
plasma,O
levels,O
of,O
3,Chemical
-,Chemical
methoxy,Chemical
-,Chemical
4,Chemical
-,Chemical
hydroxyphenethyleneglycol,Chemical
(,O
MHPG,Chemical
),O
and,O
cortisol,Chemical
were,O
determined,O
in,O
17,O
healthy,O
subjects,O
and,O
21,O
patients,O
meeting,O
DSM,O
-,O
III,O
criteria,O
for,O
agoraphobia,Disease
with,O
panic,Disease
attacks,Disease
or,O
panic,Disease
disorder,Disease
.,O
Recurrent,O
dysosmia,Disease
induced,O
by,O
pyrazinamide,Chemical
.,O
Hypotheses,O
of,O
heroin,Chemical
-,O
related,O
rhabdomyolysis,Disease
and,O
stroke,Disease
in,O
heroin,Chemical
abusers,O
are,O
discussed,O
.,O
To,O
address,O
the,O
potential,O
confounding,O
effects,O
of,O
the,O
cannabis,Chemical
use,O
of,O
the,O
ecstasy,Chemical
using,O
group,O
",",O
a,O
second,O
analysis,O
included,O
14,O
previously,O
tested,O
cannabis,Chemical
users,O
(,O
Nestor,O
",",O
L,O
.,O
",",O
Roberts,O
",",O
G,O
.,O
",",O
Garavan,O
",",O
H,O
.,O
",",O
Hester,O
",",O
R,O
.,O
",",O
2008,O
.,O
Deficits,Disease
in,Disease
learning,Disease
and,Disease
memory,Disease
:,O
parahippocampal,O
hyperactivity,Disease
and,O
frontocortical,O
hypoactivity,O
in,O
cannabis,Chemical
users,O
.,O
Neuroimage,O
40,O
",",O
1328,O
-,O
1339,O
),O
.,O
Cardiac,O
Angiography,O
in,O
Renally,O
Impaired,O
Patients,O
(,O
CARE,O
),O
study,O
:,O
a,O
randomized,O
double,O
-,O
blind,O
trial,O
of,O
contrast,O
-,O
induced,O
nephropathy,Disease
in,O
patients,O
with,O
chronic,Disease
kidney,Disease
disease,Disease
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
investigate,O
the,O
influence,O
of,O
calcium,Chemical
channel,O
blockers,O
on,O
bupivacaine,Chemical
-,O
induced,O
acute,O
toxicity,Disease
.,O
Four,O
hours,O
of,O
apnoea,Disease
ensued,O
and,O
he,O
suffered,O
generalized,O
severe,O
myalgia,Disease
lasting,O
for,O
one,O
week,O
.,O
Spasm,Disease
",",O
coronary,O
dissection,O
",",O
or,O
atheromatous,O
etiology,O
has,O
been,O
described,O
.,O
There,O
is,O
a,O
statistically,O
significant,O
reduction,O
of,O
breast,Disease
cancer,Disease
among,O
women,O
receiving,O
tamoxifen,Chemical
who,O
also,O
used,O
hormone,O
-,O
replacement,O
therapy,O
during,O
the,O
trial,O
:,O
among,O
390,O
women,O
on,O
such,O
therapy,O
and,O
allocated,O
to,O
placebo,O
",",O
we,O
found,O
eight,O
cases,O
of,O
breast,Disease
cancer,Disease
compared,O
with,O
one,O
case,O
among,O
362,O
women,O
allocated,O
to,O
tamoxifen,Chemical
.,O
Twenty,O
-,O
five,O
patients,O
with,O
rheumatoid,Disease
arthritis,Disease
(,O
RA,Disease
),O
who,O
developed,O
toxicity,Disease
while,O
taking,O
remission,O
inducing,O
drugs,O
and,O
30,O
without,O
toxicity,Disease
were,O
studied,O
for,O
possible,O
associations,O
with,O
class,O
I,O
and,O
II,O
HLA,O
antigens,O
.,O
This,O
prospective,O
study,O
determined,O
the,O
incidence,O
of,O
CIN,Disease
for,O
two,O
nonionic,O
contrast,Chemical
media,Chemical
(,O
CM,Chemical
),O
",",O
iopromide,Chemical
and,O
iohexol,Chemical
",",O
among,O
80,O
patients,O
younger,O
than,O
18,O
years,O
and,O
compared,O
the,O
rates,O
for,O
this,O
complication,O
in,O
relation,O
to,O
the,O
type,O
and,O
dosage,O
of,O
CM,Chemical
and,O
the,O
presence,O
of,O
cyanosis,Disease
.,O
Although,O
certain,O
clinical,O
and,O
experimental,O
findings,O
support,O
the,O
hypothesis,O
that,O
spasm,Disease
involves,O
the,O
epicardial,O
",",O
medium,O
-,O
size,O
vessels,O
",",O
other,O
data,O
suggest,O
intramural,O
vasoconstriction,O
.,O
Neurotoxic,Disease
esterase,O
activities,O
24,O
hr,O
after,O
TOTP,Chemical
or,O
DFP,Chemical
were,O
less,O
than,O
20,O
%,O
of,O
values,O
measured,O
in,O
chickens,O
not,O
given,O
organophosphorous,Chemical
compounds,O
.,O
Segmental,O
necrotising,O
glomerulonephritis,Disease
has,O
been,O
reported,O
as,O
complication,O
of,O
rifampicin,Chemical
therapy,O
in,O
patients,O
receiving,O
treatment,O
for,O
tuberculosis,Disease
.,O
Radiolabelling,O
",",O
following,O
the,O
in,O
vivo,O
injection,O
of,O
3H,O
-,O
17,O
beta,O
estradiol,Chemical
",",O
was,O
increased,O
only,O
over,O
the,O
nuclei,O
of,O
tumor,Disease
cells,O
;,O
stereologic,O
analysis,O
revealed,O
a,O
4,O
.,O
5,O
-,O
to,O
6,O
.,O
7,O
-,O
times,O
higher,O
concentration,O
of,O
reduced,O
silver,Chemical
grains,O
over,O
nuclei,O
than,O
cytoplasm,O
of,O
these,O
cells,O
.,O
PURPOSE,O
:,O
To,O
assess,O
the,O
effect,O
of,O
pupil,Disease
dilation,Disease
on,O
vision,O
and,O
driving,O
ability,O
.,O
Nine,O
patients,O
exhibited,O
mild,O
to,O
moderate,O
extrapyramidal,Disease
concomitant,Disease
symptoms,Disease
;,O
no,O
other,O
side,O
effects,O
were,O
observed,O
.,O
Suxamethonium,Chemical
causes,O
prolonged,O
apnea,Disease
in,O
patients,O
in,O
whom,O
pseudocholinesterase,O
enzyme,O
gets,O
deactivated,O
by,O
organophosphorus,Chemical
(,Chemical
OP,Chemical
),Chemical
poisons,Chemical
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
acute,O
cholestatic,Disease
hepatitis,Disease
following,O
exposure,O
to,O
the,O
inhalational,O
anesthetic,O
isoflurane,Chemical
.,O
Therefore,O
",",O
the,O
effects,O
of,O
carteolol,Chemical
",",O
a,O
beta,O
-,O
adrenoceptor,O
antagonist,O
",",O
on,O
haloperidol,Chemical
-,O
induced,O
catalepsy,Disease
in,O
rats,O
were,O
behaviorally,O
studied,O
and,O
compared,O
with,O
those,O
of,O
propranolol,Chemical
and,O
biperiden,Chemical
",",O
a,O
muscarinic,O
receptor,O
antagonist,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
investigated,O
the,O
changes,O
occurring,O
at,O
the,O
protein,O
level,O
in,O
striatal,O
samples,O
obtained,O
from,O
the,O
unilaterally,O
6,Chemical
-,Chemical
hydroxydopamine,Chemical
-,O
lesion,O
rat,O
model,O
of,O
PD,Disease
treated,O
with,O
saline,O
",",O
L,Chemical
-,Chemical
DOPA,Chemical
or,O
bromocriptine,Chemical
using,O
two,O
-,O
dimensional,O
difference,O
gel,O
electrophoresis,O
and,O
mass,O
spectrometry,O
(,O
MS,O
),O
.,O
Here,O
",",O
we,O
developed,O
a,O
murine,O
model,O
of,O
glucocorticoid,O
-,O
induced,O
glaucoma,Disease
that,O
exhibits,O
glaucoma,Disease
features,O
that,O
are,O
observed,O
in,O
patients,O
.,O
Toxicities,Disease
were,O
compared,O
with,O
a,O
cohort,O
of,O
patients,O
in,O
a,O
phase,O
I,O
trial,O
of,O
paclitaxel,Chemical
alone,O
at,O
identical,O
dose,O
levels,O
.,O
Hepatotoxicity,Disease
associated,O
with,O
sulfasalazine,Chemical
in,O
inflammatory,O
arthritis,Disease
:,O
A,O
case,O
series,O
from,O
a,O
local,O
surveillance,O
of,O
serious,O
adverse,O
events,O
.,O
In,O
the,O
first,O
",",O
cobalt,Chemical
cardiomyopathy,Disease
was,O
induced,O
in,O
eight,O
dogs,O
;,O
VIP,O
(,O
by,O
radioimmunoassay,O
),O
decreased,O
from,O
35,O
+,O
/,O
-,O
11,O
pg,O
/,O
mg,O
protein,O
(,O
mean,O
+,O
/,O
-,O
SD,O
),O
to,O
5,O
+,O
/,O
-,O
4,O
pg,O
/,O
mg,O
protein,O
(,O
P,O
less,O
than,O
0,O
.,O
05,O
),O
.,O
A,O
2,O
g,O
/,O
dL,O
decrease,O
in,O
hemoglobin,O
concentrations,O
in,O
patients,O
with,O
anemia,Disease
was,O
observed,O
at,O
week,O
2,O
after,O
the,O
start,O
of,O
treatment,O
.,O
Co,O
-,O
administration,O
of,O
lidocaine,Chemical
with,O
desipramine,Chemical
reversed,O
the,O
changes,O
of,O
convulsive,Disease
activity,O
of,O
lidocaine,Chemical
and,O
cocaine,Chemical
induced,O
by,O
repeated,O
administration,O
of,O
desipramine,Chemical
.,O
Apparent,O
cure,O
of,O
rheumatoid,Disease
arthritis,Disease
by,O
bone,O
marrow,O
transplantation,O
.,O
This,O
antifibrinolytic,O
agent,O
has,O
been,O
used,O
in,O
women,O
with,O
menorrhagia,Disease
to,O
promote,O
clotting,O
and,O
reduce,O
blood,Disease
loss,Disease
.,O
A,O
patient,O
with,O
sinus,O
bradycardia,Disease
and,O
atrioventricular,Disease
block,Disease
",",O
induced,O
by,O
carbamazepine,Chemical
",",O
prompted,O
an,O
extensive,O
literature,O
review,O
of,O
all,O
previously,O
reported,O
cases,O
.,O
In,O
multivariate,O
analysis,O
",",O
a,O
significant,O
correlation,O
between,O
DBP,Disease
reduction,Disease
and,O
worsening,O
of,O
the,O
neurological,O
score,O
was,O
found,O
for,O
the,O
high,O
-,O
dose,O
group,O
(,O
beta,O
=,O
0,O
.,O
49,O
",",O
P,O
=,O
0,O
.,O
048,O
),O
.,O
Liver,O
biopsy,O
showed,O
cholestasis,Disease
with,O
both,O
cytological,O
and,O
architectural,O
alterations,O
of,O
interlobular,O
bile,O
ducts,O
.,O
Unfortunately,O
",",O
acute,O
interstitial,Disease
nephritis,Disease
was,O
irreversible,O
and,O
the,O
patient,O
developed,O
end,Disease
-,Disease
stage,Disease
renal,Disease
disease,Disease
.,O
Intradermal,O
injection,O
of,O
mu,O
",",O
but,O
not,O
delta,O
or,O
kappa,O
opioid,O
-,O
agonists,O
",",O
however,O
",",O
produced,O
dose,O
-,O
dependent,O
inhibition,O
of,O
prostaglandin,Chemical
E2,Chemical
-,O
induced,O
hyperalgesia,Disease
.,O
Both,O
",",O
production,O
of,O
reactive,O
oxygen,Chemical
species,O
as,O
well,O
as,O
activation,O
of,O
NF,O
-,O
kappaB,O
have,O
been,O
implicated,O
in,O
severe,O
neuronal,Disease
damage,Disease
in,O
different,O
sub,O
-,O
regions,O
of,O
the,O
hippocampus,O
as,O
well,O
as,O
in,O
the,O
surrounding,O
cortices,O
.,O
Subcutaneous,O
injection,O
of,O
ISPH,Chemical
(,O
200,O
mg,O
/,O
kg,O
body,O
weight,O
in,O
1,O
ml,O
saline,O
),O
to,O
rats,O
for,O
2,O
consecutive,O
days,O
caused,O
myocardial,Disease
damage,Disease
in,O
rat,O
heart,O
",",O
which,O
was,O
determined,O
by,O
the,O
increased,O
activity,O
of,O
serum,O
lactate,Chemical
dehydrogenase,O
(,O
LDH,O
),O
and,O
creatine,Chemical
phosphokinase,O
isoenzymes,O
(,O
CK,O
-,O
MB,O
),O
",",O
increased,O
uric,Chemical
acid,Chemical
level,O
and,O
reduced,O
plasma,O
iron,Chemical
binding,O
capacity,O
.,O
METHODS,O
:,O
Fourteen,O
patients,O
chronically,Disease
infected,Disease
with,Disease
hepatitis,Disease
C,Disease
virus,Disease
were,O
treated,O
by,O
pegylated,Chemical
interferon,Chemical
alpha,Chemical
2a,Chemical
and,O
ribavirin,Chemical
.,O
Histologic,O
differences,O
and,O
clinical,O
similarities,O
between,O
hepatic,O
adenoma,Disease
and,O
focal,Disease
nodular,Disease
hyperplasia,Disease
of,O
the,O
liver,O
are,O
discussed,O
.,O
In,O
the,O
preceding,O
months,O
",",O
the,O
patient,O
had,O
a,O
number,O
of,O
admissions,O
with,O
transient,O
unilateral,O
hemiparesis,Disease
with,O
facial,O
droop,O
",",O
and,O
had,O
been,O
started,O
on,O
valproate,Chemical
for,O
presumed,O
hemiplegic,Disease
migraine,Disease
.,O
Clomipramine,Chemical
-,O
induced,O
sleep,Disease
disturbance,Disease
does,O
not,O
impair,O
its,O
prolactin,O
-,O
releasing,O
action,O
.,O
These,O
results,O
indicate,O
that,O
status,Disease
epilepticus,Disease
induced,O
by,O
pilocarpine,Chemical
is,O
initiated,O
by,O
cholinergic,O
overstimulation,O
and,O
propagated,O
by,O
glutamatergic,O
transmission,O
",",O
the,O
elevation,O
of,O
which,O
may,O
cause,O
brain,Disease
damage,Disease
through,O
an,O
excitatory,O
NMDA,Chemical
receptor,O
-,O
mediated,O
mechanism,O
.,O
Although,O
generally,O
well,O
-,O
tolerated,O
",",O
asymptomatic,O
abnormalities,Disease
of,Disease
liver,Disease
function,Disease
have,O
been,O
recorded,O
and,O
",",O
less,O
commonly,O
",",O
severe,O
hepatitis,Disease
induced,O
by,O
diclofenac,Chemical
.,O
Clinical,O
evaluations,O
suggested,O
an,O
initial,O
diagnosis,O
of,O
severe,O
thrombocytopenia,Disease
and,O
haemolysis,Disease
.,O
Similar,O
results,O
were,O
obtained,O
in,O
seizure,Disease
-,O
induced,O
breakdown,O
of,O
BBB,O
.,O
Twelve,O
patients,O
with,O
liver,Disease
disease,Disease
related,O
to,O
methyldopa,Chemical
were,O
seen,O
between,O
1967,O
and,O
1977,O
.,O
Transmural,O
myocardial,Disease
infarction,Disease
with,O
sumatriptan,Chemical
.,O
The,O
study,O
was,O
designed,O
to,O
have,O
a,O
power,O
of,O
greater,O
than,O
0,O
.,O
90,O
to,O
detect,O
a,O
slowing,O
to,O
25,O
%,O
of,O
the,O
expected,O
rate,O
of,O
progression,O
of,O
weakness,Disease
at,O
P,O
less,O
than,O
0,O
.,O
05,O
.,O
Angioedema,Disease
associated,O
with,O
droperidol,Chemical
administration,O
.,O
Subsequent,O
breaks,O
in,O
the,O
lateral,O
cell,O
membranes,O
of,O
the,O
superficial,O
cells,O
and,O
in,O
all,O
the,O
plasma,O
membranes,O
of,O
the,O
intermediate,O
and,O
basal,O
cells,O
",",O
intercellular,O
and,O
intracellular,O
edema,Disease
and,O
disintegration,O
of,O
the,O
desmosomes,O
and,O
hemidesmosomes,O
lead,O
to,O
progressive,O
degeneration,O
and,O
detachment,O
of,O
the,O
epithelial,O
cells,O
with,O
exposure,O
and,O
splitting,O
of,O
the,O
basal,O
membrane,O
.,O
In,O
this,O
report,O
",",O
we,O
encountered,O
a,O
patient,O
with,O
decompensated,O
HBV,O
-,O
related,O
cirrhosis,Disease
who,O
exhibited,O
the,O
dramatic,O
improvements,O
after,O
antiviral,O
therapy,O
.,O
METHODS,O
:,O
Newborn,O
piglets,O
received,O
levobupivacaine,Chemical
until,O
cardiovascular,Disease
collapse,Disease
occurred,O
.,O
Nerve,O
growth,O
factor,O
and,O
prostaglandins,Chemical
in,O
the,O
urine,O
of,O
female,O
patients,O
with,O
overactive,Disease
bladder,Disease
.,O
Effect,O
of,O
L,Chemical
-,Chemical
alpha,Chemical
-,Chemical
glyceryl,Chemical
-,Chemical
phosphorylcholine,Chemical
on,O
amnesia,Disease
caused,O
by,O
scopolamine,Chemical
.,O
Lithium,Chemical
carbonate,Chemical
may,O
be,O
a,O
factor,O
in,O
the,O
increasing,O
incidence,O
of,O
congenital,Disease
heart,Disease
disease,Disease
when,O
taken,O
during,O
early,O
pregnancy,O
.,O
Aggressive,Disease
behaviors,Disease
have,O
been,O
reported,O
in,O
patients,O
who,O
suffer,O
from,O
some,O
psychiatric,Disease
disorders,Disease
",",O
and,O
are,O
common,O
in,O
methamphetamine,Chemical
(,O
METH,Chemical
),O
abusers,O
.,O
This,O
is,O
the,O
first,O
reported,O
case,O
of,O
sinus,Disease
arrest,Disease
associated,O
with,O
continuous,O
-,O
infusion,O
cimetidine,Chemical
.,O
The,O
present,O
study,O
aimed,O
to,O
investigate,O
the,O
effects,O
of,O
pallidal,O
neurotensin,Chemical
on,O
haloperidol,Chemical
-,O
induced,O
parkinsonian,Disease
symptoms,Disease
.,O
Simvastatin,Chemical
",",O
amiodarone,Chemical
",",O
and,O
the,O
patient,O
',O
s,O
human,Disease
immunodeficiency,Disease
virus,Disease
medications,O
were,O
all,O
temporarily,O
discontinued,O
and,O
the,O
patient,O
was,O
given,O
forced,O
alkaline,O
diuresis,O
and,O
started,O
on,O
dialysis,O
.,O
DISCUSSION,O
:,O
SIADH,Disease
has,O
been,O
widely,O
reported,O
with,O
a,O
range,O
of,O
antidepressants,O
.,O
The,O
frequency,O
and,O
predictability,O
of,O
hematuria,Disease
are,O
not,O
precise,O
",",O
and,O
at,O
least,O
daily,O
monitoring,O
by,O
urine,O
Hematest,O
is,O
essential,O
",",O
adding,O
Mesna,Chemical
to,O
the,O
infusate,O
in,O
patients,O
with,O
persistent,O
hematuria,Disease
.,O
The,O
morbidity,O
and,O
mortality,O
associated,O
with,O
heparin,Chemical
-,O
induced,O
thrombosis,Disease
remain,O
high,O
despite,O
numerous,O
empirical,O
therapies,O
.,O
Urinary,O
protein,O
excretion,O
was,O
unaltered,O
by,O
rhIGF,O
-,O
I,O
treatment,O
in,O
rats,O
with,O
chronic,O
PAN,Chemical
nephropathy,Disease
.,O
Renal,O
function,O
was,O
investigated,O
by,O
measuring,O
plasma,O
and,O
urinary,O
electrolytes,O
",",O
glucosuria,Disease
",",O
proteinuria,Disease
",",O
aminoaciduria,Disease
",",O
urinary,O
pH,O
",",O
osmolarity,O
",",O
creatinine,Chemical
clearance,O
",",O
phosphate,Chemical
tubular,O
reabsorption,O
",",O
beta,O
2,O
microglobulinuria,O
",",O
and,O
lysozymuria,O
.,O
In,O
patients,O
in,O
the,O
study,O
group,O
",",O
all,O
aneurysms,Disease
were,O
located,O
in,O
the,O
anterior,O
circulation,O
.,O
Somnolence,Disease
and,O
constipation,Disease
were,O
prominent,O
toxicities,Disease
and,O
most,O
patients,O
could,O
not,O
tolerate,O
the,O
1200,O
mg,O
/,O
day,O
dose,O
level,O
.,O
The,O
severity,O
of,O
pain,Disease
due,O
to,O
etomidate,Chemical
injection,O
",",O
mean,O
arterial,O
pressure,O
",",O
heart,O
rate,O
",",O
and,O
adverse,O
effects,O
were,O
also,O
evaluated,O
.,O
A,O
case,O
of,O
polymyositis,Disease
in,O
a,O
patient,O
with,O
primary,Disease
biliary,Disease
cirrhosis,Disease
treated,O
with,O
D,Chemical
-,Chemical
penicillamine,Chemical
.,O
These,O
results,O
document,O
for,O
the,O
first,O
time,O
in,O
vivo,O
that,O
mitochondrial,Disease
oxidative,Disease
damage,Disease
precedes,O
nitrative,O
damage,O
.,O
CONCLUSIONS,O
:,O
The,O
epileptic,Disease
pregnant,O
patient,O
',O
s,O
autoimmune,Disease
disease,Disease
(,O
probably,O
drug,O
-,O
induced,O
lupus,Disease
),O
could,O
damage,O
the,O
blood,O
-,O
brain,O
barrier,O
",",O
therefore,O
the,O
therapeutic,O
dose,O
(,O
>,O
or,O
=,O
1,O
mg,O
),O
of,O
folic,Chemical
acid,Chemical
triggered,O
a,O
cluster,O
of,O
seizures,Disease
.,O
Oxidative,O
stress,O
on,O
cardiotoxicity,Disease
after,O
treatment,O
with,O
single,O
and,O
multiple,O
doses,O
of,O
doxorubicin,Chemical
.,O
To,O
elucidate,O
the,O
role,O
of,O
estrogen,Chemical
in,O
the,O
regulation,O
of,O
tumor,Disease
angiogenesis,O
in,O
the,O
pituitary,O
of,O
female,O
rats,O
",",O
the,O
density,O
of,O
blood,O
vessels,O
was,O
analysed,O
using,O
factor,O
VIII,O
related,O
antigen,O
(,O
FVIIIRAg,O
),O
immunohistochemistry,O
and,O
the,O
expression,O
of,O
vascular,O
endothelial,O
growth,O
factor,O
/,O
vascular,O
permeability,O
factor,O
(,O
VEGF,O
/,O
VPF,O
),O
was,O
examined,O
by,O
Western,O
blot,O
and,O
immunohistochemical,O
analysis,O
.,O
All,O
patients,O
received,O
CAB,O
[,O
leuprolide,Chemical
acetate,Chemical
(,O
LHRH,Chemical
-,Chemical
A,Chemical
),O
3,O
.,O
75,O
mg,O
",",O
intramuscularly,O
",",O
every,O
28,O
days,O
plus,O
250,O
mg,O
flutamide,Chemical
",",O
tid,O
",",O
per,O
Os,O
],O
and,O
were,O
evaluated,O
for,O
anemia,Disease
by,O
physical,O
examination,O
and,O
laboratory,O
tests,O
at,O
baseline,O
and,O
4,O
subsequent,O
intervals,O
(,O
1,O
",",O
2,O
",",O
3,O
and,O
6,O
months,O
post,O
-,O
CAB,O
),O
.,O
RESULTS,O
:,O
Hallucinations,Disease
occurred,O
only,O
when,O
the,O
patient,O
',O
s,O
eyes,O
were,O
closed,O
and,O
",",O
in,O
all,O
but,O
one,O
case,O
",",O
were,O
reported,O
as,O
disturbing,O
or,O
frightening,O
.,O
The,O
diagnosis,O
of,O
P,Chemical
and,O
N,Chemical
-,O
induced,O
skin,Disease
reactions,Disease
was,O
based,O
in,O
vivo,O
challenge,O
.,O
CONCLUSIONS,O
:,O
EndoMT,O
is,O
a,O
novel,O
pathway,O
leading,O
to,O
early,O
development,O
of,O
diabetic,Disease
nephropathy,Disease
.,O
The,O
major,O
advantage,O
of,O
this,O
pain,Disease
model,O
is,O
the,O
possibility,O
of,O
obtaining,O
peripheral,O
pain,Disease
-,O
related,O
activity,O
directly,O
using,O
a,O
non,O
-,O
invasive,O
technique,O
in,O
humans,O
.,O
She,O
had,O
ovarian,Disease
failure,Disease
after,O
abdominal,O
irradiation,O
and,O
chemotherapy,O
for,O
Hodgkin,Disease
disease,Disease
",",O
and,O
received,O
exogenous,O
estrogens,Chemical
",",O
a,O
treatment,O
implicated,O
in,O
the,O
development,O
of,O
endometrial,Disease
cancer,Disease
in,O
menopausal,O
women,O
.,O
Patients,O
with,O
ADSD,Disease
were,O
identified,O
.,O
A,O
healthy,O
17,O
-,O
year,O
-,O
old,O
male,O
received,O
standard,O
intermittent,O
doses,O
of,O
pethidine,Chemical
via,O
a,O
patient,O
-,O
controlled,O
analgesia,O
(,O
PCA,O
),O
pump,O
for,O
management,O
of,O
postoperative,Disease
pain,Disease
control,O
.,O
Differential,O
diagnosis,O
for,O
drug,O
-,O
induced,O
disease,O
is,O
invaluable,O
even,O
for,O
patients,O
with,O
classical,O
polyarteritis,Disease
nodosa,Disease
.,O
Heredofamilial,O
and,O
connective,Disease
tissue,Disease
disorders,Disease
were,O
rare,O
.,O
CONCLUSIONS,O
:,O
Paracetamol,Chemical
-,O
induced,O
acute,Disease
liver,Disease
failure,Disease
did,O
not,O
affect,O
long,O
-,O
term,O
mortality,O
.,O
Nonhematologic,O
toxicities,Disease
were,O
mild,O
.,O
The,O
efficacy,O
of,O
alprazolam,Chemical
and,O
placebo,O
in,O
panic,Disease
disorder,Disease
with,O
agoraphobia,Disease
",",O
and,O
the,O
side,O
-,O
effect,O
and,O
adverse,O
effect,O
profiles,O
of,O
both,O
drug,O
groups,O
were,O
measured,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
second,O
case,O
of,O
minocycline,Chemical
-,O
induced,O
vasculitis,Disease
satisfying,O
the,O
criteria,O
.,O
Schizophrenia,Disease
has,O
been,O
initially,O
associated,O
with,O
dysfunction,O
in,O
dopamine,Chemical
neurotransmission,O
.,O
In,O
4,O
of,O
13,O
patients,O
with,O
QT,Disease
prolongation,Disease
",",O
Tdp,Disease
occurred,O
.,O
The,O
Endografine,Chemical
group,O
had,O
a,O
higher,O
incidence,O
of,O
abdominal,Disease
pain,Disease
.,O
The,O
incidence,O
and,O
severity,O
of,O
succinylcholine,Chemical
-,O
associated,O
myalgia,Disease
was,O
determined,O
in,O
64,O
patients,O
pretreated,O
with,O
saline,O
or,O
dexamethasone,Chemical
before,O
succinylcholine,Chemical
(,O
n,O
=,O
32,O
for,O
each,O
),O
.,O
Prolonged,O
hypothermia,Disease
as,O
a,O
bridge,O
to,O
recovery,O
for,O
cerebral,Disease
edema,Disease
and,O
intracranial,Disease
hypertension,Disease
associated,O
with,O
fulminant,Disease
hepatic,Disease
failure,Disease
.,O
This,O
case,O
report,O
describes,O
a,O
generalized,O
seizure,Disease
associated,O
with,O
sustained,O
-,O
release,O
bupropion,Chemical
use,O
and,O
sleep,Disease
deprivation,Disease
.,O
Allergic,Disease
reaction,Disease
to,O
5,Chemical
-,Chemical
fluorouracil,Chemical
infusion,O
.,O
No,O
organic,O
cause,O
of,O
hiccups,Disease
was,O
identified,O
despite,O
extensive,O
investigation,O
.,O
Syndrome,Disease
of,Disease
inappropriate,Disease
antidiuretic,Disease
hormone,Disease
secretion,O
associated,O
with,O
desvenlafaxine,Chemical
.,O
The,O
inability,O
of,O
amiodarone,Chemical
to,O
directly,O
activate,O
either,O
human,O
or,O
mouse,O
PPARalpha,O
transiently,O
expressed,O
in,O
human,O
HepG2,O
hepatoma,Disease
cells,O
indicates,O
that,O
the,O
effects,O
of,O
amiodarone,Chemical
on,O
the,O
function,O
of,O
this,O
receptor,O
were,O
indirect,O
.,O
The,O
present,O
data,O
indicate,O
that,O
the,O
determination,O
of,O
malondialdehyde,Chemical
",",O
oxypurines,Chemical
",",O
and,O
nucleosides,Chemical
in,O
peripheral,O
blood,O
",",O
may,O
be,O
used,O
to,O
monitor,O
the,O
metabolic,O
alterations,O
of,O
tissues,O
occurring,O
during,O
ischemic,Disease
phenomena,O
.,O
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
WHAT,O
THE,O
READER,O
WILL,O
GAIN,O
:,O
The,O
reader,O
will,O
gain,O
better,O
insight,O
into,O
the,O
safety,O
of,O
capecitabine,Chemical
in,O
special,O
populations,O
such,O
as,O
patients,O
with,O
advanced,O
age,O
",",O
renal,Disease
and,Disease
kidney,Disease
disease,Disease
.,O
For,O
human,O
glioblastoma,Disease
recurrences,O
",",O
the,O
feasibility,O
",",O
safety,O
",",O
and,O
short,O
-,O
term,O
effects,O
of,O
a,O
surgical,O
intracavitary,O
application,O
of,O
paclitaxel,Chemical
and,O
carboplatin,Chemical
encapsulated,O
by,O
liquid,O
crystalline,O
cubic,O
phases,O
are,O
examined,O
in,O
a,O
pilot,O
study,O
.,O
Reye,Disease
syndrome,Disease
may,O
be,O
disappearing,O
from,O
Australia,O
despite,O
a,O
total,O
lack,O
of,O
association,O
with,O
salicylates,Chemical
or,O
aspirin,Chemical
ingestion,O
",",O
since,O
there,O
were,O
no,O
cases,O
found,O
at,O
The,O
Children,O
',O
s,O
Hospital,O
in,O
1983,O
",",O
1984,O
",",O
or,O
1985,O
.,O
CONCLUSION,O
:,O
In,O
conclusion,O
",",O
the,O
demonstration,O
of,O
an,O
inverse,O
relationship,O
between,O
infusion,O
time,O
of,O
a,O
fixed,O
and,O
convulsive,Disease
dose,O
of,O
bupropion,Chemical
and,O
the,O
risk,O
of,O
convulsions,Disease
in,O
a,O
prospective,O
study,O
is,O
novel,O
.,O
Prolactin,O
results,O
were,O
compared,O
with,O
those,O
of,O
a,O
previous,O
personal,O
cohort,O
of,O
1,O
",",O
340,O
patients,O
with,O
erectile,Disease
dysfunction,Disease
and,O
systematic,O
prolactin,O
determination,O
.,O
Acute,O
and,O
chronic,O
nephrotoxicity,Disease
is,O
becoming,O
more,O
common,O
as,O
the,O
use,O
of,O
marginal,O
kidneys,O
for,O
transplantation,O
increases,O
.,O
Diltiazem,Chemical
did,O
not,O
affect,O
ERP,O
",",O
AF,Disease
cycle,O
length,O
or,O
AF,Disease
duration,O
",",O
but,O
produced,O
conduction,O
acceleration,O
similar,O
to,O
that,O
caused,O
by,O
verapamil,Chemical
(,O
n,O
=,O
5,O
),O
.,O
One,O
patient,O
",",O
aged,O
23,O
",",O
had,O
been,O
followed,O
for,O
2,O
years,O
before,O
carcinoma,Disease
was,O
diagnosed,O
;,O
the,O
second,O
patient,O
",",O
aged,O
22,O
",",O
had,O
been,O
seen,O
on,O
a,O
regular,O
basis,O
for,O
5,O
years,O
",",O
8,O
months,O
.,O
CASE,O
SUMMARY,O
:,O
A,O
41,O
-,O
year,O
-,O
old,O
Chinese,O
man,O
with,O
a,O
history,O
of,O
hyperthyroidism,Disease
had,O
been,O
treated,O
with,O
carbimazole,Chemical
and,O
propranolol,Chemical
for,O
the,O
past,O
5,O
years,O
.,O
The,O
emergency,O
physician,O
should,O
be,O
aware,O
that,O
life,O
-,O
threatening,O
tetany,Disease
may,O
accompany,O
the,O
administration,O
of,O
intravenous,O
diltiazem,Chemical
and,O
that,O
calcium,Chemical
chloride,Chemical
may,O
be,O
a,O
rapid,O
and,O
effective,O
remedy,O
.,O
CASE,O
SUMMARIES,O
:,O
A,O
54,O
-,O
year,O
-,O
old,O
woman,O
with,O
hyperaldosteronism,Disease
was,O
treated,O
with,O
verapamil,Chemical
480,O
mg,O
/,O
d,O
and,O
spironolactone,Chemical
100,O
mg,O
/,O
d,O
.,O
Factors,O
associated,O
with,O
the,O
development,O
of,O
fulminant,Disease
hepatic,Disease
failure,Disease
were,O
female,O
sex,O
(,O
OR,O
=,O
25,O
;,O
95,O
%,O
CI,O
:,O
4,O
.,O
1,O
-,O
151,O
;,O
P,O
<,O
.,O
0001,O
),O
",",O
hepatocellular,O
damage,O
(,O
OR,O
=,O
7,O
.,O
9,O
;,O
95,O
%,O
CI,O
:,O
1,O
.,O
6,O
-,O
37,O
;,O
P,O
<,O
.,O
009,O
),O
",",O
and,O
higher,O
baseline,O
plasma,O
bilirubin,Chemical
value,O
(,O
OR,O
=,O
1,O
.,O
15,O
;,O
95,O
%,O
CI,O
:,O
1,O
.,O
09,O
-,O
1,O
.,O
22,O
;,O
P,O
<,O
.,O
0001,O
),O
.,O
At,O
diagnosis,O
there,O
was,O
no,O
significant,O
difference,O
in,O
OD,O
between,O
HIT,Disease
patients,O
with,O
thrombosis,Disease
and,O
those,O
with,O
isolated,O
-,O
HIT,Disease
.,O
To,O
this,O
day,O
",",O
transcriptome,O
analysis,O
has,O
been,O
performed,O
in,O
a,O
rat,O
model,O
of,O
LID,Disease
[,O
Neurobiol,O
.,O
Dis,O
.,O
",",O
17,O
(,O
2004,O
),O
",",O
219,O
],O
but,O
information,O
regarding,O
the,O
proteome,O
is,O
still,O
lacking,O
.,O
The,O
patient,O
was,O
in,O
near,O
syncope,Disease
and,O
had,O
QT,Disease
-,Disease
interval,Disease
prolongation,Disease
.,O
A,O
phase,O
I,O
/,O
II,O
study,O
of,O
paclitaxel,Chemical
plus,O
cisplatin,Chemical
as,O
first,O
-,O
line,O
therapy,O
for,O
head,Disease
and,Disease
neck,Disease
cancers,Disease
:,O
preliminary,O
results,O
.,O
Common,O
features,O
included,O
tachycardia,Disease
",",O
drowsiness,O
",",O
hallucinations,Disease
and,O
convulsions,Disease
.,O
Acute,O
insulin,O
treatment,O
normalizes,O
the,O
resistance,O
to,O
the,O
cardiotoxic,Disease
effect,O
of,O
isoproterenol,Chemical
in,O
streptozotocin,Chemical
diabetic,Disease
rats,O
.,O
This,O
was,O
the,O
second,O
report,O
of,O
fatal,O
aplastic,Disease
anemia,Disease
after,O
topical,O
treatment,O
with,O
chloramphenicol,Chemical
for,O
ocular,O
conditions,O
",",O
although,O
two,O
cases,O
of,O
reversible,O
bone,Disease
marrow,Disease
hypoplasia,Disease
have,O
also,O
been,O
reported,O
.,O
The,O
effect,O
of,O
nitroglycerin,Chemical
on,O
heart,O
rate,O
and,O
systolic,O
blood,O
pressure,O
was,O
compared,O
in,O
5,O
normal,O
subjects,O
",",O
12,O
diabetic,Disease
subjects,O
without,O
autonomic,Disease
neuropathy,Disease
",",O
and,O
5,O
diabetic,Disease
subjects,O
with,O
autonomic,Disease
neuropathy,Disease
.,O
Occasional,O
case,O
reports,O
have,O
shown,O
that,O
acute,O
myopathy,Disease
may,O
occur,O
in,O
patients,O
treated,O
with,O
massive,O
doses,O
of,O
corticosteroids,Chemical
.,O
FK506,Chemical
-,O
associated,O
MAHA,Disease
is,O
probably,O
rare,O
but,O
physicians,O
must,O
be,O
aware,O
of,O
this,O
severe,O
complication,O
.,O
Large,O
doses,O
of,O
triazolam,Chemical
repeatedly,O
induced,O
brief,O
episodes,O
of,O
mania,Disease
in,O
a,O
depressed,Disease
elderly,O
woman,O
.,O
Pilocarpine,Chemical
on,O
either,O
day,O
induced,O
status,Disease
epilepticus,Disease
;,O
status,Disease
epilepticus,Disease
at,O
P45,O
resulted,O
in,O
CA3,O
cell,O
loss,O
and,O
spontaneous,O
seizures,Disease
",",O
whereas,O
P20,O
rats,O
had,O
no,O
cell,O
loss,O
or,O
spontaneous,O
seizures,Disease
.,O
Granulosa,Disease
cell,Disease
tumor,Disease
of,Disease
the,Disease
ovary,Disease
associated,O
with,O
antecedent,O
tamoxifen,Chemical
use,O
.,O
A,O
multicenter,O
study,O
was,O
performed,O
in,O
110,O
patients,O
with,O
superficial,O
transitional,O
cell,O
carcinoma,Disease
of,Disease
the,Disease
bladder,Disease
.,O
The,O
combination,O
of,O
a,O
relatively,O
high,O
dose,O
of,O
clarithromycin,Chemical
in,O
face,O
of,O
chronic,Disease
renal,Disease
failure,Disease
in,O
a,O
functionally,O
anephric,O
patient,O
",",O
with,O
underlying,O
aluminum,Chemical
intoxication,O
",",O
may,O
have,O
facilitated,O
the,O
appearance,O
of,O
this,O
neurotoxic,Disease
side,O
effect,O
.,O
Hepatotoxicity,Disease
and,O
malaise,Disease
are,O
again,O
the,O
most,O
frequent,O
side,O
effects,O
.,O
He,O
was,O
found,O
unconsciousness,Disease
at,O
home,O
and,O
was,O
sent,O
to,O
our,O
hospital,O
.,O
RESULTS,O
:,O
The,O
selected,O
doses,O
of,O
WR242511,Chemical
",",O
which,O
produced,O
significant,O
methemoglobinemia,Disease
in,O
beagle,O
dogs,O
in,O
earlier,O
studies,O
conducted,O
elsewhere,O
",",O
produced,O
very,O
little,O
MHb,O
(,O
mean,O
<,O
2,O
.,O
0,O
%,O
),O
in,O
the,O
rhesus,O
monkey,O
.,O
The,O
role,O
of,O
cyclosporine,Chemical
(,O
CSA,Chemical
),O
alone,O
or,O
in,O
combination,O
with,O
various,O
chemotherapeutics,O
in,O
the,O
development,O
of,O
renal,Disease
toxicity,Disease
was,O
evaluated,O
in,O
rats,O
.,O
It,O
was,O
possible,O
to,O
suppress,O
the,O
increased,O
ornithine,Chemical
decarboxylase,O
activity,O
with,O
both,O
beta,O
-,O
blockers,O
in,O
hypertrophied,Disease
hearts,Disease
",",O
but,O
there,O
was,O
no,O
effect,O
on,O
the,O
heart,O
mass,O
.,O
AIMS,O
:,O
This,O
study,O
sought,O
to,O
assess,O
the,O
risk,O
of,O
developing,O
coronary,Disease
artery,Disease
disease,Disease
(,O
CAD,Disease
),O
associated,O
with,O
initial,O
treatment,O
of,O
type,Disease
2,Disease
diabetes,Disease
with,O
different,O
sulphonylureas,Chemical
.,O
Nine,O
days,O
after,O
her,O
second,O
cycle,O
she,O
presented,O
with,O
lethargy,Disease
and,O
weakness,Disease
associated,O
with,O
hyponatremia,Disease
.,O
THP,Chemical
exhibited,O
an,O
antipsychotic,O
-,O
like,O
profile,O
by,O
potentiating,O
haloperidol,Chemical
-,O
induced,O
catalepsy,Disease
",",O
reducing,O
amphetamine,Chemical
-,O
induced,O
hyperactivity,Disease
and,O
reducing,O
apomorphine,Chemical
-,O
induced,O
climbing,O
in,O
mice,O
.,O
OBJECTIVE,O
:,O
Myeloperoxidase,O
antineutrophil,O
cytoplasmic,O
antibody,O
(,O
MPO,O
-,O
ANCA,O
),O
-,O
positive,O
vasculitis,Disease
has,O
been,O
reported,O
in,O
patients,O
with,O
Graves,Disease
',Disease
disease,Disease
who,O
were,O
treated,O
with,O
propylthiouracil,Chemical
(,O
PTU,Chemical
),O
.,O
Biochemical,O
effects,O
of,O
Solidago,O
virgaurea,O
extract,O
on,O
experimental,O
cardiotoxicity,Disease
.,O
1,O
of,O
the,O
10,O
monkeys,O
developed,O
acute,Disease
myeloblastic,Disease
leukemia,Disease
after,O
receiving,O
324,O
mg,O
/,O
m2,O
of,O
adriamycin,Chemical
;,O
the,O
10th,O
monkey,O
is,O
alive,O
and,O
well,O
26,O
months,O
after,O
the,O
last,O
dose,O
of,O
drug,O
.,O
Azidothymidine,Chemical
(,O
AZT,Chemical
),O
-,O
induced,O
anemia,Disease
in,O
mice,O
can,O
be,O
reversed,O
by,O
the,O
administration,O
of,O
IGF,O
-,O
IL,O
-,O
3,O
(,O
fusion,O
protein,O
of,O
insulin,O
-,O
like,O
growth,O
factor,O
II,O
(,O
IGF,O
II,O
),O
and,O
interleukin,O
3,O
),O
.,O
Although,O
most,O
cases,O
of,O
antibiotic,O
induced,O
acute,O
interstitial,Disease
nephritis,Disease
are,O
benign,O
and,O
self,O
-,O
limited,O
",",O
some,O
patients,O
are,O
at,O
risk,O
for,O
permanent,O
renal,Disease
injury,Disease
.,O
CML,Disease
has,O
a,O
well,O
-,O
documented,O
association,O
with,O
ionizing,O
radiation,O
",",O
but,O
reports,O
of,O
associations,O
with,O
chemical,O
exposures,O
have,O
been,O
questioned,O
.,O
Epileptic,Disease
foci,O
delineated,O
and,O
activated,O
by,O
enflurane,Chemical
were,O
surgically,O
ablated,O
and,O
the,O
patients,O
are,O
now,O
seizure,Disease
-,O
free,O
.,O
A,O
common,O
side,O
effect,O
associated,O
with,O
succinylcholine,Chemical
is,O
postoperative,Disease
myalgia,Disease
.,O
We,O
conclude,O
that,O
previously,O
reported,O
hypoglycemia,Disease
",",O
hyperbilirubinemia,Disease
",",O
polycythemia,Disease
",",O
neonatal,Disease
apnea,Disease
",",O
and,O
bradycardia,Disease
are,O
not,O
invariable,O
and,O
cannot,O
be,O
statistically,O
correlated,O
with,O
chronic,O
propranolol,Chemical
therapy,O
.,O
Perhexiline,Chemical
maleate,Chemical
and,O
peripheral,Disease
neuropathy,Disease
.,O
Although,O
there,O
was,O
a,O
discrepancy,O
between,O
the,O
amount,O
of,O
cTnI,O
and,O
cTnT,O
after,O
DOX,Chemical
",",O
probably,O
due,O
to,O
heterogeneity,O
in,O
cross,O
-,O
reactivities,O
of,O
mAbs,O
to,O
various,O
cTnI,O
and,O
cTnT,O
forms,O
",",O
it,O
is,O
likely,O
that,O
cTnT,O
in,O
rats,O
after,O
DOX,Chemical
indicates,O
cell,O
damage,O
determined,O
by,O
the,O
magnitude,O
of,O
injury,O
induced,O
and,O
that,O
cTnT,O
should,O
be,O
a,O
useful,O
marker,O
for,O
the,O
prediction,O
of,O
experimentally,O
induced,O
cardiotoxicity,Disease
and,O
possibly,O
for,O
cardioprotective,O
experiments,O
.,O
CONCLUSION,O
:,O
Early,O
recognition,O
of,O
optic,Disease
neuropathy,Disease
should,O
be,O
considered,O
in,O
patients,O
with,O
ethambutol,Chemical
therapy,O
.,O
Posttransplant,O
anemia,Disease
:,O
the,O
role,O
of,O
sirolimus,Chemical
.,O
RESULTS,O
:,O
We,O
report,O
seven,O
cases,O
where,O
substitution,O
of,O
lithium,Chemical
",",O
either,O
fully,O
or,O
partially,O
",",O
with,O
divalproex,Chemical
sodium,Chemical
was,O
extremely,O
helpful,O
in,O
reducing,O
the,O
cognitive,Disease
",",Disease
motivational,Disease
",",Disease
or,Disease
creative,Disease
deficits,Disease
attributed,O
to,O
lithium,Chemical
in,O
our,O
bipolar,Disease
patients,O
.,O
This,O
literature,O
review,O
suggests,O
that,O
general,O
practitioners,O
should,O
prescribe,O
scabicides,O
with,O
increased,O
caution,O
for,O
certain,O
at,O
-,O
risk,O
groups,O
",",O
and,O
give,O
adequate,O
warnings,O
regarding,O
potential,O
toxicity,Disease
.,O
Free,O
NP,O
did,O
not,O
provoke,O
any,O
proteinuria,Disease
.,O
Cerebral,O
blood,O
flow,O
and,O
cerebral,O
metabolic,O
rate,O
for,O
oxygen,Chemical
were,O
measured,O
during,O
isoflurane,Chemical
-,O
induced,O
hypotension,Disease
in,O
10,O
patients,O
subjected,O
to,O
craniotomy,O
for,O
clipping,O
of,O
a,O
cerebral,Disease
aneurysm,Disease
.,O
Effects,O
of,O
amine,Chemical
pretreatment,O
on,O
ketamine,Chemical
catatonia,Disease
in,O
pinealectomized,O
or,O
hypophysectomized,O
animals,O
.,O
Specifically,O
",",O
WSP,O
mice,O
may,O
have,O
lower,O
sensitivity,O
to,O
cholinergic,O
convulsants,Disease
compared,O
with,O
WSR,O
because,O
of,O
postsynaptic,O
receptor,O
desensitization,O
brought,O
on,O
by,O
higher,O
activity,O
of,O
cholinergic,O
neurons,O
.,O
The,O
increase,O
in,O
intragastric,O
pressure,O
was,O
directly,O
related,O
to,O
the,O
intensity,O
of,O
muscle,Disease
fasciculations,Disease
(,O
regression,O
line,O
:,O
y,O
=,O
0,O
.,O
5,O
+,O
4,O
.,O
78x,O
with,O
r,O
of,O
0,O
.,O
78,O
),O
.,O
Of,O
97,O
patients,O
who,O
received,O
standard,O
prophylaxis,O
",",O
4,O
had,O
symptomatic,O
hemorrhagic,Disease
cystitis,Disease
.,O
Longitudinal,O
assessment,O
of,O
air,O
conduction,O
audiograms,O
in,O
a,O
phase,O
III,O
clinical,O
trial,O
of,O
difluoromethylornithine,Chemical
and,O
sulindac,Chemical
for,O
prevention,O
of,O
sporadic,O
colorectal,Disease
adenomas,Disease
.,O
Here,O
",",O
we,O
describe,O
the,O
case,O
of,O
a,O
15,O
-,O
year,O
-,O
old,O
girl,O
who,O
was,O
on,O
a,O
long,O
-,O
term,O
therapy,O
with,O
valproate,Chemical
due,O
to,O
epilepsy,Disease
and,O
revealed,O
impaired,Disease
consciousness,Disease
with,O
hyperammonemia,Disease
12,O
days,O
after,O
renal,O
transplantation,O
.,O
This,O
study,O
was,O
undertaken,O
to,O
determine,O
the,O
effect,O
of,O
lidocaine,Chemical
pretreatment,O
on,O
reduction,O
of,O
succinylcholine,Chemical
-,O
induced,O
myalgia,Disease
in,O
patients,O
undergoing,O
general,O
anesthesia,O
for,O
gynecological,O
surgery,O
.,O
Intraventricular,O
infusion,O
of,O
dopamine,Chemical
sufficient,O
to,O
raise,O
the,O
brain,O
dopamine,Chemical
to,O
the,O
same,O
extent,O
did,O
not,O
prevent,O
the,O
ammonia,Chemical
coma,Disease
nor,O
affect,O
the,O
blood,O
and,O
brain,O
ammonia,Chemical
concentrations,O
.,O
These,O
results,O
may,O
be,O
relevant,O
to,O
the,O
use,O
of,O
FZP,Chemical
in,O
clinical,O
situations,O
in,O
which,O
there,O
is,O
increased,O
neural,O
excitability,O
",",O
such,O
as,O
epilepsy,Disease
or,O
sedative,O
-,O
hypnotic,O
drug,O
withdrawal,O
.,O
BACKGROUND,O
:,O
Recent,O
evidence,O
suggests,O
that,O
transient,Disease
neurologic,Disease
symptoms,Disease
(,O
TNSs,Disease
),O
frequently,O
follow,O
lidocaine,Chemical
spinal,O
anesthesia,O
but,O
are,O
infrequent,O
with,O
bupivacaine,Chemical
.,O
Other,O
causes,O
include,O
drug,O
-,O
related,O
(,O
cyclosporine,Chemical
",",O
tacrolimus,Chemical
),O
toxicity,Disease
",",O
procoagulant,O
status,O
",",O
and,O
antibody,O
-,O
mediated,O
rejection,O
.,O
A,O
case,O
of,O
valproate,Chemical
-,O
induced,O
encephalopathy,Disease
is,O
presented,O
.,O
In,O
this,O
work,O
the,O
messenger,O
ribonucleic,O
acid,O
(,O
mRNA,O
),O
levels,O
of,O
angiotensinogen,O
(,O
Ao,O
),O
were,O
analyzed,O
with,O
the,O
slot,O
-,O
blot,O
hybridization,O
technique,O
in,O
liver,O
and,O
other,O
extrahepatic,O
tissues,O
:,O
kidney,O
",",O
heart,O
",",O
brain,O
",",O
and,O
adrenal,O
gland,O
from,O
control,O
",",O
nephrotic,Disease
",",O
and,O
pair,O
-,O
fed,O
(,O
PF,O
),O
rats,O
.,O
METHODS,O
:,O
Retrospective,O
chart,O
review,O
including,O
clinical,O
data,O
and,O
EEG,O
recordings,O
was,O
done,O
on,O
five,O
patients,O
",",O
admitted,O
to,O
MD,O
Anderson,O
Cancer,Disease
Center,O
between,O
years,O
2009,O
and,O
2012,O
",",O
who,O
developed,O
ifosfamide,Chemical
related,O
acute,O
encephalopathy,Disease
.,O
Underreporting,O
of,O
these,O
hallucinations,Disease
by,O
patients,O
is,O
likely,O
.,O
Case,O
patients,O
were,O
more,O
likely,O
to,O
be,O
men,O
(,O
odds,O
ratio,O
",",O
3,O
.,O
8,O
;,O
95,O
%,O
confidence,O
interval,O
",",O
1,O
.,O
2,O
-,O
12,O
.,O
1,O
),O
",",O
suffer,O
from,O
hay,Disease
fever,Disease
and,O
asthma,Disease
(,O
odds,O
ratio,O
",",O
3,O
.,O
4,O
;,O
95,O
%,O
confidence,O
interval,O
",",O
1,O
.,O
0,O
-,O
11,O
.,O
9,O
),O
;,O
to,O
participate,O
in,O
regular,O
exercise,O
(,O
odds,O
ratio,O
",",O
5,O
.,O
9,O
;,O
95,O
%,O
confidence,O
interval,O
",",O
1,O
.,O
1,O
-,O
30,O
.,O
7,O
),O
",",O
especially,O
in,O
the,O
use,O
of,O
Nautilus,O
equipment,O
(,O
p,O
=,O
0,O
.,O
02,O
),O
;,O
and,O
to,O
use,O
alcohol,Chemical
(,O
odds,O
ratio,O
",",O
4,O
.,O
4,O
;,O
95,O
%,O
confidence,O
interval,O
",",O
1,O
.,O
1,O
-,O
17,O
.,O
5,O
),O
.,O
AIM,O
:,O
Verapamil,Chemical
stimulation,O
test,O
was,O
previously,O
investigated,O
as,O
a,O
tool,O
for,O
differential,O
diagnosis,O
of,O
hyperprolactinemia,Disease
",",O
but,O
with,O
conflicting,O
results,O
.,O
Fully,O
developed,O
cyclophosphamide,Chemical
-,O
induced,O
cystitis,Disease
is,O
characterized,O
by,O
nearly,O
complete,O
detachment,O
of,O
the,O
urothelium,O
",",O
severe,O
submucosal,O
edema,Disease
owing,O
to,O
damage,O
to,O
the,O
microvascular,O
bed,O
and,O
focal,O
muscle,O
necroses,Disease
.,O
We,O
report,O
the,O
case,O
of,O
a,O
woman,O
complaining,O
of,O
dysphonia,Disease
while,O
she,O
was,O
treated,O
by,O
acitretin,Chemical
.,O
Palpable,O
purpura,Disease
is,O
a,O
concerning,O
clinical,O
finding,O
in,O
pediatric,O
patients,O
and,O
can,O
have,O
many,O
causes,O
",",O
including,O
infectious,O
and,O
autoimmune,O
processes,O
.,O
Although,O
most,O
of,O
the,O
hepatomas,Disease
were,O
well,O
-,O
differentiated,O
tumors,Disease
and,O
contained,O
a,O
considerable,O
number,O
of,O
peroxisomes,O
",",O
the,O
tumor,Disease
cells,O
did,O
not,O
respond,O
to,O
ethyl,Chemical
-,Chemical
alpha,Chemical
-,Chemical
p,Chemical
-,Chemical
chlorophenoxyisobutyrate,Chemical
with,O
proliferation,O
of,O
peroxisomes,O
.,O
The,O
data,O
demonstrate,O
that,O
CAA,Chemical
after,O
i,O
.,O
v,O
.,O
administration,O
does,O
not,O
contribute,O
to,O
bladder,Disease
damage,Disease
.,O
The,O
most,O
common,O
toxicities,Disease
encountered,O
were,O
transient,O
serum,O
transaminase,O
and,O
bilirubin,Chemical
elevations,O
",",O
neutropenia,Disease
",",O
and,O
mucositis,Disease
.,O
Gamma,Chemical
-,Chemical
hexachlorocyclohexane,Chemical
(,O
gamma,Chemical
-,Chemical
HCH,Chemical
),O
",",O
the,O
active,O
ingredient,O
of,O
the,O
insecticide,O
lindane,Chemical
",",O
has,O
been,O
shown,O
to,O
decrease,O
seizure,Disease
threshold,O
to,O
pentylenetrazol,O
(,O
PTZ,Chemical
),O
3,O
h,O
after,O
exposure,O
to,O
gamma,Chemical
-,Chemical
HCH,Chemical
and,O
conversely,O
increase,O
threshold,O
to,O
PTZ,Chemical
-,O
induced,O
seizures,Disease
24,O
h,O
after,O
exposure,O
to,O
gamma,Chemical
-,Chemical
HCH,Chemical
(,O
Vohland,O
et,O
al,O
.,O
1981,O
),O
.,O
Previous,O
studies,O
demonstrated,O
that,O
both,O
ketamine,Chemical
and,O
morphine,Chemical
induced,O
analgesia,Disease
and,O
catalepsy,Disease
in,O
the,O
rat,O
.,O
DESIGN,O
:,O
Dose,O
response,O
curves,O
for,O
nonsedating,O
doses,O
of,O
morphine,Chemical
and,O
CNSB002,Chemical
given,O
intraperitoneally,O
alone,O
and,O
together,O
in,O
combinations,O
were,O
constructed,O
for,O
antihyperalgesic,O
effect,O
using,O
paw,O
withdrawal,O
from,O
noxious,O
heat,O
in,O
two,O
rat,O
pain,Disease
models,O
:,O
carrageenan,Chemical
-,O
induced,O
paw,O
inflammation,Disease
and,O
streptozotocin,Chemical
(,O
STZ,Chemical
),O
-,O
induced,O
diabetic,Disease
neuropathy,Disease
.,O
This,O
age,O
group,O
had,O
an,O
increased,O
risk,O
of,O
myelosuppression,Disease
.,O
Heparin,Chemical
",",O
first,O
used,O
to,O
prevent,O
the,O
clotting,O
of,O
blood,O
in,O
vitro,O
",",O
has,O
been,O
clinically,O
used,O
to,O
treat,O
thrombosis,Disease
for,O
more,O
than,O
50,O
years,O
.,O
Therapy,O
should,O
be,O
discontinued,O
on,O
the,O
suspicion,O
of,O
cholestatic,Disease
injury,Disease
or,O
hepatomegaly,Disease
.,O
Comparison,O
of,O
the,O
effect,O
of,O
oxitropium,Chemical
bromide,Chemical
and,O
of,O
slow,O
-,O
release,O
theophylline,Chemical
on,O
nocturnal,O
asthma,Disease
.,O
In,O
the,O
singleton,O
pregnancy,O
",",O
the,O
mother,O
had,O
ulcerative,Disease
colitis,Disease
",",O
and,O
the,O
infant,O
",",O
a,O
male,O
",",O
had,O
coarctation,Disease
of,Disease
the,Disease
aorta,Disease
and,O
a,O
ventricular,Disease
septal,Disease
defect,Disease
.,O
Late,O
",",O
late,O
doxorubicin,Chemical
cardiotoxicity,Disease
.,O
The,O
cumulative,O
doses,O
of,O
levobupivacaine,Chemical
and,O
ropivacaine,Chemical
that,O
produced,O
seizures,Disease
were,O
similar,O
and,O
were,O
larger,O
than,O
those,O
of,O
bupivacaine,Chemical
.,O
Compared,O
with,O
the,O
score,O
at,O
rest,O
(,O
1,O
.,O
3,O
+,O
/,O
-,O
0,O
.,O
3,O
),O
",",O
a,O
significant,O
aggravation,O
of,O
the,O
dyskinesia,Disease
score,O
was,O
observed,O
during,O
speaking,O
aloud,O
(,O
5,O
.,O
2,O
+,O
/,O
-,O
1,O
.,O
1,O
",",O
p,O
<,O
0,O
.,O
05,O
),O
",",O
movements,O
of,O
right,O
(,O
4,O
.,O
5,O
+,O
/,O
-,O
1,O
.,O
0,O
",",O
p,O
<,O
0,O
.,O
05,O
),O
and,O
left,O
(,O
3,O
.,O
7,O
+,O
/,O
-,O
0,O
.,O
8,O
",",O
p,O
<,O
0,O
.,O
05,O
),O
fingers,O
",",O
movements,O
of,O
the,O
neck,O
(,O
5,O
.,O
1,O
+,O
/,O
-,O
1,O
.,O
0,O
",",O
p,O
<,O
0,O
.,O
05,O
),O
",",O
and,O
mental,O
calculation,O
(,O
3,O
.,O
1,O
+,O
/,O
-,O
1,O
.,O
0,O
",",O
p,O
<,O
0,O
.,O
05,O
),O
.,O
To,O
quantify,O
this,O
population,O
",",O
the,O
total,O
number,O
of,O
ectopic,O
hilar,O
granule,O
cells,O
was,O
estimated,O
using,O
unbiased,O
stereology,O
at,O
different,O
times,O
after,O
pilocarpine,Chemical
-,O
induced,O
status,Disease
epilepticus,Disease
.,O
The,O
long,O
-,O
term,O
safety,O
of,O
danazol,Chemical
in,O
women,O
with,O
hereditary,Disease
angioedema,Disease
.,O
Despite,O
the,O
anaemia,Disease
",",O
the,O
number,O
of,O
splenic,O
and,O
bone,O
marrow,O
BFU,O
-,O
e,O
in,O
AZT,Chemical
treated,O
mice,O
increased,O
up,O
to,O
five,O
-,O
fold,O
over,O
levels,O
observed,O
in,O
infected,O
untreated,O
animals,O
after,O
15,O
d,O
of,O
treatment,O
.,O
A,O
72,O
-,O
year,O
-,O
old,O
woman,O
was,O
admitted,O
to,O
the,O
hospital,O
with,O
"""",O
flash,O
"""",O
pulmonary,Disease
edema,Disease
",",O
preceded,O
by,O
chest,Disease
pain,Disease
",",O
requiring,O
intubation,O
.,O
Fluoxetine,Chemical
",",O
a,O
selective,O
serotonin,Chemical
reuptake,O
inhibitor,O
",",O
is,O
gaining,O
increased,O
acceptance,O
in,O
the,O
treatment,O
of,O
adolescent,O
depression,Disease
.,O
It,O
has,O
also,O
been,O
used,O
for,O
the,O
management,O
and,O
prevention,O
of,O
cardiovascular,Disease
disease,Disease
",",O
osteoporosis,Disease
and,O
dementia,Disease
in,O
older,O
women,O
but,O
the,O
evidence,O
supporting,O
its,O
use,O
for,O
these,O
indications,O
is,O
largely,O
observational,O
.,O
A,O
76,O
year,O
-,O
old,O
woman,O
with,O
a,O
history,O
of,O
coronary,O
artery,O
bypass,O
grafting,O
and,O
prior,O
myocardial,Disease
infarction,Disease
was,O
transferred,O
to,O
the,O
emergency,O
room,O
with,O
loss,Disease
of,Disease
consciousness,Disease
due,O
to,O
marked,O
bradycardia,Disease
caused,O
by,O
hyperkalemia,Disease
.,O
We,O
have,O
described,O
a,O
patient,O
with,O
severe,O
rheumatoid,Disease
arthritis,Disease
and,O
a,O
history,O
of,O
mefenamic,Chemical
acid,Chemical
nephropathy,Disease
in,O
whom,O
hyperkalemia,Disease
and,O
inappropriate,O
hypoaldosteronism,Disease
were,O
caused,O
by,O
both,O
indomethacin,Chemical
and,O
naproxen,Chemical
",",O
without,O
major,O
decline,O
in,O
renal,O
function,O
.,O
The,O
effects,O
of,O
a,O
new,O
inhaled,O
antimuscarinic,O
drug,O
",",O
oxitropium,Chemical
bromide,Chemical
",",O
and,O
of,O
a,O
slow,O
-,O
release,O
theophylline,Chemical
preparation,O
upon,O
nocturnal,O
asthma,Disease
were,O
compared,O
in,O
a,O
placebo,O
-,O
controlled,O
double,O
-,O
blind,O
study,O
.,O
The,O
effects,O
of,O
intracoronary,O
administration,O
of,O
methylergonovine,Chemical
were,O
studied,O
in,O
21,O
patients,O
with,O
variant,Disease
angina,Disease
and,O
22,O
patients,O
with,O
atypical,O
chest,Disease
pain,Disease
and,O
in,O
others,O
without,O
angina,Disease
pectoris,Disease
(,O
control,O
group,O
),O
.,O
These,O
brain,O
substrates,O
may,O
help,O
account,O
for,O
the,O
symptoms,O
of,O
MA,Chemical
abuse,O
",",O
providing,O
therapeutic,O
targets,O
for,O
drug,O
-,O
induced,O
brain,Disease
injury,Disease
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
determine,O
if,O
changes,O
occur,O
in,O
this,O
tonotopic,O
organization,O
following,O
cochlear,O
hearing,Disease
loss,Disease
.,O
A,O
respiratory,Disease
arrest,Disease
with,O
severe,O
desaturation,Disease
and,O
bradycardia,Disease
occurred,O
.,O
RESULT,O
(,O
S,O
),O
:,O
A,O
36,O
-,O
year,O
-,O
old,O
Chinese,O
woman,O
developed,O
central,O
retinal,Disease
vein,Disease
occlusion,Disease
after,O
eight,O
courses,O
of,O
CC,Chemical
.,O
CCNU,Chemical
(,O
lomustine,Chemical
),O
toxicity,Disease
in,O
dogs,O
:,O
a,O
retrospective,O
study,O
(,O
2002,O
-,O
07,O
),O
.,O
Emerging,O
evidence,O
indicates,O
that,O
voltage,O
-,O
dependent,O
Na,Chemical
(,O
+,O
),O
channels,O
have,O
pivotal,O
roles,O
in,O
the,O
cardiotoxicity,Disease
of,O
aconitine,Chemical
.,O
We,O
aimed,O
to,O
determine,O
the,O
causes,O
of,O
thrombotic,Disease
microangiopathy,Disease
in,O
a,O
population,O
of,O
renal,O
transplantation,O
recipients,O
and,O
discuss,O
the,O
literature,O
.,O
Diabetes,Disease
of,O
2,O
months,O
duration,O
resulted,O
in,O
decreases,O
in,O
body,O
weight,O
and,O
increases,O
in,O
fluid,O
consumption,O
",",O
urine,O
volume,O
",",O
frequency,O
of,O
micturition,O
",",O
and,O
average,O
volume,O
per,O
micturition,O
;,O
effects,O
which,O
were,O
prevented,O
by,O
insulin,O
treatment,O
.,O
Three,O
of,O
the,O
cases,O
were,O
most,O
likely,O
caused,O
by,O
direct,O
neurotoxicity,Disease
of,O
hyperbaric,O
5,O
%,O
lignocaine,Chemical
.,O
Comparison,O
of,O
effects,O
of,O
isotonic,O
sodium,Chemical
chloride,Chemical
with,O
diltiazem,Chemical
in,O
prevention,O
of,O
contrast,Chemical
-,O
induced,O
nephropathy,Disease
.,O
Prazosin,Chemical
-,O
induced,O
stress,Disease
incontinence,Disease
.,O
The,O
antiarrhythmic,O
effects,O
of,O
the,O
sustained,O
release,O
form,O
of,O
mexiletine,Chemical
(,O
Mexitil,Chemical
-,Chemical
Perlongets,Chemical
),O
were,O
evaluated,O
in,O
a,O
double,O
-,O
blind,O
placebo,O
trial,O
in,O
630,O
patients,O
with,O
recent,O
documented,O
myocardial,Disease
infarction,Disease
.,O
Skin,O
biopsy,O
specimens,O
showed,O
telangiectasia,Disease
and,O
noncaseating,O
epithelioid,O
granulomatous,O
tissue,O
formation,O
in,O
the,O
papillary,O
to,O
mid,O
dermis,O
.,O
Two,O
courses,O
of,O
21,O
days,O
of,O
5,O
mg,O
norethisterone,Chemical
daily,O
caused,O
reversion,O
to,O
normal,O
in,O
all,O
57,O
cases,O
of,O
cystic,O
hyperplasia,Disease
and,O
6,O
of,O
the,O
8,O
cases,O
of,O
atypical,O
hyperplasia,Disease
.,O
Adverse,O
effect,O
of,O
the,O
calcium,Chemical
channel,O
blocker,O
nitrendipine,Chemical
on,O
nephrosclerosis,Disease
in,O
rats,O
with,O
renovascular,Disease
hypertension,Disease
.,O
There,O
was,O
a,O
close,O
parallel,O
between,O
the,O
effect,O
of,O
vitamin,Chemical
D,Chemical
dose,O
on,O
artery,Disease
calcification,Disease
and,O
the,O
effect,O
of,O
vitamin,Chemical
D,Chemical
dose,O
on,O
the,O
elevation,O
of,O
serum,O
calcium,Chemical
",",O
which,O
suggests,O
that,O
vitamin,Chemical
D,Chemical
may,O
induce,O
artery,Disease
calcification,Disease
through,O
its,O
effect,O
on,O
serum,O
calcium,Chemical
.,O
CONCLUSIONS,O
:,O
This,O
work,O
clearly,O
indicates,O
a,O
protective,O
role,O
of,O
Nrf2,O
in,O
diabetic,Disease
nephropathy,Disease
",",O
suggesting,O
that,O
dietary,O
or,O
therapeutic,O
activation,O
of,O
Nrf2,O
could,O
be,O
used,O
as,O
a,O
strategy,O
to,O
prevent,O
or,O
slow,O
down,O
the,O
progression,O
of,O
diabetic,Disease
nephropathy,Disease
.,O
Mice,O
subjected,O
to,O
hypotensive,Disease
episodes,O
showed,O
a,O
significant,O
decrease,O
in,O
latency,O
time,O
(,O
178,O
+,O
/,O
-,O
156,O
s,O
),O
compared,O
with,O
those,O
injected,O
with,O
saline,O
",",O
NTG,Chemical
+,O
NIMO,Chemical
",",O
or,O
delayed,O
NTG,Chemical
(,O
580,O
+,O
/,O
-,O
81,O
s,O
",",O
557,O
+,O
/,O
-,O
67,O
s,O
",",O
and,O
493,O
+,O
/,O
-,O
146,O
s,O
",",O
respectively,O
),O
.,O
Hepatitis,Disease
may,O
develop,O
weeks,O
after,O
discontinuation,O
of,O
the,O
drug,O
and,O
may,O
run,O
a,O
prolonged,O
course,O
",",O
but,O
complete,O
remission,O
was,O
observed,O
in,O
all,O
reported,O
cases,O
.,O
There,O
have,O
been,O
concerns,O
that,O
the,O
risk,O
of,O
cardiovascular,O
thrombotic,Disease
events,O
may,O
be,O
higher,O
with,O
cyclooxygenase,O
(,O
COX,O
),O
-,O
2,O
-,O
specific,O
inhibitors,O
than,O
nonselective,O
nonsteroidal,O
antiinflammatory,O
drugs,O
(,O
NSAIDs,O
),O
.,O
A,O
2,O
-,O
wk,O
administration,O
of,O
LiCl,Chemical
(,O
4,O
mmol,O
.,O
kg,O
(,O
-,O
1,O
),O
.,O
day,O
(,O
-,O
1,O
),O
ip,O
),O
in,O
mPGES,O
-,O
1,O
+,O
/,O
+,O
mice,O
led,O
to,O
a,O
marked,O
polyuria,Disease
with,O
hyposmotic,O
urine,O
.,O
Cyclical,O
low,O
-,O
dose,O
oestrogen,Chemical
therapy,O
with,O
7,O
-,O
-,O
13,O
days,O
of,O
progestagen,Chemical
does,O
not,O
seem,O
to,O
increase,O
the,O
risk,O
of,O
endometrial,Disease
hyperplasia,Disease
or,O
carcinoma,Disease
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
myocardial,O
contrast,O
echocardiography,O
performed,O
with,O
a,O
stable,O
solution,O
of,O
sonicated,O
albumin,O
could,O
detect,O
regions,O
of,O
myocardial,O
underperfusion,O
resulting,O
from,O
various,O
degrees,O
of,O
coronary,Disease
stenosis,Disease
.,O
The,O
rabbit,Disease
syndrome,Disease
is,O
an,O
extrapyramidal,O
side,O
effect,O
associated,O
with,O
chronic,O
neuroleptic,O
therapy,O
.,O
This,O
case,O
presented,O
a,O
unique,O
opportunity,O
to,O
observe,O
the,O
histologic,O
features,O
of,O
clinically,O
reversible,O
hepatic,Disease
veno,Disease
-,Disease
occlusive,Disease
disease,Disease
over,O
time,O
",",O
and,O
may,O
be,O
the,O
first,O
case,O
of,O
veno,O
-,O
occlusive,O
related,O
solely,O
to,O
6,Chemical
-,Chemical
thioguanine,Chemical
.,O
Epicardial,O
mapping,O
with,O
240,O
epicardial,O
electrodes,O
was,O
used,O
to,O
evaluate,O
activation,O
during,O
AF,Disease
.,O
Forty,O
-,O
nine,O
percent,O
of,O
patients,O
were,O
pain,Disease
free,O
2,O
h,O
after,O
rizatriptan,Chemical
",",O
compared,O
with,O
24,O
.,O
3,O
%,O
treated,O
with,O
ergotamine,Chemical
/,O
caffeine,Chemical
(,O
p,O
<,O
or,O
=,O
0,O
.,O
001,O
),O
",",O
rizatriptan,Chemical
being,O
superior,O
within,O
1,O
h,O
of,O
treatment,O
.,O
Epicardial,O
mapping,O
suggested,O
that,O
verapamil,Chemical
promoted,O
AF,Disease
by,O
increasing,O
the,O
number,O
of,O
simultaneous,O
wavefronts,O
reflected,O
by,O
separate,O
zones,O
of,O
reactivation,O
in,O
each,O
cycle,O
.,O
Syndrome,Disease
of,Disease
inappropriate,Disease
secretion,Disease
of,Disease
antidiuretic,Disease
hormone,Disease
after,O
infusional,O
vincristine,Chemical
.,O
The,O
true,O
incidence,O
of,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
-,O
induced,O
cystitis,Disease
in,O
humans,O
must,O
be,O
clarified,O
by,O
prospective,O
clinical,O
trials,O
.,O
Patient,O
presented,O
with,O
complaints,O
of,O
increasing,O
nausea,Disease
",",O
anorexia,Disease
",",O
and,O
upper,O
abdominal,Disease
pain,Disease
.,O
Bromocriptine,Chemical
-,O
induced,O
hypotension,Disease
was,O
unaffected,O
by,O
isoproterenol,Chemical
pretreatment,O
",",O
while,O
tachycardia,Disease
was,O
reversed,O
to,O
significant,O
bradycardia,Disease
",",O
an,O
effect,O
that,O
was,O
partly,O
reduced,O
by,O
i,O
.,O
v,O
.,O
domperidone,Chemical
(,O
0,O
.,O
5,O
mg,O
/,O
kg,O
),O
.,O
In,O
conclusion,O
",",O
CNS,O
complications,O
are,O
frequent,O
events,O
during,O
ALL,Disease
therapy,O
",",O
and,O
require,O
rapid,O
detection,O
and,O
prompt,O
treatment,O
to,O
limit,O
permanent,O
damage,O
.,O
Eighty,O
-,O
one,O
consecutive,O
patients,O
(,O
54,O
with,O
coronary,Disease
artery,Disease
disease,Disease
",",O
and,O
20,O
with,O
dilated,Disease
cardiomyopathy,Disease
),O
with,O
inducible,O
sustained,O
ventricular,Disease
tachycardia,Disease
or,O
ventricular,Disease
fibrillation,Disease
received,O
oral,O
d,Chemical
",",Chemical
l,Chemical
-,Chemical
sotalol,Chemical
to,O
prevent,O
induction,O
of,O
the,O
ventricular,Disease
tachyarrhythmia,Disease
.,O
In,O
order,O
to,O
examine,O
this,O
association,O
",",O
a,O
case,O
-,O
control,O
study,O
with,O
incident,O
cases,O
of,O
ESRD,Disease
was,O
carried,O
out,O
.,O
RESULTS,O
:,O
The,O
',O
long,O
-,O
term,O
',O
group,O
had,O
significant,O
glomerular,Disease
and,Disease
tubular,Disease
lesions,Disease
",",O
depressed,O
activities,O
of,O
mtDNA,O
-,O
encoded,O
NADH,O
dehydrogenase,O
and,O
cytochrome,O
-,O
c,O
oxidase,O
(,O
COX,O
),O
and,O
increased,O
citrate,Chemical
synthase,O
activity,O
.,O
Antiarrhythmic,O
plasma,O
concentrations,O
of,O
cibenzoline,Chemical
on,O
canine,O
ventricular,Disease
arrhythmias,Disease
.,O
CONCLUSIONS,O
:,O
In,O
bipolar,Disease
mania,Disease
",",O
the,O
incidence,O
of,O
EPS,Disease
",",O
including,O
akathisia,Disease
",",O
with,O
quetiapine,Chemical
therapy,O
is,O
similar,O
to,O
that,O
with,O
placebo,O
.,O
We,O
describe,O
a,O
patient,O
where,O
intravenous,O
injection,O
of,O
metoclopramide,Chemical
was,O
immediately,O
followed,O
by,O
asystole,Disease
repeatedly,O
.,O
The,O
greater,O
LV,Disease
hypertrophy,Disease
in,O
TGR,O
rats,O
was,O
associated,O
with,O
more,O
pronounced,O
downregulation,O
of,O
beta,O
-,O
AR,O
and,O
upregulation,O
of,O
LV,O
beta,O
-,O
AR,O
kinase,O
-,O
1,O
mRNA,O
levels,O
compared,O
with,O
those,O
in,O
SD,O
rats,O
.,O
All,O
exhibited,O
generalized,O
tonic,Disease
-,Disease
clonic,Disease
seizures,Disease
within,O
the,O
first,O
two,O
wk,O
after,O
LT,O
.,O
Levodopa,Chemical
-,O
induced,O
dyskinesias,Disease
in,O
patients,O
with,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
:,O
filling,O
the,O
bench,O
-,O
to,O
-,O
bedside,O
gap,O
.,O
Coronary,Disease
aneurysm,Disease
after,O
implantation,O
of,O
a,O
paclitaxel,Chemical
-,O
eluting,O
stent,O
.,O
A,O
patient,O
with,O
transfusion,O
-,O
dependent,O
thalassemia,Disease
was,O
undergoing,O
home,O
intravenous,O
desferrioxamine,Chemical
(,O
DFX,Chemical
),O
treatment,O
by,O
means,O
of,O
a,O
totally,O
implanted,O
system,O
because,O
of,O
his,O
poor,O
compliance,O
with,O
the,O
nightly,O
subcutaneous,O
therapy,O
.,O
A,O
65,O
-,O
year,O
-,O
old,O
woman,O
with,O
adult,Disease
-,Disease
onset,Disease
diabetes,Disease
treated,O
with,O
chlorpropamide,Chemical
(,O
Diabenese,Chemical
),O
had,O
a,O
toxic,Disease
optic,Disease
neuropathy,Disease
that,O
resolved,O
with,O
discontinuation,O
of,O
chlorpropamide,Chemical
therapy,O
.,O
Second,O
degree,O
Mobitz,O
type,O
II,O
atrioventricular,Disease
block,Disease
was,O
diagnosed,O
on,O
electrocardiogram,O
",",O
and,O
temporary,O
transvenous,O
ventricular,O
pacing,O
instituted,O
in,O
the,O
peri,O
-,O
operative,O
period,O
.,O
Total,O
blindness,Disease
with,O
a,O
transient,O
tonic,Disease
pupillary,Disease
response,O
",",O
denervation,O
supersensitivity,O
",",O
and,O
abnormal,O
visual,O
-,O
evoked,O
potentials,O
developed,O
in,O
a,O
54,O
-,O
year,O
-,O
old,O
man,O
after,O
the,O
use,O
of,O
quinine,Chemical
sulfate,Chemical
for,O
leg,Disease
cramps,Disease
.,O
Pubertal,O
exposure,O
to,O
Bisphenol,Chemical
A,Chemical
increases,O
anxiety,Disease
-,O
like,O
behavior,O
and,O
decreases,O
acetylcholinesterase,O
activity,O
of,O
hippocampus,O
in,O
adult,O
male,O
mice,O
.,O
Even,O
if,O
it,O
did,O
not,O
reach,O
statistical,O
significance,O
because,O
of,O
a,O
few,O
number,O
of,O
cases,O
",",O
the,O
risk,O
was,O
lower,O
in,O
trials,O
excluding,O
patients,O
with,O
cardiac,O
history,O
",",O
and,O
seemed,O
to,O
be,O
higher,O
in,O
trials,O
including,O
patients,O
with,O
pre,O
-,O
existing,O
cardiac,Disease
diseases,Disease
.,O
Analysis,O
was,O
performed,O
on,O
61,O
women,O
with,O
chemotherapy,O
-,O
responsive,O
metastatic,O
breast,Disease
cancer,Disease
receiving,O
96,O
-,O
h,O
infusional,O
cyclophosphamide,Chemical
as,O
part,O
of,O
a,O
triple,O
sequential,O
high,O
-,O
dose,O
regimen,O
to,O
assess,O
association,O
between,O
presence,O
of,O
peritransplant,O
congestive,Disease
heart,Disease
failure,Disease
(,O
CHF,Disease
),O
and,O
the,O
following,O
pretreatment,O
characteristics,O
:,O
presence,O
of,O
electrocardiogram,O
(,O
EKG,O
),O
abnormalities,O
",",O
age,O
",",O
hypertension,Disease
",",O
prior,O
cardiac,O
history,O
",",O
smoking,O
",",O
diabetes,Disease
mellitus,Disease
",",O
prior,O
use,O
of,O
anthracyclines,Chemical
",",O
and,O
left,O
-,O
sided,O
chest,O
irradiation,O
.,O
RESULTS,O
:,O
The,O
incidence,O
of,O
pain,Disease
was,O
significantly,O
lower,O
in,O
Groups,O
R4,O
and,O
R6,O
than,O
in,O
the,O
control,O
and,O
R2,O
groups,O
(,O
12,O
/,O
32,O
and,O
6,O
/,O
31,O
vs,O
26,O
/,O
31,O
and,O
25,O
/,O
32,O
",",O
respectively,O
",",O
P,O
<,O
0,O
.,O
001,O
),O
.,O
CONCLUSIONS,O
:,O
The,O
results,O
indicated,O
a,O
favorable,O
therapeutic,O
profile,O
for,O
haloperidol,Chemical
in,O
doses,O
of,O
2,O
-,O
3,O
mg,O
/,O
day,O
",",O
although,O
a,O
subgroup,O
developed,O
moderate,O
to,O
severe,O
extrapyramidal,Disease
signs,Disease
.,O
Resuscitation,O
with,O
lipid,O
",",O
epinephrine,Chemical
",",O
or,O
both,O
in,O
levobupivacaine,Chemical
-,O
induced,O
cardiac,Disease
toxicity,Disease
in,O
newborn,O
piglets,O
.,O
The,O
reduction,O
in,O
the,O
levodopa,Chemical
dose,O
is,O
useful,O
in,O
controlling,O
drug,Disease
-,Disease
induced,Disease
dyskinesias,Disease
.,O
Rats,O
were,O
stratified,O
into,O
control,O
groups,O
and,O
ADR,Chemical
-,O
induced,O
nephropathy,Disease
groups,O
.,O
In,O
this,O
study,O
we,O
postulated,O
that,O
during,O
acute,Disease
renal,Disease
failure,Disease
induced,O
by,O
gentamicin,Chemical
the,O
transient,O
or,O
dynamic,O
response,O
of,O
blood,O
vessels,O
could,O
be,O
affected,O
",",O
and,O
that,O
antioxidants,O
can,O
prevent,O
the,O
changes,O
in,O
dynamic,O
responses,O
of,O
blood,O
vessels,O
.,O
Based,O
on,O
clinical,O
data,O
",",O
indicating,O
that,O
chloroacetaldehyde,Chemical
(,O
CAA,Chemical
),O
is,O
an,O
important,O
metabolite,O
of,O
oxazaphosphorine,O
cytostatics,O
",",O
an,O
experimental,O
study,O
was,O
carried,O
out,O
in,O
order,O
to,O
elucidate,O
the,O
role,O
of,O
CAA,Chemical
in,O
the,O
development,O
of,O
hemorrhagic,Disease
cystitis,Disease
.,O
Fatal,O
carbamazepine,Chemical
induced,O
fulminant,Disease
eosinophilic,Disease
(,O
hypersensitivity,Disease
),O
myocarditis,Disease
:,O
emphasis,O
on,O
anatomical,O
and,O
histological,O
characteristics,O
",",O
mechanisms,O
and,O
genetics,O
of,O
drug,Disease
hypersensitivity,Disease
and,O
differential,O
diagnosis,O
.,O
OBJECTIVE,O
:,O
To,O
examine,O
the,O
effects,O
of,O
dehydroepiandrosterone,Chemical
(,O
DHEA,Chemical
),O
on,O
animal,O
models,O
of,O
schizophrenia,Disease
.,O
The,O
neutropenia,Disease
was,O
due,O
to,O
maturation,O
arrest,O
of,O
the,O
myeloid,O
series,O
in,O
one,O
patient,O
.,O
Aortic,O
atherosclerosis,Disease
was,O
diagnosed,O
by,O
radiographic,O
detection,O
of,O
calcified,O
deposits,O
in,O
the,O
abdominal,O
aorta,O
",",O
which,O
have,O
been,O
shown,O
to,O
reflect,O
intima,O
atherosclerosis,Disease
.,O
Adverse,O
effects,O
included,O
a,O
mildly,O
dry,Disease
mouth,Disease
and,O
a,O
sore,Disease
throat,Disease
in,O
2,O
patients,O
(,O
2,O
%,O
glycopyrrolate,Chemical
),O
",",O
a,O
light,O
headache,Disease
in,O
1,O
patient,O
(,O
1,O
.,O
5,O
%,O
glycopyrrolate,Chemical
),O
.,O
Severe,O
nephrotoxicity,Disease
was,O
observed,O
in,O
2,O
patients,O
but,O
was,O
reversible,O
.,O
Valproate,Chemical
-,O
induced,O
hyperammonemic,Disease
encephalopathy,Disease
is,O
an,O
uncommon,O
but,O
serious,O
effect,O
of,O
valproate,Chemical
treatment,O
.,O
Cluster,Disease
headache,Disease
is,O
characterized,O
by,O
typical,O
autonomic,O
dysfunctions,O
including,O
facial,O
and,O
intracranial,Disease
vascular,Disease
disturbances,Disease
.,O
CONCLUSION,O
:,O
When,O
performing,O
intracarotid,O
injection,O
of,O
carboplatin,Chemical
",",O
we,O
must,O
be,O
aware,O
of,O
its,O
potentially,O
blinding,O
ocular,Disease
toxicity,Disease
.,O
Levodopa,Chemical
-,O
induced,O
dyskinesia,Disease
of,O
the,O
limbs,O
in,O
thirteen,O
cases,O
of,O
Parkinsonism,Disease
",",O
which,O
was,O
choreic,O
",",O
ballistic,O
or,O
dystonic,Disease
in,O
type,O
",",O
was,O
alleviated,O
almost,O
completely,O
by,O
stereotaxic,O
surgery,O
using,O
a,O
microelectrode,O
technique,O
for,O
the,O
ventralis,O
oralis,O
anterior,O
and,O
posterior,O
nuclei,O
of,O
the,O
thalamus,O
",",O
but,O
much,O
less,O
by,O
the,O
ventralis,O
intermedius,O
nucleus,O
.,O
Drug,O
-,O
induced,O
hepatotoxicity,Disease
",",O
although,O
common,O
",",O
has,O
been,O
reported,O
only,O
infrequently,O
with,O
sulfonylureas,Chemical
.,O
A,O
single,O
-,O
placebo,O
-,O
controlled,O
oral,O
challenge,O
procedure,O
with,O
nimesulide,Chemical
or,O
paracetamol,Chemical
was,O
applied,O
to,O
829,O
patients,O
with,O
a,O
history,O
of,O
NSAID,Chemical
-,O
induced,O
urticaria,Disease
/,O
angioedema,Disease
.,O
FLA,Chemical
-,Chemical
63,Chemical
",",O
a,O
dopamine,Chemical
-,O
beta,O
-,O
oxidase,O
inhibitor,O
",",O
did,O
not,O
have,O
any,O
effect,O
on,O
the,O
hypotension,Disease
",",O
bradycardia,Disease
or,O
reflex,O
-,O
enhancing,O
effect,O
of,O
L,Chemical
-,Chemical
dopa,Chemical
.,O
Quinine,Chemical
",",O
like,O
quinidine,Chemical
",",O
is,O
a,O
chincona,O
alkaloid,O
that,O
has,O
anti,O
-,O
arrhythmic,Disease
property,O
",",O
although,O
it,O
also,O
pro,O
-,O
arrhythmic,Disease
that,O
can,O
cause,O
various,O
arrhythmias,Disease
",",O
including,O
severe,O
arrhythmia,Disease
such,O
as,O
multiple,O
PVC,Disease
.,O
METHODS,O
:,O
A,O
cooperative,O
network,O
was,O
created,O
in,O
1994,O
in,O
Spain,O
to,O
identify,O
all,O
suspicions,O
of,O
DILI,Disease
following,O
a,O
prospective,O
structured,O
report,O
form,O
.,O
Low,O
functional,O
programming,O
of,O
renal,O
AT2R,O
mediates,O
the,O
developmental,O
origin,O
of,O
glomerulosclerosis,Disease
in,O
adult,O
offspring,O
induced,O
by,O
prenatal,O
caffeine,Chemical
exposure,O
.,O
CONCLUSIONS,O
:,O
Based,O
on,O
the,O
results,O
",",O
S,Chemical
-,Chemical
53482,Chemical
and,O
S,Chemical
-,Chemical
23121,Chemical
were,O
teratogenic,Disease
when,O
administered,O
dermally,O
to,O
pregnant,O
rats,O
as,O
were,O
the,O
compounds,O
administered,O
orally,O
.,O
Testosterone,Chemical
-,O
dependent,O
hypertension,Disease
and,O
upregulation,O
of,O
intrarenal,O
angiotensinogen,O
in,O
Dahl,O
salt,Chemical
-,O
sensitive,O
rats,O
.,O
METHOD,O
:,O
In,O
a,O
6,O
-,O
week,O
random,O
-,O
assignment,O
",",O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
(,O
phase,O
A,O
),O
",",O
haloperidol,Chemical
",",O
2,O
-,O
3,O
mg,O
/,O
day,O
(,O
standard,O
dose,O
),O
",",O
and,O
haloperidol,Chemical
",",O
0,O
.,O
50,O
-,O
0,O
.,O
75,O
mg,O
/,O
day,O
(,O
low,O
dose,O
),O
",",O
were,O
compared,O
in,O
71,O
outpatients,O
with,O
Alzheimer,Disease
',Disease
s,Disease
disease,Disease
.,O
We,O
used,O
chloroquine,Chemical
or,O
hydroxychloroquine,Chemical
in,O
173,O
of,O
210,O
cases,O
and,O
found,O
only,O
one,O
case,O
of,O
chorioretinopathy,Disease
attributable,O
to,O
these,O
drugs,O
.,O
Sixty,O
-,O
two,O
patients,O
with,O
a,O
heparin,Chemical
-,O
induced,O
thrombocytopenia,Disease
are,O
reported,O
.,O
A,O
minority,O
of,O
patients,O
evolve,O
to,O
psychosis,Disease
.,O
It,O
was,O
determined,O
later,O
that,O
this,O
patient,O
',O
s,O
tumor,Disease
was,O
recurring,O
at,O
the,O
time,O
of,O
her,O
hypertensive,Disease
episode,O
.,O
His,O
bundle,O
recordings,O
showed,O
an,O
atrial,Disease
tachycardia,Disease
with,O
intermittent,O
exit,O
block,O
and,O
greatly,O
prolonged,O
BH,O
and,O
HV,O
intervals,O
(,O
40,O
and,O
100,O
msec,O
",",O
respectively,O
),O
.,O
RESULTS,O
:,O
Seven,O
patients,O
showed,O
marked,O
visual,Disease
field,Disease
constriction,Disease
with,O
some,O
sparing,O
of,O
the,O
temporal,O
visual,O
field,O
.,O
Therefore,O
",",O
it,O
is,O
suggested,O
that,O
the,O
administration,O
of,O
PS,Chemical
enhances,O
the,O
toxicity,Disease
of,O
AMNS,Chemical
on,O
the,O
glomerulus,O
and,O
readily,O
produces,O
progressive,O
FSGS,Disease
in,O
rats,O
resulting,O
in,O
the,O
end,Disease
-,Disease
stage,Disease
renal,Disease
disease,Disease
.,O
In,O
this,O
way,O
they,O
obtained,O
appreciable,O
changes,O
in,O
body,O
weight,O
(,O
increased,O
from,O
50,O
to,O
70,O
g,O
after,O
forty,O
days,O
at,O
a,O
dose,O
of,O
5,O
mg,O
per,O
day,O
of,O
anabolizing,O
agent,O
),O
",",O
but,O
most,O
of,O
all,O
they,O
found,O
histological,O
changes,O
due,O
to,O
"""",O
regenerative,O
"""",O
changes,O
in,O
the,O
muscle,O
tissue,O
",",O
which,O
however,O
maintained,O
its,O
myopathic,Disease
characteristics,O
in,O
the,O
control,O
animals,O
that,O
were,O
not,O
treated,O
with,O
the,O
anabolizing,O
agent,O
.,O
In,O
patients,O
premedicated,O
with,O
scopolamine,Chemical
+,O
morphine,Chemical
(,O
+,O
5,O
mg,O
nitrazepam,Chemical
the,O
evening,O
before,O
surgery,O
),O
",",O
the,O
sleep,O
-,O
inducing,O
effect,O
of,O
midazolam,Chemical
0,O
.,O
15,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
was,O
clearly,O
slower,O
in,O
onset,O
than,O
that,O
of,O
thiopentone,Chemical
4,O
.,O
67,O
mg,O
/,O
kg,O
i,O
.,O
v,O
.,O
Somewhat,O
fewer,O
cardiovascular,O
and,O
local,O
sequelae,O
were,O
found,O
in,O
the,O
midazolam,Chemical
group,O
",",O
but,O
",",O
although,O
apnoea,Disease
occurred,O
less,O
often,O
in,O
the,O
midazolam,Chemical
group,O
it,O
lasted,O
longer,O
.,O
In,O
a,O
double,O
-,O
blind,O
6,O
-,O
week,O
trial,O
",",O
458,O
patients,O
with,O
acute,O
schizophrenia,Disease
were,O
randomly,O
assigned,O
to,O
fixed,O
-,O
dose,O
treatment,O
with,O
asenapine,Chemical
at,O
5,O
mg,O
twice,O
daily,O
(,O
BID,O
),O
",",O
asenapine,Chemical
at,O
10,O
mg,O
BID,O
",",O
placebo,O
",",O
or,O
haloperidol,Chemical
at,O
4,O
mg,O
BID,O
(,O
to,O
verify,O
assay,O
sensitivity,O
),O
.,O
Thirty,O
-,O
five,O
patients,O
with,O
primary,Disease
pulmonary,Disease
hypertension,Disease
and,O
85,O
matched,O
controls,O
were,O
recruited,O
over,O
32,O
months,O
(,O
1992,O
-,O
1994,O
),O
in,O
Belgium,O
.,O
In,O
cardiac,O
transplantation,O
",",O
the,O
incidence,O
of,O
proteinuria,Disease
associated,O
with,O
Srl,Chemical
is,O
unknown,O
.,O
The,O
potential,O
for,O
acetaminophen,Chemical
to,O
produce,O
cardiovascular,Disease
toxicities,Disease
is,O
very,O
low,O
.,O
CONCLUSIONS,O
:,O
Verapamil,Chemical
promotes,O
AF,Disease
in,O
normal,O
dogs,O
by,O
promoting,O
multiple,O
circuit,O
reentry,O
",",O
an,O
effect,O
dependent,O
on,O
intact,O
autonomic,O
tone,O
and,O
not,O
shared,O
by,O
diltiazem,Chemical
.,O
One,O
patient,O
had,O
focal,O
seizures,Disease
and,O
transient,Disease
hemiparesis,Disease
but,O
recovered,O
completely,O
.,O
Routine,O
EKG,O
monitoring,O
during,O
infusional,O
cyclophosphamide,Chemical
did,O
not,O
predict,O
CHF,Disease
development,O
.,O
A,O
catch,O
in,O
the,O
Reye,Disease
.,O
Phenylpropanolamine,Chemical
(,O
PPA,Chemical
),O
overdose,Disease
can,O
cause,O
severe,O
hypertension,Disease
",",O
intracerebral,Disease
hemorrhage,Disease
",",O
and,O
death,O
.,O
OBSERVATIONS,O
:,O
A,O
keratome,O
skin,O
specimen,O
from,O
1,O
patient,O
with,O
sirolimus,Chemical
-,O
induced,O
capillary,Disease
leak,Disease
syndrome,Disease
had,O
a,O
2,O
.,O
3,O
-,O
fold,O
increase,O
in,O
percentage,O
of,O
apoptotic,O
cells,O
(,O
to,O
48,O
%,O
),O
compared,O
with,O
an,O
unaffected,O
sirolimus,Chemical
-,O
treated,O
patient,O
with,O
psoriasis,Disease
(,O
21,O
%,O
),O
.,O
After,O
the,O
addition,O
of,O
a,O
minimal,O
dose,O
of,O
clonidine,Chemical
(,O
0,O
.,O
15,O
mg,O
bid,O
),O
",",O
she,O
developed,O
complete,O
AV,Disease
block,Disease
and,O
severe,O
hypotension,Disease
",",O
which,O
resolved,O
upon,O
cessation,O
of,O
all,O
medications,O
.,O
The,O
rise,O
in,O
blood,O
pressure,O
became,O
less,O
marked,O
when,O
higher,O
concentrations,O
of,O
sevoflurane,Chemical
or,O
enflurane,Chemical
were,O
administered,O
and,O
the,O
blood,O
pressure,O
at,O
convulsions,Disease
decreased,O
significantly,O
in,O
1,O
.,O
6,O
%,O
sevoflurane,Chemical
",",O
and,O
in,O
0,O
.,O
8,O
%,O
and,O
1,O
.,O
6,O
%,O
enflurane,Chemical
.,O
Vincristine,Chemical
was,O
accidentally,O
given,O
intrathecally,O
to,O
a,O
child,O
with,O
leukaemia,Disease
",",O
producing,O
sensory,Disease
and,Disease
motor,Disease
dysfunction,Disease
followed,O
by,O
encephalopathy,Disease
and,O
death,O
.,O
In,O
cisapride,Chemical
-,O
treated,O
diarrhoea,Disease
-,O
predominant,O
patients,O
the,O
mean,O
contraction,O
amplitude,O
was,O
higher,O
(,O
29,O
.,O
3,O
+,O
/,O
-,O
3,O
.,O
2,O
versus,O
24,O
.,O
9,O
+,O
/,O
-,O
2,O
.,O
6,O
mm,O
Hg,O
",",O
cisapride,Chemical
versus,O
placebo,O
(,O
P,O
<,O
0,O
.,O
001,O
),O
;,O
pretreatment,O
",",O
25,O
.,O
7,O
+,O
/,O
-,O
6,O
.,O
0,O
mm,O
Hg,O
),O
",",O
the,O
mean,O
contraction,O
duration,O
longer,O
(,O
3,O
.,O
4,O
+,O
/,O
-,O
0,O
.,O
2,O
versus,O
3,O
.,O
0,O
+,O
/,O
-,O
0,O
.,O
2,O
sec,O
",",O
cisapride,Chemical
versus,O
placebo,O
(,O
P,O
<,O
0,O
.,O
001,O
),O
;,O
pretreatment,O
",",O
3,O
.,O
1,O
+,O
/,O
-,O
0,O
.,O
5,O
sec,O
),O
",",O
and,O
the,O
mean,O
contraction,O
frequency,O
lower,O
(,O
2,O
.,O
0,O
+,O
/,O
-,O
0,O
.,O
2,O
versus,O
2,O
.,O
5,O
+,O
/,O
-,O
0,O
.,O
4,O
cont,O
.,O
/,O
min,O
",",O
cisapride,Chemical
versus,O
placebo,O
(,O
P,O
<,O
0,O
.,O
001,O
),O
;,O
pretreatment,O
",",O
2,O
.,O
5,O
+,O
/,O
-,O
1,O
.,O
1,O
cont,O
.,O
/,O
min,O
],O
than,O
patients,O
treated,O
with,O
placebo,O
.,O
In,O
conclusion,O
",",O
this,O
study,O
provides,O
new,O
insights,O
into,O
the,O
protein,O
changes,O
occurring,O
in,O
LID,Disease
.,O
A,O
34,O
-,O
year,O
-,O
old,O
patient,O
developed,O
metastic,O
endometrial,Disease
carcinoma,Disease
after,O
Hodgkin,Disease
disease,Disease
in,O
childhood,O
.,O
During,O
monitoring,O
",",O
visual,Disease
hallucinations,Disease
did,O
not,O
correlate,O
with,O
EEG,O
readings,O
",",O
nor,O
did,O
video,O
recording,O
capture,O
any,O
of,O
the,O
described,O
events,O
.,O
In,O
both,O
sets,O
(,O
four,O
),O
of,O
eyes,O
of,O
the,O
subjects,O
with,O
persistent,O
visual,Disease
deficits,Disease
(,O
patients,O
B,O
and,O
C,O
),O
",",O
there,O
was,O
an,O
average,O
loss,O
of,O
79,O
%,O
of,O
nerve,O
fiber,O
thickness,O
in,O
the,O
temporal,O
quadrant,O
.,O
In,O
one,O
patient,O
",",O
enflurane,Chemical
administered,O
during,O
a,O
donor,O
nephrectomy,O
resulted,O
in,O
unexpected,O
partial,O
motor,O
seizures,Disease
.,O
This,O
study,O
focuses,O
on,O
behavioral,O
syndromes,O
that,O
may,O
used,O
as,O
models,O
for,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
",",O
or,O
tardive,Disease
dyskinesia,Disease
",",O
and,O
its,O
response,O
after,O
glutamatergic,O
blockage,O
.,O
Phasic,O
pain,Disease
was,O
applied,O
by,O
means,O
of,O
short,O
pulses,O
of,O
CO2,Chemical
to,O
the,O
nasal,O
mucosa,O
(,O
stimulus,O
duration,O
500,O
ms,O
",",O
interval,O
approximately,O
60,O
s,O
),O
",",O
and,O
tonic,O
pain,Disease
was,O
induced,O
in,O
the,O
nasal,O
cavity,O
by,O
means,O
of,O
dry,O
air,O
of,O
controlled,O
temperature,O
",",O
humidity,O
and,O
flow,O
rate,O
(,O
22,O
degrees,O
C,O
",",O
0,O
%,O
relative,O
humidity,O
",",O
145,O
ml,O
.,O
s,O
-,O
1,O
),O
.,O
We,O
report,O
the,O
case,O
of,O
a,O
patient,O
who,O
developed,O
acute,O
hepatitis,Disease
with,O
extensive,Disease
hepatocellular,Disease
necrosis,Disease
",",O
7,O
months,O
after,O
the,O
onset,O
of,O
administration,O
of,O
clotiazepam,Chemical
",",O
a,O
thienodiazepine,Chemical
derivative,O
.,O
This,O
patient,O
underwent,O
a,O
10,O
-,O
month,O
regimen,O
of,O
rifampin,Chemical
and,O
isoniazid,Chemical
for,O
pulmonary,Disease
tuberculosis,Disease
and,O
was,O
discovered,O
to,O
have,O
developed,O
signs,O
of,O
severe,O
renal,Disease
failure,Disease
five,O
weeks,O
after,O
completion,O
of,O
therapy,O
.,O
Combination,O
of,O
SKF,Chemical
38393,Chemical
with,O
quinpirole,Chemical
did,O
not,O
cause,O
potentiated,O
inhibitory,O
effect,O
on,O
catalepsy,Disease
induced,O
by,O
dopamine,Chemical
antagonists,O
.,O
Statistical,O
analysis,O
was,O
carried,O
out,O
using,O
Kruskal,O
-,O
Wallis,O
test,O
for,O
hyper,Disease
locomotion,O
",",O
and,O
one,O
-,O
way,O
ANOVA,O
for,O
climbing,O
and,O
catalepsy,Disease
tests,O
.,O
Specific,O
gravity,O
(,O
SG,O
),O
was,O
determined,O
in,O
the,O
subcortex,O
and,O
in,O
two,O
sites,O
in,O
the,O
cortex,O
(,O
core,O
and,O
periphery,O
of,O
the,O
ischemic,Disease
territory,O
),O
.,O
The,O
most,O
common,O
pathogen,O
was,O
Klebsiella,O
pneumoniae,Disease
and,O
this,O
",",O
together,O
with,O
Escherichia,O
coli,O
and,O
Pseudomonas,O
aeruginosa,O
",",O
accounted,O
for,O
74,O
%,O
of,O
all,O
gram,Disease
-,Disease
negative,Disease
bacillary,Disease
infections,Disease
.,O
This,O
case,O
report,O
carries,O
an,O
important,O
clinical,O
application,O
given,O
the,O
frequent,O
usage,O
of,O
amiodarone,Chemical
among,O
CHF,Disease
patients,O
.,O
Curcumin,Chemical
prevents,O
maleate,Chemical
-,O
induced,O
nephrotoxicity,Disease
:,O
relation,O
to,O
hemodynamic,O
alterations,O
",",O
oxidative,O
stress,O
",",O
mitochondrial,O
oxygen,Chemical
consumption,O
and,O
activity,O
of,O
respiratory,O
complex,O
I,O
.,O
Previous,O
studies,O
indicate,O
that,O
ecstasy,Chemical
users,O
have,O
marked,O
and,O
persistent,O
neurocognitive,O
and,O
sleep,Disease
-,Disease
related,Disease
impairments,Disease
.,O
Regular,O
motor,O
activity,O
has,O
many,O
benefits,O
for,O
mental,O
and,O
physical,O
condition,O
but,O
its,O
implications,O
for,O
epilepsy,Disease
are,O
still,O
controversial,O
.,O
OBJECTIVE,O
:,O
Nephrotoxicity,Disease
is,O
the,O
major,O
adverse,O
effect,O
of,O
amphotericin,Chemical
B,Chemical
(,O
AmB,Chemical
),O
",",O
often,O
limiting,O
administration,O
of,O
full,O
dosage,O
.,O
The,O
incidence,O
of,O
neurotoxicity,Disease
may,O
be,O
reduced,O
by,O
employing,O
lower,O
doses,O
of,O
methotrexate,Chemical
in,O
the,O
presence,O
of,O
central,Disease
nervous,Disease
system,Disease
leukemia,Disease
",",O
in,O
older,O
children,O
and,O
adults,O
",",O
and,O
in,O
the,O
presence,O
of,O
epidural,O
leakage,O
.,O
An,O
analysis,O
of,O
the,O
75,O
cases,O
that,O
had,O
been,O
adequately,O
followed,O
up,O
suggested,O
that,O
16,O
",",O
including,O
three,O
deaths,Disease
",",O
were,O
probably,O
related,O
to,O
treatment,O
with,O
the,O
drug,O
.,O
The,O
data,O
indicate,O
that,O
diazepam,Chemical
acts,O
through,O
the,O
benzodiazepine,Chemical
-,O
GABA,Chemical
-,O
chloride,Chemical
channel,O
macromolecular,O
complex,O
within,O
the,O
central,O
nervous,O
system,O
to,O
facilitate,O
reflex,O
bradycardia,Disease
mediated,O
through,O
baroreceptor,O
reflexes,O
in,O
response,O
to,O
an,O
acute,O
increase,O
in,O
arterial,O
pressure,O
.,O
DSMM,O
XI,O
study,O
:,O
dose,O
definition,O
for,O
intravenous,O
cyclophosphamide,Chemical
in,O
combination,O
with,O
bortezomib,Chemical
/,O
dexamethasone,Chemical
for,O
remission,O
induction,O
in,O
patients,O
with,O
newly,O
diagnosed,O
myeloma,Disease
.,O
Risk,O
of,O
transient,O
hyperammonemic,Disease
encephalopathy,Disease
in,O
cancer,Disease
patients,O
who,O
received,O
continuous,O
infusion,O
of,O
5,Chemical
-,Chemical
fluorouracil,Chemical
with,O
the,O
complication,O
of,O
dehydration,Disease
and,O
infection,Disease
.,O
Effects,O
of,O
uninephrectomy,O
and,O
high,O
protein,O
feeding,O
on,O
lithium,Chemical
-,O
induced,O
chronic,Disease
renal,Disease
failure,Disease
in,O
rats,O
.,O
In,O
recent,O
years,O
working,O
memory,Disease
deficits,Disease
have,O
been,O
reported,O
in,O
users,O
of,O
MDMA,Chemical
(,O
3,Chemical
",",Chemical
4,Chemical
-,Chemical
methylenedioxymethamphetamine,Chemical
",",O
ecstasy,Chemical
),O
.,O
Despite,O
the,O
underlying,O
diseases,O
",",O
the,O
prognosis,O
for,O
drug,O
-,O
induced,O
de,O
novo,O
absence,Disease
seizure,Disease
is,O
good,O
because,O
it,O
subsides,O
rapidly,O
after,O
discontinuing,O
the,O
use,O
of,O
the,O
offending,O
drugs,O
.,O
Finally,O
",",O
only,O
five,O
cases,O
of,O
acute,O
parenchymal,O
renal,Disease
disease,Disease
occurred,O
",",O
none,O
likely,O
to,O
be,O
caused,O
by,O
a,O
study,O
drug,O
.,O
Although,O
all,O
of,O
the,O
currently,O
available,O
H2,O
-,O
receptor,O
antagonists,O
have,O
shown,O
the,O
propensity,O
to,O
cause,O
delirium,Disease
",",O
only,O
two,O
previously,O
reported,O
cases,O
have,O
been,O
associated,O
with,O
famotidine,Chemical
.,O
Atorva,Chemical
reversed,O
dex,Chemical
-,O
induced,O
hypertension,Disease
(,O
129,O
+,O
/,O
-,O
0,O
.,O
6,O
mmHg,O
",",O
vs,O
.,O
135,O
+,O
/,O
-,O
0,O
.,O
6,O
mmHg,O
P,O
',O
<,O
0,O
.,O
05,O
),O
and,O
decreased,O
plasma,O
superoxide,Chemical
(,O
7931,O
+,O
/,O
-,O
392,O
.,O
8,O
dex,Chemical
",",O
1187,O
+,O
/,O
-,O
441,O
.,O
2,O
atorva,Chemical
+,O
dex,Chemical
",",O
P,O
<,O
0,O
.,O
0001,O
),O
.,O
Cardiotoxicity,Disease
is,O
not,O
an,O
uncommon,O
adverse,O
effect,O
of,O
chemotherapeutic,O
agents,O
.,O
MK,Chemical
-,Chemical
801,Chemical
(,O
0,O
.,O
1,O
mg,O
/,O
kg,O
),O
administration,O
attenuated,O
the,O
catalepsy,Disease
and,O
tremor,Disease
induced,O
by,O
reserpine,Chemical
.,O
Progestational,O
agents,O
and,O
blood,Disease
coagulation,Disease
.,O
Activation,O
of,O
poly,Chemical
(,Chemical
ADP,Chemical
-,Chemical
ribose,Chemical
),Chemical
polymerase,O
contributes,O
to,O
development,O
of,O
doxorubicin,Chemical
-,O
induced,O
heart,Disease
failure,Disease
.,O
Oral,O
thrush,Disease
did,O
not,O
recur,O
",",O
but,O
60,O
%,O
(,O
3,O
/,O
5,O
),O
of,O
patients,O
with,O
hoarseness,Disease
had,O
recurrence,O
.,O
Phenytoin,Chemical
induced,O
fatal,O
hepatic,Disease
injury,Disease
.,O
Ventricular,Disease
fibrillation,Disease
occurred,O
significantly,O
more,O
often,O
with,O
Renografin,Chemical
",",O
suggesting,O
that,O
chelating,O
agents,O
contribute,O
to,O
toxicity,Disease
in,O
coronary,O
angiography,O
.,O
Within,O
8,O
hours,O
after,O
initiation,O
of,O
therapy,O
the,O
patient,O
died,O
with,O
a,O
clinical,O
picture,O
resembling,O
massive,O
pulmonary,Disease
obstruction,Disease
due,O
to,O
choriocarcinomic,O
tissue,O
plugs,O
",",O
probably,O
originating,O
from,O
the,O
uterus,O
.,O
Comparison,O
of,O
the,O
two,O
biopsies,O
showed,O
that,O
temsirolimus,Chemical
inhibited,O
tumor,Disease
cell,O
proliferation,O
through,O
cell,O
cycle,O
arrest,O
",",O
but,O
did,O
not,O
induce,O
any,O
change,O
in,O
the,O
number,O
of,O
apoptotic,O
tumor,Disease
cells,O
.,O
It,O
evokes,O
convulsions,Disease
mainly,O
trough,O
the,O
blockage,O
of,O
GABA,Chemical
(,O
A,O
),O
receptors,O
.,O
Reduction,O
in,O
injection,O
pain,Disease
using,O
buffered,O
lidocaine,Chemical
as,O
a,O
local,O
anesthetic,O
before,O
cardiac,O
catheterization,O
.,O
In,O
particular,O
it,O
illustrates,O
the,O
derangements,O
of,O
thyroid,O
function,O
seen,O
in,O
pregnant,O
women,O
with,O
eating,Disease
disorders,Disease
and,O
reminds,O
us,O
that,O
when,O
a,O
cause,O
for,O
thyrotoxicosis,Disease
remains,O
obscure,O
",",O
thyroxine,Chemical
abuse,O
should,O
be,O
considered,O
and,O
explored,O
.,O
CONCLUSIONS,O
:,O
In,O
our,O
series,O
",",O
the,O
occurrence,O
of,O
HIT,Disease
after,O
liver,O
transplantation,O
was,O
uncommon,O
.,O
Urinary,O
symptoms,O
and,O
quality,O
of,O
life,O
changes,O
in,O
Thai,O
women,O
with,O
overactive,Disease
bladder,Disease
after,O
tolterodine,Chemical
treatment,O
.,O
This,O
study,O
was,O
undertaken,O
to,O
determine,O
the,O
effects,O
of,O
OCT,Chemical
on,O
serum,O
PTH,O
levels,O
and,O
bone,O
turnover,O
in,O
states,O
of,O
normal,O
or,O
impaired,Disease
renal,Disease
function,Disease
.,O
In,O
pre,O
-,O
nephrotic,Disease
stage,O
the,O
plasma,O
level,O
of,O
fatty,Chemical
acids,Chemical
",",O
triacylglycerol,Chemical
and,O
VLDL,O
decreased,O
while,O
that,O
of,O
phospholipid,O
",",O
cholesteryl,Chemical
esters,Chemical
and,O
HDL,O
remained,O
constant,O
.,O
A,O
47,O
-,O
year,O
-,O
old,O
patient,O
suffering,O
from,O
coronary,Disease
artery,Disease
disease,Disease
was,O
admitted,O
to,O
the,O
CCU,O
in,O
shock,Disease
with,O
III,O
.,O
We,O
suggest,O
that,O
sleep,Disease
deprivation,Disease
may,O
add,O
to,O
the,O
risk,O
of,O
bupropion,Chemical
-,O
associated,O
seizures,Disease
.,O
An,O
unexpected,O
diagnosis,O
in,O
a,O
renal,O
-,O
transplant,O
patient,O
with,O
proteinuria,Disease
treated,O
with,O
everolimus,Chemical
:,O
AL,Disease
amyloidosis,Disease
.,O
Massive,O
bleeding,Disease
appeared,O
during,O
surgery,O
which,O
lasted,O
for,O
six,O
hours,O
.,O
Depression,Disease
had,O
a,O
significant,O
negative,O
effect,O
on,O
CD4,O
+,O
T,O
-,O
cell,O
counts,O
over,O
time,O
regardless,O
of,O
ART,O
use,O
.,O
Twenty,O
-,O
eight,O
percent,O
of,O
patients,O
showed,O
increased,O
proteinuria,Disease
to,O
the,O
nephrotic,Disease
range,O
.,O
Screening,O
for,O
stimulant,O
use,O
in,O
adult,O
emergency,O
department,O
seizure,Disease
patients,O
.,O
On,O
transthoracic,O
echocardiogram,O
",",O
she,O
had,O
moderate,O
left,Disease
ventricular,Disease
dysfunction,Disease
with,O
regional,O
variability,O
and,O
moderate,O
mitral,Disease
regurgitation,Disease
.,O
BACKGROUND,O
:,O
Cisplatin,Chemical
-,O
based,O
chemotherapy,O
combinations,O
improve,O
quality,O
of,O
life,O
and,O
survival,O
in,O
advanced,O
nonsmall,Disease
cell,Disease
lung,Disease
carcinoma,Disease
(,O
NSCLC,Disease
),O
.,O
HIT,Disease
antibody,O
levels,O
were,O
measured,O
the,O
day,O
before,O
surgery,O
and,O
on,O
POD,O
7,O
and,O
14,O
.,O
Despite,O
increasing,O
reports,O
on,O
nonionic,O
contrast,Chemical
media,Chemical
-,O
induced,O
nephropathy,Disease
(,O
CIN,Disease
),O
in,O
hospitalized,O
adult,O
patients,O
during,O
cardiac,O
procedures,O
",",O
the,O
studies,O
in,O
pediatrics,O
are,O
limited,O
",",O
with,O
even,O
less,O
focus,O
on,O
possible,O
predisposing,O
factors,O
and,O
preventive,O
measures,O
for,O
patients,O
undergoing,O
cardiac,O
angiography,O
.,O
The,O
enhancement,O
of,O
aminonucleoside,Chemical
nephrosis,Disease
by,O
the,O
co,O
-,O
administration,O
of,O
protamine,O
.,O
Two,O
of,O
14,O
patients,O
with,O
Cushing,Disease
',Disease
s,Disease
syndrome,Disease
treated,O
on,O
a,O
long,O
-,O
term,O
basis,O
with,O
ketoconazole,Chemical
developed,O
sustained,O
hypertension,Disease
.,O
Is,O
Dysguesia,Disease
Going,O
to,O
be,O
a,O
Rare,O
or,O
a,O
Common,O
Side,O
-,O
effect,O
of,O
Amlodipine,Chemical
?,O
Cases,O
were,O
patients,O
who,O
developed,O
hyperkalemia,Disease
(,O
K,Chemical
(,O
+,O
),O
>,O
5,O
.,O
0,O
mEq,O
/,O
L,O
),O
or,O
renal,Disease
insufficiency,Disease
(,O
Cr,Chemical
>,O
or,O
=,O
2,O
.,O
5,O
mg,O
/,O
dL,O
),O
",",O
and,O
they,O
were,O
compared,O
to,O
2,O
randomly,O
selected,O
controls,O
per,O
case,O
.,O
RESULTS,O
:,O
24,O
patients,O
were,O
evaluable,O
for,O
response,O
with,O
one,O
partial,O
response,O
of,O
11,O
months,O
duration,O
of,O
a,O
patient,O
with,O
hepatic,O
and,O
pulmonary,O
metastases,Disease
(,O
4,O
%,O
),O
",",O
one,O
minor,O
response,O
",",O
and,O
2,O
patients,O
stable,O
for,O
over,O
6,O
months,O
.,O
Both,O
anti,O
-,O
asthmatic,Disease
and,O
tremorgenic,Disease
effects,O
of,O
procaterol,Chemical
were,O
dose,O
-,O
related,O
.,O
A,O
CD50,O
dose,O
of,O
local,O
anesthetic,O
(,O
causing,O
convulsions,Disease
in,O
50,O
%,O
of,O
mice,O
),O
was,O
fatal,O
in,O
90,O
%,O
of,O
bupivacaine,Chemical
-,O
induced,O
seizures,Disease
",",O
in,O
57,O
%,O
of,O
the,O
chloroprocaine,Chemical
group,O
",",O
and,O
in,O
6,O
%,O
of,O
the,O
lidocaine,Chemical
group,O
.,O
This,O
study,O
evaluated,O
yohimbine,Chemical
as,O
a,O
treatment,O
for,O
the,O
sexual,Disease
side,Disease
effects,Disease
caused,O
by,O
serotonin,Chemical
reuptake,O
blockers,O
.,O
When,O
CPA,Chemical
",",O
diazepam,Chemical
or,O
2PAM,Chemical
was,O
given,O
immediately,O
after,O
DFP,Chemical
-,O
atropine,Chemical
",",O
these,O
treatments,O
prevented,O
",",O
delayed,O
or,O
shortened,O
the,O
occurrence,O
of,O
serious,O
signs,O
of,O
poisoning,Disease
.,O
These,O
results,O
suggest,O
that,O
activation,O
of,O
CB1,O
receptors,O
offers,O
neuroprotection,O
against,O
dopaminergic,O
lesion,O
and,O
the,O
development,O
of,O
L,Chemical
-,Chemical
DOPA,Chemical
-,O
induced,O
dyskinesias,Disease
.,O
Hyperalgesia,Disease
and,O
myoclonus,Disease
in,O
terminal,O
cancer,Disease
patients,O
treated,O
with,O
continuous,O
intravenous,O
morphine,Chemical
.,O
The,O
long,O
-,O
term,O
use,O
of,O
nondepolarizing,Chemical
neuromuscular,Chemical
blocking,Chemical
agents,Chemical
(,O
ND,Chemical
-,Chemical
NMBA,Chemical
),O
has,O
recently,O
been,O
implicated,O
as,O
a,O
cause,O
of,O
prolonged,O
muscle,Disease
weakness,Disease
",",O
although,O
the,O
site,O
of,O
the,O
lesion,O
and,O
the,O
predisposing,O
factors,O
have,O
been,O
unclear,O
.,O
Patients,O
with,O
convulsive,Disease
seizures,Disease
had,O
2,O
.,O
5,O
times,O
higher,O
in,O
-,O
hospital,O
mortality,O
rates,O
and,O
twice,O
the,O
length,O
of,O
hospital,O
stay,O
compared,O
with,O
patients,O
without,O
convulsive,Disease
seizures,Disease
.,O
Further,O
",",O
we,O
show,O
that,O
mice,O
genetically,O
engineered,O
to,O
be,O
deficient,O
in,O
brain,O
DA,Chemical
develop,O
METH,Chemical
neurotoxicity,Disease
",",O
as,O
long,O
as,O
the,O
thermic,O
effects,O
of,O
METH,Chemical
are,O
preserved,O
.,O
Inhibition,O
of,O
NO,Chemical
-,O
synthase,O
induced,O
a,O
reversible,O
hypertension,Disease
accompanied,O
by,O
depressed,Disease
Na,Chemical
+,O
-,O
extrusion,O
from,O
cardiac,O
cells,O
as,O
a,O
consequence,O
of,O
deteriorated,O
Na,Chemical
+,O
-,O
binding,O
properties,O
of,O
the,O
(,O
Na,Chemical
",",O
K,Chemical
),O
-,O
ATPase,O
.,O
The,O
antiangiogenic,O
effects,O
of,O
thalidomide,Chemical
have,O
been,O
assessed,O
in,O
clinical,O
trials,O
in,O
patients,O
with,O
various,O
solid,O
and,O
haematological,Disease
malignancies,Disease
.,O
The,O
dose,O
levels,O
incorporate,O
escalating,O
paclitaxel,Chemical
doses,O
",",O
and,O
intrapatient,O
escalations,O
within,O
a,O
given,O
dose,O
level,O
are,O
permitted,O
if,O
toxicity,Disease
permits,O
.,O
During,O
the,O
last,O
2,O
1,O
/,O
2,O
years,O
",",O
38,O
patients,O
with,O
ovarian,Disease
cancer,Disease
were,O
treated,O
with,O
a,O
combination,O
of,O
cisplatinum,Chemical
(,O
CPDD,Chemical
),O
",",O
50,O
mg,O
/,O
m2,O
",",O
adriamycin,Chemical
",",O
30,O
mg,O
/,O
m2,O
",",O
cyclophosphamide,Chemical
",",O
300,O
mg,O
/,O
m2,O
",",O
on,O
day,O
1,O
;,O
and,O
hexamethylmelamine,Chemical
(,O
HMM,Chemical
),O
",",O
6,O
mg,O
/,O
kg,O
daily,O
",",O
for,O
14,O
days,O
.,O
Immunoprecipitation,O
/,O
Western,O
blotting,O
showed,O
that,O
Smad3,O
was,O
activated,O
by,O
AGEs,O
but,O
was,O
inhibited,O
by,O
SIS3,O
in,O
MMECs,O
and,O
in,O
STZ,Chemical
-,O
induced,O
diabetic,Disease
nephropathy,Disease
.,O
He,O
complained,O
of,O
pain,Disease
and,Disease
visual,Disease
disturbance,Disease
in,Disease
the,Disease
ipsilateral,Disease
eye,Disease
30,O
h,O
after,O
the,O
injection,O
.,O
Our,O
findings,O
suggest,O
that,O
the,O
changes,O
leading,O
to,O
an,O
alteration,O
of,O
myocardial,O
dynamic,O
imaging,O
with,O
I,Chemical
-,Chemical
131,Chemical
HA,Chemical
are,O
not,O
the,O
initiating,O
factor,O
in,O
doxorubicin,Chemical
cardiotoxicity,Disease
.,O
HBV,O
lamivudine,Chemical
-,O
resistant,O
strains,O
were,O
detected,O
in,O
3,O
of,O
15,O
mono,O
-,O
infected,O
chronic,O
hepatitis,Disease
B,Disease
patients,O
and,O
10,O
of,O
20,O
HBV,Disease
-,Disease
HIV,Disease
co,Disease
-,Disease
infected,Disease
patients,O
.,O
The,O
administration,O
of,O
lamivudine,Chemical
to,O
patients,O
with,O
HBV,O
-,O
related,O
cirrhosis,Disease
",",O
like,O
our,O
present,O
case,O
",",O
should,O
be,O
considered,O
as,O
an,O
initial,O
medical,O
therapeutic,O
option,O
",",O
especially,O
in,O
countries,O
where,O
liver,O
transplantation,O
is,O
not,O
reliably,O
available,O
.,O
The,O
development,O
of,O
schizophrenia,Disease
may,O
include,O
an,O
early,O
neurodevelopmental,O
stress,O
component,O
which,O
increases,O
vulnerability,O
to,O
later,O
stressful,O
life,O
events,O
",",O
in,O
combination,O
leading,O
to,O
overt,O
disease,O
.,O
In,O
six,O
dogs,O
with,O
doxorubicin,Chemical
-,O
induced,O
heart,Disease
failure,Disease
",",O
VIP,O
decreased,O
from,O
31,O
+,O
/,O
-,O
7,O
to,O
11,O
+,O
/,O
-,O
4,O
pg,O
/,O
mg,O
protein,O
(,O
P,O
less,O
than,O
0,O
.,O
05,O
),O
.,O
No,O
more,O
tic,Disease
-,Disease
like,Disease
symptoms,Disease
or,O
other,O
side,O
effects,O
have,O
been,O
reported,O
.,O
This,O
report,O
describes,O
a,O
patient,O
with,O
mild,O
language,Disease
delay,Disease
and,O
mental,Disease
retardation,Disease
",",O
who,O
was,O
found,O
to,O
have,O
nonketotic,Disease
hyperglycinemia,Disease
following,O
her,O
presentation,O
with,O
acute,O
encephalopathy,Disease
and,O
chorea,Disease
shortly,O
after,O
initiation,O
of,O
valproate,Chemical
therapy,O
.,O
It,O
is,O
unclear,O
whether,O
a,O
coronary,O
CTA,O
strategy,O
would,O
be,O
efficacious,O
in,O
cocaine,Chemical
-,O
associated,O
chest,Disease
pain,Disease
",",O
as,O
coronary,Disease
vasospasm,Disease
may,O
account,O
for,O
some,O
of,O
the,O
ischemia,Disease
.,O
Caffeine,Chemical
produced,O
significantly,O
greater,O
increases,O
in,O
subject,O
-,O
rated,O
anxiety,Disease
",",O
nervousness,O
",",O
fear,O
",",O
nausea,Disease
",",O
palpitations,Disease
",",O
restlessness,Disease
",",O
and,O
tremors,Disease
in,O
the,O
patients,O
compared,O
with,O
healthy,O
subjects,O
.,O
Subarachnoid,Disease
and,Disease
cerebral,Disease
hemorrhage,Disease
was,O
noted,O
in,O
18,O
%,O
of,O
the,O
hypertensive,Disease
rats,O
.,O
In,O
DOX,Chemical
B1R,O
(,O
-,O
/,O
-,O
),O
mice,O
",",O
cardiac,Disease
dysfunction,Disease
was,O
improved,O
compared,O
to,O
DOX,Chemical
control,O
mice,O
",",O
which,O
was,O
associated,O
with,O
normalization,O
of,O
the,O
bax,O
/,O
bcl,O
-,O
2,O
ratio,O
and,O
interleukin,O
6,O
",",O
as,O
well,O
as,O
AKT,O
activation,O
state,O
.,O
Effect,O
of,O
captopril,Chemical
on,O
pre,O
-,O
existing,O
and,O
aminonucleoside,Chemical
-,O
induced,O
proteinuria,Disease
in,O
spontaneously,O
hypertensive,Disease
rats,O
.,O
CASE,O
REPORT,O
:,O
A,O
62,O
-,O
year,O
-,O
old,O
Taiwanese,O
widow,O
with,O
bipolar,Disease
disorder,Disease
was,O
diagnosed,O
with,O
hepatocellular,Disease
carcinoma,Disease
at,O
age,O
60,O
.,O
Tremor,Disease
was,O
measured,O
simultaneously,O
by,O
two,O
independent,O
observers,O
.,O
The,O
plasticity,O
of,O
primary,O
motor,O
cortex,O
(,O
M1,O
),O
in,O
patients,O
with,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
(,O
PD,Disease
),O
and,O
levodopa,Chemical
-,O
induced,O
dyskinesias,Disease
(,O
LIDs,Disease
),O
is,O
severely,O
impaired,O
.,O
Animal,O
behavior,O
",",O
seizures,Disease
(,O
time,O
to,O
and,O
incidence,O
),O
",",O
death,O
(,O
time,O
to,O
and,O
incidence,O
),O
",",O
and,O
cortical,O
EEG,O
tracings,O
were,O
recorded,O
.,O
METHODS,O
:,O
A,O
review,O
of,O
admissions,O
during,O
a,O
6,O
-,O
year,O
period,O
revealed,O
14,O
patients,O
with,O
cocaine,Chemical
-,O
related,O
aneurysms,Disease
.,O
Survival,O
for,O
patients,O
with,O
advanced,O
head,Disease
and,Disease
neck,Disease
carcinoma,Disease
and,O
esophageal,Disease
carcinoma,Disease
is,O
poor,O
with,O
radiotherapy,O
and,O
/,O
or,O
surgery,O
.,O
Immunocytochemical,O
techniques,O
were,O
used,O
to,O
examine,O
alterations,O
in,O
the,O
expression,O
of,O
neuronal,O
nitric,Chemical
oxide,Chemical
synthase,O
(,O
NOS,O
),O
in,O
bladder,O
pathways,O
following,O
acute,O
and,O
chronic,O
irritation,Disease
of,Disease
the,Disease
urinary,Disease
tract,Disease
of,O
the,O
rat,O
.,O
We,O
report,O
on,O
an,O
infant,O
with,O
multiple,Disease
cranial,Disease
-,Disease
nerve,Disease
involvement,Disease
attributable,O
to,O
brainstem,Disease
dysgenesis,Disease
",",O
born,O
to,O
a,O
cocaine,Disease
-,Disease
addicted,Disease
mother,O
.,O
This,O
was,O
a,O
case,O
of,O
acute,O
palsy,Disease
of,O
the,O
recurrent,O
laryngeal,O
nerve,O
and,O
superimposed,O
severe,O
acute,O
sensorimotor,O
axonal,O
polyneuropathy,Disease
caused,O
by,O
high,O
-,O
dose,O
disulfiram,Chemical
intoxication,O
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
evaluate,O
the,O
cardioprotective,O
potential,O
of,O
salvianolic,Chemical
acid,Chemical
A,Chemical
on,O
isoproterenol,Chemical
-,O
induced,O
myocardial,Disease
infarction,Disease
in,O
rats,O
.,O
Histopathological,O
examination,O
revealed,O
many,O
lipophages,O
in,O
the,O
periorbital,O
fat,O
surrounding,O
the,O
optic,O
nerve,O
in,O
1,O
eye,O
",",O
indicative,O
of,O
phagocytosis,O
of,O
previously,O
existing,O
fat,O
cells,O
and,O
suggesting,O
prior,O
fat,O
necrosis,Disease
.,O
Microscopic,O
evaluation,O
revealed,O
that,O
treatment,O
with,O
DOX,Chemical
alone,O
induced,O
significant,O
cardiac,Disease
damage,Disease
in,O
comparison,O
to,O
the,O
saline,O
control,O
group,O
(,O
P,O
<,O
0,O
.,O
001,O
),O
.,O
The,O
rash,Disease
disappeared,O
after,O
three,O
weeks,O
and,O
renal,O
function,O
returned,O
to,O
normal,O
.,O
OBJECTIVE,O
:,O
We,O
wanted,O
to,O
test,O
whether,O
assessment,O
of,O
both,O
a,O
central,O
pain,Disease
-,O
related,O
signal,O
(,O
chemo,O
-,O
somatosensory,O
evoked,O
potential,O
",",O
CSSEP,O
),O
and,O
a,O
concomitantly,O
recorded,O
peripheral,O
signal,O
(,O
negative,O
mucosal,O
potential,O
",",O
NMP,O
),O
allows,O
for,O
separation,O
of,O
central,O
and,O
peripheral,O
effects,O
of,O
NSAIDs,O
.,O
Recently,O
",",O
we,O
demonstrated,O
the,O
hepatoprotective,O
effects,O
of,O
nicotinic,Chemical
acid,Chemical
amide,Chemical
",",O
a,O
selective,O
inhibitor,O
of,O
poly,Chemical
(,Chemical
ADP,Chemical
-,Chemical
ribose,Chemical
),Chemical
polymerase,O
(,O
PARP,O
;,O
EC,O
2,O
.,O
4,O
.,O
2,O
.,O
30,O
),O
on,O
mice,O
suffering,O
from,O
acetaminophen,Chemical
(,O
AAP,Chemical
),O
-,O
hepatitis,Disease
",",O
suggesting,O
that,O
the,O
AAP,Chemical
-,O
induced,O
liver,Disease
injury,Disease
involves,O
a,O
step,O
which,O
depends,O
on,O
adenoribosylation,O
.,O
Under,O
isoflurane,Chemical
anesthesia,O
",",O
the,O
MCA,O
of,O
14,O
spontaneously,O
hypertensive,Disease
rats,O
was,O
occluded,O
.,O
Myxedema,Disease
coma,Disease
is,O
a,O
life,O
threatening,O
condition,O
that,O
carries,O
a,O
mortality,O
reaching,O
as,O
high,O
as,O
20,O
%,O
with,O
treatment,O
.,O
Swallowing,Disease
abnormalities,Disease
and,O
dyskinesia,Disease
in,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
.,O
Given,O
the,O
seriousness,O
and,O
increasing,O
prevalence,O
of,O
adenovirus,Disease
disease,Disease
in,O
certain,O
hosts,O
",",O
especially,O
children,O
",",O
a,O
large,O
",",O
multicenter,O
clinical,O
trial,O
of,O
potentially,O
useful,O
anti,O
-,O
adenoviral,O
therapies,O
",",O
such,O
as,O
intravenous,O
ribavirin,Chemical
",",O
is,O
clearly,O
required,O
to,O
demonstrate,O
the,O
most,O
effective,O
and,O
least,O
toxic,O
therapy,O
.,O
Neurotoxicity,Disease
was,O
largely,O
moderate,O
.,O
This,O
is,O
the,O
first,O
reported,O
patient,O
with,O
neuroleptic,Disease
malignant,Disease
syndrome,Disease
probably,O
caused,O
by,O
methylphenidate,Chemical
.,O
Furosemide,Chemical
may,O
be,O
deleterious,O
in,O
the,O
prevention,O
of,O
radiocontrast,O
nephropathy,Disease
.,O
In,O
the,O
vitro,O
human,O
platelet,Disease
aggregations,Disease
induced,O
by,O
the,O
agonists,O
used,O
in,O
tests,O
",",O
TET,Chemical
and,O
FAN,Chemical
showed,O
the,O
inhibitions,O
dose,O
dependently,O
.,O
In,O
recent,O
years,O
",",O
evidence,O
from,O
animal,O
models,O
of,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
has,O
provided,O
important,O
information,O
to,O
understand,O
the,O
effect,O
of,O
specific,O
receptor,O
and,O
post,O
-,O
receptor,O
molecular,O
mechanisms,O
underlying,O
the,O
development,O
of,O
dyskinetic,Disease
movements,Disease
.,O
Possible,O
intramuscular,O
midazolam,Chemical
-,O
associated,O
cardiorespiratory,Disease
arrest,Disease
and,O
death,Disease
.,O
Recovery,O
of,O
tacrolimus,Chemical
-,O
associated,O
brachial,Disease
neuritis,Disease
after,O
conversion,O
to,O
everolimus,Chemical
in,O
a,O
pediatric,O
renal,O
transplant,O
recipient,O
-,O
-,O
case,O
report,O
and,O
review,O
of,O
the,O
literature,O
.,O
CONCLUSIONS,O
:,O
This,O
is,O
the,O
first,O
demonstration,O
of,O
multiple,O
symptoms,O
consistent,O
with,O
an,O
OCD,Disease
-,O
like,O
profile,O
in,O
animals,O
.,O
Effect,O
of,O
green,Chemical
tea,Chemical
and,O
vitamin,Chemical
E,Chemical
combination,O
in,O
isoproterenol,Chemical
induced,O
myocardial,Disease
infarction,Disease
in,O
rats,O
.,O
Our,O
in,O
vitro,O
and,O
in,O
vivo,O
results,O
suggest,O
that,O
incorporation,O
of,O
amphotericin,Chemical
B,Chemical
into,O
lipid,O
nanospheres,O
of,O
NS,O
-,O
718,O
attenuates,O
the,O
nephrotoxicity,Disease
of,O
amphotericin,Chemical
B,Chemical
.,O
The,O
selective,O
deficit,Disease
in,Disease
fear,Disease
recognition,Disease
accuracy,O
manifested,O
by,O
the,O
RC,O
group,O
cannot,O
be,O
explained,O
by,O
the,O
subacute,O
effects,O
of,O
cocaine,Chemical
",",O
or,O
ecstasy,Chemical
",",O
because,O
recent,O
and,O
less,O
recent,O
users,O
of,O
these,O
drugs,O
within,O
this,O
group,O
were,O
similarly,O
impaired,O
.,O
Our,O
data,O
indicate,O
that,O
ER,O
stress,O
contributes,O
to,O
glucocorticoid,O
-,O
induced,O
ocular,Disease
hypertension,Disease
and,O
suggest,O
that,O
reducing,O
ER,O
stress,O
has,O
potential,O
as,O
a,O
therapeutic,O
strategy,O
for,O
treating,O
glucocorticoid,O
-,O
induced,O
glaucoma,Disease
.,O
Bpd,Chemical
was,O
administered,O
to,O
459,O
patients,O
(,O
361,O
males,O
",",O
63,O
+,O
/,O
-,O
12,O
years,O
old,O
),O
comprising,O
378,O
AF,Disease
and,O
81,O
AFL,Disease
cases,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
venlafaxine,Chemical
overdose,Disease
.,O
Previously,O
recognized,O
side,O
effects,O
",",O
particularly,O
tremor,Disease
and,O
gastrointestinal,Disease
problems,Disease
",",O
were,O
more,O
frequent,O
in,O
the,O
mexiletine,Chemical
group,O
than,O
in,O
the,O
placebo,O
group,O
.,O
Polymyositis,Disease
/,O
dermatomyositis,Disease
can,O
develop,O
as,O
one,O
of,O
the,O
autoimmune,O
complications,O
of,O
D,Chemical
-,Chemical
penicillamine,Chemical
treatment,O
",",O
but,O
its,O
exact,O
pathogenesis,O
remains,O
unclear,O
.,O
Spontaneous,O
pain,Disease
behaviors,O
following,O
the,O
administration,O
of,O
CYP,Chemical
were,O
observed,O
.,O
Differential,O
diagnosis,O
of,O
high,O
serum,O
creatine,Chemical
kinase,O
levels,O
in,O
systemic,Disease
lupus,Disease
erythematosus,Disease
.,O
However,O
",",O
the,O
increased,O
rearings,O
and,O
the,O
amphetamine,Chemical
-,O
induced,O
stereotypies,Disease
were,O
not,O
blocked,O
by,O
pretreatment,O
with,O
DSP4,Chemical
.,O
Results,O
show,O
that,O
cumulative,O
HAART,O
caused,O
mitochondrial,O
CM,Disease
with,O
elevated,O
LA,Chemical
in,O
AIDS,Disease
transgenic,O
mice,O
.,O
Bortezomib,Chemical
(,O
bort,Chemical
),O
-,O
dexamethasone,Chemical
(,O
dex,Chemical
),O
is,O
an,O
effective,O
therapy,O
for,O
relapsed,O
/,O
refractory,O
(,O
R,O
/,O
R,O
),O
multiple,Disease
myeloma,Disease
(,O
MM,Disease
),O
.,O
We,O
postulate,O
that,O
both,O
LID,Disease
and,O
grip,O
force,O
excess,O
share,O
common,O
pathophysiological,O
mechanisms,O
related,O
to,O
motor,O
fluctuations,O
.,O
Preclinical,O
murine,O
studies,O
demonstrated,O
that,O
the,O
toxicity,Disease
of,O
lometrexol,Chemical
can,O
be,O
prevented,O
by,O
low,O
dose,O
folic,Chemical
acid,Chemical
administration,O
",",O
i,O
.,O
e,O
.,O
for,O
7,O
days,O
prior,O
to,O
and,O
7,O
days,O
following,O
a,O
single,O
bolus,O
dose,O
.,O
Milk,Disease
-,Disease
alkali,Disease
syndrome,Disease
induced,O
by,O
1,Chemical
",",Chemical
25,Chemical
(,Chemical
OH,Chemical
),Chemical
2D,Chemical
in,O
a,O
patient,O
with,O
hypoparathyroidism,Disease
.,O
Short,O
-,O
term,O
use,O
of,O
steroid,Chemical
is,O
very,O
effective,O
in,O
ATRA,Chemical
-,O
induced,O
erythema,Disease
nodosum,Disease
.,O
CONCLUSIONS,O
:,O
Supratherapeutic,O
flecainide,Chemical
plasma,O
concentrations,O
may,O
cause,O
delirium,Disease
.,O
Lindane,Chemical
(,O
gamma,Chemical
-,Chemical
hexachlorocyclohexane,Chemical
),O
is,O
an,O
organochlorine,O
insecticide,O
with,O
known,O
neurotoxic,Disease
effects,O
.,O
AIM,O
:,O
To,O
study,O
the,O
effects,O
of,O
testosterone,Chemical
on,O
streptozotocin,Chemical
(,O
STZ,Chemical
),O
-,O
induced,O
memory,Disease
impairment,Disease
in,O
male,O
rats,O
.,O
All,O
of,O
the,O
rats,O
in,O
the,O
saline,O
-,O
treated,O
epileptic,Disease
control,O
group,O
developed,O
SRS,Disease
",",O
whereas,O
none,O
of,O
the,O
BMC,O
-,O
treated,O
epileptic,Disease
animals,O
had,O
seizures,Disease
in,O
the,O
short,O
term,O
(,O
15,O
days,O
after,O
transplantation,O
),O
",",O
regardless,O
of,O
the,O
BMC,O
source,O
.,O
As,O
no,O
other,O
medications,O
known,O
to,O
effect,O
serum,O
potassium,Chemical
had,O
been,O
given,O
concomitantly,O
",",O
this,O
course,O
of,O
events,O
is,O
suggestive,O
of,O
a,O
cause,O
-,O
and,O
-,O
effect,O
relationship,O
between,O
sulindac,Chemical
and,O
hyperkalemia,Disease
.,O
RESULTS,O
:,O
The,O
cumulative,O
incidence,O
of,O
persistent,O
sterile,O
leukocyturia,Disease
(,O
>,O
or,O
=,O
75,O
cells,O
/,O
micro,O
L,O
in,O
at,O
least,O
2,O
consecutive,O
visits,O
),O
after,O
96,O
weeks,O
was,O
53,O
%,O
.,O
Co,O
-,O
morbid,O
major,O
depressive,Disease
disorder,Disease
(,O
OR,O
=,O
7,O
.,O
18,O
",",O
95,O
CI,O
=,O
2,O
.,O
612,O
-,O
19,O
.,O
708,O
),O
",",O
bipolar,Disease
disorder,Disease
(,O
OR,O
=,O
13,O
.,O
807,O
",",O
95,O
CI,O
=,O
5,O
.,O
194,O
-,O
36,O
.,O
706,O
),O
",",O
antisocial,Disease
personality,Disease
disorder,Disease
(,O
OR,O
=,O
12,O
.,O
619,O
",",O
95,O
CI,O
=,O
6,O
.,O
702,O
-,O
23,O
.,O
759,O
),O
and,O
heavy,O
methamphetamine,Chemical
uses,O
were,O
significantly,O
associated,O
with,O
lifetime,O
methamphetamine,Chemical
-,O
induced,O
psychosis,Disease
after,O
adjusted,O
for,O
other,O
factors,O
.,O
OBJECTIVE,O
:,O
There,O
are,O
several,O
complications,O
associated,O
with,O
heroin,Disease
abuse,Disease
",",O
some,O
of,O
which,O
are,O
life,O
-,O
threatening,O
.,O
In,O
addition,O
",",O
there,O
is,O
convincing,O
clinical,O
evidence,O
that,O
monotherapy,O
with,O
continuous,O
subcutaneous,O
apomorphine,Chemical
infusions,O
is,O
associated,O
with,O
marked,O
reductions,O
of,O
preexisting,O
levodopa,Chemical
-,O
induced,O
dyskinesias,Disease
.,O
We,O
wanted,O
to,O
study,O
whether,O
tAMCA,Chemical
retains,O
its,O
convulsive,Disease
action,O
if,O
incorporated,O
into,O
a,O
FS,O
.,O
To,O
evaluate,O
amikacin,Chemical
-,O
associated,O
nephrotoxicity,Disease
in,O
an,O
adult,O
hematology,O
/,O
oncology,O
population,O
",",O
a,O
prospective,O
",",O
randomized,O
",",O
open,O
-,O
label,O
trial,O
was,O
conducted,O
at,O
a,O
university,O
-,O
affiliated,O
medical,O
center,O
.,O
Amiodarone,Chemical
is,O
an,O
effective,O
antiarrhythmic,O
agent,O
whose,O
utility,O
is,O
limited,O
by,O
many,O
side,O
-,O
effects,O
",",O
the,O
most,O
problematic,O
being,O
pneumonitis,Disease
.,O
Protective,O
effects,O
of,O
antithrombin,O
on,O
puromycin,Chemical
aminonucleoside,Chemical
nephrosis,Disease
in,O
rats,O
.,O
Immunological,O
activation,O
has,O
been,O
proposed,O
to,O
play,O
a,O
role,O
in,O
methamphetamine,Chemical
-,O
induced,O
dopaminergic,Disease
terminal,Disease
damage,Disease
.,O
Thirty,O
-,O
four,O
patients,O
with,O
juvenile,Disease
rheumatoid,Disease
arthritis,Disease
",",O
who,O
were,O
treated,O
with,O
flurbiprofen,Chemical
at,O
a,O
maximum,O
dose,O
of,O
4,O
mg,O
/,O
kg,O
/,O
day,O
",",O
had,O
statistically,O
significant,O
decreases,O
from,O
baseline,O
in,O
6,O
arthritis,Disease
indices,O
after,O
12,O
weeks,O
of,O
treatment,O
.,O
A,O
new,O
infarct,Disease
-,O
avid,O
radiopharmaceutical,O
based,O
on,O
glucaric,Chemical
acid,Chemical
was,O
prepared,O
in,O
the,O
hospital,O
radiopharmacy,O
of,O
the,O
INCMNSZ,O
.,O
We,O
therefore,O
hypothesized,O
that,O
overexpression,O
of,O
Cu,Chemical
/,O
Zn,Chemical
-,O
superoxide,Chemical
dismutase,O
(,O
h,O
-,O
SOD1,O
),O
should,O
protect,O
transgenic,O
mice,O
from,O
ototoxicity,Disease
.,O
Thus,O
",",O
temsirolimus,Chemical
reduced,O
tumor,Disease
burden,O
through,O
associated,O
cytostatic,O
and,O
anti,O
-,O
angiogenic,O
effects,O
.,O
This,O
dual,O
effect,O
of,O
temsirolimus,Chemical
on,O
tumor,Disease
tissue,O
could,O
contribute,O
to,O
its,O
recently,O
reported,O
efficiency,O
in,O
refractory,O
MCL,Disease
resistant,O
to,O
conventional,O
chemotherapy,O
.,O
After,O
stopping,O
the,O
beta,O
-,O
agonist,O
",",O
and,O
after,O
a,O
week,O
with,O
the,O
atenolol,Chemical
",",O
the,O
arrhythmia,Disease
disappeared,O
.,O
Aged,O
GF,O
Sprague,O
-,O
Dawley,O
(,O
SD,O
),O
rats,O
have,O
not,O
developed,O
prostate,Disease
cancer,Disease
spontaneously,O
.,O
These,O
results,O
demonstrate,O
that,O
",",O
in,O
these,O
experimental,O
conditions,O
",",O
DXNP,O
killed,O
less,O
animals,O
than,O
free,O
DX,Chemical
",",O
despite,O
of,O
an,O
enhanced,O
renal,Disease
toxicity,Disease
of,O
the,O
former,O
.,O
Heparan,Chemical
sulphate,Chemical
-,O
associated,O
anionic,O
sites,O
in,O
the,O
glomerular,O
basement,O
membrane,O
were,O
studied,O
in,O
rats,O
8,O
months,O
after,O
induction,O
of,O
diabetes,Disease
by,O
streptozotocin,Chemical
and,O
in,O
age,O
-,O
adn,O
sex,O
-,O
matched,O
control,O
rats,O
",",O
employing,O
the,O
cationic,O
dye,O
cuprolinic,Chemical
blue,Chemical
.,O
We,O
describe,O
a,O
case,O
of,O
neuroleptic,Disease
malignant,Disease
syndrome,Disease
(,O
NMS,Disease
),O
associated,O
with,O
the,O
use,O
of,O
ziprasidone,Chemical
.,O
In,O
TD,O
group,O
",",O
three,O
patients,O
developed,O
decreased,Disease
auditory,Disease
function,Disease
",",O
of,O
which,O
one,O
presented,O
with,O
an,O
auditory,Disease
loss,Disease
of,O
-,O
30,O
dB,O
",",O
whereas,O
in,O
the,O
OD,O
group,O
only,O
one,O
patient,O
presented,O
decreased,Disease
auditory,Disease
function,Disease
.,O
Downbeat,Disease
nystagmus,Disease
is,O
often,O
associated,O
with,O
structural,O
lesions,O
at,O
the,O
craniocervical,O
junction,O
",",O
but,O
has,O
occasionally,O
been,O
reported,O
as,O
a,O
manifestation,O
of,O
metabolic,O
imbalance,O
or,O
drug,O
intoxication,O
.,O
In,O
bladder,O
afferent,O
cells,O
in,O
DRG,O
",",O
p75,O
(,O
NTR,O
),O
-,O
IR,O
was,O
also,O
increased,O
(,O
P,O
<,O
or,O
=,O
0,O
.,O
01,O
),O
with,O
cystitis,Disease
.,O
After,O
hypotension,Disease
there,O
was,O
no,O
rebound,O
phenomenon,O
in,O
either,O
blood,O
pressure,O
or,O
heart,O
rate,O
.,O
Rhabdomyolysis,Disease
in,O
association,O
with,O
simvastatin,Chemical
and,O
dosage,O
increment,O
in,O
clarithromycin,Chemical
.,O
Intracranial,Disease
aneurysms,Disease
or,O
arteriovenous,Disease
malformations,Disease
were,O
present,O
in,O
17,O
of,O
32,O
patients,O
studied,O
angiographically,O
or,O
at,O
autopsy,O
;,O
cerebral,Disease
vasculitis,Disease
was,O
present,O
in,O
two,O
patients,O
.,O
Nociceptin,Chemical
/,O
orphanin,Chemical
FQ,Chemical
and,O
nocistatin,Chemical
on,O
learning,Disease
and,Disease
memory,Disease
impairment,Disease
induced,O
by,O
scopolamine,Chemical
in,O
mice,O
.,O
The,O
clinically,O
apparent,O
occlusion,O
may,O
be,O
preceded,O
by,O
gastrointestinal,Disease
and,Disease
musculoskeletal,Disease
symptoms,Disease
that,O
appear,O
to,O
be,O
ischemic,Disease
in,O
origin,O
",",O
and,O
might,O
serve,O
to,O
warn,O
the,O
clinician,O
of,O
these,O
complications,O
.,O
CONCLUSIONS,O
:,O
Hypersensitivity,Disease
myocarditis,Disease
is,O
a,O
rare,O
and,O
dangerous,O
manifestation,O
of,O
allergy,Disease
to,O
penicillins,Chemical
.,O
Antiandrogenic,O
therapy,O
can,O
cause,O
coronary,Disease
arterial,Disease
disease,Disease
.,O
She,O
also,O
had,O
advanced,O
breast,Disease
cancer,Disease
when,O
the,O
combination,O
therapy,O
was,O
initiated,O
.,O
AZT,Chemical
has,O
induced,O
a,O
macrocytic,Disease
anemia,Disease
in,O
AIDS,Disease
patients,O
on,O
long,O
term,O
AZT,Chemical
therapy,O
.,O
We,O
studied,O
two,O
groups,O
of,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
patients,O
with,O
(,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
+,O
LID,Disease
",",O
n,O
=,O
23,O
),O
and,O
without,O
levodopa,Chemical
-,O
induced,O
dyskinesias,Disease
(,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
-,O
LID,Disease
",",O
n,O
=,O
10,O
),O
",",O
and,O
age,O
-,O
matched,O
healthy,O
controls,O
.,O
The,O
ECG,O
showed,O
a,O
junctional,O
rhythm,O
without,O
ventricular,Disease
arrhythmia,Disease
.,O
Paclitaxel,Chemical
/,O
cisplatin,Chemical
is,O
an,O
effective,O
first,O
-,O
line,O
regimen,O
for,O
locoregionally,O
advanced,O
head,Disease
and,Disease
neck,Disease
cancer,Disease
and,O
continued,O
study,O
is,O
warranted,O
.,O
In,O
phase,O
A,O
",",O
extrapyramidal,Disease
signs,Disease
tended,O
to,O
be,O
greater,O
with,O
the,O
standard,O
dose,O
than,O
in,O
the,O
other,O
two,O
conditions,O
",",O
primarily,O
because,O
of,O
a,O
subgroup,O
(,O
20,O
%,O
),O
who,O
developed,O
moderate,O
to,O
severe,O
signs,O
.,O
She,O
reported,O
her,O
use,O
of,O
methamphetamine,Chemical
for,O
five,O
years,O
and,O
had,O
not,O
experienced,O
any,O
major,O
carious,Disease
episodes,Disease
before,O
she,O
started,O
using,O
the,O
drug,O
.,O
As,O
inhibitors,O
of,O
isolated,O
L1210,O
TS,O
",",O
CB,O
3717,O
di,O
-,O
",",O
tri,O
-,O
",",O
tetra,O
-,O
and,O
pentaglutamate,O
are,O
26,O
-,O
",",O
87,O
-,O
",",O
119,O
-,O
and,O
114,O
-,O
fold,O
more,O
potent,O
than,O
CB,Chemical
3717,Chemical
",",O
respectively,O
",",O
and,O
their,O
formation,O
may,O
",",O
therefore,O
",",O
be,O
an,O
important,O
determinant,O
of,O
CB,Chemical
3717,Chemical
cytotoxicity,Disease
.,O
Reserpine,Chemical
also,O
produced,O
tremor,Disease
and,O
catalepsy,Disease
",",O
which,O
are,O
signs,O
suggestive,O
of,O
Parkinson,Disease
',Disease
s,Disease
disease,Disease
.,O
Continuous,O
infusion,O
tobramycin,Chemical
combined,O
with,O
carbenicillin,Chemical
for,O
infections,Disease
in,O
cancer,Disease
patients,O
.,O
MAIN,O
OUTCOME,O
MEASURES,O
:,O
Fasting,O
plasma,O
glucose,Chemical
and,O
fasting,O
serum,O
insulin,O
levels,O
",",O
insulin,Disease
sensitivity,Disease
index,O
",",O
homeostasis,O
model,O
assessment,O
of,O
insulin,Disease
resistance,Disease
",",O
and,O
glucose,Chemical
effectiveness,O
.,O
T,Chemical
alone,O
had,O
no,O
effect,O
on,O
locomotion,O
",",O
irritability,Disease
",",O
or,O
sexual,O
behavior,O
but,O
increased,O
partner,O
preference,O
and,O
aggression,Disease
.,O
Microinjection,O
of,O
ritanserin,Chemical
into,O
the,O
CA1,O
region,O
of,O
hippocampus,O
improves,O
scopolamine,Chemical
-,O
induced,O
amnesia,Disease
in,O
adult,O
male,O
rats,O
.,O
RESULTS,O
:,O
The,O
incidence,O
and,O
severity,O
of,O
visible,O
muscle,Disease
fasciculation,Disease
was,O
significantly,O
less,O
with,O
increasing,O
the,O
amount,O
of,O
precurarizing,O
dose,O
of,O
rocuronium,Chemical
(,O
P,O
<,O
0,O
.,O
001,O
),O
.,O
Myelosuppression,Disease
was,O
more,O
in,O
patients,O
with,O
hepatic,Disease
dysfunction,Disease
.,O
Rats,O
were,O
given,O
a,O
single,O
dose,O
of,O
adriamycin,Chemical
and,O
one,O
month,O
later,O
divided,O
into,O
four,O
groups,O
matched,O
for,O
albuminuria,Disease
",",O
blood,O
pressure,O
",",O
and,O
plasma,O
albumin,O
concentration,O
.,O
INTERPRETATION,O
:,O
Tranexamic,Chemical
acid,Chemical
retains,O
its,O
convulsive,Disease
action,O
within,O
FS,O
.,O
Histopathological,O
examination,O
of,O
the,O
kidney,O
showed,O
tubular,Disease
necrosis,Disease
in,O
D,Chemical
-,Chemical
AmB,Chemical
-,O
treated,O
rats,O
but,O
no,O
change,O
in,O
NS,O
-,O
718,O
-,O
treated,O
rats,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
We,O
conducted,O
a,O
prospective,O
surveillance,O
study,O
on,O
patients,O
diagnosed,O
with,O
pulmonary,Disease
hypertension,Disease
at,O
12,O
large,O
referral,O
centers,O
in,O
North,O
America,O
.,O
The,O
impact,O
of,O
immune,O
-,O
mediated,O
heparin,Chemical
-,O
induced,O
thrombocytopenia,Disease
type,Disease
II,Disease
(,O
HIT,Disease
type,Disease
II,Disease
),O
as,O
a,O
cause,O
of,O
thrombocytopenia,Disease
after,O
liver,O
transplantation,O
is,O
not,O
yet,O
understood,O
",",O
with,O
few,O
literature,O
citations,O
reporting,O
contradictory,O
results,O
.,O
Apparent,O
clinical,O
success,O
in,O
the,O
treatment,O
of,O
severe,O
adenovirus,Disease
disease,Disease
is,O
limited,O
to,O
a,O
few,O
case,O
reports,O
and,O
small,O
series,O
.,O
Pretreatment,O
with,O
ammonium,Chemical
acetate,Chemical
(,O
NH4Ac,Chemical
),O
(,O
6,O
mmol,O
/,O
kg,O
s,O
.,O
c,O
.,O
),O
approximately,O
doubled,O
the,O
time,O
morphine,Chemical
-,O
treated,O
mice,O
remained,O
on,O
a,O
hot,O
surface,O
and,O
similarly,O
increased,O
muscular,O
incoordination,Disease
by,O
diazepam,Chemical
",",O
but,O
NH4Ac,Chemical
treatment,O
alone,O
had,O
no,O
effect,O
.,O
Patients,O
who,O
are,O
given,O
this,O
drug,O
regimen,O
should,O
be,O
observed,O
very,O
carefully,O
for,O
early,O
signs,O
of,O
nephrotoxicity,Disease
.,O
In,O
the,O
present,O
case,O
",",O
complete,O
atrioventricular,Disease
(,Disease
AV,Disease
),Disease
block,Disease
with,O
syncopal,Disease
attacks,Disease
developed,O
secondary,O
to,O
lithium,Chemical
therapy,O
",",O
necessitating,O
permanent,O
pacemaker,O
implantation,O
.,O
The,O
effect,O
of,O
treatment,O
with,O
gum,Chemical
Arabic,Chemical
on,O
gentamicin,Chemical
nephrotoxicity,Disease
in,O
rats,O
:,O
a,O
preliminary,O
study,O
.,O
The,O
administration,O
of,O
FR,Chemical
139317,Chemical
(,O
10,O
mg,O
.,O
kg,O
-,O
1,O
.,O
d,O
-,O
1,O
),O
prevented,O
FK,Chemical
506,Chemical
-,O
induced,O
hypertension,Disease
in,O
rats,O
.,O
The,O
patient,O
had,O
no,O
apparent,O
associated,O
conditions,O
which,O
might,O
have,O
predisposed,O
him,O
to,O
the,O
development,O
of,O
bradyarrhythmias,Disease
;,O
and,O
",",O
thus,O
",",O
this,O
probably,O
represented,O
a,O
true,O
idiosyncrasy,O
to,O
lidocaine,Chemical
.,O
Surreptitious,O
diuretic,O
ingestion,O
has,O
been,O
described,O
",",O
mainly,O
in,O
women,O
who,O
are,O
concerned,O
that,O
they,O
are,O
obese,Disease
or,O
edematous,Disease
.,O
The,O
effects,O
of,O
the,O
adjunctive,O
bupropion,Chemical
on,O
male,O
sexual,Disease
dysfunction,Disease
induced,O
by,O
a,O
selective,Chemical
serotonin,Chemical
reuptake,Chemical
inhibitor,Chemical
:,O
a,O
double,O
-,O
blind,O
placebo,O
-,O
controlled,O
and,O
randomized,O
study,O
.,O
Hemoglobin,O
concentrations,O
decrease,O
mainly,O
as,O
a,O
result,O
of,O
ribavirin,Chemical
-,O
induced,O
hemolysis,Disease
",",O
and,O
this,O
anemia,Disease
can,O
be,O
problematic,O
in,O
patients,O
with,O
HCV,Disease
infection,Disease
",",O
especially,O
those,O
who,O
have,O
comorbid,O
renal,Disease
or,Disease
cardiovascular,Disease
disorders,Disease
.,O
The,O
impairment,Disease
of,Disease
the,Disease
renal,Disease
function,Disease
in,O
these,O
children,O
occurred,O
in,O
the,O
absence,O
of,O
clinical,O
symptoms,O
of,O
nephrolithiasis,Disease
.,O
Investigation,O
of,O
more,O
specific,O
anti,O
-,O
inflammatory,O
agents,O
and,O
hemodiluting,O
agents,O
are,O
warranted,O
in,O
intracerebral,Disease
hemorrhage,Disease
.,O
Fatal,O
aplastic,Disease
anemia,Disease
due,O
to,O
indomethacin,Chemical
-,O
-,O
lymphocyte,O
transformation,O
tests,O
in,O
vitro,O
.,O
Patients,O
treated,O
with,O
alkylating,Chemical
agents,Chemical
have,O
an,O
increased,O
risk,O
of,O
development,O
of,O
acute,Disease
nonlymphocytic,Disease
leukemia,Disease
",",O
and,O
both,O
alkylating,Chemical
agents,Chemical
and,O
azathioprine,Chemical
are,O
associated,O
with,O
the,O
development,O
of,O
non,Disease
-,Disease
Hodgkin,Disease
',Disease
s,Disease
lymphoma,Disease
.,O
These,O
immunohistochemical,O
changes,O
of,O
NFs,O
can,O
serve,O
as,O
a,O
marker,O
for,O
axonal,Disease
damage,Disease
in,O
various,O
experimental,O
traumatic,Disease
or,O
ischemic,O
lesions,O
.,O
METHODS,O
:,O
Consecutive,O
AL,Disease
patients,O
who,O
underwent,O
PBSCT,O
were,O
studied,O
retrospectively,O
.,O
RAD001,Chemical
",",O
an,O
oral,O
inhibitor,O
of,O
the,O
mammalian,O
target,O
of,O
rapamycin,Chemical
(,O
mTOR,O
),O
",",O
has,O
shown,O
phase,O
I,O
efficacy,O
in,O
NSCLC,Disease
.,O
The,O
operating,O
conditions,O
regarding,O
bleeding,Disease
were,O
estimated,O
in,O
a,O
double,O
-,O
blind,O
manner,O
",",O
and,O
did,O
not,O
differ,O
significantly,O
between,O
the,O
groups,O
.,O
Despite,O
treatment,O
",",O
the,O
children,O
continued,O
to,O
have,O
choreoathetosis,Disease
for,O
approximately,O
24,O
hours,O
.,O
Anaesthetic,O
complications,O
associated,O
with,O
myotonia,Disease
congenita,Disease
:,O
case,O
study,O
and,O
comparison,O
with,O
other,O
myotonic,Disease
disorders,Disease
.,O
Intracavitary,O
chemotherapy,O
(,O
paclitaxel,Chemical
/,O
carboplatin,Chemical
liquid,O
crystalline,O
cubic,O
phases,O
),O
for,O
recurrent,O
glioblastoma,Disease
-,O
-,O
clinical,O
observations,O
.,O
METHODS,O
:,O
The,O
son,O
of,O
an,O
84,O
-,O
year,O
-,O
old,O
male,O
discovered,O
a,O
newspaper,O
report,O
stating,O
clinical,O
success,O
with,O
plant,O
extracts,O
in,O
Alzheimer,Disease
',Disease
s,Disease
disease,Disease
.,O
We,O
hypothesized,O
that,O
cocaine,Disease
abuse,Disease
may,O
lead,O
to,O
altered,O
mitochondrial,O
function,O
that,O
in,O
turn,O
may,O
cause,O
left,Disease
ventricular,Disease
dysfunction,Disease
.,O
Improvement,O
by,O
denopamine,Chemical
(,O
TA,Chemical
-,Chemical
064,Chemical
),O
of,O
pentobarbital,Chemical
-,O
induced,O
cardiac,Disease
failure,Disease
in,O
the,O
dog,O
heart,O
-,O
lung,O
preparation,O
.,O
Despite,O
administration,O
of,O
phenytoin,Chemical
and,O
lorazepam,Chemical
",",O
the,O
seizures,Disease
persisted,O
and,O
occurred,O
only,O
during,O
amphotercin,Chemical
B,Chemical
administration,O
.,O
Cystitis,Disease
was,O
evaluated,O
24,O
h,O
after,O
its,O
induction,O
by,O
the,O
changes,O
in,O
bladder,O
wet,O
weight,O
and,O
by,O
macroscopic,O
and,O
microscopic,O
analysis,O
.,O
Evidence,O
of,O
peripheral,Disease
sensory,Disease
neuropathy,Disease
was,O
found,O
in,O
nine,O
of,O
13,O
men,O
before,O
treatment,O
.,O
Empirical,O
treatment,O
with,O
intravenous,O
calcium,Chemical
gluconate,Chemical
was,O
initiated,O
",",O
and,O
muscle,Disease
contractions,Disease
slowly,O
subsided,O
over,O
approximately,O
10,O
to,O
15,O
minutes,O
.,O
Different,O
lobular,O
distributions,O
of,O
altered,O
hepatocyte,O
tight,O
junctions,O
in,O
rat,O
models,O
of,O
intrahepatic,Disease
and,Disease
extrahepatic,Disease
cholestasis,Disease
.,O
Of,O
these,O
recurrences,O
",",O
27,O
were,O
T1,O
tumors,Disease
while,O
five,O
progressed,O
to,O
more,O
highly,O
invasive,O
lesions,O
.,O
In,O
vivo,O
evidences,O
suggesting,O
the,O
role,O
of,O
oxidative,O
stress,O
in,O
pathogenesis,O
of,O
vancomycin,Chemical
-,O
induced,O
nephrotoxicity,Disease
:,O
protection,O
by,O
erdosteine,Chemical
.,O
In,O
all,O
patients,O
with,O
variant,Disease
angina,Disease
",",O
coronary,Disease
spasm,Disease
was,O
provoked,O
at,O
a,O
mean,O
dose,O
of,O
28,O
+,O
/,O
-,O
13,O
micrograms,O
(,O
mean,O
+,O
/,O
-,O
SD,O
),O
.,O
Cerebral,Disease
haemorrhage,Disease
induced,O
by,O
warfarin,Chemical
-,O
the,O
influence,O
of,O
drug,O
-,O
drug,O
interactions,O
.,O
Paclitaxel,Chemical
and,O
5,Chemical
-,Chemical
fluorouracil,Chemical
have,O
additive,O
cytotoxicity,Disease
in,O
MCF,O
-,O
7,O
cell,O
lines,O
.,O
Recently,O
",",O
we,O
found,O
that,O
therapy,O
with,O
selegiline,Chemical
and,O
L,Chemical
-,Chemical
dopa,Chemical
was,O
associated,O
with,O
selective,O
systolic,Disease
orthostatic,Disease
hypotension,Disease
which,O
was,O
abolished,O
by,O
withdrawal,O
of,O
selegiline,Chemical
.,O
Leg,Disease
and,Disease
back,Disease
pain,Disease
after,O
spinal,O
anaesthesia,O
involving,O
hyperbaric,O
5,O
%,O
lignocaine,Chemical
.,O
CASE,O
SUMMARY,O
:,O
A,O
68,O
-,O
year,O
-,O
old,O
white,O
woman,O
with,O
Candida,O
glabrata,O
isolated,O
from,O
a,O
presacral,O
abscess,O
developed,O
TDP,Disease
eight,O
days,O
after,O
commencing,O
oral,O
fluconazole,Chemical
The,O
patient,O
had,O
no,O
other,O
risk,O
factors,O
for,O
TDP,Disease
",",O
including,O
coronary,Disease
artery,Disease
disease,Disease
",",O
cardiomyopathy,Disease
",",O
congestive,Disease
heart,Disease
failure,Disease
",",O
and,O
electrolyte,O
abnormalities,O
There,O
was,O
a,O
temporal,O
association,O
between,O
the,O
initiation,O
of,O
fluconazole,Chemical
and,O
TDP,Disease
.,O
Anesthetized,O
rats,O
received,O
the,O
tricyclic,O
antidepressant,O
desipramine,Chemical
IP,O
to,O
produce,O
hypotension,Disease
",",O
QRS,O
prolongation,O
",",O
and,O
bradycardia,Disease
.,O
Heavy,O
proteinuria,Disease
was,O
common,O
after,O
the,O
use,O
of,O
SRL,Chemical
as,O
rescue,O
therapy,O
for,O
renal,O
transplantation,O
.,O
Second,O
",",O
we,O
investigated,O
the,O
effect,O
of,O
IT,O
MK,Chemical
-,Chemical
801,Chemical
(,O
30,O
mug,O
),O
on,O
the,O
histopathologic,O
changes,O
in,O
the,O
spinal,O
cord,O
after,O
morphine,Chemical
-,O
induced,O
spastic,Disease
paraparesis,Disease
.,O
Consistent,O
with,O
other,O
reports,O
this,O
case,O
of,O
TdP,Disease
occurred,O
in,O
the,O
context,O
of,O
multiple,O
exacerbating,O
factors,O
including,O
hypokalemia,Disease
and,O
digoxin,Chemical
excess,O
.,O
Piperacillin,Chemical
-,O
induced,O
encephalopathy,Disease
should,O
be,O
considered,O
in,O
any,O
uremic,Disease
patients,O
with,O
unexplained,O
neurological,O
manifestations,O
.,O
The,O
protective,O
role,O
of,O
salvianolic,Chemical
acid,Chemical
A,Chemical
against,O
isoproterenol,Chemical
-,O
induced,O
myocardial,Disease
damage,Disease
was,O
further,O
confirmed,O
by,O
histopathological,O
examination,O
.,O
Both,O
",",O
Ro4368554,Chemical
(,O
3,O
and,O
10,O
mg,O
/,O
kg,O
",",O
intraperitoneally,O
(,O
i,O
.,O
p,O
.,O
),O
),O
and,O
metrifonate,Chemical
(,O
10,O
mg,O
/,O
kg,O
",",O
p,O
.,O
o,O
.,O
",",O
respectively,O
),O
reversed,O
memory,Disease
deficits,Disease
induced,O
by,O
scopolamine,Chemical
and,O
TRP,Chemical
depletion,O
(,O
10,O
mg,O
/,O
kg,O
",",O
i,O
.,O
p,O
.,O
",",O
and,O
3,O
mg,O
/,O
kg,O
",",O
p,O
.,O
o,O
.,O
",",O
respectively,O
),O
.,O
D,Chemical
-,Chemical
penicillamine,Chemical
-,O
induced,O
angiopathy,Disease
in,O
rats,O
.,O
This,O
study,O
was,O
conducted,O
to,O
examine,O
whether,O
prolonged,O
pretreatment,O
with,O
isoproterenol,Chemical
could,O
abolish,O
bromocriptine,Chemical
-,O
induced,O
tachycardia,Disease
in,O
conscious,O
rats,O
.,O
Single,O
dose,O
of,O
DOX,Chemical
was,O
associated,O
with,O
increased,O
cardiac,Disease
disarrangement,Disease
",",O
necrosis,Disease
",",O
and,O
DNA,O
damage,O
(,O
strand,O
breaks,O
(,O
SBs,O
),O
and,O
oxidized,O
pyrimidines,O
),O
and,O
decreased,O
TAP,O
.,O
Tranexamic,Chemical
acid,Chemical
(,O
TNA,Chemical
),O
1,O
g,O
8,O
-,O
hourly,O
was,O
administered,O
to,O
her,O
to,O
control,O
bleeding,Disease
per,O
vaginum,O
.,O
Sensitivities,O
",",O
specificities,O
",",O
and,O
positive,O
and,O
negative,O
likelihood,O
ratios,O
for,O
predicting,O
cardiac,Disease
death,Disease
or,O
significant,O
disease,O
were,O
high,O
for,O
both,O
CK,O
-,O
MB,O
MI,Disease
and,O
cTnI,O
and,O
were,O
not,O
significantly,O
different,O
.,O
Late,O
recovery,O
of,O
renal,O
function,O
in,O
a,O
woman,O
with,O
the,O
hemolytic,Disease
uremic,Disease
syndrome,Disease
.,O
Effect,O
of,O
intravenous,O
metoprolol,Chemical
or,O
intravenous,O
metoprolol,Chemical
plus,O
glucagon,O
on,O
dobutamine,Chemical
-,O
induced,O
myocardial,Disease
ischemia,Disease
.,O
Histopathological,O
examination,O
of,O
kidney,O
",",O
heart,O
and,O
lung,O
sections,O
revealed,O
moderate,O
to,O
massive,O
tissue,Disease
damage,Disease
with,O
a,O
variety,O
of,O
morphological,O
aberrations,O
by,O
all,O
the,O
three,O
drugs,O
in,O
the,O
absence,O
of,O
GSPE,Chemical
preexposure,O
than,O
in,O
its,O
presence,O
.,O
Discontinuations,O
from,O
renovascular,O
AEs,O
",",O
although,O
less,O
common,O
than,O
discontinuations,O
from,O
GI,Disease
AEs,Disease
",",O
were,O
significantly,O
higher,O
with,O
etoricoxib,Chemical
.,O
A,O
41,O
-,O
year,O
-,O
old,O
woman,O
with,O
a,O
strong,O
history,O
of,O
postoperative,Disease
nausea,Disease
and,Disease
vomiting,Disease
presented,O
for,O
abdominal,O
hysterectomy,O
3,O
months,O
after,O
a,O
previous,O
anaesthetic,O
where,O
ondansetron,Chemical
prophylaxis,O
had,O
been,O
used,O
.,O
Surprisingly,O
",",O
the,O
F1,O
hybrid,O
tumors,Disease
were,O
not,O
hemorrhagic,Disease
and,O
had,O
hemoglobin,O
content,O
and,O
outward,O
appearance,O
identical,O
to,O
that,O
of,O
BN,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
hypothesized,O
that,O
blocking,O
EndoMT,O
reduces,O
the,O
early,O
development,O
of,O
diabetic,Disease
nephropathy,Disease
.,O
The,O
case,O
report,O
questions,O
the,O
long,O
term,O
use,O
of,O
pain,Disease
killers,O
combined,O
with,O
psycho,O
-,O
active,O
drugs,O
in,O
chronic,O
non,O
malignant,O
pain,Disease
",",O
especially,O
if,O
pain,Disease
is,O
under,O
control,O
.,O
Six,O
patients,O
(,O
12,O
%,O
),O
had,O
World,O
Health,O
Organization,O
Grade,O
3,O
-,O
4,O
neutropenia,Disease
",",O
2,O
patients,O
(,O
4,O
%,O
),O
had,O
Grade,O
3,O
-,O
4,O
thrombocytopenia,Disease
",",O
and,O
2,O
patients,O
(,O
4,O
%,O
),O
had,O
Grade,O
3,O
neurotoxicity,Disease
.,O
